Abstract_Title,Clinical Trial Details,Date,Disease Statistic,Drug Application,Educational and Research,Endpoints,FDA Review Outcomes,KOL,Late-Breaking Abstracts,New Entries,Preclinical,Recruitment status,Relevance,Session_Title,Treatment Details,Trial Readouts,id,Priority
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1,Medium
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with<em> BRAF V600</em>mutant unresectable or metastatic melanoma.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,2,Ignore
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.,1,04-06-2019,0,0,0,1,0,0,1,0,0,0,1,Breast CancerMetastatic,0,0,3,High
FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,1,4,High
"Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma.",0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,1,5,High
"A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).",1,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,6,Medium
"Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.",0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,7,Medium
Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).,0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,8,Medium
Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,9,Medium
"Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.",1,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,10,Medium
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,11,Medium
Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,12,Ignore
"Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).",1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,13,Medium
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-a2b for resected high-risk melanoma.,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,14,Medium
"IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + <em>nab-</em>paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).",1,04-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,15,Medium
Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).,0,04-06-2019,0,0,1,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,16,Low
First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidationFinal results of the AATT study.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,1,17,High
A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,18,Ignore
"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with = 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.",1,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,19,Medium
Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,20,Ignore
"Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.",0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,21,Medium
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).,0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,22,Medium
"TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).",0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,23,Medium
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,24,Medium
Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,25,Ignore
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.,0,04-06-2019,0,0,0,1,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,26,Medium
Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,27,Medium
Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.,1,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,28,Medium
Reduced 90-day postoperative mortality through geriatric comanagement after cancer surgery.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,29,Low
A phase I study of convection-enhanced delivery of <sup>124</sup>I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,30,Medium
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,31,Ignore
Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,32,Medium
Outcomes that matter to patients: The Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery (GOSAFE) studyAnalysis of 471 patients.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,33,Low
Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,34,Medium
Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,35,Ignore
Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,36,Medium
Validating the Cancer and Aging Research Group (CARG) toxicity prediction tool in older men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) and extending it to androgen receptor targeted agents.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,37,Ignore
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free studyNSGO-AVANOVA2/ENGOT-OV24.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,38,Ignore
Efficacy and safety of selinexor in recurrent glioblastoma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,39,Medium
Predictive factors of grade 3-5 toxicity in older patients with cancer treated with chemotherapy: A prospective multicenter study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,40,Ignore
Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive <em>IDH1</em> mutant gliomas.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,41,Medium
Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,42,Ignore
"A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,43,Medium
"Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,44,Ignore
Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,45,Ignore
Evaluating unconscious bias: Speaker introductions at an international oncology conference.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,46,Ignore
Survey of sexual harassment and gender disparities among gynecologic oncologists.,0,03-06-2019,0,0,0,0,0,0,1,0,0,0,0,Education Research and Workplace Inequities,0,0,47,High
"Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,48,Medium
Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,49,Medium
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,50,Ignore
Which factors are influencing good digital education? Analysis on ecancer programs from major international congresses.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,51,Ignore
Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,52,Medium
"A randomized phase 3 trial of paclitaxel (P) plus carboplatin  (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,53,Medium
Feasibility of implementing a resident oncology video curriculum.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,54,Ignore
"A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1<sup>+</sup> soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,55,Ignore
TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBCEvaluating the homologous recombination deficiency (HRD) biomarker.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,56,Medium
"Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus<em> </em>partial breast irradiation (PBI) in stage 0, I, or II breast cancer.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,57,Medium
Pilot study of NKTR214 and nivolumab in patients with sarcomas.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,58,Ignore
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,59,Medium
Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,60,Ignore
Relative risks of prostate cancer associated with different family cancer histories.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,61,Ignore
Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifenTo offer more? (aTTom) trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,62,Ignore
"Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,63,Medium
Breast radiotherapy among <em>ATM</em>-mutation carriers.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,64,Ignore
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,65,Ignore
"Risk of subsequent cancer diagnosis in patients treated with 3D conformal, intensity modulated, or proton beam radiation therapy.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,66,Ignore
Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,67,Ignore
"Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,68,Ignore
"Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,69,Medium
"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).",0,03-06-2019,0,0,1,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,70,Medium
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,71,Ignore
Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,72,Medium
Association of baseline cardiovascular risk factors and health care utilization and costs in elderly breast cancer patients enrolled in SWOG clinical trials.,0,03-06-2019,0,0,0,0,0,0,0,0,0,1,1,Symptoms and Survivorship,0,0,73,Medium
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,74,High
Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,75,Ignore
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,76,Ignore
"Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,77,Ignore
Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,78,Ignore
A predictive model for survival in non-small cell lung cancer (NSCLC) based on electronic health record (EHR) and tumor sequencing data at the Department of Veterans Affairs (VA).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,79,Ignore
HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,80,Ignore
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in <em>BRCA1</em> and <em>BRCA2</em> wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,81,Medium
"SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,82,Medium
Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a <em>BRCA</em> mutation (<em>mBRCA</em>): Results of an international cohort study.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,83,Medium
Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,84,Medium
"Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,85,Ignore
Impact of a breast cancer (BC) polygenic risk score (PRS) on the decision to take preventive endocrine therapy (ET): The Genetic Risk Estimate (GENRE) trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,86,Ignore
Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.,0,03-06-2019,0,0,0,0,0,0,1,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,87,High
"Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,88,Ignore
Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,89,Medium
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,90,Ignore
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.,0,03-06-2019,0,0,0,0,0,0,1,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,91,High
Phase II study of tepotinib in NSCLC patients with <em>MET</em>ex14 mutations.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,92,Medium
"ABI-009 (<em>nab</em>-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,93,Medium
Randomized controlled trial (RCT) of a patient navigation (PN) intervention to increase early access to supportive care (SC) for patients with metastatic cancer in a resource-limited setting.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,94,Ignore
"First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.",1,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,95,High
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,96,Medium
Capmatinib (INC280) in <em>MET<U+0394>ex14</em>-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,97,Medium
Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,98,Medium
Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,1,99,High
"Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <em>KRAS<sup>G12C</sup></em> inhibitor, in advanced solid tumors.",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,100,Medium
"CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,101,Medium
"A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,102,Medium
"Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).",0,03-06-2019,0,0,0,1,0,0,0,1,0,0,0,Sarcoma,0,0,103,High
"A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,104,Medium
"A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,105,Ignore
Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,106,Medium
"A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,107,Ignore
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,108,Medium
"A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,109,Ignore
"Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,110,Ignore
"RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,111,Medium
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,112,Medium
"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,1,113,High
A phase II RCT of high-dose vitamin D supplementation and exercise for cancer treatment-induced bone loss in breast cancer patients on aromatase inhibitors.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,114,Medium
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.,1,02-06-2019,0,0,0,0,0,0,1,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,115,High
"ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).",0,02-06-2019,0,0,0,0,0,0,1,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,116,High
"Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.",1,02-06-2019,0,0,0,1,0,0,1,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,117,High
"S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,118,Medium
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.,0,02-06-2019,0,0,0,0,0,0,1,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,119,High
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.,1,02-06-2019,0,0,0,0,0,0,1,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,120,High
"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.",0,02-06-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,1,121,High
Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,122,Medium
"First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,123,Medium
Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)<i>(</i>Alliance A021202<i>)</i>.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,124,Medium
"Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,125,Medium
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,126,Medium
"A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,127,Ignore
"ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,128,Medium
Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,129,Medium
Comparing late mortality risks among childhood cancer survivors: A report from the Childhood Cancer Survivor Study and British Childhood Cancer Survivor Study.,0,02-06-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,130,Low
Impact of Electronically Accessible Pathways (EAPathways) on clinical trial enrollment at a large multisite cancer center.,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,131,Medium
"First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.",0,02-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,132,High
Insurance status and survival of multiple myeloma (MM) patients.,0,02-06-2019,0,0,0,0,0,0,1,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,133,High
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,134,Medium
Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.,0,02-06-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,135,Low
Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,136,Ignore
The Affordable Care Act and cost-related medication non-compliance in cancer survivors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,137,Ignore
A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,138,Medium
Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,139,Medium
Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,140,Ignore
Risk prediction of anthracycline-related cardiomyopathy (AC) in childhood cancer survivors (CCS): A COG-ALTE03N1 and CCSS report.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,141,Ignore
Integrating psychosocial care into routine cancer care: a stepped-wedge design cluster randomized controlled trial (SWD-RCT) to evaluate effectiveness of the HuCare Quality Improvement Strategy (HQIS) on health-related quality of life (HRQoL).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,142,Ignore
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,143,High
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,144,Medium
Genetic predisposition to breast cancer among African American women.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,145,Ignore
"APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <em>nab</em>-paclitaxel plus gemcitabine (<em>nab</em>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,146,Medium
Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,147,Ignore
"Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,148,Medium
Randomized use of anti-GD<sub>2</sub> antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,149,Ignore
The use of optimal evidence-based chemotherapy (chemo) regimens in physician offices versus hospital outpatient facilities.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,150,Ignore
"Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.",0,02-06-2019,0,0,0,1,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,151,High
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD<sub>2</sub> antibody dinutuximab beta (DB) long-term infusion (LTI) in frontline high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,152,Ignore
Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,153,Ignore
"A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A<sub>3</sub> adenosine receptor agonist (A<sub>3</sub>AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,154,Medium
A revised childrens oncology group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,155,Ignore
A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC ).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,156,Medium
PIK3CA mutation as a prognostic factor in HPV-associated oropharynx cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,157,Ignore
"Population-based cohort of prostate cancer patients on active surveillance (AS): guideline adherence, conversion to treatment and decisional regret.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,158,Ignore
Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,159,Medium
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,160,Medium
"Phase III non-randomized controlled trial of PROMPT-Care, an eHealth intervention utilizing patient reported outcomes in routine clinical care: Impact on emergency department presentations.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,161,Medium
"Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,162,Ignore
Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,163,Ignore
Phase I study of pembrolizumab in people with HIV and cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,164,Ignore
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,165,Medium
The impact of routine ESAS use on overall survival: Results of a population-based retrospective matched cohort analysis.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,166,Medium
Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,167,Ignore
"Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,1,168,High
Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,169,Medium
Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with =3 baseline circulating tumor cells (bCTCs).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,170,Medium
"End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,171,Medium
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)First experimental arm (EA) initial results.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,172,Medium
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,173,Ignore
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,174,Ignore
Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,175,Medium
Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,176,Medium
Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,177,Ignore
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Targeting Breast Cancer: Breaking the Code,0,0,178,Ignore
Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,179,Ignore
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,180,Ignore
"Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,181,Medium
"Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia.",0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,182,Low
Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Targeting Breast Cancer: Breaking the Code,0,0,183,Ignore
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,184,Medium
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,185,Ignore
A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,186,Ignore
"Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,187,Medium
"Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,188,Ignore
Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Targeting Breast Cancer: Breaking the Code,0,0,189,Ignore
Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,190,Medium
Effect of gilteritinib on survival in patients with <em>FLT3</em>-mutated <em>(FLT3</em><sup>mut+</sup>) relapsed/refractory (R/R) AML who have common AML co-mutations or a high <em>FLT3</em>-ITD allelic ratio.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,191,Ignore
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,192,Ignore
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,193,Ignore
"Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,194,Medium
Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,195,Medium
Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,196,Ignore
Using machine learning to predict mortality in older patients with cancer: Decision tree and random forest analyses from the ELCAPA and ONCODAGE prospective cohorts.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,197,Low
Association of polybromo-associated baf (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,198,Medium
Prediction of treatment (tx)-induced fatigue in breast cancer (BC) patients (pts) using machine learning on genome-wide association (GWAS) data in the prospective CANTO cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,199,Ignore
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,200,Ignore
A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,201,Ignore
Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,202,Ignore
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,203,Ignore
Randomized trial of a hospice video decision aid for patients with advanced cancer and their caregivers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,204,Ignore
"Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,205,Medium
Impact of a same-day breast biopsy program on disparities in time to biopsy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,206,Ignore
Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Childrens Oncology Group (COG) study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,207,Ignore
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,208,Medium
Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,1,209,High
Quality of end-of-life cancer care at minority-serving US cancer centers: A retrospective study of Medicare claims data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,210,Ignore
A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL):  A COG ACCL1033 study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,211,Ignore
"First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,212,Ignore
"Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: A randomized, multicenter, non-inferiority trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,213,Ignore
Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,214,Medium
A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy versus trans-oral robotic surgery (ORATOR).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,215,Medium
Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Childrens Oncology Group (COG).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,216,Ignore
The financial impact of physician practice patterns: An analysis of as-needed filgrastim versus prophylactic pegfilgrastim in patients with prostate cancer receiving docetaxel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,217,Ignore
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,218,Medium
A process to reduce hospital admissions in the OCM population through focused intervention of super-utilizers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,219,Ignore
TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,220,Medium
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,221,Medium
Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,222,Ignore
Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,223,Medium
Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,1,224,High
"Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,225,Medium
"AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Childrens Oncology Group.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,226,Medium
Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Childrens Oncology Group.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,227,Ignore
Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer: More is better? A large international population-based cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,228,Ignore
PSMA heterogeneity and DNA repair defects in prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,229,Ignore
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,230,Ignore
Preventing excess narcotic prescriptions in MIS urologic oncology discharges (PENN): A prospective cohort quality improvement initiative.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,231,Ignore
Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,232,Medium
Ado-trastuzumab emtansine in patients with <em>HER2</em> amplified salivary gland cancers (SGCs): Results from a phase II basket trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,233,Ignore
Comparison of normal saline versus heparin flush solutions for maintaining patency of central venous catheter in cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,234,Ignore
Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trialA European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,235,Medium
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,236,Medium
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,237,Ignore
"Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost of administration.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,238,Ignore
"Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,239,Medium
Safety and preliminary clinical activity of repotrectinib in patients with advanced <em>ROS1</em> fusion-positive non-small cell lung cancer (TRIDENT-1 study).,0,31-05-2019,0,0,1,1,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,240,Medium
"Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,241,Medium
Toward Targeting NHL Subsets,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,242,Ignore
Optimizing Targeted Therapy in Melanoma,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,243,Ignore
CDK4/6 Inhibitors: Optimizing Care in ER-Positive Breast Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,244,Ignore
Novel Therapeutics in Breast Cancer: Crossing the Subtype Divide,0,04-06-2019,0,0,0,0,0,0,0,1,0,0,1,Breast CancerMetastatic,0,0,245,High
Rethinking Melanoma Treatment Pre- and Postsurgery,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,246,Ignore
Chipping Away at T-cell Lymphomas,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,247,Ignore
Tuberous Sclerosis: Evolving Treatment Paradigms,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,From Mutations to Management: Diagnosis and Treatment of Central Nervous System Tumor Susceptibility Syndromes,0,0,248,Ignore
Target Practice: HER2 Blockade in Metastatic Breast Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,249,Ignore
CLL: The Future Is Now,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,250,Ignore
Neurofibromatosis Type 1 and 2: From DNA to Bedside,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,From Mutations to Management: Diagnosis and Treatment of Central Nervous System Tumor Susceptibility Syndromes,0,0,251,Ignore
A New Era for the Treatment of Brain Metastases in Melanoma,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,252,Ignore
Thromboembolism in Pancreatic Ductal Adenocarcinoma,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Breadth and Depth of Pancreatic Ductal Adenocarcinoma,0,0,253,Ignore
Constitutional Mismatch Repair Deficiency and Glioblastoma: Emerging Role of Immunotherapy,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,From Mutations to Management: Diagnosis and Treatment of Central Nervous System Tumor Susceptibility Syndromes,0,0,254,Ignore
The Opportunities of CAR T for Solid and Liquid Tumors,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,255,Ignore
Symptoms and Survivorship,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,256,Ignore
The Challenges of CAR T for Solid and Liquid Tumors,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,257,Ignore
Understanding Ethical and Legal Implications of Right to Try in Metastatic Breast Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Current Controversies in Metastatic Breast Cancer: A 360° View,0,0,258,Ignore
Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for Selected Patients,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia,0,0,259,Ignore
"Targeting Choangiocarcinoma: Fibroblast Growth Receptors, IDH, and Beyond",0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Landscapes in Liver Cancer,0,0,260,Ignore
Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Modern Management of Brain and Spinal Metastases in the Era of Targeted Therapy and Immuno-Oncology,0,0,261,Ignore
Sarcoma,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,262,Ignore
Emerging Systemic Therapies: What's New in 2019?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Current Controversies in Metastatic Breast Cancer: A 360° View,0,0,263,Ignore
No Maintenance Required: Arguing in Favor of Observation after Frontline Therapy in Follicular Lymphoma,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia,0,0,264,Ignore
Sequencing Systemic Therapy in Hepatocellular Carcinoma: Immune Checkpoint Inhibitor or Tyrosine Kinase Inhibitor First?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Landscapes in Liver Cancer,0,0,265,Ignore
Will Targeted Therapy Replace Radiation for Melanoma Brain Metastases?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Modern Management of Brain and Spinal Metastases in the Era of Targeted Therapy and Immuno-Oncology,0,0,266,Ignore
Genitourinary (Nonprostate) Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,267,Ignore
What Is the Role of Surgery in Metastatic Breast Cancer?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Current Controversies in Metastatic Breast Cancer: A 360° View,0,0,268,Ignore
Indefinite Oral Therapy for Frontline Chronic Lymphocytic Leukemia Treatment: Give Me All Youve Got.,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia,0,0,269,Ignore
Upfront Immunotherapy for Brain Metastases: Is It Ready for Primetime?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Modern Management of Brain and Spinal Metastases in the Era of Targeted Therapy and Immuno-Oncology,0,0,270,Ignore
Developmental Therapeutics and Tumor Biology (Nonimmuno),0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,271,Ignore
Opportunities and Barriers to High Quality Care in Metastatic Breast Cancer From a Patient Perspective,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Current Controversies in Metastatic Breast Cancer: A 360° View,0,0,272,Ignore
Defined Duration Frontline Chemoimmunotherapy in Chronic Lymphocytic Leukemia: Less Is More,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia,0,0,273,Ignore
Optimizing Transplant Oncology in Liver Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Landscapes in Liver Cancer,0,0,274,Ignore
"The Who, What, and Where of CAR T",0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,275,Ignore
Precision Medicine in Lung Cancer Brain Metastases: Are We There Yet?,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Modern Management of Brain and Spinal Metastases in the Era of Targeted Therapy and Immuno-Oncology,0,0,276,Ignore
Breast CancerLocal/Regional/Adjuvant,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,277,Ignore
Lung CancerNon-Small Cell Metastatic,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,278,Ignore
Gynecologic Cancer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session III,0,0,279,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,280,Ignore
Hearts and Brains: Pediatric Cancer Survivorship,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,281,Ignore
Classification and Management of Infrequent Genitourinary Malignancies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,282,Ignore
New Solutions to Old(er) Problems,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,283,Ignore
Updates for the Treatment of Rare Melanoma Subtypes,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,284,Ignore
Against,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,285,Ignore
Future of Novel Agents for Squamous Cell Carcinoma:  Lung-MAP Trial,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,New Options in Metastatic Squamous Cell Carcinoma,0,0,286,High
For,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,287,Ignore
Options Beyond the First Line for Squamous Cell Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,New Options in Metastatic Squamous Cell Carcinoma,0,0,288,Ignore
Who Should We Be Testing?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,289,Ignore
Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,290,Ignore
Novel Cooperating Factors of Allogeneic Transplant Outcomes,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,291,Ignore
Searching for a Crystal Ball: Biomarkers in Melanoma Management,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,292,Ignore
Against,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,293,Ignore
Current Frontline Therapy Options for Squamous Cell Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,New Options in Metastatic Squamous Cell Carcinoma,0,0,294,Ignore
For,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,295,Ignore
Gastrointestinal Malignancies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,296,Ignore
Sarcomatoid RCC: Defining a New Treatment Paradigm?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,297,Ignore
Follow-up and Safety in the Chronic Leukemias,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,298,Medium
Peripheral Blood and Tumor Microenvironment Considerations for Immunotherapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,299,Ignore
Train the Brain,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,300,Ignore
Systemic Treatment of Elderly Patients With Metastatic Stage IV Non-Small Cell Lung Cancer: From Nihilism to Reasonable Hope,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology,0,0,301,Ignore
What Do I Do: Immune Toxicity? Overview of Immunotherapy Toxicity? Oncologist Overview,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Recognizing, Understanding, and Overcoming Toxicities From Immune Checkpoint Inhibitors",0,0,302,Ignore
Lessons Learned From the ASCO Roundtable on Financial Barriers to Clinical Trial Participation,0,03-06-2019,0,0,0,0,0,0,0,0,0,1,0,Financial Assistance for Participation in Clinical Trials: What Works Best for Patients?,0,0,303,Medium
Debate Moderator,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma,0,0,304,Ignore
Presentation of the 2019 B. J. Kennedy Award for Scientific Excellence in Geriatric Oncology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology,0,0,305,Ignore
Identifying Genomic Targets for Squamous Cell Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,New Options in Metastatic Squamous Cell Carcinoma,0,0,306,Ignore
CHIP-ing Away at Heme Malignancies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,307,Ignore
Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,308,Ignore
Hitting the Bull's-eye With Targeted Treatments in AML,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,309,Ignore
Long-term Clinical Outcomes in Advanced Melanoma,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,310,Medium
Attention Gen AYA,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,311,Ignore
Improving Surgical Outcomes With Team-Based Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,312,Ignore
Pushing the Frontiers in GE Cancers,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,313,Ignore
The Rationale for New Brain Tumor Treatments: How Can We Do Better?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,314,Ignore
Old Standards and New Tricks for Ovarian Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,315,Ignore
Impact of Hospital Quality on Disparities in Cancer Survival,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,How to Measure Quality in Value-Based Systems,0,0,316,Ignore
How Are Payers Using Big Data and Predictive Analytics?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology,0,0,317,Ignore
Is Neoadjuvant or Adjuvant Immunotherapy in Our Future for Resected Non-Small Cell Lung Cancer?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Local-Regionally Advanced NonSmall Cell Lung Cancer: Advances in Multimodality Treatment,0,0,318,Ignore
The Future of Genomic Profiling: Next-Generation Sequencing and Beyond,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Molecular Profiling in Breast Cancer: Past, Present, and Future",0,0,319,Ignore
Risk Stratification and Modelling in Oncology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,How to Measure Quality in Value-Based Systems,0,0,320,Ignore
Partnership With Silicon Valley: The Way Forward?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology,0,0,321,Ignore
PDA: Target or Not?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,322,Ignore
Tools of the Trade: Predicting Toxicity in Geriatric Oncology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,323,Ignore
Changing the Concurrent Chemotherapy-Radiation Paradigm: Can We Replace Chemotherapy with Immunotherapy?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Local-Regionally Advanced NonSmall Cell Lung Cancer: Advances in Multimodality Treatment,0,0,324,Ignore
Future of Maintenance Therapy After Transplant in Relapsed Hodgkin Lymphoma: How Do We Do It Best?,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy,1,0,325,High
Germline Testing in the PARP Inhibitor Era,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Molecular Profiling in Breast Cancer: Past, Present, and Future",0,0,326,Ignore
Electronic Capture: Changing the Landscape of Quality Measurement,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,How to Measure Quality in Value-Based Systems,0,0,327,Ignore
Operationalizing a Risk Model in Clinical Practice: A Community Oncology Perspective,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology,0,0,328,Ignore
Utilizing Quality Data to Motivate Change,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,How to Measure Quality in Value-Based Systems,0,0,329,Ignore
Current Standards: Pacific and Ongoing Consolidation Trials,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Local-Regionally Advanced NonSmall Cell Lung Cancer: Advances in Multimodality Treatment,0,0,330,Ignore
Pre-Transplant Salvage Options: Bringing Conventional Versus Novel Combinations to Practice,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy,0,0,331,High
Starting a National Conversation  Cross Disciplinary Efforts with Other Subspecialty Societies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions,0,0,332,Ignore
Controversies in the Medical Treatment of Angiosarcoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Multidisciplinary Care in Challenging Sarcoma Scenarios,0,0,333,Ignore
"Genomic Profiling in ER-Positive Breast Cancer, From MINDACT to TAILORx",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Molecular Profiling in Breast Cancer: Past, Present, and Future",0,0,334,Ignore
Checking Up on Checkpoint Inhibitors,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,335,Ignore
IDH: From Target to Therapies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,336,Ignore
The Shifting Winds of Cervical Cancer Treatment,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,337,Ignore
There's More Than Multiple Myeloma: Other Plasma Cell Dyscrasias,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,338,Ignore
Gender Bias and Discrimination,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,339,Ignore
Checkpoint Inhibitor Resistance Mechanism in High Tumor Mutation Overload Tumors,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?,0,0,340,Ignore
Beyond the M Spike: Diagnostic and Monitoring Platforms,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,341,Ignore
Building Programs to Prevent Burnout and Suicide in Oncology Providers,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers,0,0,342,Ignore
New Options in Small Cell Lung Cancer: To Immunotherapy or Not,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma",0,0,343,Ignore
Uterine Cancer: Match or Mismatch?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,344,Ignore
Sarcoma Care and Access in Brazil and Other South American Countries,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,International Collaborations and Regional Challenges in Sarcoma,0,0,345,Ignore
Clinical Genomics and Resistance to Cancer Immunotherapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?,0,0,346,Ignore
Temozolomide: How Much Is Enough?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,347,Ignore
Enhancing Education Through Technology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,348,Ignore
To BCMA and Beyond,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,349,Ignore
Emotional Challenges Unique to Oncology Practice,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers,0,0,350,Ignore
Immunotherapies in Mesothelioma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma",0,0,351,Ignore
CTLA4 Resistance Mechanism: Why Some Tumors Are Not Sensitive to PD1 and CTLA4 Inhibitor Combination Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?,0,0,352,Ignore
Crossing European Borders in Sarcoma Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,International Collaborations and Regional Challenges in Sarcoma,0,0,353,Ignore
Progress and Challenges in Clinical Cancer Genetics,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Cancer Society Award and Lecture,0,0,354,Ignore
Physician Depression and Suicide: The Extent of the Problem,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers,0,0,355,Ignore
Immunotherapies in Thymic Malignancies,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma",0,0,356,Ignore
Unique Sarcoma Networks in Asia,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,International Collaborations and Regional Challenges in Sarcoma,0,0,357,Ignore
Making Sense of the Evolving Landscape of Rectal Cancer Management,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Conundrums in the Management of Rectal Cancer,0,0,358,Ignore
Heterogeneity of Resistant Mechanisms to PD-1 Checkpoint Inhibitors,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?,0,0,359,Ignore
Presentation of the 2019 ASCO/American Cancer Society Award,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Cancer Society Award and Lecture,0,0,360,Ignore
"No Reason to Fear, New Treatments Are Here: Amyloidosis",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,361,Ignore
Prognostic Markers for Early-Stage Disease,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,362,Ignore
Awakening the Immune System in DLBCL,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,363,Ignore
Tumor-Specific Antigen-Based Immunotherapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,364,Ignore
New Directions for Treatment Selection: Triple-Negative Breast Cancer and Locoregional Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,365,Ignore
Oncology Reimbursement Reform: Lessons Learned From the Oncology Care Model and the Future of High-Value Oncology Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care?,0,0,366,Ignore
Update on T-Cell Receptor Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application,0,0,367,Ignore
"CAR T: The Good, the Bad, and the Ugly",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,368,Ignore
Surgery: Techniques and Teamwork,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,369,Ignore
Cancer Center Engagement With Rural Appalachian Communities to Improve Cancer Disparities,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Academic-Community Partnerships: Approaches to Engagement,0,0,370,Ignore
Can We Find a Sweet Spot in Dual Immuno-Stimulation?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,371,Ignore
Immuno-Oncology: Managing Expectations,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,372,Ignore
Improving Hereditary Risk Assessment Approaches: A Focus in Pancreas and Prostate Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,373,Ignore
Evolving Options in Follicular Lymphoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,374,Ignore
HIPEC: Standard of Care or Hype?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The More Things Change: Ovarian Cancer Edition,1,0,375,Low
The Role of Social Epigenomic Approaches in Addressing Underserved Populations,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Academic-Community Partnerships: Approaches to Engagement,0,0,376,Ignore
Fee for Service and Physician Facility Ownership,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care?,0,0,377,Ignore
Tumor Infiltrating Lymphocytes Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application,0,0,378,Ignore
Cytotoxics Plus Checkpoint Inhibitors: The Search for Synergy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,379,Ignore
The Art and Science of Cancer Survivorship,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care,0,0,380,Ignore
Implementing Palliative Care in a Community United States Hospital,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Implementing Palliative and Supportive Care in Cancer Care Worldwide,1,0,381,Low
Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The More Things Change: Ovarian Cancer Edition,0,0,382,Ignore
Moderator and Panelist,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging New Standards of Care for Advanced Kidney Cancer,0,0,383,Ignore
Approaches to Optimizing Value in Cancer Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care?,0,0,384,Ignore
Can We Hit the Targets in Colorectal Cancer?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,385,Ignore
CAR T: Expanding Clinical Indications,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application,0,0,386,Ignore
"Promises, Promises: Informing Long-term Expectations in WM and CLL",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,387,Ignore
Community Engagement Mandate for Academia: Building From the Ground Up,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Academic-Community Partnerships: Approaches to Engagement,0,0,388,Ignore
Adjuvant Endocrine Therapy: Selecting the Optimal Path,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,389,Ignore
Insights Into Radiation Therapy Risks and Benefits,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,390,Ignore
Using Big Data to Identify Outcomes of Uncommon Population: Are We Ready?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,391,Ignore
Expanding the Horizon of Synthetic Lethality,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,392,Ignore
Integrating Local and Systemic Modalities in Bladder and Renal Cancers,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,393,Ignore
Emerging Therapies for New Targets,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,394,High
Refining Strategies Across the Sarcoma Spectrum,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,395,Ignore
Navigating the Cancer Journey Beyond Breast Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,396,Ignore
Histologic-Agnostic Trials: Challenges and OpportunitiesTranslational Science Perspective in the Era of Immuno-Oncology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Association for Cancer Research (AACR) Joint Session: Histology-Agnostic Clinical Trials and Approvals  Challenges of Design and Implementation at the Bedside,0,0,397,Ignore
When the Tumor Is Not the Target: Long-term Care of Patients With Low Grade Glioma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?,0,0,398,Ignore
Novel Approaches to Enhance the Educational Process and Improve Patient Engagement,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Navigating a New Cancer Diagnosis: Guiding Communication and Education,0,0,399,Low
Utilizing Big Data to Advance Personalized Therapy,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,400,Ignore
Anti-HER2 Therapy at the Forefront: Stepping Closer to De-escalation,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,401,Ignore
Histologic-Agnostic Trials: Challenges and OpportunitiesClinical Trialist Perspective,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Association for Cancer Research (AACR) Joint Session: Histology-Agnostic Clinical Trials and Approvals  Challenges of Design and Implementation at the Bedside,0,0,402,Ignore
"To Chemo or Not to Chemo: The Question for High-Risk, Low-Grade Gliomas",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?,0,0,403,Ignore
Tam 2.0: Tamoxifen Chemoprevention in the Modern Era,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,404,Ignore
Remarks,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Practical Tips for Successful Disclosure,0,0,405,Ignore
Communicating a New Cancer Diagnosis: From the Lens of the Patient and Family Caregiver,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Navigating a New Cancer Diagnosis: Guiding Communication and Education,0,0,406,Ignore
Histologic-Agnostic Trials: Challenges and OpportunitiesA Payor Perspective,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Association for Cancer Research (AACR) Joint Session: Histology-Agnostic Clinical Trials and Approvals  Challenges of Design and Implementation at the Bedside,0,0,407,Ignore
Remarks,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Practical Tips for Successful Disclosure,0,0,408,Ignore
To Radiate or Not to Radiate: Nuances of Radiation Therapy for Low-Grade Gliomas,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?,0,0,409,Ignore
Can We Capture Every Patient?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,410,Ignore
Remarks,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Practical Tips for Successful Disclosure,0,0,411,Ignore
Histologic-Agnostic Trials: Challenges and OpportunitiesA Regulatory Perspective,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Association for Cancer Research (AACR) Joint Session: Histology-Agnostic Clinical Trials and Approvals  Challenges of Design and Implementation at the Bedside,0,0,412,Ignore
New Drugs and Resistance: Have We MET Expectations?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,413,Ignore
Integration of Molecular Diagnostics Into Surgical Management of Low-Grade Gliomas,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?,0,0,414,Ignore
Patterns of Multiple Myeloma Relapse and When to Treat,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Early Relapse in Multiple Myeloma,0,0,415,Ignore
Multidisciplinary Communication and Education Milestones Following a Cancer Diagnosis,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Navigating a New Cancer Diagnosis: Guiding Communication and Education,0,0,416,Ignore
Welcome and Introductions,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Practical Tips for Successful Disclosure,0,0,417,Ignore
Chemotherapy and Antiangiogenic Therapy in 2019: Who Needs It?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,418,Ignore
M-CODE (Minimal Common Oncology Data Elements) in Cancer Practice,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Impact of Big Data Research on Practice, Policy, and Patient Care",0,0,419,Ignore
Ethical Care Practices: Respecting Cultural and Societal Differences to Safeguard the Therapeutic Relationship,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges,0,0,420,Ignore
Less Is More,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy,0,0,421,Ignore
Male Breast Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Uncommon and Rare Breast Cancers,0,0,422,Ignore
Value-Based Propositions in Lung Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes,0,0,423,Ignore
Targeting MAPK Pathways: How Low Should We Go?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,424,Ignore
Evolving Front-Line Therapy in Metastatic Renal Cell Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,425,Ignore
Neoadjuvant Strategies in Localized Disease: Dissecting the Results of Three Phase III Studies,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,426,Medium
Give Me a Break: Optimizing Bone Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,427,Ignore
Using Administrative Data to Understand Care Delivery,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Impact of Big Data Research on Practice, Policy, and Patient Care",0,0,428,Ignore
Clinical Genomics and Big Data: Protecting the Patient and Advancing Science,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges,0,0,429,Ignore
More Is Better,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy,0,0,430,Ignore
Clinical Management of Uncommon and Rare Breast Cancer Subtypes,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Management of Uncommon and Rare Breast Cancers,0,0,431,Ignore
Value-Based Propositions in Prostate Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes,0,0,432,Ignore
Big Data to Examine Uncertainties About Effects of Treatment,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Impact of Big Data Research on Practice, Policy, and Patient Care",0,0,433,Ignore
Hematologic MalignanciesPlasma Cell Dyscrasia,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session II,0,0,434,Ignore
Combatting Moral Distress and Burnout in Oncology with Moral Resiliency: What It Is and Why It Matters,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fostering Moral Resilience: Steps You Can Take to Manage Moral Distress and Burnout in Oncology,0,0,435,Ignore
Informed Consent and the Electronic Health Record: Using Novel Approaches to Address the Challenges of Informed Consent,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges,0,0,436,Ignore
Protons versus Photons: What's the Difference?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Bringing New and Innovative Glioblastoma Treatments to Daily Practice,0,0,437,Ignore
Setting the Stage,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy,0,0,438,Ignore
Natural History and Pathology of Rare Breast Cancer Subtypes,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,1,Management of Uncommon and Rare Breast Cancers,0,0,439,Low
How to Implement and Disseminate Clinical Trial and Big Data Results,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Impact of Big Data Research on Practice, Policy, and Patient Care",0,0,440,Ignore
Gastrointestinal (Noncolorectal) Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session II,0,0,441,Ignore
Value Propositions in Colorectal Cancer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes,0,0,442,Ignore
"Health Services Research, Clinical Informatics, and Quality of Care",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session II,0,0,443,Ignore
Developmental Immunotherapy and Tumor Immunobiology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session II,0,0,444,Ignore
Local Therapy and Lifestyles: What's New?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,445,Ignore
Incorporating Gene and Viral Therapies in Brain Tumor Treatment,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,446,Ignore
"Old Targets, New Approaches",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,447,Ignore
Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies,0,0,448,Ignore
"Yes, There Is Still a Role for Minimally Invasive Surgery in Cervical Cancer",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancers: Is It Time to Put Away the Knife?,0,0,449,Ignore
Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Anti-PD-1/PD-L1 Therapy in Urothelial Cancer,0,0,450,Ignore
Moving Forward When It Is Time to Stop,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Optimizing Palliation for Older Adults: Old and New Challenges in a Changing Landscape,0,0,451,Ignore
Photon Beam Radiation: An Oldie but a Goodie,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Proton Versus Photon in Radiation Therapy,0,0,452,Ignore
Is Pseudoprogression Real in Head and Neck Cancer?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Immunotherapy Mythbusters in Head and Neck Cancer,0,0,453,Ignore
Ablative and Microinvasive Techniques in the Treatment of Dysplasia and Cervical Cancer: How to Make Them Affordable in Low-Resource Settings,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Innovative and Affordable Global Cancer Technologies,0,0,454,Ignore
Has Laparoscopy Sung Its Final Song in Cervix Cancer?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancers: Is It Time to Put Away the Knife?,0,0,455,Ignore
Are There Geographical Variations in Immunotherapy Outcome Around the Globe?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies,0,0,456,Ignore
"Chemotherapy, Antibody Drug Conjugates, and Radiation With or Without Anti-PD1/Anti-PD-L1",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Anti-PD-1/PD-L1 Therapy in Urothelial Cancer,0,0,457,Ignore
Immunotherapy for Older Adults: When Is It Palliative and When Does It Hinder Palliation?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Optimizing Palliation for Older Adults: Old and New Challenges in a Changing Landscape,0,0,458,Ignore
Neo/adjuvant Chemotherapy Optimization: Is This End of the Quest?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,459,Ignore
Exploring New Directions in Glioma Immunotherapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,460,Ignore
Dynamic Changes in Plasma: Ready for Prime Time?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,461,Ignore
Proton Beam: The Not So New Kid on the Block,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Proton Versus Photon in Radiation Therapy,0,0,462,Ignore
The Gap Between Preclinical Science and Clinical Experience With Immunotherapy and the Abscopal Effect,0,02-06-2019,0,0,0,0,0,0,0,0,1,0,0,Immunotherapy Mythbusters in Head and Neck Cancer,0,0,463,Medium
The Role of Point-of-Care Diagnostics and Affordable Innovative Technologies in Imaging and Pathology in Our Global Drive to Eliminate Cervical Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Innovative and Affordable Global Cancer Technologies,0,0,464,Ignore
We Need a Smarter Sharper Knife,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancers: Is It Time to Put Away the Knife?,0,0,465,Ignore
Biomarkers for Better Treatment and Patient Selection,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies,0,0,466,Ignore
Additional Immunotherapeutic Options Beyond Anti-PD1/Anti-PD-L1,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Anti-PD-1/PD-L1 Therapy in Urothelial Cancer,0,0,467,Ignore
Quality and Quantity: Living Your Best Life,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,468,Ignore
Tailoring Palliation to Older Adults,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Optimizing Palliation for Older Adults: Old and New Challenges in a Changing Landscape,0,0,469,Ignore
Molecular Diagnostics and Precision Medicine for Brain Tumors,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,470,Ignore
Advanced Ovarian Cancer: Time to Put Away the Knife,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancers: Is It Time to Put Away the Knife?,0,0,471,Ignore
Overview of Liquid Biopsy Platform and Interpretation,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Liquid Biopsy: How to Interpret and Use Results in Clinical Practice,0,0,472,Ignore
Furthering Our Knowledge of Biomarkers for Checkpoint Inhibitors in NSCLC,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,473,Ignore
Tumor Biology and Heterogeneity to Guide Development of Immunotherapy and Its Combination,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies,0,0,474,Ignore
Conceptual Framework for Therapeutic Development Beyond Anti-PD1/PD-L1,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Anti-PD-1/PD-L1 Therapy in Urothelial Cancer,0,0,475,Ignore
"Frontline Therapy For Mantle Cell Lymphoma, Including Induction Therapy and Transplant",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Frontline Therapy in Mantle Cell Lymphoma: To Transplant or Not to Transplant?,0,0,476,Ignore
Are We Getting It Right? Tools and Strategies to Estimate Life Expectancy for Older Adults,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Optimizing Palliation for Older Adults: Old and New Challenges in a Changing Landscape,0,0,477,Ignore
Neuro-Oncology Perspectives on Radiotherapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Proton Versus Photon in Radiation Therapy,0,0,478,Ignore
National Institutes of Health Efforts to Promote the Development of Affordable Innovative Cancer Technologies: Where We Are and Where We Want to Be,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Innovative and Affordable Global Cancer Technologies,0,0,479,Ignore
Extraordinary Response With Chemotherapy Following Immunotherapy: Fact or Fiction,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Immunotherapy Mythbusters in Head and Neck Cancer,0,0,480,Ignore
Precision in Targeted Treatment Selection: New Advances,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,481,Ignore
Optimizing Efficacy and Safety of Radiation Therapy for Brain Tumors,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,482,Medium
Discussion,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,483,Ignore
Parsing the Data for Checkpoint Inhibitors in 2019,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,484,Ignore
Discussion,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,485,Ignore
Discussion,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,486,Ignore
Discussion,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,487,Ignore
The Role of Patient Navigators in Clinical Trial Participation,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,488,Medium
Science of Oncology Award Lecture: Tumor Cell Stress Management in Progression and Therapy Resistance,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,489,Ignore
Welcome and Introductory Remarks,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,490,Ignore
Expanding Options in GE Cancers,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,491,Ignore
Surgery and Maintenance Therapy for Mesothelioma,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,1,0,492,Low
The American Society of Clinical Pathology Support for City Cancer Challenge,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,City Cancer Challenge: Changing the Future of Cancer in Urban Populations,0,0,493,Ignore
Letting Genomics Lead the Way,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,494,Ignore
Elephant in the Room: Financial Toxicity in Cancer Care,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care,0,0,495,Ignore
Evolving Role of Nephrectomy and Metastatectomy With Modern Immunotherapy and Combinations,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Surgery or No Surgery: Evaluating the Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma,0,0,496,Ignore
Decision-making: The Informed Consent Process,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,497,Medium
It's Not All About CAR T: What's New in Immunotherapy?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,498,Ignore
HER2-Positive Disease: How Far We Have Come?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,499,Ignore
From Trials to Treatment: Addressing Disparities in Access to Prostate Cancer Care,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care,0,0,500,Ignore
Relapsed SCLC: A Difficult Path Ahead,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,501,Ignore
Case Closed: CARMENA Puts an End to Unnecessary Surgery,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Surgery or No Surgery: Evaluating the Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma,0,0,502,Ignore
Learnings from City Cancer Challenge: Asuncion,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,City Cancer Challenge: Changing the Future of Cancer in Urban Populations,0,0,503,Ignore
Advancing Our Knowledge in ER-Positive Breast Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,504,Ignore
The Burden of Financial Toxicity,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,505,Medium
Adding to Chemoradiation in Locally Advanced NSCLC,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,506,Ignore
The Molecular Pathology of Pediatric Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology Award and Lecture,0,0,507,Ignore
"More Than Skin Deep: Investigating Disease Biology, Treatment Response, and Side Effect Differences by Race",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care,0,0,508,Ignore
City Cancer Challenge: Global Perspective,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,City Cancer Challenge: Changing the Future of Cancer in Urban Populations,0,0,509,Ignore
"Case Presentations and Management of Common Immunotherapy Toxicities (Colitis, Pneumonitis, Hepatitis)",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Immuno-Oncology Toxicity in Melanoma,0,0,510,Ignore
Cytoreductive Nephrectomy Still an Important Tool in Management of Metastatic Renal Cell Carcinoma,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Surgery or No Surgery: Evaluating the Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma,0,0,511,Ignore
Presentation of the 2019 Pediatric Oncology Award,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology Award and Lecture,0,0,512,Ignore
Development of a Molecular Tumor Board in the Community Setting,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Development of a Molecular Tumor Board for Gynecologic Oncology,0,0,513,Ignore
Disparities in Prostate Cancer Across the Cancer Continuum,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care,0,0,514,Ignore
Advances in Advanced Disease,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,515,Ignore
Presentation of the 2019 Partners in Progress Award,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,516,Medium
The Many Faces of Monoclonal Antibody Targeting of CD38,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,517,Ignore
Refining Immunotherapy Strategies in Breast Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,518,Ignore
Expanding the Horizon of Rational Immunotherapy Combinations,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,519,Ignore
Global Application of Risk Stratification in Childhood Cancer Survivors,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,520,Ignore
Building on the Standards for Operable Lung Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,521,Ignore
Bringing Clinical Trials to Cancer Care Delivery,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,522,Ignore
Legal Landscape for Medical Marijuana in the United States: Implications for Clinical Care,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Is There a Role for Cannabis in Cancer Symptom Management?,0,0,523,Ignore
Leveling the Playing Field: Health Policy and Cancer Disparities,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,524,Ignore
Screening in the Geriatric Population: Timing Is Everything,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings,0,0,525,Low
The Sarcoma Perspective in Gynecologic Oncology,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer,0,0,526,Ignore
Preparing the Next Generation: Serving the Needs of Oncology Trainees,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Caring for Our Trainees: Lessons From Around the World,0,0,527,Ignore
Potential Pitfalls of a Research Program in the Community,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know",0,0,528,Ignore
Immunotherapy Versus BRAF/MEK Inhibitors in the Adjvuant Setting: Is There a Clear Winner?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaches to High-Risk Resected Stage II and III Melanoma,0,0,529,Ignore
Integrating Therapies in Localized Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,530,Ignore
"Something Old, Something New: Evolving Paradigms in Untreated Multiple Myeloma",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,531,Ignore
Pharmacology of Cannabis in Older Adults With Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Is There a Role for Cannabis in Cancer Symptom Management?,0,0,532,Ignore
Maintenance Therapy: Not Ready for Prime Time,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer,1,0,533,Low
Cancer Prevention Considerations in the LGBTQ Population,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings,0,0,534,Ignore
A Global Perspective from an International Training Program,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Caring for Our Trainees: Lessons From Around the World,0,0,535,Ignore
What Infrastructure You Need to Do Community Clinical Research,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know",0,0,536,Ignore
Stage II Melanoma: What Patients Are Appropriate for Adjuvant Therapy?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaches to High-Risk Resected Stage II and III Melanoma,0,0,537,Ignore
Cannabis for Symptom Management,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Is There a Role for Cannabis in Cancer Symptom Management?,0,0,538,Ignore
Maintenance Therapy: Standard of Care,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer,1,0,539,Low
Addressing and Overcoming Cancer Prevention Disparities in Minority Populations,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings,0,0,540,Ignore
Ethnicity: Does It Influence One's Inheritable Cancer Risk and What Are the Implications for Care?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,541,Ignore
Preparing Fellows for Real-World Practice: A Cultural Perspective,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Caring for Our Trainees: Lessons From Around the World,0,0,542,Ignore
Clinical Trials in the Community Setting: Is It Possible?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know",0,0,543,Ignore
Cannabinoids in Oncology: A Growing Role,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Is There a Role for Cannabis in Cancer Symptom Management?,0,0,544,Ignore
Changing the Perspective for Successful Maintenance Therapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer,1,0,545,Low
When Is Observation Appropriate for Resected Stage II or III Melanoma?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaches to High-Risk Resected Stage II and III Melanoma,0,0,546,Ignore
The Challenge of Cancer Prevention in Rural Populations,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings,0,0,547,Ignore
Picking Out the Worst in HPV-Positive Head and Neck Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,548,Ignore
Dissecting a Negative Trial: Finding a Niche for Immunotherapy in Ovarian Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,549,Ignore
Asking and Listening to Deliver Better Care,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,550,Ignore
Fulfilling Common Program Requirements VI.C: Well-Being,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,551,Ignore
What Is Available for the Treatment of Uveal/Mucosal Melanoma?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Rare Melanomas and Non-melanoma Skin Cancers,0,0,552,Ignore
Urothelial and Variant Cases: Medical Oncology Perspective,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract,0,0,553,Ignore
Recognizing and Treating Depression in Older Patients With Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,A Practical Guide to Geriatric Syndromes in Patients With Cancer,0,0,554,Ignore
HPV Vaccination in Latin America: Global Challenges and Feasible Solutions,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,HPV Vaccination: Why Is It So Difficult to Implement a Vaccine That Prevents Cancer?,0,0,555,Ignore
European Perspective on Optimal Induction Regimens,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Choosing the Right Induction Regimen for Newly Diagnosed Multiple Myeloma,0,0,556,Ignore
Considerations for Systemic Therapy in Optimal Management of Oligometastatic Disease,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity?,0,0,557,Ignore
Is Circulating Tumor DNA Testing Ready for Prime Time in Colorectal Cancer Management?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management: What Is Today's Standard?,0,0,558,Ignore
Endocrine Therapy: The Old Frontier Revisited?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,559,Ignore
On the Right TRK: Finding the Next Success in Pediatric Precision Oncology,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,560,Ignore
Expanding Patient Populations for Immunotherapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,561,Ignore
The Guardian of the Genome,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,562,Ignore
Fulfilling Common Program Requirements VI.C: Well-Being,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,563,Ignore
Fall Prevention in Older Patients With Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,A Practical Guide to Geriatric Syndromes in Patients With Cancer,0,0,564,Ignore
Urothelial and Variant Cases: Radiation Oncology Perspective,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract,0,0,565,Ignore
Biomarkers and Treatment Updates for Merkel Cell Carcinoma,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Rare Melanomas and Non-melanoma Skin Cancers,0,0,566,Ignore
Genitourinary (Prostate) Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session I,0,0,567,Ignore
The Power of Social Media for HPV Vaccination: Not Fake News!,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,HPV Vaccination: Why Is It So Difficult to Implement a Vaccine That Prevents Cancer?,0,0,568,Ignore
Treatment of the Primary in the Setting of Oligometastatic Disease: Review of Pros and Cons,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity?,0,0,569,Ignore
Picking Induction Regimens Based on Disease Risk,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Choosing the Right Induction Regimen for Newly Diagnosed Multiple Myeloma,0,0,570,Ignore
The Right and Left of Incorporating Targeted Therapy Into the Management of Colorectal Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management: What Is Today's Standard?,0,0,571,Ignore
Assessing and Maintaining Cognition in Older Patients With Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,A Practical Guide to Geriatric Syndromes in Patients With Cancer,0,0,572,Ignore
How to Appropriately Use Hedgehog in Advanced Basal Cell Carcinoma?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Rare Melanomas and Non-melanoma Skin Cancers,0,0,573,Ignore
Urothelial and Variant Cases: Urologic Oncology Perspective,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract,0,0,574,Ignore
Head and Neck Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session I,0,0,575,Ignore
HPV Vaccine Discovery and Successful Vaccination Down Under,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,HPV Vaccination: Why Is It So Difficult to Implement a Vaccine That Prevents Cancer?,0,0,576,Ignore
Sugar and Sex: Identifying Biomarkers in Endometrial Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,577,Ignore
Oral Precancer Biomarkers for Progression,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,578,Ignore
How to Prepare Fellows for the Transition to Government,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,579,Ignore
Special Issues With Prescriptions in Older Patients With Cancer: Drug Interactions and Polypharmacy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,A Practical Guide to Geriatric Syndromes in Patients With Cancer,0,0,580,Ignore
Defining Oligometastatic Disease: Shifting Definitions and Potential Effects on Patient Outcomes,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity?,0,0,581,Ignore
Recent Advances in Cutaneous Squamous Cell Carcinoma,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Rare Melanomas and Non-melanoma Skin Cancers,0,0,582,Ignore
Monoclonal Antibody-Based Induction Regimens,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Choosing the Right Induction Regimen for Newly Diagnosed Multiple Myeloma,0,0,583,Ignore
Current Approaches to Urothelial and Variant Cancers: Tumor Board Presentation,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract,0,0,584,Ignore
How to Approach Biomarker Testing for Colorectal Cancer in 2019,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management: What Is Today's Standard?,0,0,585,Ignore
"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session I,0,0,586,Ignore
Why Is HPV Vaccine Uptake so Low in the United States?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,HPV Vaccination: Why Is It So Difficult to Implement a Vaccine That Prevents Cancer?,0,0,587,Ignore
How to Prepare Fellows for the Transition to Private Practice,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,588,Ignore
How to Prepare Fellows for the Transition to Academia,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,589,Ignore
Gastrointestinal (Colorectal) Cancer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session I,0,0,590,Ignore
Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Highlights of the Day Session I,0,0,591,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,592,Ignore
Predictive Biomarkers in Prostate Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,593,Ignore
Playing the PARP,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,594,Ignore
Optimizing Radiotherapy for Head and Neck Cancers,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,595,Ignore
"Adoptive immunity: Something old, something new.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,596,Ignore
Understanding the Role of Autologous Transplant and Consolidation Strategies: Opinions and Options,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Evolving Treatments for Primary Central Nervous System Lymphoma: A New Horizon?,0,0,597,Ignore
Antiangiogenesis and Immune-Checkpoint Combinations for the Treatment of Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies,0,0,598,Ignore
Patient Driven Genomics Initiative: Applications in Sarcoma and Rare Disease,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating the Genetics and Epigenetics of Sarcoma for the Clinician,0,0,599,Ignore
Metastatic Disease: Can We Do Better With the Worst?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,600,Ignore
The Recurrent Search for the Holy Grail in Ovarian Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,601,Ignore
Taking Patient Preferences to Heart,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,602,Ignore
Turning the Corner in Relapsed/Refractory CNS Lymphoma: Applying Precision and Immune-Based Treatments,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Evolving Treatments for Primary Central Nervous System Lymphoma: A New Horizon?,0,0,603,Ignore
The Best of the Rest: Thyroid and Salivary,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,604,Ignore
Oncohistones and Applications in Cancer Care,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating the Genetics and Epigenetics of Sarcoma for the Clinician,0,0,605,Ignore
Regulatory T Cells in The Tumor Microenvironment and Cancer Progression: What's New in Therapeutic Targeting Strategies?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies,0,0,606,Ignore
Optimizing Breast Cancer Care Across the Continuum,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,607,Ignore
PSMA: Is Seeing Believing?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,608,Ignore
Immunotherapy: Can't Get Enough of IT!,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,609,Ignore
Studying the Zebras: Rare but Not Forgotten,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,610,Ignore
Expanding Treatments for the Frail Patient: What to Do for the Elderly Patient With Central Nervous System Lymphoma?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Evolving Treatments for Primary Central Nervous System Lymphoma: A New Horizon?,0,0,611,Ignore
"Care Delivery in Anytown, USA: What Is Feasible?",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,612,Ignore
The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: A 60 year Odyssey,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Gianni Bonadonna Breast Cancer Award and Lecture,0,0,613,Ignore
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Bench to Bedside,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies,0,0,614,Ignore
Management of Lifestyle Risk Factors for Breast Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Many Challenges, Many Opportunities: Cancer Prevention in Patients With Multiple Risk Factors",0,0,615,Ignore
Involving Genetics From the Bench to the Surgical Suite in Sarcomas,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating the Genetics and Epigenetics of Sarcoma for the Clinician,0,0,616,Ignore
Where Are We Now? Induction Strategies for Primary CNS Lymphoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Evolving Treatments for Primary Central Nervous System Lymphoma: A New Horizon?,0,0,617,Ignore
Presentation of the 2019 Gianni Bonadonna Breast Cancer Award,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Gianni Bonadonna Breast Cancer Award and Lecture,0,0,618,Ignore
Neoadjuvant Therapy: Should Medical Oncologists Go First?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,619,Ignore
Chronic leukemias: From start to finish.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,620,Ignore
ENZA-mining: Resistance and Combination Therapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,621,Ignore
How Much Is Too Much? Achieving a Balance in Treatment Intensity,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,622,Ignore
"Therapy for Recurrent/Metastatic HNSCC: One Step Forward, Two Steps Back",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,623,Ignore
Recognizing Value When You See It,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,624,Ignore
Circulating Biomarkers: It's in the Blood,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,625,Ignore
Tyrosine Kinase Inhibition: Are We Making Progress?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,626,Ignore
Analysis of the Tumor Microenvironment to Guide Immunotherapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,627,Ignore
Adjuvant Targeted Therapy: When Is More Better?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Targeting Breast Cancer: Breaking the Code,0,0,628,Ignore
"Adjuvant Therapy: Maximizing Benefit, Minimizing Toxicity, Getting Answers Sooner",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,629,Ignore
Precision Testing and Precision Medicine,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,630,Ignore
Genomic and Pathologic Considerations in Sarcoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,631,Ignore
"AML: Disease risk factors, biology, and treatment.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,632,Ignore
Toward the Future of Noninvasive Monitoring of Response to Targeted Therapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,633,Ignore
Relapsed SCLC: New Cytotoxic Strategies,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,634,Ignore
Beyond ER: Unraveling CDK4/6 Resistance,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Targeting Breast Cancer: Breaking the Code,0,0,635,Ignore
Targeting Cell Death and Epigenetic Pathways,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,636,Ignore
Building the Evidence for Immunotherapy in Sarcoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,637,Ignore
Moderator: Panel Discussion on the New Alternative Maintenance of Certification Pathway,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ABIM/MOC Oncology Learning and Assessment: The New Alternative MOC Pathway,0,0,638,Ignore
GITR as an Emerging Novel Checkpoint in Immunotherapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,639,Ignore
Clinical Trials and Their Application: Should We Believe What We Read?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Allen S. Lichter Visionary Leader Award and Lecture,0,0,640,Ignore
Private Practice Genitourinary Medical Oncology Specialist,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Updated Approaches to Treatment Sequencing in the Era of M0CRPC Approvals,0,0,641,Ignore
Presentation of the 2019 Allen S. Lichter Visionary Leader Award,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Allen S. Lichter Visionary Leader Award and Lecture,0,0,642,Ignore
Next-Generation ADC Platforms and Combinations,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,643,Ignore
Breaking New Ground in Bone Sarcoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,644,Ignore
Discussion Moderator,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Town Hall: Drug Pricing,0,0,645,Ignore
American Board of Internal Medicine/ASCO Medical Oncology Learning and Assessment: The New Alternative Maintenance of Certification Pathway,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ABIM/MOC Oncology Learning and Assessment: The New Alternative MOC Pathway,0,0,646,Ignore
"Neoadjuvant Immunotherapy: Why, How, When?",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,647,Ignore
Novel Combinations With Distinct Mechanisms of Action,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,648,Ignore
"Early Interventions to Support Patients, Parents, and Survivors",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,649,Ignore
Challenges to Access in the United States,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines,0,0,650,Ignore
New Directions for Cellular Therapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,651,Ignore
Novel Combination Agents Trials Targeting Metabolism,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Where Are We With Cancer Drugs Targeting Metabolism in Solid Tumors?,0,0,652,Ignore
Fast and Furious Cars: Looking Ahead to Next-Generation Treatments and New Combinations,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Driving CARs in Aggressive Lymphoma,0,0,653,Ignore
Surveillance Following Colon Cancer Surgery: What Does the Data Say?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating IDEA to Practice and Beyond: How Should Stage II and III Colon Cancer Be Managed in 2019?,0,0,654,Ignore
Implementing Effective Weight Management and Physical Activity Throughout the Breast Cancer Care Continuum,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Furthering Fitness: Implementing Wellness to Improve Breast Cancer Outcomes,0,0,655,Ignore
New Genes Implicated in Triple-Negative Breast Cancer Risk,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,The Expanding Phenotype of Cancer Predisposition Syndromes,0,0,656,Ignore
Patient Heroics in Trial-Finding,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Biden Cancer Initiative Colloquium: Clinical Trial Enrollment  Breaking the 5% Barrier Once and For All,0,0,657,Medium
"Patients, Agents, and Combinations",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,658,Ignore
ESMO's Emerging Perspective,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines,0,0,659,Ignore
Investigating Pediatric Solid Tumors: From Single Institution to International Collaboration,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,660,Ignore
Safe and Effective Opioid Prescribing for Patients Receiving Cancer-Directed Therapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Effective Cancer Pain Management in an Era of Opioid Aberrancy,0,0,661,Ignore
The Evolving Role of Biomarkers in Immune Checkpoint Inhibition,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,662,Ignore
Novel Metabolic Agents in Solid Tumors,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Where Are We With Cancer Drugs Targeting Metabolism in Solid Tumors?,0,0,663,Ignore
So Many Cars: Which One Do You Drive?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Driving CARs in Aggressive Lymphoma,0,0,664,Ignore
Lessons From IDEA: Duration in Stage II and III Colon Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating IDEA to Practice and Beyond: How Should Stage II and III Colon Cancer Be Managed in 2019?,0,0,665,Ignore
BWEL and Beyond: Examining the Diet and Exercise Interventions on Reducing Breast Cancer Recurrences,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Furthering Fitness: Implementing Wellness to Improve Breast Cancer Outcomes,0,0,666,Ignore
The Role of <em>BRCA</em> Testing in Hereditary Prostate and Pancreatic Cancer Families,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,The Expanding Phenotype of Cancer Predisposition Syndromes,0,0,667,Ignore
Drug Pricing in the United States,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines,0,0,668,Ignore
Effectively Advocating for Your Patients With Cancer Pain,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Effective Cancer Pain Management in an Era of Opioid Aberrancy,0,0,669,Ignore
Discovering Therapeutic Metabolic Targets in Solid Tumors,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Where Are We With Cancer Drugs Targeting Metabolism in Solid Tumors?,0,0,670,Ignore
What Is Working in Clinical Trial Recruitment? - Panel Moderator,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Biden Cancer Initiative Colloquium: Clinical Trial Enrollment  Breaking the 5% Barrier Once and For All,0,0,671,Medium
Driving Forces in Patient Selection for CAR T-Cell Therapy in Aggressive Lymphoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Driving CARs in Aggressive Lymphoma,0,0,672,Ignore
Decision-Making for Stage II Colon Cancer: To Treat or Not to Treat?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating IDEA to Practice and Beyond: How Should Stage II and III Colon Cancer Be Managed in 2019?,0,0,673,Ignore
Global Access to Essential Medicines,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines,0,0,674,Ignore
Impact of Body Mass Index Reduction in Primary Breast Cancer Prevention,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Furthering Fitness: Implementing Wellness to Improve Breast Cancer Outcomes,0,0,675,Ignore
Lynch Syndrome: More Than Hereditary (Nonpolyposis) Colorectal Cancer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Expanding Phenotype of Cancer Predisposition Syndromes,0,0,676,Ignore
Seeking Balance in Prescribing Opioids in Oncology,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Effective Cancer Pain Management in an Era of Opioid Aberrancy,0,0,677,Ignore
Advances in Immune Checkpoint Inhibition,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,678,Ignore
Precision Medicine in the Era of Patient-Centered Care,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,679,Ignore
Moderator,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Establishing a Mutually Respectful Environment in the Workplace,0,0,680,Ignore
Welcome and Introductions,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Biden Cancer Initiative Colloquium: Clinical Trial Enrollment  Breaking the 5% Barrier Once and For All,0,0,681,Medium
The Obligation of the Cured,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Voices,0,0,682,Ignore
Doing Everything,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Voices,0,0,683,Ignore
I Promised,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Voices,0,0,684,Ignore
Whose Breast Is It Anyway? Breast Cancer and Sexuality in Sub-Saharan Africa,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,ASCO Voices,0,0,685,Ignore
Surgery Is Never Elegant When Women Are in the Operating Room,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Voices,0,0,686,Ignore
Breast Cancer: 40 Years of Research and Progress,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,687,Ignore
President's Address,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,688,Ignore
Chemoboy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,689,Ignore
Rise of the Machines,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,690,Ignore
Learning From Patients Treated With Immunotherapy: Molecular Markers of Benefit and Resistance,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,691,Ignore
To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pharma to Table: What's New in Gynecologic Oncology,0,0,692,Ignore
Is There One Answer to Correct Frontline Therapy?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Stage IV Melanoma Consult in 2019: What Biomarkers and Treatments Are Appropriate in the Frontline Setting?,0,0,693,Ignore
Whats the Role for Immunotherapy With and Without Chemotherapy in Oncogene Mutated NSCLC?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations,0,0,694,Ignore
Systemic Therapy for Anal Squamous Cell Carcinoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Management and Prevention of Anal Squamous Cell Carcinoma,0,0,695,Ignore
Tools to Improve Delivery of Genetic Testing in Low-Income Populations,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Outside the Box: A Practical Guide to Providing Genetic Services by Alternative Models,0,0,696,Ignore
The Role of Adjuvant Radiotherapy in Management of Nodal Disease,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,697,Ignore
Professional Opportunities after Practice,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Continued Professional Engagement and Personal Fulfillment for Clinicians After Full-Time Practice,0,0,698,Ignore
"Chip, CCUS, IDUS, and Other Acronyms: Definition, Implications, and Impact on Practice",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaching Clonal Hematopoiesis: Can You Be Too Precise?,0,0,699,Ignore
Rebuttal: Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic Therapy  No,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,700,Ignore
Rebuttal: Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic TherapyYes,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,701,Ignore
Response Prediction and Signatures for Immunotherapy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pharma to Table: What's New in Gynecologic Oncology,0,0,702,Ignore
Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing  Immunotherapy Sequencing Should Be Frontline,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Stage IV Melanoma Consult in 2019: What Biomarkers and Treatments Are Appropriate in the Frontline Setting?,0,0,703,Ignore
Sequencing the <em>ALK</em> Tyrosine Kinase Inhibitors,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations,0,0,704,Ignore
Evaluation for Genetic Risk of Breast Cancer in Mammography Centers,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Outside the Box: A Practical Guide to Providing Genetic Services by Alternative Models,0,0,705,Ignore
Molecular Landscape of Cytopenias: Implications for Diagnosis and Prognostication,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaching Clonal Hematopoiesis: Can You Be Too Precise?,0,0,706,Ignore
Transitions in the Life of a Community Oncologist,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Continued Professional Engagement and Personal Fulfillment for Clinicians After Full-Time Practice,0,0,707,Ignore
Initial Argument: Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic Therapy  No,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,708,Ignore
Recognizing and Managing Immune Related Toxicities,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pharma to Table: What's New in Gynecologic Oncology,0,0,709,Ignore
Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing  Immunotherapy Targeted Therapy Should Be Frontline,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Stage IV Melanoma Consult in 2019: What Biomarkers and Treatments Are Appropriate in the Frontline Setting?,0,0,710,Ignore
New Options for EGFR Exon 20 and HER2 Mutations,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations,0,0,711,Ignore
Telemedicine in Genetics,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Outside the Box: A Practical Guide to Providing Genetic Services by Alternative Models,0,0,712,Ignore
Treatment for Localized Anal Squamous Cell Carcinoma,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Management and Prevention of Anal Squamous Cell Carcinoma,0,0,713,Ignore
Initial Argument: Complete Axillary Nodal Dissection Is Indicated for All Patients With Positive Nodes Prior to Neoadjuvant Systemic Therapy  Yes,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,714,Ignore
Trends in Oncologist Employment and Retirement: Considering the Possibilities,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Continued Professional Engagement and Personal Fulfillment for Clinicians After Full-Time Practice,0,0,715,Ignore
Immunotherapy in Gynecologic Malignancies: What have we learned to date?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pharma to Table: What's New in Gynecologic Oncology,0,0,716,Ignore
PD-L1 Testing: Is It Needed to Decide an Immunotherapy Treatment Plan?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Stage IV Melanoma Consult in 2019: What Biomarkers and Treatments Are Appropriate in the Frontline Setting?,0,0,717,Ignore
Moderator/Panelist,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Molecular Tumor Board: Determining the Right Therapy for the Right Patients,0,0,718,Ignore
Whats New with Therapies for EGFR-Sensitive Mutations,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations,0,0,719,Ignore
Models of Genetic Counseling and Testing in Community Practices,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Outside the Box: A Practical Guide to Providing Genetic Services by Alternative Models,0,0,720,Ignore
When You Least Expect It: Clonal Hematopoiesis as an Incidental Finding,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaching Clonal Hematopoiesis: Can You Be Too Precise?,0,0,721,Ignore
Introduction,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,722,Ignore
Curable in Squamous Cell Carcinoma of the Head and Neck Doesnt Necessarily Mean Easy,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Multidisciplinary Tumor Board: Bread-and-Butter Cases Made Challenging by the New Staging System,0,0,723,Ignore
Cancer Prevention Through Human Papillomavirus Vaccination,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Management and Prevention of Anal Squamous Cell Carcinoma,0,0,724,Ignore
Division Culture and Change Management,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Division Chiefs and Department Chairs Breakfast,0,0,725,Ignore
Finances and Compensation Plans,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Division Chiefs and Department Chairs Breakfast,0,0,726,Ignore
Growing Your Academic Enterprise,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Division Chiefs and Department Chairs Breakfast,0,0,727,Ignore
Androgen Targeted Therapy: Is More Better?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,728,Ignore
Disparities: Measurement to Action,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,729,Ignore
Preventing Relapse in ALL by Optimizing Chemotherapy Exposure,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,730,Ignore
What Is New in DNA Damage Response,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,DDR: The DNA Damaging Revolution,0,0,731,Ignore
Rules of Engagement: Regulatory Guidelines when Using Social Media in Healthcare,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients",0,0,732,Ignore
Barriers to CAR T-Cell Treatment in the Community,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden",0,0,733,Ignore
Novel DNA Damage Response Modulators in the Clinic Today: Is the Hype Worthy of the Hope?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,DDR: The DNA Damaging Revolution,0,0,734,Ignore
Three Ways That Less May Be More: Deintensifying Surgery,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,735,Ignore
The Patient Perspective: Improving Patient Engagement in Clinical Trials and Research,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients",0,0,736,Ignore
"Neurotoxicity From CAR T-Cell Therapy: Why It Happens, How to Manage It, and Who Is at Risk?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden",0,0,737,Ignore
Partners With PARP?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,DDR: The DNA Damaging Revolution,0,0,738,Ignore
Costs Matter: Strategies for Success,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,739,Ignore
"The Metastatic Breast Cancer Project: Engaging Patients, Advancing Research",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients",0,0,740,Ignore
Case 4: Managing Immune-Related Adverse Events in the Fragile Diabetic Patient,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Challenges in Use of Immunotherapy in NonSmall Cell Lung Cancer: Where the Rubber Meets the Road,0,0,741,Ignore
Assessment and Management of Cytokine Release Syndrome,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden",0,0,742,Ignore
PARP Inhibitors: When and Who,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,DDR: The DNA Damaging Revolution,0,0,743,Ignore
Treatment of Older Adults With Colon Cancer in the Adjuvant and Metastatic Setting,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk the Walk With Older Patients With Cancer: Multidisciplinary Care Across the Cancer Continuum,0,0,744,Ignore
Aggressive Therapy for Aggressive Disease,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,745,Ignore
Creating Connections and Building Community: Social Media and Physician Quality of Life,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients",0,0,746,Ignore
Believe it or Not! <em>Intensification</em> of Therapy for Nasopharynx Cancer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,747,Ignore
Pediatric AML: Can We Move Beyond Cytarabine?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,748,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,749,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,750,Ignore
Practically Addressing the Practical Stuff,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,751,Ignore
Risk-Stratified Follow-up Care: Making It Work in the United States,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Implementing Risk-Stratified Cancer Follow-up Care: How, Why, and What Is the Return on Investment?",0,0,752,Ignore
Weighing the Evidence: How to Read These Molecular Profiling Reports,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?",0,0,753,Ignore
The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer",0,0,754,Ignore
Racial Disparities in Multiple Myeloma Care,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Many Shades of Disparities in Myeloma Care,0,0,755,Ignore
"Therapeutic Advances, Balancing Quality of Life",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,756,Ignore
The Three Pillars of Systemic Therapy,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,757,Ignore
"Implementing Risk-Stratified Follow-up Care in the United Kingdom: Facilitators, Outcomes, and Return on Investment",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Implementing Risk-Stratified Cancer Follow-up Care: How, Why, and What Is the Return on Investment?",0,0,758,Ignore
"What Types of Plasma Testing (Tumor Mutational Burden, Next Generation Sequencing) Work?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?",0,0,759,Ignore
The Evolution of ALK Small Molecules,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,From First- to Third-Generation Small Molecule Inhibitors,0,0,760,Ignore
Chemotherapy Combinations for Solid Tumors: The Whole Is Not Greater Than the Sum of the Parts,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,761,Ignore
Targeting Treatment According to Molecular Assessment of Acute Myeloid Leukemia,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Molecular Analysis of Myeloid Disorders: Is Precision Medicine Changing Practice?,0,0,762,Ignore
Targeted Therapy: The New Frontier,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer",0,0,763,Ignore
Global Disparities in MM Care,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Many Shades of Disparities in Myeloma Care,0,0,764,Ignore
The Evolution of Epidermal Growth Factor Receptor Inhibitors,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,From First- to Third-Generation Small Molecule Inhibitors,0,0,765,Ignore
What Are the Types of Tumor Testing (Technologies IHC vs FISH vs NGS vs WES),0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?",0,0,766,Ignore
Implementing Risk-Stratified Follow-up Care in Australia: Addressing Rural and Cultural Barriers,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Implementing Risk-Stratified Cancer Follow-up Care: How, Why, and What Is the Return on Investment?",0,0,767,Ignore
Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid Disorders,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Molecular Analysis of Myeloid Disorders: Is Precision Medicine Changing Practice?,0,0,768,Ignore
American Cancer Society/ASCO Summit on Risk Stratified Follow-up Care: Key Findings and Recommendations,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Implementing Risk-Stratified Cancer Follow-up Care: How, Why, and What Is the Return on Investment?",0,0,769,Ignore
A Career in Lung Cancer: Pushing Beyond Chemotherapy,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer",0,0,770,Ignore
"Guidelines, Barriers, Access to Molecular Testing in NSCLC",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?",0,0,771,Ignore
Disparities in Multiple Myeloma Care in Rural America,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Many Shades of Disparities in Myeloma Care,0,0,772,Ignore
The Changing Landscape of Small Molecules Over the Years,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,From First- to Third-Generation Small Molecule Inhibitors,0,0,773,Ignore
NCI Training and Career Development Grants,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,774,Ignore
Conquer Cancer Foundation Grants Program,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,775,Ignore
cROS1ng Barriers in Resistance,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,776,Ignore
Working with a Biostatistician,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,777,Ignore
Sharpening Skills and Training Future Leaders,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Improving Quality of Care and Patient Outcomes by Maximizing the Efficiency of the Oncology Team,0,0,778,Ignore
Positive Rebuttal to Negative Position,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,779,Ignore
Uses for PSMA Diagnostics and Therapeutic Approaches in Localized Disease: A Urologist's Perspective,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Evolving Role of PSMA-Based Diagnostics and Therapeutics in Prostate Cancer,0,0,780,Ignore
Transplantation in the Older Patient With Multiple Myeloma,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Assessment in the Management of Multiple Myeloma,0,0,781,Ignore
Oncology Drug Approval in Europe,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,Point/Counterpoint: Does the Bar for Oncology Drug Approval Affect Quality of Care/Life?,0,0,782,High
The Future of Wearable Technologies and Remote Monitoring in Health Care,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk This Way: Wearable Devices and Remote Monitoring for Patients With Cancer,0,0,783,Ignore
Grant Writing Pearls,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,784,Ignore
Using Antibodies in a TKI World,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,785,Ignore
"Optimizing Access to High Quality Diagnostics (Lab, Histology, Radiology) in Low- and Middle-Income Countries",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Improving Quality of Care and Patient Outcomes by Maximizing the Efficiency of the Oncology Team,0,0,786,Ignore
Rational Approaches to Integrating Novel Imaging Into Clinical Trial Design,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Evolving Role of PSMA-Based Diagnostics and Therapeutics in Prostate Cancer,0,0,787,Ignore
Managing High Risk-Myeloma in Older Patients,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Assessment in the Management of Multiple Myeloma,0,0,788,Ignore
"Embarrassment of Riches: Storing, Managing, and Interpreting the Vast Data Produced by These Technologies",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk This Way: Wearable Devices and Remote Monitoring for Patients With Cancer,0,0,789,Ignore
Clinical Trial Participation From the Patient Perspective,0,31-05-2019,0,0,0,0,1,0,0,0,0,1,0,Point/Counterpoint: Does the Bar for Oncology Drug Approval Affect Quality of Care/Life?,0,0,790,High
What to Do When Your First Grant Application Gets Rejected,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,791,Ignore
"Listening to the Patient: Patient Reported Outcomes and Benefits of Their Implementation in Routine Practice, Including in Resource-Strained Settings",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Improving Quality of Care and Patient Outcomes by Maximizing the Efficiency of the Oncology Team,0,0,792,Ignore
Finding Light in the Darkness: PSMA-Based Therapeutic/Theranostic Approaches Currently in Clinical Development,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Evolving Role of PSMA-Based Diagnostics and Therapeutics in Prostate Cancer,0,0,793,Ignore
Octogenarians With Multiple Myeloma,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Assessment in the Management of Multiple Myeloma,0,0,794,Ignore
The Value Proposition of Wearable Technologies and Remote Monitoring in Oncology Care,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk This Way: Wearable Devices and Remote Monitoring for Patients With Cancer,0,0,795,Ignore
Expedited Program Use and Patient Experiences in Clinical Trials,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,Point/Counterpoint: Does the Bar for Oncology Drug Approval Affect Quality of Care/Life?,0,0,796,High
Affirmative Position: For De-Intensification Now,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,797,Ignore
How Can We Overcome TKI Resistance in EGFR-Mutant NSCLC?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,798,Ignore
Developing a Functioning Multidisciplinary Team That Shares Established Best Practice and Delivers Innovation Within the Cancer Care Continuum,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Improving Quality of Care and Patient Outcomes by Maximizing the Efficiency of the Oncology Team,0,0,799,Ignore
Closing the Gap: Knowledge Gaps and Interpreting Current Data in the Era of Novel Imaging  Medical Oncologist,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Evolving Role of PSMA-Based Diagnostics and Therapeutics in Prostate Cancer,0,0,800,Ignore
Role of Geriatric Assessment in Newly Diagnosed Multiple Myeloma,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Assessment in the Management of Multiple Myeloma,0,0,801,Ignore
Walk This Way: Wearable Devices and Remote Monitoring of Oncology Patients Outside the Healthcare Environment,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk This Way: Wearable Devices and Remote Monitoring for Patients With Cancer,0,0,802,Ignore
How to Use Hypomethylating Agents in Combination Therapy,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Do We Know How to Use Hypomethylating Agents in Myeloid Disorders?,0,0,803,Ignore
Clinical Benefit and Quality of Life Associated with Approved Drugs,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,Point/Counterpoint: Does the Bar for Oncology Drug Approval Affect Quality of Care/Life?,0,0,804,High
Primary Care Panelist,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Bringing the Primary Care Physician Back Into Cancer Care,0,0,805,Ignore
Choosing a Mentor and Obtaining Letters of Support,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,806,Ignore
CAR T-Cells: Whats Next?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Moving Forward: Beyond Immune Checkpoint Inhibitors,0,0,807,Ignore
"An Update on Recent Approvals for Checkpoint Inhibitors: Dose, Schedule, Duration, and Combinations",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,808,Ignore
Next Generation Immunotherapy: Immunocytokines and Oncolytic Viruses,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Moving Forward: Beyond Immune Checkpoint Inhibitors,0,0,809,Ignore
BRAF/MEK Inhibitors: Encorafenib and Binimetinib for Melanoma,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,810,Ignore
PARP Inhibitors for BRCA Patients: Talazoparib and Olaparib,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,811,Ignore
Data Supports that Hyper-Progression is a Myth,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hyper-Progression: Myth or Reality?,0,0,812,Ignore
An Update on Oncology Price Trends,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,813,Ignore
Pancreatic Cancer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,814,Ignore
Data Supports that Hyper-Progression is Real,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hyper-Progression: Myth or Reality?,0,0,815,Ignore
Lorlatinib for (ALK)-Positive Metastatic Non-Small Cell Lung Cancer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,816,Ignore
Prostate Cancer: The Genetic Landscape and Prognostic/Predictive Implications,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,817,Ignore
Delivering Innovative Care: Barriers and Opportunities,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Paying for Innovative Treatments,0,0,818,Ignore
Larotrectinib for Solid Tumors with NTRK Gene Fusions,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,819,Ignore
Germline and Tumor: Whos the Driver?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,820,Ignore
Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,821,Ignore
Closing the Door on Cures: The Sustainability of CAR-T,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Paying for Innovative Treatments,0,0,822,Ignore
Germline Implications of Liquid Biopsy,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,823,Ignore
Alternative Payment Models for Curative Therapies,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Paying for Innovative Treatments,0,0,824,Ignore
One New Indication Per Week  Handling Information Overload,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Keynote Lecture,0,0,825,Ignore
Hematologic Malignancies,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Immunotherapy into Clinical Practice - Changes Over the Past Year (Part 2),0,0,826,Ignore
Hope Versus Reality: The Ethics of Tumor Testing of Patients with Advanced Disease,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Set Up a Molecular Tumor Board,0,0,827,Ignore
What is the Optimal Profiling Strategy for Clinical Practice?,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,ImmunOncology: Determining the Patients Most Likely to Benefit,0,0,828,Ignore
Care Delivery for Genetic Testing,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Set Up a Molecular Tumor Board,0,0,829,Ignore
Cost-Effectiveness Analysis in the United States,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,International Experience with Health Technology Assessment (HTA) & Lessons for the United States,0,0,830,Ignore
The U.S. and Community Perspectives,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Set Up a Molecular Tumor Board,0,0,831,Ignore
Non-Genomic Predictors of IO Response,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,ImmunOncology: Determining the Patients Most Likely to Benefit,0,0,832,Ignore
The International and Academic Perspectives,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Set Up a Molecular Tumor Board,0,0,833,Ignore
Trends of Cost-Effectiveness over Time,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,International Experience with Health Technology Assessment (HTA) & Lessons for the United States,0,0,834,Ignore
Genomic Predictors of IO Response,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,ImmunOncology: Determining the Patients Most Likely to Benefit,0,0,835,Ignore
Gastrointestinal Malignancies,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Immunotherapy into Clinical Practice - Changes Over the Past Year (Part 2),0,0,836,Ignore
An Update on the Affordability and Effectiveness of Cancer Medicines,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,International Experience with Health Technology Assessment (HTA) & Lessons for the United States,0,0,837,Ignore
Overview of Immuno-Oncology,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,ImmunOncology: Determining the Patients Most Likely to Benefit,0,0,838,Ignore
Genomic Signatures,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genomics,0,0,839,Medium
Head and Neck Cancers,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Immunotherapy into Clinical Practice - Changes Over the Past Year (Part 1),0,0,840,Ignore
Targeted Therapies and Identifying Targetable Driver Mutations,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genomics,0,0,841,Medium
Online Tools to Help Find Trials for Patients,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,From Rarity to Common Expectation: Tripling Clinical Trial Recruitment,0,0,842,Ignore
Melanoma/Skin Cancers,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Immunotherapy into Clinical Practice - Changes Over the Past Year (Part 1),0,0,843,Ignore
The Pros and Cons of Different Genomic Panels,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genomics,0,0,844,Medium
Clinical Trials Access for the Community Oncologists,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,From Rarity to Common Expectation: Tripling Clinical Trial Recruitment,0,0,845,Ignore
The Evolution of Financial Support Programs in the Oncology Setting,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Toxicity: How Costs Negatively Impact Patients and What Can be Done About It,0,0,846,Ignore
Increasing Clinical Trial Accessibility,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,From Rarity to Common Expectation: Tripling Clinical Trial Recruitment,0,0,847,Ignore
Breast and Gynecologic Cancers,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Immunotherapy into Clinical Practice - Changes Over the Past Year (Part 1),0,0,848,Ignore
Broadening Clinical Trials Eligibility to Make Them More Representative,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,From Rarity to Common Expectation: Tripling Clinical Trial Recruitment,0,0,849,Ignore
Mitigating Financial Toxicity by Supporting Employment,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Toxicity: How Costs Negatively Impact Patients and What Can be Done About It,0,0,850,Ignore
The Pros and Cons of Tumor Matched Germline Testing,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genetics,0,0,851,Medium
Health Insurance Coverage and Medical Financial Hardship Among Cancer Survivors,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Toxicity: How Costs Negatively Impact Patients and What Can be Done About It,0,0,852,Ignore
Management of Moderately Penetrant Genes,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genetics,0,0,853,Medium
Seamless Mammoth Trials can Pose Substantial Challenges in Practice,0,30-05-2019,0,0,0,1,0,0,0,0,0,0,0,Is Bigger Better? A Debate on Efficacy of Mammoth Trials,0,0,854,Medium
The Biology and Biomarkers of Immunotherapy,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Biology and Biomarkers of Immunotherapy,0,0,855,Ignore
Continued Financial Toxicity: Beyond Treatment,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Toxicity: How Costs Negatively Impact Patients and What Can be Done About It,0,0,856,Ignore
How Big Should Your Panel Be? Is Less more?,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genetics,0,0,857,Medium
Seamless Mammoth Trials can be Efficient and Expedite Drug Development,0,30-05-2019,0,0,0,1,0,0,0,0,0,0,0,Is Bigger Better? A Debate on Efficacy of Mammoth Trials,0,0,858,Medium
"Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.",0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,859,Ignore
A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,860,Medium
MET inhibitor resistance in patients with MET exon 14-altered lung cancers.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,861,Ignore
Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,862,Ignore
"Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,863,Medium
"ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,1,0,864,Low
Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,865,Ignore
Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,866,Medium
"Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,867,Ignore
Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,868,Medium
"A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,869,Medium
Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,870,Ignore
Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,871,Ignore
"JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,872,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,873,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,874,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,875,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,876,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,877,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,878,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,From Mutations to Management: Diagnosis and Treatment of Central Nervous System Tumor Susceptibility Syndromes,0,0,879,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,880,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,881,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,882,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Who, What, and Where of CAR T",0,0,883,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,1,Current Controversies in Metastatic Breast Cancer: A 360° View,0,0,884,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia,0,0,885,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Landscapes in Liver Cancer,0,0,886,Ignore
Panel Question and Answer,0,04-06-2019,0,0,0,0,0,0,0,0,0,0,0,Modern Management of Brain and Spinal Metastases in the Era of Targeted Therapy and Immuno-Oncology,0,0,887,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,888,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,889,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,890,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,891,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,New Options in Metastatic Squamous Cell Carcinoma,0,0,892,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,893,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,894,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,895,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,896,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,897,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,898,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Assistance for Participation in Clinical Trials: What Works Best for Patients?,0,0,899,Ignore
Talk to Me: Communication in Cancer Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,900,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,901,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,902,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,903,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,904,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,905,Ignore
Diagnosis and Management of Immune-Related Gastrointestinal Toxicity: Including Hepatitis and Pancreatitis,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Recognizing, Understanding, and Overcoming Toxicities From Immune Checkpoint Inhibitors",0,0,906,Ignore
Diagnosis and Management of Immune-Related Pulmonary Toxicity,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Recognizing, Understanding, and Overcoming Toxicities From Immune Checkpoint Inhibitors",0,0,907,Ignore
Challenges and Solutions to Recruiting Patients to International Trials,0,03-06-2019,0,0,0,0,0,0,0,0,0,1,0,Financial Assistance for Participation in Clinical Trials: What Works Best for Patients?,0,0,908,Medium
Lazarex Cancer Foundation Solutions to Reduce Patient Financial Barriers to Clinical Trial Participation,0,03-06-2019,0,0,0,0,0,0,0,0,0,1,0,Financial Assistance for Participation in Clinical Trials: What Works Best for Patients?,0,0,909,Medium
Navigate Program: The National Cancer Institute/Veterans Affairs Approach to Recruiting Patients to Clinical Trials,0,03-06-2019,0,0,0,0,0,0,0,0,0,1,0,Financial Assistance for Participation in Clinical Trials: What Works Best for Patients?,0,0,910,Medium
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,911,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,912,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,913,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Oncology: Innovative Approaches Leading to Improved Outcomes,0,0,914,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,915,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,916,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,917,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,How to Measure Quality in Value-Based Systems,0,0,918,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,919,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Local-Regionally Advanced NonSmall Cell Lung Cancer: Advances in Multimodality Treatment,0,0,920,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy,0,0,921,High
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology,0,0,922,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Molecular Profiling in Breast Cancer: Past, Present, and Future",0,0,923,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,924,Ignore
When Transplant Has Failed or Is Not an Option: What Do I Do for My Patient with Hodgkin Lymphoma?,0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy,0,0,925,High
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Multidisciplinary Care in Challenging Sarcoma Scenarios,0,0,926,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,927,Ignore
Current Environment in Risk Stratification in Oncology,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology,0,0,928,Ignore
Does the Surgeon Still Have a Role in the Treatment of Recurrent Desmoid Tumors?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Multidisciplinary Care in Challenging Sarcoma Scenarios,0,0,929,Ignore
The Radiation Oncologist's Approach to Retroperitoneal Sarcomas,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Multidisciplinary Care in Challenging Sarcoma Scenarios,0,0,930,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,931,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,932,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,933,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Workplace Inequities,0,0,934,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers,0,0,935,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma",0,0,936,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,International Collaborations and Regional Challenges in Sarcoma,0,0,937,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients?,0,0,938,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,939,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,940,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Controversies in Breast Cancer Adjuvant Therapy,0,0,941,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,942,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,943,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,944,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,945,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,946,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Emerging Combinations in Sarcoma Immunotherapy,0,0,947,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The More Things Change: Ovarian Cancer Edition,0,0,948,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,949,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care?,0,0,950,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application,0,0,951,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Academic-Community Partnerships: Approaches to Engagement,0,0,952,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,953,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,954,Ignore
Low Grade Ovarian Carcinoma: Fitting the Square Peg into the Round Hole,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,The More Things Change: Ovarian Cancer Edition,0,0,955,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,956,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,957,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,958,Ignore
Fee for Service and End-of-Life Care,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care?,0,0,959,Ignore
Personalized Neoantigen Vaccine,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application,0,0,960,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,961,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,962,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,963,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,964,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Using Real-World Data to Advance Research and Care,0,0,965,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/American Association for Cancer Research (AACR) Joint Session: Histology-Agnostic Clinical Trials and Approvals  Challenges of Design and Implementation at the Bedside,0,0,966,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,967,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,968,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,969,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,970,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,971,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?,0,0,972,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Navigating a New Cancer Diagnosis: Guiding Communication and Education,0,0,973,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,974,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,975,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Practical Tips for Successful Disclosure,0,0,976,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,977,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,978,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,979,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,980,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,981,Ignore
The Role of Stem Cell Transplantation for Relapsed Multiple Myeloma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Early Relapse in Multiple Myeloma,0,0,982,Ignore
Sequencing Regimens at First Relapse,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Early Relapse in Multiple Myeloma,0,0,983,Ignore
Breaking the Code: Drugging Difficult Targets and Tumors,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,984,Ignore
Novel Treatment Strategies in Metastatic Urothelial Carcinoma,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,985,Ignore
Taking Aim at Histology-Specific Targets,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,986,Ignore
Supportive Care Is Global,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,987,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges,0,0,988,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy,0,0,989,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Management of Uncommon and Rare Breast Cancers,0,0,990,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"The Impact of Big Data Research on Practice, Policy, and Patient Care",0,0,991,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes,0,0,992,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,993,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,994,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,995,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,996,Ignore
Panel Question and Answer,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,997,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,998,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,999,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,1000,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancers: Is It Time to Put Away the Knife?,0,0,1001,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies,0,0,1002,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Beyond Anti-PD-1/PD-L1 Therapy in Urothelial Cancer,0,0,1003,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Optimizing Palliation for Older Adults: Old and New Challenges in a Changing Landscape,0,0,1004,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Proton Versus Photon in Radiation Therapy,0,0,1005,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Immunotherapy Mythbusters in Head and Neck Cancer,0,0,1006,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Innovative and Affordable Global Cancer Technologies,0,0,1007,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1008,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,1009,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,1010,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Liquid Biopsy: How to Interpret and Use Results in Clinical Practice,0,0,1011,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Frontline Therapy in Mantle Cell Lymphoma: To Transplant or Not to Transplant?,0,0,1012,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1013,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,1014,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,1015,Ignore
Clinical Case #2,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Liquid Biopsy: How to Interpret and Use Results in Clinical Practice,0,0,1016,Ignore
Clinical Case #1,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Liquid Biopsy: How to Interpret and Use Results in Clinical Practice,0,0,1017,Ignore
"Frontline Therapy For Mantle Cell Lymphoma, Including Induction Therapy and Transplant",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Frontline Therapy in Mantle Cell Lymphoma: To Transplant or Not to Transplant?,0,0,1018,Ignore
"Frontline Therapy For Mantle Cell Lymphoma, Including Induction Therapy and Transplant",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Frontline Therapy in Mantle Cell Lymphoma: To Transplant or Not to Transplant?,0,0,1019,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1020,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,1021,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,1022,Ignore
Introduction to Plenary Session.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,1023,Ignore
Presentation of the Science of Oncology Award,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,1024,Ignore
Distinguished Achievement Award Recipient,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,1025,Ignore
Presentation of the Distinguished Achievement Award,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture,0,0,1026,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,1027,Medium
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1028,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1029,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,1030,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Surgery or No Surgery: Evaluating the Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma,0,0,1031,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,City Cancer Challenge: Changing the Future of Cancer in Urban Populations,0,0,1032,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care,0,0,1033,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1034,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1035,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,1036,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,1037,Ignore
ASCO Engagement in City Cancer Challenge,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,City Cancer Challenge: Changing the Future of Cancer in Urban Populations,0,0,1038,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1039,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1040,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1041,Ignore
Partners in Progress Award Recipient,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Overcoming Barriers to Clinical Trial Enrollment (Includes Presentation of Partners in Progress Award),0,0,1042,Medium
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,1043,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1044,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1045,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,1046,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,1047,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Caring for Our Trainees: Lessons From Around the World,0,0,1048,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Is There a Role for Cannabis in Cancer Symptom Management?,0,0,1049,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Building a Sustainable Research Program in the Community Practice Setting: First Steps, Essential Priorities, and Pitfalls Every Investigator Should Know",0,0,1050,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaches to High-Risk Resected Stage II and III Melanoma,0,0,1051,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Wanna Get Away? Continuous Treatments Versus Treatment Holidays in Gynecologic Cancer,0,0,1052,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Evidence, Care, Impact: Making Inroads Against Cancer Disparities",0,0,1053,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Epidemiology and Implementation of Cancer Prevention in Disparate Populations and Settings,0,0,1054,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1055,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1056,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1057,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,1058,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,1059,Ignore
Expanding Targets for Immunotherapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1060,Ignore
Neuroblastoma in 2019: Refining Classification and Therapy,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,1061,Ignore
"On the Path to Effective, Patient-Centered Policy",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,1062,Ignore
Open Discussion: What Keeps You Up at Night?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,1063,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,1064,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Dissecting Genomic Biomarkers in Head and Neck Cancer,0,0,1065,Ignore
Table Talk: How Are You Addressing Well-Being?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,1066,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,A Practical Guide to Geriatric Syndromes in Patients With Cancer,0,0,1067,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Management of Rare Melanomas and Non-melanoma Skin Cancers,0,0,1068,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Care of Oligometastatic Disease: Enhancing Survival or Increasing Toxicity?,0,0,1069,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Choosing the Right Induction Regimen for Newly Diagnosed Multiple Myeloma,0,0,1070,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract,0,0,1071,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management: What Is Today's Standard?,0,0,1072,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,HPV Vaccination: Why Is It So Difficult to Implement a Vaccine That Prevents Cancer?,0,0,1073,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care II",0,0,1074,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1075,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology II,0,0,1076,Ignore
Panel Question and Answer,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,1077,Ignore
Breakfast and Networking,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Training Program Directors Breakfast (Training Program Directors and Associate Training Program Directors Only),0,0,1078,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1079,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,1080,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1081,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1082,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating the Genetics and Epigenetics of Sarcoma for the Clinician,0,0,1083,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Evolving Treatments for Primary Central Nervous System Lymphoma: A New Horizon?,0,0,1084,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1085,Ignore
Reinforcing Bones and Bone Marrow,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1086,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,1087,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1088,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1089,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1090,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1091,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,1092,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1093,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1094,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1095,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1096,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1097,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,1098,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1099,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1100,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,1101,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,1102,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Next-Generation Therapeutics and Biomarkers in Melanoma,0,0,1103,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1104,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,1105,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,1106,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1107,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1108,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,1109,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,1110,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,1111,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,1112,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1113,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1114,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,1115,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Where Are We With Cancer Drugs Targeting Metabolism in Solid Tumors?,0,0,1116,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Driving CARs in Aggressive Lymphoma,0,0,1117,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Translating IDEA to Practice and Beyond: How Should Stage II and III Colon Cancer Be Managed in 2019?,0,0,1118,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO/European Society for Medical Oncology (ESMO) Joint Session: Global Access to Essential Medicines,0,0,1119,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Furthering Fitness: Implementing Wellness to Improve Breast Cancer Outcomes,0,0,1120,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1121,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,The Expanding Phenotype of Cancer Predisposition Syndromes,0,0,1122,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Effective Cancer Pain Management in an Era of Opioid Aberrancy,0,0,1123,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,1124,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,1125,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1126,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,1127,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,1128,Ignore
Welcome and Introductions,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,ASCO Voices,0,0,1129,Ignore
Presentation of the 2019 David A. Karnofsky Memorial Award,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1130,Ignore
Presentation of the Fellows of the American Society of Clinical Oncology (FASCO),0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1131,Ignore
Guest Speaker's Address: Will We Be Technicians or Counselors?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1132,Ignore
"Introduction of Atul Gawande, MD, MPH",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1133,Ignore
"Introduction of Edmond Ang, MBBCh, MRCP",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1134,Ignore
"Introduction of Monica M. Bertagnolli, MD, FACS, FASCO",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1135,Ignore
Conquer Cancer Welcome and Top Donor Recognition Awards,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Opening Session With Fellows of the American Society of Clinical Oncology, Guest Speaker's Address, Presidential Address, and David A. Karnofsky Memorial Award and Lecture",0,0,1136,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,1137,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,1138,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Continued Professional Engagement and Personal Fulfillment for Clinicians After Full-Time Practice,0,0,1139,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Stage IV Melanoma Consult in 2019: What Biomarkers and Treatments Are Appropriate in the Frontline Setting?,0,0,1140,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Outside the Box: A Practical Guide to Providing Genetic Services by Alternative Models,0,0,1141,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations,0,0,1142,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Approaching Clonal Hematopoiesis: Can You Be Too Precise?,0,0,1143,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,The Management and Prevention of Anal Squamous Cell Carcinoma,0,0,1144,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Debate: Breast Cancer Axillary Management of Nodal Disease in the Neoadjuvant Era: Less Is More or More or Less the Same?,0,0,1145,Ignore
Panel Question and Answer,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Molecular Tumor Board: Determining the Right Therapy for the Right Patients,0,0,1146,Ignore
Digital Care in the Digital Age,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Harnessing Technology in Symptoms and Survivorship,0,0,1147,Ignore
Identifying Biomarkers That Predict Benefit: Hope for the Future,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,1148,Ignore
Molecularly-guided Therapy in Neuro-Oncology,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Molecular Tumor Board: Determining the Right Therapy for the Right Patients,0,0,1149,Ignore
Precision Medicine in Pediatric Solid Tumors,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Molecular Tumor Board: Determining the Right Therapy for the Right Patients,0,0,1150,Ignore
Applying Personalized Medicine to Leukemia,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Molecular Tumor Board: Determining the Right Therapy for the Right Patients,0,0,1151,Ignore
Breakfast and Networking,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Oncology Division Chiefs and Department Chairs Breakfast,0,0,1152,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1153,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1154,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,1155,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden",0,0,1156,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,DDR: The DNA Damaging Revolution,0,0,1157,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Tweets, Chats, and Posts: Using Social Media to Transcend Boundaries and Create Opportunities for Patients",0,0,1158,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1159,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Challenges in Use of Immunotherapy in NonSmall Cell Lung Cancer: Where the Rubber Meets the Road,0,0,1160,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk the Walk With Older Patients With Cancer: Multidisciplinary Care Across the Cancer Continuum,0,0,1161,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1162,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1163,Ignore
Case 3: Managing Immunotherapy in Patients with Renal Insufficiency (PD-L1 Low),0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Challenges in Use of Immunotherapy in NonSmall Cell Lung Cancer: Where the Rubber Meets the Road,0,0,1164,Ignore
Case 1: Managing Immunotherapy in Autoimmune Diseases,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Challenges in Use of Immunotherapy in NonSmall Cell Lung Cancer: Where the Rubber Meets the Road,0,0,1165,Ignore
Case 2: Managing Immunotherapy in Poor Performance Status Stage III Patients: Sink or Swim?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Challenges in Use of Immunotherapy in NonSmall Cell Lung Cancer: Where the Rubber Meets the Road,0,0,1166,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1167,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,1168,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Implementing Risk-Stratified Cancer Follow-up Care: How, Why, and What Is the Return on Investment?",0,0,1169,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer",0,0,1170,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?",0,0,1171,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Molecular Analysis of Myeloid Disorders: Is Precision Medicine Changing Practice?,0,0,1172,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Many Shades of Disparities in Myeloma Care,0,0,1173,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,1174,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,1175,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,1176,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,1177,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,1178,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Grant Writing Workshop,0,0,1179,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology I,0,0,1180,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,EGFR and ROS1: Targeting Resistance,0,0,1181,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1182,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Improving Quality of Care and Patient Outcomes by Maximizing the Efficiency of the Oncology Team,0,0,1183,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,The Evolving Role of PSMA-Based Diagnostics and Therapeutics in Prostate Cancer,0,0,1184,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Geriatric Assessment in the Management of Multiple Myeloma,0,0,1185,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Walk This Way: Wearable Devices and Remote Monitoring for Patients With Cancer,0,0,1186,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,Point/Counterpoint: Does the Bar for Oncology Drug Approval Affect Quality of Care/Life?,0,0,1187,High
Negative Rebuttal to Affirmative Position,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1188,Ignore
Negative Position: Against De-Intensification Now,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1189,Ignore
Introduction,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1190,Ignore
Additional Rebuttal,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1191,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Initiate and Integrate Clinical Trials Into Your Practice,0,0,1192,Ignore
Additional Rebuttal,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Point/Counterpoint: Do We De-intensify Treatment for HPV-Positive Oropharynx Cancer Now? And How?,0,0,1193,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Initiate and Integrate Clinical Trials Into Your Practice,0,0,1194,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Initiate and Integrate Clinical Trials Into Your Practice,0,0,1195,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,1196,Ignore
Panel Discussion,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,1197,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Moving Forward: Beyond Immune Checkpoint Inhibitors,0,0,1198,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,1199,Ignore
Case Discussion,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Case Presentations and Discussion,0,0,1200,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hyper-Progression: Myth or Reality?,0,0,1201,Ignore
Trade-offs: the interaction between incentives and pricing,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,1202,Ignore
Trade-offs: the interaction between incentives and pricing,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,1203,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,FDA Approvals and Their Incorporation into Clinical Practice,0,0,1204,Ignore
The Patient Perspective,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,1205,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Paying for Innovative Treatments,0,0,1206,Ignore
Panel Question and Answer,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Immune Toxicities: A Case-Based Discussion with Experts,0,0,1207,Ignore
Panel Question and Answer,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,International Experience with Health Technology Assessment (HTA) & Lessons for the United States,0,0,1208,Ignore
Panel Question and Answer,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,ImmunOncology: Determining the Patients Most Likely to Benefit,0,0,1209,Ignore
Panel Question and Answer,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Set Up a Molecular Tumor Board,0,0,1210,Ignore
Panel Question and Answer,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genomics,0,0,1211,Medium
Panel Question and Answer,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,From Rarity to Common Expectation: Tripling Clinical Trial Recruitment,0,0,1212,Ignore
The NICE Approach to HTA,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,International Experience with Health Technology Assessment (HTA) & Lessons for the United States,0,0,1213,Ignore
Panel Question and Answer,0,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Financial Toxicity: How Costs Negatively Impact Patients and What Can be Done About It,0,0,1214,Ignore
Panel Question and Answer,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genetics,0,0,1215,Medium
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1216,Ignore
Panel Question and Answer,0,30-05-2019,0,0,0,1,0,0,0,0,0,0,0,Is Bigger Better? A Debate on Efficacy of Mammoth Trials,0,0,1217,Medium
Effect of germline ATM mutations on clonal hematopoiesis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1218,Ignore
Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1219,Ignore
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Womens Health Initiative.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1220,Low
Adequacy of self-reported family history in electronic health record for genetic risk assessment for Lynch syndrome.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1221,Ignore
Genome-wide association study using whole-genome sequencing to identify a novel locus associated with cardiomyopathy risk in adult survivors of childhood cancer: Utility of a two-stage analytic approach.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1222,Ignore
Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel adenocarcinoma (SBA).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1223,Medium
Racial and ethnic differences in the results of multigene panel testing of inherited cancer predisposition genes in breast cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1224,Ignore
New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1225,Low
Gliomas in the context of Li-Fraumeni syndrome: An international cohort.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1226,Ignore
Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1227,Medium
A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1228,Medium
Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1229,Ignore
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1230,Ignore
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1231,Ignore
Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1232,Medium
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1233,Ignore
Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1234,Medium
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1235,Ignore
"FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.",0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1236,Low
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1237,Ignore
Efficacy of immune checkpoint inhibitors (ICI) & genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1238,Medium
Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1239,Medium
Inferior survival after microbiota injury: A multicenter allo-HCT study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1240,Ignore
Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1241,Ignore
Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1242,Ignore
Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1243,Ignore
Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1244,Medium
"Clinical features, molecular aberrations, treatments, and outcomes in histiocytic sarcoma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1245,Ignore
Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1246,Ignore
Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1247,Ignore
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.,1,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1248,High
Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1249,Medium
Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1250,Ignore
Pharmacodynamic effect of IMCgp100 (TCRCD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1251,Medium
Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1252,Ignore
"One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1253,Ignore
Circulating PD-L1-exosomes to monitor tumor response in melanoma patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1254,Ignore
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1255,Medium
Update on Overall Survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <em>BRAF </em>V600mutant melanoma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1256,Medium
"Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced <em>BRAF</em> V600mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1257,Ignore
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1258,Ignore
Three-year survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1259,Ignore
A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1260,Medium
Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1261,Ignore
Impact of cancer on physical and mental activities of daily living in young adult (YA) survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1262,Ignore
"Improving person-centered communication of goals, proxy, and advance directives in older patients with advanced cancer: Secondary analysis from a University of Rochester NCI Community Oncology Research Program (NCORP) cluster randomized controlled trial (CRCT).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1263,Ignore
Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A randomized controlled multicenter trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1264,Ignore
Candidate SNPs enhance prediction of cognitive impairment after blood or marrow transplantation (BMT) for hematologic malignancy (HM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1265,Ignore
Predictors of suicide risk in adolescent and young adults (AYA) with cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1266,Ignore
Age disparities among cancer clinical trial participants: The role of industry sponsorship.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1267,Ignore
Comparing nonverbal synchrony in racially concordant and racially discordant oncology interactions.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1268,Ignore
Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Final results of the randomized Motivate AYAMAYA trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,1,1269,High
Cumulative burden of new-onset chronic health conditions (CHCs) among older cancer survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1270,Ignore
Accelerated sarcopenia and outcomes in older adults with cancer: The Health ABC Study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1271,Ignore
Prognostic understanding in hematologic malignancies: A multicenter longitudinal study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1272,Ignore
Acupuncture versus cognitive behavioral therapy for cognitive impairment in cancer survivors with insomnia: Implications for personalized medicine.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1273,Ignore
"Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1274,Medium
Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1275,Medium
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1276,Ignore
"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1277,Ignore
Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1278,Ignore
Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1279,Medium
Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1280,Medium
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1281,Medium
PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1282,Ignore
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1283,Medium
Phase I trial of endoxifen gel versus placebo gel in women undergoing breast surgery.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1284,Medium
Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1285,Ignore
Epidemiology and survival in patients with urethral clear cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1286,Ignore
Unselected germline screening in pancreatic adenocarcinoma yields high rates of pathogenic and likely pathogenic variants (PV) in hereditary cancer susceptibility genes.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1287,Low
Preimplantation genetic diagnosis: What do BRCA mutation carriers think?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1288,Ignore
Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1289,Ignore
"Analysis of healthy breast tissue from Komen Tissue Bank shows distinct histology, decreased proliferation, and lower periductal collagen deposition in women with prolonged history of breastfeeding.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1290,Ignore
Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Womens Health Initiative (WHI) Dietary Modification randomized trial.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1291,Low
Improving risk assessment of obesity-associated breast cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1292,Ignore
The impact of smoking cessation on breast cancer patients survival.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1293,Ignore
Opportunistic off-target cancer screening in organized programs: The EDIFICE 6 survey.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1294,Low
Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1295,Ignore
Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1296,Ignore
"Incidence of second primary neoplasms among cancer survivors in the United States, 2000 through 2015.",0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1297,Low
Genetic identification and characterization of Lynch syndrome in a multi-ethnic biobank.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1298,Ignore
"Insulin resistance measured by the triglyceride-glucose index and risk of obesity-related cancers: An epidemiological investigation in more than 500,000 individuals.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1299,Ignore
Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1300,Ignore
A pan-cancer analysis of microsatellite instability as a predictor of Lynch syndrome in Chinese population.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1301,Ignore
"Test of InheRET, an online tool to facilitate NCCN Guideline compliant referrals for cancer genetic counseling.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1302,Ignore
Germline mutation profile among Hispanic women with epithelial ovarian cancer (EOC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1303,Ignore
Preventive surgery after multiplex genetic panel testing (MGPT).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1304,Ignore
Safety and efficacy of aspirin for primary prevention of cancer: A meta-analysis of randomized controlled trials.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1305,Medium
Characteristics of cancer patients with a history of solid organ transplantation: Analysis of a patient cohort reporting to a large cancer center.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1306,Ignore
Contralateral breast cancer risk according to first breast cancer characteristics among United States women from 1992 to 2015.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1307,Ignore
Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1308,Ignore
Adverse effects of early bilateral oophorectomy on body composition: Results from a nationally representative sample of United States women.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1309,Ignore
Characterization of Lynch syndrome (LS) associated cancers in patients with immune dysfunction.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1310,Ignore
Risk of colon adenoma in patients with breast cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1311,Ignore
Omega-3 fatty acids and ERPR(-) and HER2/neu(+/-) breast cancer prevention.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1312,Ignore
The PHACT Study: Population Health and Cancer Testing.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1313,Ignore
Role of vitamin D supplementation for primary prevention of cancer: Meta-analysis of randomized controlled trials.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1314,Ignore
Implications of incidental germline findings identified in the context of clinical whole exome sequencing (WES) for guiding cancer therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1315,Ignore
"Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts).",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1316,Medium
Incidental atypical hyperplasia/LCIS in mammoplasty specimens and subsequent risk of breast cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1317,Ignore
Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1318,Ignore
Genomic profiling of pulmonary lymphoepithelioma-like carcinoma (PLELC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1319,Ignore
Gaining insights into the DICER1 syndrome: An early report from the Italian DICER1 registry.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1320,Ignore
Rare tumor with matched germline whole exome sequencing to identify somatic and inherited variants of clinical significance.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1321,Ignore
Implementation of a low-dose computerized tomography (LDCT) lung cancer screening program (LCSP) across a large integrated health system.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1322,Low
"Health insurance literacy, financial hardship and financial sacrifices among cancer survivors in the United States.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1323,Ignore
Blood-based genomic profiling of circulating tumor DNA from patients with advanced biliary tract cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1324,Ignore
Relationship of liver cancer with LRP1B or TP53 mutation and tumor mutation burden and survival.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1325,Ignore
Characterization of genomic alterations in Chinese LCNEC and SCLC via comprehensive genomic profiling.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1326,Ignore
"Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1327,Ignore
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1328,Ignore
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1329,Ignore
Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1330,Ignore
Burden of thrombocytopenia in adult cancer patients receiving chemotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1331,Ignore
Association of geographic clustering of cutaneous T-cell lymphoma in the state of Georgia with environmental exposure to benzene and trichloroethylene.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1332,Ignore
Cardiometabolic risk factors and survival after cancer in the womens health initiative.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1333,Ignore
Predicting future cancer incidence by age and gender.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1334,Low
Early results from the BRCA Founder Outreach (BFOR) Study: Population genetic screening using a medical model.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1335,Low
A comparison of risk factors for cigarette and e-cigarette use in the United States adult population.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1336,Ignore
Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1337,Ignore
Prospective Registry of Multiplex Testing (PROMPT): Follow-up.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1338,Ignore
Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs).,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1339,Low
A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by g<em>BRCA</em> mutation status.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1340,Ignore
Association between breast cancer mortality-to-incidence ratios and state health disparities in the United States.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1341,Low
Comorbidity and racial differences in risk of mortality of men with breast cancer.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1342,Low
Insurance disparity in the United States cancer survivors smoking rates: A trend study from NHIS 2008-2017.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1343,Ignore
Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts).,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1344,Low
"Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1345,Ignore
Breast cancer screening adherence at multiple timepoints over eight years among women in a familial cohort.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,1,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1346,Low
Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.,0,03-06-2019,1,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1347,Low
Disparities in pretest genetic counseling among a population-based sample of young breast cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1348,Ignore
Racial disparities in cancer survival: A trend analysis based on SEER data (1973-2010).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1349,Ignore
Sex-specific mortality trends in adolescents and young adults with cancer from 2007 to 2016.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1350,Low
Early impact of the lung cancer screening in United States population in the SEER Registries.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1351,Low
Effectiveness of low-dose CT scan for lung cancer screening in the community setting.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,1352,Low
Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1353,Medium
Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1354,Ignore
Proximity to oil refineries and risk of bladder cancer: A population-based analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1355,Ignore
Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1356,Medium
Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1357,Ignore
Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1358,Ignore
Causes of patient ineligibility in clinical trials of metastatic urothelial cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1359,Ignore
Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with chemotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1360,Ignore
Multi-omics profiling of upper-tract urothelial carcinomas.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1361,Ignore
Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1362,Ignore
Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1363,Ignore
Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1364,Medium
"Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1365,Ignore
Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1366,Medium
Interim analysis of ibrutinib plus paclitaxel for patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1367,Ignore
PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk nonmuscle invasive bladder cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1368,Ignore
"FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1369,Ignore
Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1370,Ignore
Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1371,Ignore
"Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1372,Medium
Preliminary phase 2 clinical results of IL-15RaFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1373,Medium
Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1374,Ignore
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1375,Medium
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1376,Ignore
"A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1377,Medium
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1378,Medium
PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1379,Medium
Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1380,Ignore
A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1381,Ignore
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1382,Ignore
KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1383,Ignore
A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1384,Ignore
Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1385,High
TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1386,Ignore
"Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1387,Ignore
Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1388,Ignore
An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1389,High
"Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY).",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1390,Medium
"Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1391,Medium
"Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1392,Ignore
Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1393,Ignore
Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) with metastatic urothelial cancer (mUC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1394,Ignore
Prognostic value of sequential <sup>18</sup>F-FDG + Na<sup>18</sup>F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1395,Ignore
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1396,Ignore
Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1397,Medium
Analysis of <em>EGFR</em> mutant urothelial carcinoma (UC) reveals distinct mutational landscape.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1398,Ignore
First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1399,Ignore
Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1400,Ignore
Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1401,Ignore
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1402,High
Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1403,Medium
A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1404,Medium
Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1405,Ignore
Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1406,High
Immune correlates of CD73 expression in patients with urothelial carcinoma (UC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1407,Ignore
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1408,Medium
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1409,Ignore
KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) Updated response and survival results.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1410,Medium
Comparative genomic profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111 patients (Pts) with metastatic clear cell renal cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1411,Ignore
RNAseq and DNA whole-exome sequence analysis reveal novel response signatures to IO treatment in muscle invasive bladder cancer (MIBC) patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1412,Ignore
Association of cell-free DNA (cfDNA) levels with myeloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1413,Ignore
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US clinical practice.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1414,Ignore
Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1415,Ignore
Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,1,0,1416,Low
"Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1417,Ignore
Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1418,High
"Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1419,Ignore
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1420,Medium
"ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1421,Medium
PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1422,Medium
"A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,1,0,1423,Low
A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1424,Ignore
A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,0,1425,Medium
Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1426,Medium
Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer,0,1,1427,High
Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1428,Ignore
Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1429,Medium
"Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1430,Ignore
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1431,Medium
"Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1432,Ignore
Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1433,Ignore
Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1434,Ignore
Seeking light-chain amyloidosis very early: The SAVE trialidentifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1435,Ignore
Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1436,Ignore
Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1437,Ignore
Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1438,Ignore
Mutation landscape of Chinese melanoma patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1439,Ignore
Immune profile of metastatic uveal melanoma during treatment with pembrolizumab.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1440,Ignore
Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1441,Medium
"Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1442,Ignore
Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1443,Ignore
Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1444,Ignore
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1445,Medium
"KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1446,Medium
KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1447,Medium
Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1448,Ignore
"An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1449,Ignore
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1450,Ignore
Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1451,Medium
Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1452,Ignore
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to antiPD-1/PD-L1 agents: Phase 2 LEAP-004 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1453,Medium
A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (laBCC) or metastatic basal cell carcinoma (mBCC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1454,Medium
Extra-mammary Pagets disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1455,Ignore
Pretreatment steroid use and completion of immunotherapy: A population-based study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1456,Ignore
"Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1457,Medium
The antiPD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced <em>BRAF</em> V600mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1458,Medium
Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1459,Medium
Phase I-II open label multicenter study of PD0332991 in <em>BRAF<sup>V600mut</sup></em> metastatic melanoma patients harboring <em>CDKN2A</em> loss and RB1 expression and treated with vemurafenib.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1460,Medium
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1461,Medium
Stereotactic radiotherapy combined with immunotherapy is safe and effective: Results from a phase I clinical trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1462,Medium
"Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1463,Ignore
Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1464,Ignore
Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: The risk of over and undertreatment stress the need for expert pathology review.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1465,Ignore
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1466,Medium
Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1467,Ignore
Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III macroscopic melanoma: A matched cohort study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1468,Ignore
Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1469,Ignore
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1470,Ignore
Comprehensive genomic profiling reveals distinct patterns of driver mutations and chromosomal alterations in acral and mucosal melanomas.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1471,Ignore
Use of immunotherapy for stage-III and IV melanoma and likelihood of regional and distant lymph node resection and surgical resection for distant metastasis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1472,Ignore
Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1473,Ignore
Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1474,Ignore
Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1475,Ignore
Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1476,Ignore
Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1477,Medium
Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1478,Ignore
Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1479,Ignore
Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1480,Ignore
Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1481,Ignore
"Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1482,Medium
The relationship between obesity and immunotherapy: It's complicated.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1483,Ignore
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with <em>BRAF</em> V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1484,Ignore
An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1485,Medium
Anal melanoma: A comparative comprehensive genomic profiling study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1486,Ignore
Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1487,Ignore
High incidence of brain metastases (BrM) in patients with metastatic cutaneous melanoma (MCM) and mutations in the APC/ß-catenin (CTNNB1).,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1488,Low
Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1489,Ignore
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1490,Medium
Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1491,Ignore
Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1492,Medium
IL-12p40 and MIP3a to predict clinical responses to anti-PD-1 therapy in patients with metastatic melanoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1493,Ignore
Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1494,Ignore
ctDNA as a noninvasive monitoring tool in metastatic melanoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1495,Ignore
Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1496,Ignore
Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1497,Medium
"Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCRanti-CD3, in patients with advanced melanoma.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1498,Medium
The clinical utility of neuron-specific enolase serum levels as a biomarker for Merkel cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1499,Ignore
"Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1500,Medium
The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th edition.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1501,Ignore
Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1502,Ignore
A population-based model for predicting sentinel lymph node (SLN) status for cutaneous melanoma patients and a clinical decision rule (CDR) for sparing a SLN biopsy (SLNB).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1503,Ignore
Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced <em>BRAFV600<sup>mut</sup></em> melanoma patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1504,Ignore
Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1505,Medium
"A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1506,Medium
Neutrophil to Lymphocyte ratio (NLR): A prognostic marker in melanoma patients receiving immunotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1507,Ignore
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1508,Medium
"Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1509,Medium
"CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1510,Medium
Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1511,Medium
Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1512,Ignore
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1513,Medium
Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1514,Ignore
"A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1515,Medium
Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1516,Ignore
Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,1517,Medium
The psychosocial and financial burden on caregivers of young-onset colorectal cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1518,Ignore
"Lower costs of care, improved discharge disposition, and improved survival of advanced cancer patients (ACP) receiving early inpatient palliative care (PC) compared to standard oncologic care (SOC).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1519,Low
"Supportive care medications (SCMs) and pharmacogenomics (PGx) relevance in 6,985 cancer patients (pts) undergoing distress screening.",0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1520,Low
Naldemedine for opioid-induced constipation in patients receiving palliative care: A real-world registry study (Phase-R OIC Study).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1521,Low
Total body irradiation (TBI) and risk of breast subsequent malignant neoplasm (SMN) after blood or marrow transplantation (BMT): A report from the BMT survivor study (BMTSS).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1522,Ignore
Early mortality after resection of locally advanced rectal cancer in elderly United States patients.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1523,Low
Prospective trial in early-stage breast cancer (EBC) patients (pts) submitted to nutrition evidence-based educational intervention: Early results of adherence to dietary guidelines (ADG) and body weight change (BWC).,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1524,Low
"Improve: A community-based physical activity intervention to improve functional and health outcomes in older breast cancer survivors: Rationale, design, and methods.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1525,Ignore
"Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1526,Ignore
"Patient controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain: A randomized, controlled, multicenter, phase III trial, HMORCT09-1.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1527,Medium
A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1528,Ignore
eMouvoir: Randomized study estimating the impact of a personalized and remote support centered on physical activity (PA) for patients (pts) after breast cancer (BC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1529,Ignore
Communicating Oncologic Prognosis with Empathy (COPE) Pilot Study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1530,Ignore
Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1531,Ignore
Physical activity platform to improve bone health in cancer survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1532,Ignore
Functional impairment on admission and associated symptom burden and health outcomes among hospitalized patients with advanced cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1533,Ignore
Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC = 4.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1534,Ignore
The development of a nomogram to determine the risk for inappropriate opioid use in cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1535,Ignore
Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: Results from the ReDOS trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1536,Ignore
Effect on pain outcomes in patients treated for painful bone metastases with biopolar RFA: The OPuS One study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1537,Ignore
"A phase II, double-blinded, randomized study using a proprietary amino acid mixture as diarrhea prevention in patients undergoing autologous stem cell transplantation (AST) for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1538,Medium
Unraveling the high cost of end-of-life care: An oncology care model experience.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1539,Ignore
"High temporal variability of clinical side effects with and without adjuvant chemotherapy in 4,684 early breast cancer patients in the CANTO trial.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1540,Ignore
Engaging care partners in breast cancer care and communication.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1541,Ignore
Economics of using telehospice to supplement hospice care in rural areas.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1542,Ignore
Survival and safety of monosialotetrahexosylganglioside in GI cancer patients with oxaliplatin-induced peripheral neurotoxicity-result from TJMUCH-GI-001 trial.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1543,Medium
Growth of palliative care (PC) in United States cancer centers: A national survey.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1544,Low
"Predicting severe toxicity of targeted therapies in elderly patients with cancer (PreToxE): A multicenter, prospective, and retrospective study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1545,Ignore
How far do laypersons believe in the cure of cancer? Results of the EDIFICE6 survey.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1546,Ignore
Cardiorespiratory fitness and cardiovascular mortality after prolonged androgen deprivation therapy for prostate cancer.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1547,Low
Therapy discontinuation processes in a gynecologic oncology population.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1548,Ignore
The effect of structured exercise during chemotherapy on chemotherapy-induced peripheral neuropathy (CIPN): A role for interoceptive brain circuitry.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1549,Ignore
Prognostic value of routine biomarkers in older patients with cancer: Pooled analysis of three prospective cohorts.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1550,Ignore
Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1551,Ignore
Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1552,Ignore
Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care service among gynecologic oncology patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1553,Low
Lung cancer stigma: A ten-year look at patient and oncologist attitudes about lung cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1554,Ignore
Phase 2 trial of Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer.,1,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1555,Low
Current practice for screening and management of financial distress at NCCN member institutions.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1556,Low
End-of-life care and immune checkpoint inhibitors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1557,Ignore
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1558,Medium
Predictive value of an electronic frailty index (FI) in U.S. Veterans with newly diagnosed non-small cell lung cancer (NSCLC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1559,Ignore
Advanced cancer patients changes in terminal illness understanding (TIU) and their psychological well-being.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1560,Ignore
Immune checkpoint inhibitor use near the end of life.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1561,Ignore
Polypharmacy risk among five-year cancer survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1562,Ignore
Palliative Prognostic Index application at an inpatient palliative care service from a Brazilian tertiary Hospital: A prospective observational study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1563,Low
"Cognitive function in chronic lymphocytic leukemia (CLL): Examining effects of disease, treatment, and inflammation.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1564,Ignore
A community oncology palliative program: Early results for cost and quality measures within OCM program claims data.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1565,Ignore
"Obesity paradox in older cancer patients for middle and long-term mortality: A prospective multicenter cohort study of 2,071 patients.",0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1566,Low
Physiological and psychosocial effects of a highly structured exercise program on breast cancer survivorship.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1567,Ignore
Interim analyses of the efficacy of a collaborative care intervention for patients diagnosed with comorbid cancer and depression.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1568,Medium
"Progress and trends in the utilization and adoption of palliative care in patients with terminal gynecologic cancer in the United States: A study of 4,264 women.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,1,0,1569,Low
Goals of care designation associated with improved survival and indicators of quality end-of-life care in pancreatic cancer (PC) patients (pts) undergoing palliative chemotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1570,Ignore
Identifying patient-reported anxiety and depression in older adults with cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1571,Ignore
"Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1572,Ignore
Risk factors for opioid abuse/dependence in hospitalized cancer patients in the United States.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1573,Ignore
"If you dont ask, you wont know: Do patient-reported outcome (PRO) instruments capture the symptom experience of patients treated with immune checkpoint inhibitors (ICIs)?",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1574,Ignore
Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1575,Ignore
The individualized Goals of Care Discussion Guide: A simple tool to empower patients with metastatic breast cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1576,Ignore
"Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1577,Ignore
Is there a shift in use of subacute rehabilitation (SAR) instead of hospice referral since immunotherapy became available?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1578,Ignore
Relationship between perceptions of treatment goals and psychological distress in patients with advanced cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1579,Ignore
"Guided geriatric interventions (GI) in older adults with cancer: What, how, and for whom? The French PACA EST Cohort Experience.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1580,Ignore
Pilot randomized trial of a transdisciplinary geriatric intervention for older adults with cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1581,Ignore
Patient level factors associated with chronic opioid use in cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1582,Ignore
Comparing outcomes data from dedicated oncology-subspecialist hospitalists to those from a traditional care model on an inpatient oncology service.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1583,Ignore
"Effect of whey protein isolate supplementation on body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1584,Ignore
Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1585,Ignore
ELAN-ONCOVAL (Elderly Head and Neck Cancer-Oncology Evaluation) study: Evaluation of the G8 screening tool and the ELAN geriatric evaluation (EGE) for elderly patients (pts) with head and neck squamous cell carcinomas (HNSCC).,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1586,Low
Analysis of financial sustainability of survivorship clinics led by advanced practice providers.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1587,Ignore
Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1588,Ignore
"Cancer-specific mortality and competing causes of death in older adults: A prospective, multicenter cohort study (ELCAPA-19).",0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1589,Low
"After cancer, whats more important? The survivorship care plan or the survivorship care visit?",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1590,Ignore
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1591,Ignore
"The CAROLE (CArdiac Related Oncologic Late Effects) Study: A Phase II, single-arm feasibility trial.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1592,Medium
The importance of altruism to biomarker development for pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1593,Ignore
Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1594,Ignore
Temporal trends among survivors of rhabdomyosarcoma: A report from the Childhood Cancer Survivor Study (CCSS).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1595,Ignore
Write to recover: The impact of group led creative writing on behavioral health outcomes in cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1596,Ignore
Predictors and trajectories of fatigue in ovarian and uterine cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1597,Ignore
"Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1598,Ignore
Return to work after breast cancer: Comprehensive longitudinal analyses of its determinants.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1599,Ignore
Learning from best scalp cooling practices in a registry: Differences in results from n>7000 patients with solid tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1600,Ignore
Validation of a new prognostic body composition parameter in cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1601,Ignore
Female fertility preservation (FP) at pediatric cancer centers: A report from the Childrens Oncology Group (COG).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1602,Ignore
Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1603,Ignore
Depression and anxiety symptoms in bereaved caregivers of patients with advanced cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1604,Ignore
"Till death do us part: Existential loneliness (EL), psychosocial distress, and survival of advanced cancer patients (ACPs), and their spousal caregivers (SCs).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1605,Ignore
"Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient-reported survivorship needs, symptoms, and illness mindsets (N=220).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1606,Ignore
"Variation in the intensity of end-of-life care, hospice enrollment, and the cost of care by cancer site.",0,03-06-2019,0,0,0,0,0,0,0,0,0,1,0,Symptoms and Survivorship,0,0,1607,Medium
Body weight changes in young breast cancer survivors and associated predictors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship,0,0,1608,Ignore
Association of obesity with breast cancer outcome in relation to cancer subtypes.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1609,Ignore
Role of the oncological-multidimensional prognostic index in older patients with metastatic colorectal cancer treated in a real-world setting.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1610,Ignore
Impact of a regular exercise program on amount of exercise and QOL metrics in patients on immune therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1611,Ignore
Combination of olanzapine and aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1612,Ignore
Implementation of complex perioperative intervention in older patients with cancer (IMPROVED program).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1613,Ignore
Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1614,Ignore
"Older adults preferred and perceived roles in decision making about palliative chemotherapy: Their decision priorities, and information preferences.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1615,Ignore
Correlates of distress for cancer patients: Results from multi-institution use of holistic patient-reported screening tool.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1616,Low
"Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship,0,1,1617,High
Effectiveness of psychological distress reduction with cognitive behavioral therapy for oncological patients: A one-year follow-up study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,1618,Ignore
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1619,Ignore
Long-term survival after laparoscopic versus open resection for colorectal liver metastases.,0,03-06-2019,0,0,0,0,0,0,1,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1620,High
A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Primary analysis of Japan Clinical Oncology Group study JCOG1006.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1621,Ignore
A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1622,Ignore
Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1623,Ignore
Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1624,Ignore
Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1625,Medium
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,1,1626,High
A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1627,Ignore
"A randomized phase II trial of second-line CAPTEM versus FOLFIRI in <em>MGMT</em> methylated,<em> RAS</em> mutated metastatic colorectal cancer (mCRC) patients.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1628,Medium
A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1629,Medium
Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,1,1630,High
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1631,Ignore
"Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1632,Ignore
Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1633,Ignore
Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1634,Medium
Second cancer incidence in CLL patients receiving BTK inhibitors.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1635,Low
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1636,Ignore
"Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R<sup>2</sup>-CHOP in subjects with previously untreated, high-risk DLBCL.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1637,Medium
Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1638,Medium
The role of maintenance strategy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1639,Ignore
"A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,1,1640,High
Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1641,Medium
A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1642,Ignore
"Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1643,Ignore
Intratumoral CD3<sup>+</sup> and CD8<sup>+</sup> T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1644,Ignore
"Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1645,Ignore
"Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1646,Ignore
Tumor and microenvironment evolution during chemotherapy combine with bevacizumab in colorectal cancer liver metastasis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1647,Ignore
Serial ctDNA analysis as a real-time indicator of neoadjuvant chemoradiotherapy in rectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1648,Ignore
Association of TGF-ß expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1649,Ignore
Gender differences in prognostic value of immune-related biomarkers in colon cancer patients randomized to surgery or surgery and adjuvant chemotherapy treatment.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1650,Ignore
Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by <sup>18</sup>F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1651,Medium
Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with <em>RAS </em>wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1652,Medium
Outcomes of salvage surgery for anal squamous cell carcinoma: A systematic review and meta-analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1653,Ignore
"Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1654,Ignore
Feasibility of a national expert panel to determine resectability in patients with initially unresectable colorectal cancer liver metastases (CRLM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1655,Ignore
"Differences in pathology and mutational status among colorectal cancer (CRC) patients pre-, post-, and during screening age.",0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1656,Low
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1657,Ignore
cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1658,Ignore
Screening patients for fluoropyrimidine-related toxicity risk.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1659,Low
Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1660,Ignore
Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1661,Medium
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1662,Ignore
Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1663,Ignore
Pathway analysis of hypoxia-related factors in early colorectal cancer patients with poor prognosis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1664,Ignore
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1665,Ignore
Preoperative platelet leukocyte ratio as an independent risk factor for postoperative outcomes in colorectal cancers.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1666,Ignore
Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1667,Low
Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1668,Medium
Differences in clinical outcomes in young-onset colorectal cancer based on ethnicity in an NCI designated comprehensive cancer center.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1669,Medium
"RAS-amplified colorectal cancers: Microsatellite stability status,  RAS/BRAF mutations, and prediction of anti-EGFR resistance.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1670,Ignore
Aspirin as adjuvant treatment for colorectal cancer: Rationale and progress of the Add-Aspirin trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1671,Ignore
The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1672,Ignore
"Efficacy of aspirin for stage III colorectal cancer: A randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial).",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1673,Medium
"Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1674,Medium
Clinical features and survival among patients with standard-onset versus early-onset colorectal cancer by age groups.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1675,Ignore
Molecular landscape of colorectal cancers harboring R-spondin fusions.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1676,Ignore
Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1677,Ignore
Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1678,Ignore
"ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3<sup>rd</sup>/4<sup>th</sup> line colorectal cancer.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1679,Medium
Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1680,Ignore
Young-onset colorectal cancer patients disproportionately diagnosed with advanced disease: Patient self-reported journey of symptom duration and misdiagnosis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1681,Ignore
Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1682,Ignore
Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1683,Medium
Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1684,Medium
High incidence of advanced stage cancer and prolonged rectal bleeding history before diagnosis in young-onset patients with colorectal cancer.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1685,Low
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1686,Medium
Comparison of HER2 overexpression with total<em> Her2</em> mutation on resistance of EGFR-targeted therapy in<em> Ras</em> wild-type mCRC patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1687,Ignore
"Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1688,Ignore
Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1689,Medium
A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,1,0,1690,Low
Combination of tissues analysis and immune infiltrate in localized colon cancer using artificial intelligence in PETACC8 study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1691,Ignore
Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21s influence on gene expression in the EGFR signaling pathway.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1692,Medium
"Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFIA randomized, open label, phase-2 study (AIO KRK0109).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1693,Ignore
The genomic landscape and its prognostic significance for stage III colorectal cancer in Japan: An ancillary study of JCOG0910 trialJCOG1506A1.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1694,Ignore
"Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1695,Ignore
ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with watch and wait approach.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1696,Ignore
The 55 STAR study: Prognostic and predictive value of the 55-gene classifier (55GC) in stage III colon cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1697,Ignore
"Randomized phase II study on the influence of <em>BRAF</em> and <em>PIK3CA</em> mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with <em>RAS</em> wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1698,Medium
Long-term outcomes after high-dose chemoradiotherapy for non-surgical management of distal rectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1699,Ignore
Factors affecting differential outcomes in the definitive treatment of anal cancer between HIV+ and HIV- patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1700,Ignore
Performance comparison of the methylated <em>BCAT1</em>/<em>IKZF1</em> ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1701,Ignore
Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1702,Ignore
Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1703,Ignore
Recent changes in overall survival of real-life stage IV colorectal cancer patients.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1704,Medium
"Urban/rural disparities in stage at presentation of colorectal cancer among young adults in the United States, 2007-2015.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1705,Ignore
Association between pretreatment Fusobacterium nucleatum and cancer pain at six months postsurgery in newly diagnosed colorectal cancer patients: Results from the ColoCare Study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1706,Ignore
Dissection of the lateral lymph nodes with short axis of = 5 mm affects the prognosis in rectal cancer patients: A central review of 738 lower rectal cancer magnetic resonance images.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1707,Ignore
Germline multigene panel testing in colorectal cancer: Precision therapy and clinical management implications.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1708,Ignore
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1709,Medium
Population-based screening for <em>BRAF </em>V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1710,Low
Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1711,Ignore
Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1712,Medium
Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1713,Ignore
Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1714,Medium
Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1715,Ignore
Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110)- study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1716,Ignore
"Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1717,Ignore
Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1718,Medium
POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancerA phase III randomized study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1719,Medium
Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1720,Ignore
PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1721,Medium
"A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1722,Medium
Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1723,Medium
Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1724,Medium
"Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: A multicenter, single-arm, prospective study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1725,Ignore
Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1726,Ignore
Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1727,Ignore
Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1728,Medium
<section class=section section-content id=section-content> <div class=zone-wrapper zone-content-wrapper clearfix id=zone-content-wrapper> <div class=zone zone-content clearfix equal-height-container container-24 id=zone-content> <div class=grid-18 push-6 region region-content equal-height-element id=region-content> <div class=region-inner region-content-inner> <div class=block block-system block-main block-system-main even block-without-title id=block-system-main> <div class=block-inner clearfix> <div class=content clearfix> <article class=node node-page node-publis,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1729,Ignore
A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1730,Ignore
Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1731,Ignore
Effect of neoadjuvant treatment on locally advanced rectal mucinous adenocarcinoma or signet-ring cell carcinoma: A post-hoc analysis from 3 prospective studies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1732,Ignore
Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1733,Low
Prediction model for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1734,Ignore
"Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1735,Medium
Preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer: Preliminary analysis of the PePiTA study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1736,Ignore
Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1737,Ignore
Association of <em>PIK3CA</em> mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1738,Ignore
Stage-based variation in the impact of colon cancer surveillance.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer,0,0,1739,Ignore
"Long-term survival and safety from a multi-center, open-label, pivotal phase 2 study of iobenguane I 131 in patients (Pts) with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1740,Medium
Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1741,Ignore
Surgery and peptide receptor radionuclide therapy: An effective multimodal approach for metastatic neuroendocrine tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1742,Ignore
SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1743,Ignore
DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced biliary tract cancer (BTC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1744,Ignore
"Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1745,Medium
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1746,Medium
Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1747,Ignore
Clinical and prognostic significance of serum levels of fatty acid binding proteins in hepatocellular carcinoma (HCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1748,Ignore
Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1749,Ignore
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1750,Medium
Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing gFOLFIRINOX for gastroesophageal adenocarcinoma (GEA).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1751,Ignore
Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1752,Ignore
A digital pathology demonstration of an immune hot ICOS+/CD45RO+ immunephenotype and the impact on survival in patients with esophageal adenocarcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1753,Ignore
Homologous recombination deficiency as prognostic marker in metastatic gastric cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1754,Ignore
A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1755,Medium
The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1756,Ignore
Hereditary cancer genetic testing among patients with pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1757,Ignore
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1758,Medium
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1759,Ignore
A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1760,Medium
"Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1761,Medium
A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium: Cohort 1 results.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1762,Ignore
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1763,Medium
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1764,Ignore
Metformin use and pancreatic cancer survival in US veterans with diabetes mellitus: Are there racial differences?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1765,Ignore
"POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1766,Medium
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1767,Ignore
"Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,1768,High
Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1769,Ignore
"Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1770,Medium
A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1771,Ignore
Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1772,Medium
Novel staging system using carbohydrate antigen (CA) 19-9 in extrahepatic cholangiocarcinoma (ECCC) and its implications on overall survival (OS).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1773,Medium
Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1774,Medium
Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1775,Medium
Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1776,Ignore
"Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1777,Ignore
"A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1778,Medium
Association of <em>BRCA</em>-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1779,Ignore
Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1780,Ignore
H3B-6527 clinical biomarker assay development and characterization of HCC patient samples.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1781,Ignore
Final results of JASPAC05: Phase II trial of neoadjuvant S-1 and concurrent radiotherapy followed by surgery in borderline resectable pancreatic cancer.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,1782,High
Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1783,Ignore
"An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1784,Medium
"A single-arm, open phase II clinical trial of anti-programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1785,Medium
"RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1786,Medium
Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1787,Medium
A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,1,0,1788,Low
"NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1789,Medium
"KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1790,Medium
Prospective evaluation of metabolic intratumoral heterogeneity using <sup>18</sup>F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1791,Ignore
"A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1792,Medium
NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1793,Ignore
"Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1794,Medium
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy In patients (pts) with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1795,Medium
"A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1796,Medium
"Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1797,Medium
"CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1798,Ignore
Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1799,Medium
"Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1800,Medium
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,1801,High
Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1802,Ignore
"Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1803,Medium
"A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1804,Ignore
Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1805,Ignore
The prognostic role of soluble transforming growth factor-ß related with soluble programmed death-ligand 1 in biliary tract cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1806,Ignore
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1807,Ignore
Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx).,0,03-06-2019,0,0,0,1,0,0,0,0,0,1,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1808,Medium
Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1809,Medium
Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1810,Medium
Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1811,Medium
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,1812,High
"Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1813,Medium
Perioperative chemotherapy alone versus preoperative chemoradiotherapy for locally advanced distal esophageal and gastroesophageal junction cancer: A 10-year review of the British Columbia (BC) cancer registry.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1814,Ignore
SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1815,Ignore
Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1816,Ignore
"NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313) Safety interim analysis.",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1817,Medium
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1818,Ignore
Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1819,Medium
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1820,Medium
Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs): A pooled analysis of two phase II trials with pazopanib and lenvatinib.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1821,Medium
Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1822,Medium
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1823,Medium
First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1824,Medium
"Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1825,Medium
Recurrence risk evaluation in stage IB gastric cancer with <em>TP53</em> codon 72 polymorphism.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1826,Ignore
Elevated pretreatment serum IL-8 and PD-L1 and overall survival in a phase III randomized advanced pancreatic cancer clinical trial.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1827,Medium
Clinicopathological features of EpsteinBarr virus associated gastric carcinoma with submucosal invasion.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1828,Ignore
Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1829,Medium
"PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine + nab-paclitaxel (GNP) chemotherapies.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1830,Ignore
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1831,Medium
A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,1,1832,High
The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of thecombination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve forsystemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1833,Medium
BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1834,Ignore
Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1835,Medium
Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1836,Ignore
Cell-free junctional DNA fragment from hepatitis B virus integration in HCC for monitoring postresection recurrence and clonality.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1837,Ignore
A phase II study of antiPD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1838,Ignore
Prospective validation of a serum miRNA panel for early detection of gastric cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1839,Ignore
CT-based radiogenomic signature to identify <em>isocitrate dehydrogenase (IDH)1/2</em> mutations in advanced intrahepatic cholangiocarcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1840,Ignore
Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged =65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1841,Ignore
"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1842,Ignore
Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1843,Medium
Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1844,Ignore
IGF-Child-Pugh score as a predictor of treatment outcome in advanced hepatocellular carcinoma patients treated with sorafenib.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1845,Ignore
Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1846,Ignore
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1847,Ignore
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) ß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1848,Medium
Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1849,Ignore
Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1850,Medium
Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1851,Ignore
Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1852,Ignore
Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1853,Medium
"Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1854,Medium
Randomized clinical trial of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization for hepatocellular carcinoma with intermediate stage (BCLC stage B) hepatocellular carcinoma beyond Milan criteria.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1855,Ignore
A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1856,Medium
"Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocarcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1857,Medium
The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1858,Medium
TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1859,Medium
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1860,Medium
"Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1861,Medium
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1862,Ignore
"A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1863,Medium
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1864,Medium
"Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The genetic education, risk assessment and testing (GENERATE) study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1865,Ignore
Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1866,Ignore
Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1867,Medium
"PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and <i>nab</i>-paclitaxel (FA) and <i>nab</i>-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1868,Medium
"Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1869,Medium
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1870,Medium
Landscape of innate and adaptive immunity targets in oesophagogastric adenocarcinoma (OGA).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,1871,Ignore
Mast cells as mediators of fibrosis and effector cell recruitment in dermal chronic graft-versus-host disease.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1872,Ignore
Patterns of leukemic transformation in patients with <em>TP53</em>-mutant myelodysplastic syndromes.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1873,Ignore
Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long term benefits.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1874,Medium
Predictive accuracy of the low erythropoietin level for the diagnosis of polycythemia vera.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1875,Ignore
Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1876,Ignore
Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,1,1877,High
Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1878,Ignore
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1879,Medium
A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) <em>FLT3</em>-ITD acute myeloid leukemia (AML).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1880,Ignore
FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1881,Medium
A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1882,Ignore
"A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with =2 tyrosine kinase inhibitors (TKIs).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1883,Ignore
"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.",0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1884,High
A phase II study of myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT) for acute lymphoblastic leukemia (ALL) in older patients using fludarabine and total body irradiation (Flu/TBI).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1885,Medium
A video decision aid to improve acute myeloid leukemia patients illness understanding: Results of a pilot trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1886,Ignore
Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1887,Ignore
The Transplant Optimization Program (TOP): Implementing a geriatric assessment (GA)-guided interdisciplinary clinic (IDC) prior to allogeneic hematopoietic cell transplantation (HCT) in older adults.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1888,Ignore
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1889,Ignore
Discrepancy of blast percentage between the bone marrow aspirate and biopsy and its impact on survival outcomes in patients with myelodysplastic syndromes excess blast (MDS-EB).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1890,Ignore
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1891,Medium
IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1892,Medium
Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1893,Ignore
Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (<sup>131</sup>I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1894,Medium
Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,1,1895,High
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1896,Medium
Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1897,Ignore
"Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.",0,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1898,High
Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1899,Ignore
Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1900,Medium
Activity of venetoclax-based therapy in <em>TP53</em>-mutated acute myeloid leukemia.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1901,Ignore
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1902,Medium
Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1903,Ignore
Identifying Mcl-1 protein dependencies using dimerization-specific antibody biomarker for predicting response to targeted apoptosis inducing therapies.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1904,Ignore
"Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1905,Medium
Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1906,Medium
"A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1907,Ignore
Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1908,Medium
Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1909,Ignore
Time from randomization to first subsequent induction/salvage therapy (ST) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1910,Medium
Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1911,Ignore
Late infectious complications in hematopoietic cell transplantation survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1912,Ignore
Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1913,Ignore
"Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1914,Medium
Clinical validation of long-range PCR assay for MLL partial tandem duplications for acute myeloid leukemia.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1915,Ignore
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed <em>FLT3</em> mutated AML.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1916,Ignore
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1917,Medium
A phase I/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1918,Medium
MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1919,Medium
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosomepositive (Ph+) ALL.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1920,Medium
A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,1921,Medium
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1922,Medium
A phase I study of a selective PI3Kd inhibitor YY-20394 in patients with relapsed or refractory B Cell malignancies.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1923,Medium
Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1924,Ignore
Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1925,Ignore
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1926,Medium
Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1927,Ignore
Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1928,Medium
Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1929,Ignore
Extranodal (EN) and spleen disease by FDG-PET/CT is associated with early clinical failure in untreated follicular lymphoma (FL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1930,Ignore
Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1931,Ignore
Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1932,Ignore
"Outcomes of patients (pts) = 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL).",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1933,Medium
Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operations on response.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1934,Medium
Survival disparities of diffuse large B-cell lymphoma in a community-based cancer center.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1935,Ignore
Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1936,Ignore
Response to A+CHP by CD30 expression in the ECHELON-2 trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1937,Ignore
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1938,Medium
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1939,Medium
"A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1940,Medium
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1941,Medium
"ELARA: A phase II, single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).",1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1942,Medium
Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1943,Ignore
Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1944,Ignore
Prognostic value of baseline SUV<sub>max</sub> in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1945,Ignore
Long-term follow-up of patients (pts) with relapsed or refractory (r/r) follicular lymphoma (FL) treated with copanlisib.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1946,Ignore
Outcomes in chronic lymphocytic leukemia (CLL) patients with NOTCH1 signaling pathway mutations.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1947,Ignore
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1948,Ignore
Circulating tumor DNA to predict response and resistance by anti-PD-1 therapy in Chinese relapsed/refractory classic Hodgkin lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1949,Ignore
Efficacy of frontline treatment regimens in follicular lymphoma: A network meta-analysis of phase III randomized controlled trials.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1950,Medium
Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,1,0,1951,Low
Assessing the potential of immunotherapy in treating chronic lymphocytic leukemia through meta-analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1952,Ignore
Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1953,Medium
Prediagnosis cardiovascular risk and subsequent myocardial infarction (MI) among lymphoma survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1954,Ignore
Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1955,Medium
Impact on survival of surveillance imaging after first remission in follicular lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1956,Ignore
Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1957,Ignore
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1958,Ignore
Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1959,Ignore
Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1960,Ignore
A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1961,Medium
Early progression of disease (POD24) as survival predictor in MALT lymphoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1962,Ignore
Outcomes of stem cell transplant in patients with Richter transformation.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1963,Ignore
Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1964,Medium
"Sintilimab for relapsed/refractory classical Hodgkins lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1965,Medium
Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1966,Ignore
Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1967,Ignore
ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1968,Medium
"Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1969,Medium
ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high risk diffuse large B cell lymphoma patients with novel genomic biomarker DGM1.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1970,Medium
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1971,Medium
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1972,Ignore
"Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,1973,Ignore
Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma (R/R LBCL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,1,1974,High
Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1975,Ignore
Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1976,Medium
Minimal residual disease clinical monitoring and depth of response in multiple myeloma.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1977,Medium
Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1978,Ignore
"Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1979,Ignore
The myeloma-developing regimens using genomics (MyDRUG) master protocol.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1980,Ignore
Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory multiple myeloma (rrMM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1981,Ignore
"Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1982,Ignore
Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1983,Ignore
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1984,Ignore
Prognosis of young patients with monoclonal gammopathy of undetermined significance.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1985,Ignore
A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1986,Ignore
Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1987,Medium
"Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1988,Medium
Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1989,Ignore
Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1990,Medium
"A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1991,Ignore
"SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1992,Medium
"Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1993,Ignore
"ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.",1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1994,Medium
"Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).",1,03-06-2019,0,0,1,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,1995,Medium
Association between tumor biology and occult lymph node metastases before and after primary neoadjuvant therapy (NAT) for patients with early breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1996,Ignore
"NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1997,Ignore
"Adjuvant endocrine monotherapy (ET) versus adjuvant breast radiation (RT) alone in healthy older women with stage I, estrogen receptor-positive (ER+) breast cancer: An analysis of the National Cancer Database (NCDB).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1998,Ignore
Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Womens Health Initiative randomized clinical trial.,0,02-06-2019,1,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,1999,Low
Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2000,Medium
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2001,Medium
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2002,Ignore
"Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2003,Ignore
"Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2004,Ignore
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2005,Medium
Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2006,Ignore
Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2007,Medium
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2008,Ignore
NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2009,Medium
Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2010,Ignore
First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.,1,02-06-2019,0,0,0,0,0,0,0,1,0,0,0,Central Nervous System Tumors,0,0,2011,High
"A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2012,Medium
Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2013,Ignore
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2014,Ignore
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2015,Medium
Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2016,Ignore
Quantitative radiographic analysis of phase II and III trials in recurrent glioblastoma treated with VB-111 with or without bevacizumab or bevacizumab monotherapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2017,Ignore
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2018,Ignore
SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2019,Ignore
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2020,Ignore
IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2021,Medium
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2022,Ignore
"A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2023,Medium
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2024,Ignore
Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2025,Ignore
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2026,Medium
S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C <em>KRAS</em> mutation positive (+) recurrent non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2027,Medium
c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2028,Ignore
"A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2029,Medium
Characterization of mutational processes in ER+ metastatic breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2030,Ignore
Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.,0,02-06-2019,0,0,0,1,0,0,1,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2031,High
Genomic landscape of de novo stage IV breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2032,Ignore
"End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2033,Medium
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2034,Medium
Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2035,Ignore
Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2036,Ignore
"A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2037,Ignore
mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2038,Ignore
Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2039,Ignore
In-depth gene expression analysis of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2040,Medium
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2041,Medium
"Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2- advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2042,Medium
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for malignant pleural mesothelioma (Japan Mesothelioma Interest Group 1101 Trial).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2043,Ignore
Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2044,Medium
"Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2045,Medium
Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2046,Ignore
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2047,Medium
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory studyFinal data of patients who underwent surgical assessment.,1,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2048,Medium
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III <em>EGFR</em> mutant NSCLC.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2049,Medium
"Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2050,Medium
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2051,Ignore
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2052,Medium
Phase II trial of carfilzomib and irinotecan in relapsed small cell lung cancer (NCT01941316).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2053,Medium
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2054,Ignore
Influence of competing risks on estimates of recurrence risk and breast cancer-specific mortality in analyses of the Early Breast Cancer Trialists Collaborative Group.,0,02-06-2019,1,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2055,Low
Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2056,Ignore
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2057,Medium
Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2058,Ignore
"Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2059,Ignore
"Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.",0,02-06-2019,1,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2060,Low
Impact of the extent of resection on primary breast angiosarcoma survival.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2061,Ignore
"NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorpositive (HR+), human epidermal growth factor receptor 2negative (HER2) early breast cancer (EBC).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2062,Ignore
The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2063,Medium
"Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2064,Ignore
"Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).",0,02-06-2019,0,0,0,0,0,0,0,0,0,1,1,Breast CancerLocal/Regional/Adjuvant,0,0,2065,Medium
No relationship of axillary total tumor load (TTL) by PCR (OSNA) in early breast cancer and local and distant clinical outcomes.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2066,Medium
On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2067,Ignore
"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2068,Ignore
Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2069,Ignore
Oncotype DX testing in early-stage node-positive breast cancer and impact on chemotherapy use at a comprehensive cancer center.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2070,Ignore
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2071,Ignore
Heterogeneity in signaling pathway activity within primary breast cancer and between primary and metastases.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2072,Ignore
Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2073,Ignore
Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2074,Ignore
Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2075,Medium
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2076,Medium
Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2077,Ignore
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2078,Ignore
A prospective validation cohort study of a prediction model on non-sentinel lymph node involvement in early breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2079,Ignore
Comparative performance of Breast Cancer Index (BCIN+) and CTS5 in hormone receptor-positive (HR+) lymph node-positive (N+) breast cancer patients with one to three positive nodes (N1).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2080,Ignore
TARGIT E(lderly): Prospective phase II trial of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2081,Medium
Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2082,Ignore
Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2083,Ignore
"Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2084,Ignore
Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2085,Ignore
Screening for cancer-related distress among women with newly diagnosed breast cancer (BC).,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2086,Low
Breast cancer-specific survival outcomes among patients based on 21-gene recurrence score.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2087,Ignore
"KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptorpositive, human epidermal growth factor receptor 2negative (ER+/HER2-) breast cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2088,Medium
A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2089,Medium
Cognitive impairment in breast cancer patients before surgery?: Results of a subgroup of the French CANTO cohort.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerLocal/Regional/Adjuvant,0,0,2090,Ignore
Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2091,Ignore
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2092,Ignore
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2093,Ignore
Biomarker analysis of PALLET: A neoadjuvant trial of letrozole (L) ± palbociclib (P).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2094,Ignore
Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2095,Ignore
Does the innovative 4R Care Delivery Model improve timing and sequencing of guideline recommended breast cancer care in safety net and non-safety net centers?,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2096,Medium
De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2097,Ignore
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2098,Ignore
Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2099,Ignore
Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2100,Ignore
Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2101,Ignore
"Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2102,Ignore
Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2103,Ignore
Prediction of neoadjuvant chemotherapeutic efficacy by CTC and cfDNA in patients with locally advanced breast cancer.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2104,Medium
NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2105,Medium
Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2106,Ignore
A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2107,Ignore
Prognostic value of a new clinical-genomic model to predict 10-year risk of recurrence in patients with operable breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2108,Ignore
ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerLocal/Regional/Adjuvant,0,0,2109,Medium
"Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2110,Medium
Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.,1,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2111,Medium
Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2112,Ignore
"A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2113,Ignore
Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2114,Ignore
Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2115,Ignore
Prediction of occult axillary metastases in treatment-naïve patients with breast cancer: A transSENTINA analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2116,Ignore
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2117,Medium
Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2118,Ignore
Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2119,Ignore
Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2120,Medium
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerLocal/Regional/Adjuvant,0,0,2121,Medium
Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2122,Ignore
"The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2123,Ignore
Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2124,Ignore
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2125,Ignore
Evidence that neoadjuvant anthracycline based combination chemotherapy (NACT) in breast cancer (BC) induces phenotypical changes which guides the optimal adjuvant therapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2126,Ignore
Adherence to adjuvant endocrine therapy after breast cancer in Sweden 2008-2010: A nationwide survey.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2127,Ignore
"Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2128,Medium
Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2129,Ignore
Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2130,Ignore
Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2131,Ignore
Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2132,Ignore
EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2133,Ignore
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2134,Medium
"KX-ORAX-001: An open label, randomized, multicenter, phase III registrational study to determine the safety, tolerability, and tumor response of oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC).",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2135,Medium
"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <em>PIK3CA-</em>mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2136,Ignore
Risk stratification in earl- stage luminal breast cancer patients treated with and without RT.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,2137,Ignore
Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2138,Medium
A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2139,Medium
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2140,Medium
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2141,Medium
"CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2142,Ignore
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2143,Ignore
"VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2144,Medium
"Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERa Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).",0,02-06-2019,0,0,0,0,0,0,0,1,0,0,1,Breast CancerMetastatic,0,0,2145,High
Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2 advanced breast cancer (ABC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,1,2146,High
A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2147,Medium
"Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2148,Medium
"TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2149,Medium
"High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2150,Ignore
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2151,Medium
Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2152,Medium
"Association of <em>HER2</em> alterations and <em>ESR1</em> mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2153,Ignore
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerMetastatic,0,0,2154,Ignore
Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2155,Medium
Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2156,Medium
"Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2 locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2157,Ignore
Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2158,Ignore
"RIBECCA: A phase IIIb, multicenter, open label study for women with estrogen receptor-positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozoleResults of the second interim analysis.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2159,Medium
"Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2160,Ignore
"Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with <em>PIK3CA-</em>mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2161,Ignore
"A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2162,Medium
A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2163,Medium
Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2164,Ignore
"IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2165,Medium
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2166,Ignore
A randomized phase II study of nab<em>-</em>paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2167,Ignore
The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2168,Ignore
A phase II study of dual immune checkpoint blockade (ICB) plus androgen receptor (AR) blockade to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer (MBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2169,Medium
Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2170,Ignore
"EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigators choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2171,Medium
Measuring on-treatment genome-wide tumor copy number alterations in cell-free DNA (cfDNA) in plasma is highly prognostic in metastatic breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2172,Ignore
Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2173,Ignore
"A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2174,Medium
"A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigators choice in HER2-low breast cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2175,Medium
Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2176,Ignore
A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer patients.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2177,Medium
"Patient-reported outcomes (PROs) in patients (pts) with <em>PIK3CA</em>-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2negative (HER2) advanced breast cancer (ABC) from SOLAR-1.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2178,Ignore
Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2179,Medium
"First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2180,Medium
A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2181,Medium
Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2182,Medium
First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2183,Ignore
Effect of metformin on PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 expression in triple-negative breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2184,Ignore
Survival outcomes of premenopausal patients diagnosed with invasive lobular carcinoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2185,Ignore
Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2186,Ignore
"Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2187,Ignore
"ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2188,Ignore
"A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2189,Medium
Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2190,Ignore
Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2191,Ignore
A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2192,Ignore
AL101 mediated tumor inhibition in notch-altered TNBC PDX models.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2193,Ignore
PIPA: A phase Ib study of ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in <em>PIK3CA</em>-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in <em>PIK3CA</em>-mutant (mt) ER-negative advanced breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2194,Medium
Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2195,Medium
Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2196,Ignore
"Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2197,Ignore
"Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2198,Medium
Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2199,Ignore
Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with <em>BRCA1/2</em>-mutant metastatic breast cancer (MBC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2200,Ignore
Germline BRCA1and BRCA2<em> </em>mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2201,Ignore
Development and validation of novel microenvironment-based immune molecular subtypes of breast cancer: Implications for immunotherapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2202,Ignore
Association of SOX9 expression with sensitivity to CDK7 inhibition and overall survival in triple-negative breast cancer.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2203,Medium
Gaps in metastatic breast cancer patient knowledge and understanding in Mexico.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2204,Ignore
"Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2205,Medium
Brain metastasis in patients with hereditary <em>BRCA-</em>mutated invasive breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerMetastatic,0,0,2206,Ignore
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2207,Ignore
Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2208,Medium
Differences in breast cancer outcomes amongst Black United States-born and Caribbean-born immigrants.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2209,Ignore
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2210,Ignore
Clinical characteristics and outcome of metaplastic breast cancer: A retrospective tertiary care center experience.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2211,Ignore
Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2212,Ignore
"B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2213,Medium
Hyperprogressive disease in advanced triple-negative breast cancer (aTNBC) treated with immunotherapy (IO).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerMetastatic,0,0,2214,Ignore
Association of secondary somatic mutations in <em>BRCA1/2</em> with clinical resistance to PARP inhibitors and chemotherapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2215,Ignore
Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2216,Ignore
Association of drug-related polymorphisms with palbociclib-related neutropenia: Pharmacogenetic analysis of PALOMA-2/-3 (P2/3).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2217,Ignore
Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2218,Medium
"SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2219,Medium
NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,1,0,2220,Low
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2221,Ignore
Effect of HER2/neu 655 polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2222,Ignore
XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2223,Medium
Patients with metastatic breast cancer enrolled in phase I clinical trials: Clinical outcomes and cohort trends.,1,02-06-2019,0,0,0,0,0,0,0,0,0,1,1,Breast CancerMetastatic,0,0,2224,Medium
"A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic,0,0,2225,Medium
"Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).",1,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Central Nervous System Tumors,0,0,2226,Medium
The timing of chemoradiotherapy after surgical resection and its impact on overall survival in glioblastoma.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2227,Medium
Correlation of systemic and local inflammation with survival prognosis in glioma patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2228,Ignore
Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2229,Medium
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2230,Medium
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2231,Medium
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without <em>EGFR</em>-amplified recurrent glioblastoma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2232,Medium
A gene signature of response to radiotherapy in patients with grade II-III oligodendrogliomas.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2233,Ignore
"Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2234,Ignore
Insight into the brain metastasis journey: Initial survey results from patients and caregivers.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2235,Ignore
A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed glioblastoma utilizing global microRNA expression data.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2236,Ignore
Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2237,Medium
"Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2238,Ignore
Stereotactic radiosurgery for resected brain metastases: Does the surgical corridor need to be treated?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2239,Ignore
EGFR amplification predicted selective sensitivity to PARP inhibitors with high PARP-DNA trapping potential in human GBM.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2240,Ignore
"Clinical characteristics, treatment (Tx) patterns, and overall survival (OS) in advanced (Adv) NSCLC patients (Pts) with and without brain metastases (BM).",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2241,Medium
Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using <em>TERT </em>promoter mutation-specific droplet digital PCR assays.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2242,Ignore
Barriers to accrual and enrollment in brain tumor trials.,0,02-06-2019,0,0,0,0,0,0,0,0,0,1,0,Central Nervous System Tumors,0,0,2243,Medium
Evaluating the capacity of connectome analysis to predict survival in high-grade astrocytoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2244,Ignore
Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2245,Ignore
Cancer differentiation analysis technology as a novel technology for cerebral cancer screening.,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2246,Low
Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2247,Medium
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2248,Ignore
A phase I/II study of nivolumab plus or minus ipilimumab in combination with multifraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2249,Medium
"Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2250,Medium
Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2251,Ignore
"Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2252,Ignore
"Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).",0,02-06-2019,0,0,0,1,0,0,0,1,0,0,0,Central Nervous System Tumors,0,0,2253,High
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2254,Medium
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2255,Medium
A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2256,Medium
"A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2257,Medium
"Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2258,Medium
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2259,Ignore
"Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2260,Medium
Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2261,Ignore
Are patients with oligodendroglioma at higher risk for radiation neurotoxicity?,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2262,Ignore
Study of tumor infiltrating immune CELLS and vasculature in human gliomas: Differences in IDH1/2 mutant versus IDH1/2WT tumors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2263,Ignore
MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2264,Ignore
"Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2265,Medium
Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2266,Medium
Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2267,Ignore
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2268,Medium
Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2269,Ignore
Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2270,Ignore
DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2271,Ignore
Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,1,2272,High
Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2273,Ignore
Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2274,Ignore
Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2275,Ignore
Novel anti-EGFRvIII bispecific T cell engager (BiTE) antibody construct in glioblastoma (GBM): Trial in progress of AMG 596 in patients with recurrent or newly diagnosed disease.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2276,Ignore
A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2277,Medium
Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2278,Medium
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors,0,0,2279,Medium
Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2280,Medium
"Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2281,Medium
"Development of a prognostic risk model for small cell lung cancer: Identification of high-, intermediate-, and low-risk cohorts based on clinical-genomic data.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2282,Ignore
Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2283,Ignore
Thoracic twice-daily radiotherapy and brain metastasis in patients with small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2284,Ignore
Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2285,Medium
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for responsePreliminary results from the SCLC cohort.,1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,1,2286,High
Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2287,Ignore
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancerPreliminary findings from part 1 dose-defining phase.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2288,Ignore
Lung cancer diagnosed by an incidental lung nodule program or lung cancer screening.,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2289,Low
Retrospective study of capecitabine and temozolomide in advanced lung neuroendocrine neoplasms.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2290,Ignore
EGFR L858R mutation as a possible target for individual-independent immunotherapy in Chinese population.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2291,Ignore
Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2292,Ignore
Outcome of neo-adjuvant chemotherapy in 225 surgical candidates with malignant pleural mesothelioma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2293,Ignore
"Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2294,Medium
"PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2295,Medium
"Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III nonsmall-cell lung cancer (NSCLC): KEYNOTE-799.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2296,Medium
The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2297,Ignore
Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2298,Medium
ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IBIIIA anaplastic lymphoma kinase-positive (<em>ALK</em>+) non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2299,Medium
"Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2300,Medium
"Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2301,Medium
The risk of second primary malignancy in patients with localized thymoma: A U.S. population-based study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2302,Ignore
Anti-EGFR target therapy in advanced thymic epithelial tumors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2303,Ignore
S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2304,Medium
Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE  randomized phase III trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2305,Ignore
Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2306,Ignore
Identifying actionable somatic mutations in lung cancer using cell-free DNA from bronchial washing fluid.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2307,Ignore
Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC).,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2308,Medium
Alteration in tumor immune microenvironment after chemo-radiotherapy for locally advanced non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2309,Ignore
Three-year overall survival update from the PACIFIC trial.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2310,Medium
Real-world experience and molecular features of response to immune checkpoint blockade in patients with recurrent small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2311,Ignore
Randomized phase <U+2161> trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage <U+2162> non-squamous non-small-cell lung cancer: NJLCG1001.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2312,Ignore
Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2313,Medium
"10-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea real-time automatically updated data warehouse in health care (UNIVERSE - ROOT study).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2314,Ignore
Phase II study of S-1 in patients (pts) with previously treated Invasive thymoma (IT) and thymic carcinoma (TC): North Japan Lung Cancer Study Group Trial 1203.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2315,Medium
Impact of large-scale nationwide genomic screening project for small cell lung cancer (LC-SCRUM-Japan).,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2316,Low
Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2317,Ignore
Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2318,Medium
Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma (MPM).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2319,Medium
T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2320,Ignore
Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2321,Medium
The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2322,Ignore
"Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,1,2323,High
Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2324,Medium
Mutational landscapes and PD-L1 expression in non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2325,Ignore
Comprehensive genomic profiling in Chinese patients with lung squamous cell carcinoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2326,Ignore
Clinical application of circulating cell-free DNA for monitoring the biological course of thymic epithelial tumors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2327,Ignore
Neutrophil-to-lymphocyte ratio and subsequent recurrence of non-small cell lung cancer patients in remission.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2328,Ignore
The spatiotemporal evolution of early-stage non-small-cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2329,Ignore
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2330,Medium
"Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2331,Medium
NRG Oncology CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2332,Medium
Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2333,Ignore
CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,2334,Ignore
"Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous nonsmall-cell lung cancer (NSCLC): LEAP-006.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2335,Medium
Prospective study of germline and somatic alterations for Early Onset LUNG cancer patients (EOLUNG MASTER protocol).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2336,Ignore
Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2337,Medium
"A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for <em>EGFR</em> mutation-positive non-squamous non-small cell lung cancer: TORG1833.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2338,Medium
"Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2339,Medium
Early mortality in metastatic lung cancer: A SEER population data analysis.,0,02-06-2019,1,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2340,Low
"A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2341,Medium
Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2342,Ignore
Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2343,Medium
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2344,Ignore
Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2345,Ignore
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2346,Medium
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2347,Ignore
Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world <em>ROS1</em> fusion-positive (<em>ROS1</em>+) NSCLC patients.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2348,Medium
Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2349,Ignore
"Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2350,Medium
Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2351,Ignore
"A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2352,Medium
Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with <em>EGFR</em>-mutant lung cancers.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2353,Ignore
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2354,Medium
Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2355,Ignore
NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2356,Ignore
Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2357,Ignore
Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2358,Medium
"Variation in the assessment of immune-related adverse event occurrence, grade, and timing.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2359,Ignore
Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2360,Ignore
Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <em>CDKN2A</em> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2361,Ignore
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score =90%.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2362,Ignore
"Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2363,Medium
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2364,Medium
DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2365,Ignore
Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).,1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2366,Medium
"A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.",1,02-06-2019,0,0,0,1,0,0,0,1,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2367,High
Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2368,Ignore
Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced non-squamous NSCLC with wild-type EGFR and ALK.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2369,Medium
Non-small cell lung cancer (NSCLC) case study examining whether results in a randomized control arm are replicated by a synthetic control arm (SCA).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2370,Ignore
Crizotinib in patients with advanced or metastatic <em>ROS1</em>-rearranged lung cancer (EUCROSS): A European phase II clinical trialUpdated report on progression-free and overall survival.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2371,Medium
A plasma miRNA signature classifier identifies PD-L1 = 50% NSCLC nonresponders to immune checkpoint inhibitors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2372,Ignore
Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2373,Ignore
Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2374,Ignore
Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2375,Medium
Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2376,Ignore
Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2377,Ignore
Prognostic significance of radiologic features of pneumonitis induced by anti-PD-1 therapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2378,Ignore
"First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2379,Ignore
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2380,Ignore
Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2381,Ignore
Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2382,Ignore
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,1,2383,High
A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2384,Ignore
"Lazertinib, a 3<sup>rd  </sup>generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,1,2385,High
Acquired resistance to MET inhibition in MET driven NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2386,Ignore
Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2387,Medium
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2388,Ignore
The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2389,Ignore
"Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2390,Medium
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2391,Medium
Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2392,Ignore
Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2393,Ignore
Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2394,Ignore
Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2395,Medium
"Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2396,Ignore
Brigatinib in pretreated patients with ALK-positive advanced NSCLC.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2397,Ignore
Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2398,Ignore
A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2399,Medium
Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2400,Ignore
ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2401,Ignore
Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in <em>ALK</em> + non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,1,2402,High
Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2403,Ignore
Circulating free DNA as a prognostic biomarker in patients with advanced <em>ALK</em>+ NSCLC treated with alectinib from the global phase III ALEX trial.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2404,Medium
First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,1,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2405,High
First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.,1,02-06-2019,0,0,0,0,0,0,0,1,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2406,High
"Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2407,Ignore
"Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)deficient non-squamous non-small cell lung cancer.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2408,Medium
Efficacy of platinum-pemetrexed combination chemotherapy in ALK<em>+ </em>non-small cell lung cancer refractory to second-generation ALK TKIs.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2409,Medium
Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2410,Medium
"Determinants of early discontinuation of first-line chemotherapy, and associated outcomes among elderly with advanced non-small cell lung cancer.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2411,Ignore
Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2412,Medium
Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome screening in Japan (LC-SCRUM-Japan).,0,02-06-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2413,Low
Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2414,Ignore
"Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).",0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2415,Medium
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2416,Medium
Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2417,Medium
Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2418,Ignore
Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2419,Ignore
Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2420,Ignore
Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique <em>HER2</em> exon 20 insertions.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2421,Ignore
Clinicopathologic profile and treatment outcomes of non-sensitizing <em>EGFR</em> and <em>HER2 (ERBB2) </em>activating mutations in NSCLC: Results from a single-center retrospective study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2422,Ignore
Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.,0,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2423,Medium
TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.,1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2424,Medium
"SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <em>EGFR</em>-mutant, <em>MET</em>-driven (<em>MET</em>+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2425,Medium
"ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).",1,02-06-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,1,0,2426,Low
Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2427,Medium
"ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2428,Ignore
"Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced nonsmall cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.",1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2429,Medium
The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2430,Ignore
MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.,1,02-06-2019,0,0,1,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2431,Medium
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,2432,Ignore
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2433,Medium
Diagnostic performance of <sup>18</sup>F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of <sup>18</sup>F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2434,Medium
"Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2435,Ignore
HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2436,Medium
Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2437,Medium
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,1,2438,High
Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2439,Ignore
Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2440,Ignore
Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2441,Ignore
Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2442,Ignore
Prospective head-to-head comparative phase 3 study between <sup>18</sup>F-fluciclovine and <sup>68</sup>Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2443,Medium
Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2444,Ignore
Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2445,Ignore
"Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2446,Ignore
A comparison of adjuvant therapy approaches for patients with early-stage uterine serous carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2447,Ignore
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2448,Medium
"A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2449,Medium
Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2450,Medium
"Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2451,Medium
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2452,Medium
"Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2453,Ignore
The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2454,Medium
"Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,1,2455,High
Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancerA Princess Margaret Consortium  GCIG Phase II Trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2456,Medium
Longitudinal circulating EpsteinBarr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2457,Ignore
"Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2458,Medium
"Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2459,Medium
Mature results of the LCCC1413 phase II trial of de-intensified chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2460,Medium
Discordant treatment response in primary tumors and lymph node metastases after four weeks of preoperative PD-1 blockade in head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2461,Ignore
"Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2462,Medium
"Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2463,Medium
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2464,Medium
"EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2465,Medium
Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,1,2466,High
"Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2467,Medium
"NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma (HNSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2468,Medium
Early case ascertainment and prospective multidisciplinary review for management of new melanoma diagnoses within an integrated healthcare system: The Kaiser Permanente Northern California experience.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2469,Ignore
Quantification of the financial burden of antineoplastic agent price increases.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2470,Ignore
Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2471,Ignore
"Enhancing community capacity to improve cancer care delivery and the effect on patient-reported outcomes, healthcare utilization and total costs of care.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2472,Ignore
Effect of exercise during adjuvant chemotherapy for breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2473,Ignore
Previsit breast cancer educational microlearning videos: Impact on patient satisfaction and engagement.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2474,Low
The financial impact of fractionation scheme and treatment planning method for rectal cancer in the United States.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2475,Ignore
Trends in financial relationships between industry and individual medical oncologists in the United States from 2014 to 2017: A cohort study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2476,Ignore
Comparative effectiveness of proton therapy versus photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2477,Ignore
Clinical outcomes and cost-effectiveness of breast cancer screening for childhood cancer survivors treated with chest radiation: A comparative modeling study.,1,01-06-2019,0,0,1,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2478,Medium
Growth factor use and rate of neutropenic complications in breast cancer patients treated with dose-dense paclitaxel: A 5-year experience from a safety net hospital.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2479,Medium
"Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2480,Medium
Genome-wide cell-free DNA fragmentation profiling for early cancer detection.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2481,Ignore
Design and development of the molecular analysis for Therapy Choice (NCI-MATCH) Designated Laboratory Network.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2482,Ignore
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2483,Medium
"Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2484,High
Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2485,Medium
"Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2486,Medium
A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.,0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2487,High
Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2488,Medium
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2489,Ignore
"A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,2490,Medium
Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG) COMET study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,1,2491,High
Clinical activity of avapritinib in = fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Sarcoma,0,0,2492,Low
"Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2493,Medium
ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2494,Medium
A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor(GIST).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2495,Ignore
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Sarcoma,0,1,2496,High
Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2497,Ignore
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,2498,Medium
A three-gene signature to predict survival in pediatric osteosarcoma (OS) to follow patients toward liquid biopsy: A collaborative work in OS2006 protocol.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2499,Ignore
"Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2500,Ignore
"SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,2501,Medium
"Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2502,Medium
Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,2503,Medium
"A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2504,Ignore
Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2505,Ignore
"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2506,Medium
"Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2507,Medium
"CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2508,High
Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies:  A systematic analysis by the United States Food and Drug Administration (FDA).,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2509,Low
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2510,Medium
Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2511,Ignore
"First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts).",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2512,High
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2513,Ignore
"Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2514,Medium
IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2515,Ignore
Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2516,Medium
"A phase III, multicenter study to assess the diagnostic performance and clinical impact of <sup>18</sup>F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2517,Medium
"PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2518,Medium
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2519,Ignore
"Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2520,Medium
ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2521,Medium
SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2522,Ignore
"Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.",0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2523,Low
A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2524,Medium
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2525,Medium
A phase II multicenter biomarker trial to study the predictive value of <i>TMPRSS2-ERG </i>before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2526,Ignore
ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2527,Ignore
Is there a role for testosterone replacement therapy in reducing biochemical recurrence following radical prostatectomy?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2528,Ignore
Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2529,Ignore
"Ductal (PDC), acinar (PAC) and neuroendocrine (PNC) carcinomas of the prostate: A comparative comprehensive genomic profiling (CGP) study.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2530,Ignore
Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2531,Ignore
"Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2532,Ignore
"Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,1,2533,High
WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2534,Ignore
Clinical and genomic hallmarks of low PSA secretors in metastatic castration-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2535,Ignore
Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naïve prostate cancer: A single center analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2536,Ignore
Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2537,Ignore
"Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, <i>de novo </i>metastatic prostate cancer (M1PCa).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2538,Ignore
Contemporary trends in treatment for low-risk prostate cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2539,Ignore
Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2540,Ignore
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2541,Medium
Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2542,Ignore
Human prostate cancer immune phenotypes after androgen deprivation therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2543,Ignore
"Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2544,Ignore
"Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).",1,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2545,Low
Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2546,Ignore
Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Genitourinary (Prostate) Cancer,0,0,2547,Medium
Impact of enzalutamide and sequential flutamide and enzalutamide therapy for castration-resistant prostate cancer after bicalutamide-combined androgen blockade therapy onoverall survival: A follow-up study of randomized phase 2 trial (OCCU-CRPC study).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2548,Medium
Evolving natural history of metastatic prostate cancer.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2549,Low
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2550,Ignore
Clinical outcomes and genomic analysis in patients with very high-risk clinically localized prostate cancer treated by radical prostatectomy.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2551,Medium
"The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration Medical Centers (VAMCs).",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2552,Medium
Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2553,Ignore
Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2554,Medium
"CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2555,Ignore
"Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2556,Medium
Risk of depression following prostate cancer work-up: A nationwide study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2557,Ignore
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2558,Medium
Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2559,Medium
AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2560,Ignore
"Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2561,Ignore
Interlesional response assessment with <sup>18</sup>F-sodium fluoride (<sup>18</sup>F-NaF) PET/CT in men with chemotherapy-naive bone metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2562,Ignore
Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2563,Ignore
Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancerResults from the SPARE-trial (NCT02077634).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2564,Ignore
Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2565,Medium
Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2566,Medium
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2567,Medium
"PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2568,Ignore
Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2569,Ignore
Complex biologic heterogeneity of <em>de novo</em> hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2570,Ignore
Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2571,Medium
A circulating tumor cell specific RNA assay for assessment of androgen receptor signaling inhibitor sensitivity in metastatic castration-resistant prostate cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2572,Ignore
Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2573,Ignore
Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2574,Medium
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,1,2575,High
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2576,Ignore
Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,1,2577,High
"Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2578,Ignore
Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2579,Ignore
IMRT pelvic radiotherapy with simultaneous integrated boost in high-risk prostate cancer: Results after 10 years.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2580,Ignore
Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2581,Medium
Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2582,Ignore
TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2583,Medium
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: the CHAARTED 2 Trial: A trial of the ECOG-ACRIN Cancer Research Group (EA8153).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2584,Ignore
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2585,Ignore
"Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or <em>BRCA </em>defects: A trial in progress.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2586,Ignore
An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2587,Medium
A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2588,Medium
Randomized prospective phase 3 trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2589,Medium
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2590,Ignore
"VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of <sup>177</sup>Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2591,Medium
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,2592,Ignore
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2593,Ignore
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2594,Medium
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2595,Medium
"Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2596,Medium
Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2597,Medium
"ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2598,Ignore
Recurrence and survival after robotic-assisted radical hysterectomy (RRH) for early-stage cervical cancer (CC): Experience may matter.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2599,Ignore
"CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer-A phase III, randomized, double-blind, multicenter study.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2600,Medium
Prognostic significance of the number of pelvic lymph-nodes resection in patients with cervical adenocarcinoma: An analysis from JGOG 1070S study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2601,Ignore
Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2602,Ignore
Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,1,0,2603,Low
"The prognostic significance of white adipose tissue inflammation in advanced-stage, high-grade, and serous endometrial cancers.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2604,Ignore
Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2605,Medium
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Gynecologic Cancer,0,0,2606,High
SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (<em>gBRCAmut</em>).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,1,0,2607,Low
Impact of BRCA mutation status and time to platinum resistance on patients with advanced ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2608,Ignore
Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2609,Ignore
Use of nivolumab as salvage therapy in heavily pretreated patients with gynecologic malignancies.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2610,Ignore
Trends of endometrial cancer incidence from 2000 to 2015 in the United States.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2611,Low
Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,1,0,2612,Low
Association of total hysterectomy with survival among newly diagnosed uterine cancer patients with distant organ metastasis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2613,Ignore
p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE-translational study group.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2614,Ignore
"A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2615,Medium
Molecular stratification of endometrioid ovarian carcinomas.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2616,Ignore
Comprehensive genomic analysis of mucinous ovarian cancer reveals unique therapeutic vulnerabilities.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2617,Ignore
Feasibility of visual inspection with acetic acid (VIA) screening for cervical cancer in Tanzania with emphasis on special populations.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2618,Low
"Impact of non-compliance with guidelines in early type 1 endometrial cancers management, study from FRANCOGYN group.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2619,Ignore
Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2620,Ignore
BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2621,Ignore
Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2622,Ignore
Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2623,Ignore
"Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2624,Ignore
Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2625,Ignore
DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE<sup>1</sup> trial): T cell responses and tumor infiltration correlate with tumor regression.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2626,Ignore
Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: Association of favorable response rates in a phase I/II study with an immunotherapeutic effect.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2627,Medium
Recurrence of ovarian cancer in <em>BRCA</em>wt patients without maintenance therapy: Real-world evidence.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,1,0,2628,Low
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2629,Ignore
"PD-L1 expression, DNA mismatch repair genes, and HPV types in cervical squamous cell carcinoma.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2630,Ignore
The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2631,Ignore
"Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2632,Ignore
Comparative benefit of interstitial needles in addition to intracavitary applicators in the treatment of locally advanced cervical cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2633,Ignore
Real life efficacy and safety data of bevacizumab-based front line treatment in advance or metastatic ovarian cancer patients: Focus on patients with malignant ascitesA phase IV study.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2634,Medium
Clinically significant discrepancy between clinical and pathologic stage of early-operable cervical cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2635,Ignore
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2636,Medium
Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2637,Ignore
Mismatch repair deficiency as a predictor of adjuvant radiotherapy response in endometrioid endometrial carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2638,Ignore
"Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2<em> </em>mutation in the phase III SOLO1 trial.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2639,Medium
How long have we got? The accuracy of physicians estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2640,Ignore
Cervical cancer harboring a Rb1 mutation may sensitize to cisplatin via PI3K/AKT pathway by regulating apoptosis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2641,Ignore
Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials.,1,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Gynecologic Cancer,0,0,2642,Medium
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m<sup>2</sup> and 40 mg/m<sup>2</sup> in patients with platinum-resistant Müllerian carcinoma (JGOG3018).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2643,Medium
Comparison of definitive cervical cancer management with concurrent chemotherapy and radiation between two centers with variable resources and opportunities for improved treatment delivery.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2644,Ignore
Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,1,0,0,0,0,Gynecologic Cancer,0,0,2645,High
Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2646,Ignore
Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2647,Ignore
"Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2648,Ignore
Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2649,Ignore
Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2650,Ignore
Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2651,Ignore
Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2652,Ignore
T cell trafficking within the peritoneal tumor environment and ovarian cancer progression.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2653,Ignore
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2654,Ignore
"Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2655,Medium
Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2656,Ignore
Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2657,Ignore
Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2658,Ignore
"A phase II, open labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer: KCOGG1303 study.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2659,Medium
Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)A real-life ambispective study.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2660,Medium
Patient preferences for maintenance PARP therapy in ovarian cancer treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2661,Ignore
Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous ovarian cancer.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2662,Medium
Everolimus plus letrozole treatment of recurrent gynecologic cancers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2663,Ignore
"ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2664,Medium
"Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2665,Medium
"NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2666,Medium
"BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2667,Ignore
"KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2668,Medium
EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2669,Medium
"DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2670,Medium
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2671,Medium
"ENGOT-Ov41/ GEICO-69-O/ ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,2672,Medium
A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2673,Ignore
"Tumor volume, circulating tumor cells, and cfDNA changes during radiotherapy in patients with head and neck cancer.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2674,Ignore
Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2675,Medium
Risk of mortality varies by type of fat consumed in a longitudinal cohort of head and neck cancer patients.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2676,Low
Cost-effectiveness analysis of chemoradiation compared to radiation alone in the treatment of nonmetastatic oropharyngeal cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2677,Ignore
"A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physicians choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,1,0,2678,Low
Is there a benefit of adding surveillance imaging to frequent history and physical exams in patients treated definitively for head and neck squamous cell carcinoma?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2679,Ignore
"Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using EpsteinBarr virus DNA and TNM stage: A Big data analysis of 9,160 endemic cases.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2680,Ignore
Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2681,Ignore
"ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notch<sup>act mut</sup>).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2682,Ignore
"A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2683,Medium
Safety of nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2684,Medium
Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2685,Medium
"KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,1,0,2686,Low
Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2687,Ignore
"Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2688,Ignore
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2689,Medium
A phase II  randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2690,Medium
"Association of single nucleotide polymorphisms within genes in NF-<U+03BA>B, TGF-ß, and JNK signaling pathways with the risks of nasopharyngeal carcinoma in Chinese Han.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2691,Ignore
Immune signatures associated with response to neoadjuvant PD-1 blockade in oral cavity cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2692,Ignore
Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2693,Medium
Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2694,Ignore
Safety and efficacy of docetaxel combined with cisplatin as induction chemotherapy followed by cisplatin concurrent chemoradiotherapy plus gemcitabine as adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A prospective and multicenter phase II trial.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2695,Medium
"Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally ad­vanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2696,Medium
Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC.,0,01-06-2019,0,0,0,1,0,0,0,0,1,0,0,Head and Neck Cancer,0,0,2697,Medium
Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2698,Medium
Impact of antiviral prophylaxis in HSV positive patients treated with concurrent chemoradiotherapy for head and neck cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2699,Ignore
Impact of smoking cessation in locally advanced head and neck cancers undergoing radiation.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2700,Ignore
Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)An update and retrospective review of non-study patients.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2701,Medium
Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of the head and neck.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2702,Medium
Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2703,Ignore
Efficacy and safety of immune checkpoint inhibitors in elderly patients (=70 years) with squamous cell carcinoma of the head and neck.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2704,Medium
"Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2705,Medium
Outcomes of post-operative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2706,Ignore
Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2707,Ignore
Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2708,Ignore
"An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2709,Medium
Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2710,Ignore
Prophylactic gabapentin decreases fatigue and swallowing difficulty in patients undergoing concurrent chemo-radiation (CCR) for head and neck cancer (HNC): Interim results from a randomized controlled trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,1,2711,High
"A randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2712,Ignore
Role of the oral and gut microbiota as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2713,Ignore
Hafnium oxide nanoparticles NBTXR3 activated by radiotherapy as a new therapeutic option for elderly/frail HNSCC patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2714,Ignore
Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2715,Ignore
Prognostic impact of baseline circulating tumor cells (CTCs) detected by the isolation by size of epithelial tumor cells (ISET) in locally advanced head and neck squamous cell carcinoma (LAHNSCC): Results of a prospective study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2716,Ignore
Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally-advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2717,Ignore
Pretreatment obesity prolongs survival in elderly patients (=65 years) with head and neck cancer (HNC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2718,Ignore
Depth of invasion in early oral cancers: Is it an independent prognostic factor.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2719,Ignore
Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2720,Ignore
Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2721,Ignore
A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients<span style=color: #1a1a1a; font-family: Helvetica; font-size: x-large; color=#1a1a1a face=Helvetica size=5></span><span style=color: #1a1a1a; font-family: Helvetica; font-size: x-large; color=#1a1a1a face=Helvetica size=5></span>The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2722,Medium
A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2723,Medium
"High-dose, short-duration, intra-arterial cisplatin therapy for oral cancer.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2724,Ignore
Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2725,Medium
A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2726,Medium
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2727,Medium
"Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2728,Medium
Safety and antitumor activity of accelerator-based boron neutron capture therapy in patients with inoperable recurrent and locally advanced head and neck cancer: A phase II study.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2729,Medium
Metformin treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients induces an anti-tumorigenic immune response.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2730,Ignore
Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2731,Ignore
Racial disparities in outcome among head and neck cancer patients in the United States: An analysis using SEER-Medicare linked database.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2732,Ignore
Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2733,Ignore
"A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2734,Ignore
A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2735,Ignore
CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2736,Ignore
Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2737,Ignore
Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2738,Ignore
Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2739,Ignore
Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2740,Medium
PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2741,Ignore
"NISCAHN: A Phase II, multicenter nonrandomized trial aiming at evaluating Nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2742,Medium
Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,2743,Ignore
A Prospective blinded study of 1000 cases analyzing the role of artificial intelligence: Watson for oncology and change in decision making of a Multidisciplinary Tumor Board (MDT) from a tertiary care cancer center.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2744,Ignore
Does the innovative 4R Cancer Care Delivery Model improve patient self-management in safety net and non-safety net centers?,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2745,Medium
Multi-institution quality improvement in supportive oncology: Results of the Coleman Supportive Oncology Collaborative (CSOC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2746,Ignore
Impact of race/ethnicity in the clinical presentation and outcomes of patients with multiple myeloma in an underserved urban population.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2747,Ignore
Analysis of racial distribution amongst patients in phase III cancer clinical trials.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2748,Medium
Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2749,Ignore
Prospective study of pain outcomes associated with contralateral prophylactic mastectomy in women with nonhereditary breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2750,Ignore
"Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2751,Ignore
Cervical cancer screening in incarcerated women: An experience from the first cervical cancer screening campaign in a southern Thailand correctional facility.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2752,Low
Impact of cancer in pulmonary embolism presentation and outcomes: A large academic center study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2753,Ignore
Reasons for discordance in treatment approaches between oncology practice and clinical decision support in China.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2754,Ignore
Capacity to provide specialized care for older adults in community oncology practices: Results of the NCI Community Oncology Research Program (NCORP) Landscape survey.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2755,Ignore
Utilization of value stream mapping to improve chimeric antigen receptor (CAR) T-cell patient experience at an academic medical center (AMC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2756,Ignore
Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2757,Ignore
Decreasing postoperative opioid prescriptions in ambulatory extended recovery patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2758,Ignore
Active search for toxicity reduces delay on chemotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2759,Ignore
Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) in TRANSCEND NHL 001.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2760,Ignore
"Proactive, multidisciplinary approach to supportive medicine: Improving health outcomes and care utilization.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2761,Ignore
The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network.,0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2762,High
Patient related outcomes in cancer patients in Croatia.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2763,Ignore
Clinical and economic outcomes of pegfilgrastim in metastatic colorectal cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2764,Ignore
Impact of an oncology urgent care clinic on emergency department rates.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2765,Ignore
Venous thromboembolism (VTE) in patients with ALK-rearranged non-small cell lung cancer (ALK-LC): A population-based cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2766,Ignore
Esophageal cancer in Hispanic patients: A demographic analysis of the National Cancer Database.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2767,Ignore
"Incidence and outcome of interval breast cancer among women participating in the provincial population based screening program in manitoba, Canada.",0,01-06-2019,1,0,1,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2768,Low
"Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2769,Ignore
A weighted criterion-based approach to value assessment of oncology drugs.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2770,Ignore
QOL assessment integrated into the clinical care of cancer survivors to identify needs and direct care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2771,Ignore
Reproductive health in cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2772,Ignore
Evaluating the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) value frameworks for Food and Drug Administration (FDA) approved checkpoint inhibitors (CIs).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2773,Ignore
"Virtual visits for children, adolescents, and young adults with cancer.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2774,Ignore
Evaluation of a risk-based approach to follow-up care for breast cancer survivors: From oncology specialist to primary care provider (PCP).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2775,Ignore
Leveraging a conversational agent to support adherence to oral anticancer agents: A usability study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2776,Ignore
"Association between age, risk of severe (Grade 3-4) immune-related adverse events (sirAE), and mortality in patients receiving immune checkpoint inhibitors (ICI).",0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2777,Low
Impact of timing of lung resection on survival for clinical stage I and II lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2778,Ignore
Racial comparisons in receipt of timely guideline-based colon cancer treatment in an equal-access health system.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2779,Ignore
Use of machine learning to identify relevant research publications in clinical oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2780,Ignore
Disparities in lung cancer outcomes for veterans with comorbid mental disorders.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2781,Ignore
Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2782,Ignore
Clinical impact of the Mexican healthcare system Seguro Popular on breast cancer survival.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2783,Ignore
Mortality within 30 days of immunotherapy (checkpoint inhibitors) in metastatic cancer patients treated at Australian tertiary cancer center.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2784,Low
The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2785,Ignore
The effects of immunotherapy and novel therapies on medical oncology work load in a Canadian province.,0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2786,High
A blinded evaluation of a clinical decision-support system at a regional cancer care center.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2787,Ignore
Scope of practice of advanced practice providers (APP) in US community oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2788,Ignore
"Adherence to the guidelines: A comparison of biomarker testing implementation in metastatic non-squamous, non-small cell lung cancer in university versus community institutions.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2789,Ignore
Clinical benefit and prices of cancer drugs in the United States and Europe.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2790,Ignore
Australian population-based study of single- versus multi-fraction palliative radiotherapy for bone metastases.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2791,Ignore
"Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2792,Medium
Impact of Oncology Care Model (OCM) reporting requirements on quality of care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2793,Ignore
A living systematic review of immune checkpoint inhibitors in cancer patients: A novel platform for evidence synthesis in oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2794,Ignore
Unique perspectives from the transgender community: A retrospective chart review of cancer care needs for transgender patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2795,Ignore
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2796,Ignore
Deployment and integration of a cognitive technology in China: Experiences and lessons learned.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2797,Ignore
Trends in the use of proton beam therapy among newly diagnosed cancer patients in the United States.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2798,Ignore
Diagnostic and treatment delays in young women with breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2799,Ignore
"A novel patient-centric approach between sites, CRO, and sponsor to accelerate FPI and drive more patients into oncology protocols.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2800,Ignore
Low nationwide utilization of adjuvant chemotherapy (AC) in elderly patients with localized non-small cell lung cancer (NSCLC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2801,Ignore
Watson for oncology applied to teaching and remote consulting model.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2802,Ignore
"Evaluation of quality of life, satisfaction and cost of care in metastatic colorectal cancer patients receiving ambulatory chemotherapy.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2803,Ignore
Assessment of enrollment characteristics for Childrens Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2804,Medium
Economic impact of the 31-gene expression profile test in the Medicare-eligible population with cutaneous melanoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2805,Ignore
Impact of specialist palliative care delivered over three months prior to death on a colorectal cancer patients risk of experiencing aggressive end-of-life care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",1,0,2806,Low
Association of diagnosing physician and hospital characteristics with the use of radical cystectomy among patients with muscle-invasive bladder cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2807,Ignore
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2808,Low
Risk stratification and daily symptom monitoring for oncology patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2809,Ignore
A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2810,Ignore
Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2811,Ignore
Real-world effectiveness of approved anticancer agents among Medicare beneficiaries.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2812,Ignore
Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (Febrile) neutropenia and expanded access based on budget neutral basis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2813,Ignore
Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2814,Ignore
Forecasting the global need for high-dose methotrexate to prevent and mitigate shortages.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2815,Ignore
Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2816,Ignore
Prospective comparative effectiveness trial of multidisciplinary lung cancer (LC) care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2817,Ignore
Validation of an oncology-specific instrument to measure cancer patients perception of care coordination.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2818,Ignore
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2819,Ignore
Wheres my doctor? the impact of the primary oncologists visit with their hospitalized patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2820,Ignore
Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2821,Ignore
Creation of a virtual cancer care network for remote oncology treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2822,Ignore
Delay in receipt of newly prescribed oral anticancer drugs.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2823,Ignore
Identifying and predicting the most costly patients in oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2824,Ignore
Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCOs CancerLinQ database.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2825,Low
Impact of cardiovascular comorbidities on mortality in patients admitted for neutropenic fever in 2016.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2826,Low
The diagnosis and outcomes when the outpatients receiving chemotherapy visited the emergency room: A tertiary referral center retrospective study of 734 cases.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2827,Ignore
Caveat medicus: Harrowing experiences of clinicians who identify and publish near-fatal oncology associated adverse drug reactions.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2828,Ignore
Safety and outcomes of a cancer patient urgent care clinic.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2829,Medium
Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2830,Ignore
Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2831,Medium
Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer?,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2832,Medium
Nurse Navigators telephone and web application follow-up intervention for patients treated with oral anticancer medication: an optimization of oncologists' medical time.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2833,Ignore
Sustaining the gains in cancer care from the oncology care model.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2834,Ignore
Association of providers prescribing patterns with postsurgical opioid use among cancer patients undergoing curative-intent surgery.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2835,Ignore
Desire to address costs at time of treatment decisions among patients with metastatic breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2836,Ignore
Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2837,Ignore
"National cancer expenditure analysis in the United States Medicare population, 2013.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2838,Ignore
Survivorship care: Improving delivery of care plans for hematology patients at the Washington Cancer Institute (WCI).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2839,Ignore
Development of a financial navigation program to ease the burden of financial toxicity.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2840,Ignore
Total cost of care for patients (pts) with stage II colon cancer (CC-II): A SEER-Medicare analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2841,Ignore
Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2842,Ignore
Self-reported health and survival in older patients diagnosed with multiple myeloma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2843,Ignore
Impact of travel time on healthcare costs and resource utilization by phase of care for older cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2844,Ignore
Qualifying sites for oncology clinical trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2845,Ignore
National lung cancer screening utilization trends in the Veterans Health Administration.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2846,Low
Cost-effectiveness of CHOP in treating DLBCL in Malawi.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2847,Ignore
Effectiveness of mobile computerized tomographic (CT) lung scanning unit for early diagnosis of lung cancer in under-served populations.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2848,Ignore
Reporting of patient reported outcome (PRO) in clinical trials: A systematic review of clinical trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2849,Ignore
Patient reported outcomes and predictors of distress.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2850,Ignore
Online advertising and marketing claims by providers of proton beam therapy: Are they guideline based?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2851,Ignore
A framework for building a clinically relevant risk model.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2852,Ignore
Can high-volume surgeons achieve optimal outcomes at low-volume hospitals? Implications for the Leapfrog Initiative and regionalization of high-risk surgical oncology procedures.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2853,Ignore
Clinical utility and reimbursement for expanded genomic panel testing in adult oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2854,Ignore
"Hormone replacement therapy (HRT) and risk of distant recurrence in newly diagnosed ER+, node-negative (N-) breast-cancer (BC) patients: A retrospective population-based matched-cohort study.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2855,Ignore
"Access to care and financial burden for patients with breast cancer in Ghana, Kenya, and Nigeria.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2856,Ignore
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2857,Ignore
"Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2858,Ignore
A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2859,Ignore
Cost of oral cancer drugs: Trends in the United States Medicare population in 2013 and 2015.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2860,Ignore
Using real-world cohorts to assess the generalizability and relevance of randomized clinical trials (RCTs).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2861,Ignore
Followup mammography after breast conservation therapy: Is 3D Tomosynthesis(3DT) worth it?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2862,Ignore
Evaluating the impact of telephonic nurse care management during high toxicity chemotherapy treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2863,Ignore
Relationship of emergency department use pre- and post-cancer diagnosis in safety-net adults.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2864,Medium
Progression free survival (PFS) benefits of immuno-oncology agents (IOs) and implications for market cost-sharing inefficiencies.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2865,Medium
High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2866,Medium
Quality control system of Watson for oncology: Artificial intelligence for supporting clinical decisions in oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2867,Ignore
Population-based cancer predisposition testing as a component of newborn screening: A cost-effectiveness analysis.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2868,Low
Participant hopes and expectations regarding outcomes of genomic sequencing research in pediatric oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2869,Ignore
Characterization of oncologic patient visits at the emergency department (ED) at an Austrian tertiary care center.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care",0,0,2870,Ignore
Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2871,Ignore
Frailty among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2872,Ignore
Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2873,Ignore
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,1,2874,High
Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2875,Ignore
Impact of protein supplementation on lean muscle mass in adult survivors of childhood cancer engaged in resistance training.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2876,Ignore
Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2877,Ignore
Subsequent neoplasm risk associated with rare variants in DNA repair and clinical radiation sensitivity syndrome genes: A report from the Childhood Cancer Survivor Study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2878,Ignore
Using blended learning to improve education on clinical pathways for breast cancer management in Nigeria: Preliminary results.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Education Research and Professional Development,0,1,2879,High
The promoting resilience in stress management (PRISM) intervention for parents of children with cancer: A randomized controlled trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,2880,Ignore
Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2881,Ignore
Training of oncologists: Results of a global survey.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2882,Ignore
From presentation to paper: Gender disparities in oncological research.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2883,Ignore
Implementing a quality improvement curriculum for medical oncology residents: A pilot study at the Ottawa Hospital Cancer Centre.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2884,Ignore
Working together in cancer care: An academic community partnership for a diverse patient population.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2885,Ignore
Burnout and level of mental functioning in oncology staff.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2886,Ignore
Online education about immunotherapy for melanoma: Outcomes over time.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2887,Ignore
Humanism in global oncology curricula: An emerging priority.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2888,Ignore
The higher school of oncology: An educational program adopting the western oncology experience in Russia.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2889,Low
Medical oncologists experience with returning molecular tumor profiling to patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2890,Ignore
Targeting B-cell malignancies: Impact of an educational curriculum on BTK inhibitors.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2891,Low
Cross-cultural validation of a medical leadership competencies survey in Latin-American physicians: A multinational study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2892,Ignore
Developing an inspired leader: How to maximize human talent to maximize operating results.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2893,Ignore
Implementation of competency-based medical education in a Canadian medical oncology training program: Lessons from our first year.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2894,Ignore
Collaborative learning workshops to optimize integration of cancer immunotherapies in the community setting.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2895,Ignore
Oncology fellows knowledge and current practice regarding outpatient oncology and palliative care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,1,0,2896,Low
Medical oncology trainees perceptions of their education and preparedness for independent practice.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2897,Ignore
ASCO Direct GU: A multistakeholder blended-learning project to make global education local.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2898,Ignore
Satisfaction of general versus specialized continuity clinic in hematology oncology fellowship training: A survey.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2899,Ignore
"It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical oncology (SO) program leadership positions.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2900,Ignore
TeamX integrative oncology scholars: Harnessing the potentials of students in shaping oncological care.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2901,Ignore
Believe the H.I.P.E.: Hematology-Oncology Inter Professional Education to improve provider collaboration at an inpatient tertiary medical center.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2902,Ignore
Enhancing evidence-based medicine skills in oncology training with cognitive technology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2903,Ignore
Gender-based analysis of pre-residency research productivity among a current United States radiation oncology resident class.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2904,Ignore
Support structures for female physicians: Motivations and barriers to gender-specific conferences and symposia.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2905,Ignore
Management of muscle-invasive bladder cancer with bladder preservation in Russia: A survey-based analysis of current practice and the impact of an educational workshop on clinical expertise.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2906,Low
FitFirms: A wellness option for oncology trainees.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2907,Ignore
Choosing oncology as specialization: Medical students' perception after clinical rotation in cancer center.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2908,Ignore
Creation and development of the National Cancer Control Plan in Russia.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2909,Ignore
Mindful fellows: Study results from a pilot wellness curriculum in hematology oncology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2910,Ignore
Non-oncologist physician knowledge of radiation therapy at an urban community hospital.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2911,Ignore
Evaluation of Colorado oncology providers on the use of medical marijuana.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2912,Ignore
Development of an Art of Oncology curriculum to mitigate burnout and foster solidarity among hematology/oncology fellows.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2913,Ignore
Integrating concept maps into a medical student oncology curriculum.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2914,Ignore
"Innovation, education, and research: A multidisciplinary survivorship care model.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2915,Ignore
A novel qualitative methodology study to characterize discrimination and inclusion among hematology/oncology trainees.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2916,Ignore
Simulated patient encounter to assess and improve fellows' ability to manage chemotherapy infusion reactions.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Education Research and Professional Development,0,0,2917,Ignore
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2918,High
Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2919,Ignore
"IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2920,Medium
Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2921,Ignore
A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2922,Ignore
"Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T<sup> </sup>cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2923,High
Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2924,Ignore
Association between MDM2/MDM4 amplification and PD-1/PD-L1 inhibitors-related hyperprogressive disease: A pan-cancer analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2925,Ignore
Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2926,Medium
"Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2927,Ignore
"An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (<i>P</i>) in previously treated metastatic triple-negative breast cancer (mTNBC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2928,Medium
Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2929,High
Efficacy and safety of CAR19/22 t-cell cocktail therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2930,Medium
Tissue immune response in epithelial ovarian carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2931,Ignore
Gut microbiota and clinical outcomes treated with nivolumab in Chinese non-small cell lung cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2932,Medium
Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2933,Ignore
Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2934,Medium
Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCOs CancerLinQ.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2935,Ignore
Overcoming genetically-based resistance mechanisms to PD-1 blockade.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2936,Ignore
"Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2937,High
Correlation of circulating EBV-targeted cytotoxic T lymphocyte precursors (EBV-CTLp) and clinical response following tabelecleucel (tab-cel) infusion in patients with EBV-driven disease.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2938,Ignore
MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2939,Medium
ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2940,Ignore
"Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2941,High
Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multi-site multi-agent study.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2942,Medium
CD8+ T cells in tumor parenchyma and stroma by image analysis (IA) and gene expression profiling (GEP): Potential biomarkers for immuno-oncology (I-O) therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2943,Ignore
Tumor mutational burden (TMB) profile of <em>K-RAS/TP-53</em> co-mutation in metastatic non-small cell lung cancer (m-NSCLC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2944,Ignore
Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2945,Ignore
"A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2946,Medium
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2947,Ignore
Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2948,Ignore
Application of artificial intelligence to predict a new class of novel synthetic lethal targets.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2949,Ignore
Response to immune checkpoint inhibition and survival in <em>BRCA-</em>associated recurrent ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2950,Ignore
Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2951,Ignore
Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2952,Ignore
Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2953,Ignore
"Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2954,Ignore
"Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2955,Ignore
"Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2956,High
Pan-tumor prognostic value of multiple immune protein expressions.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2957,Ignore
"Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2958,Medium
CD4<sup>+ </sup>T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2959,Ignore
Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2960,Medium
Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2961,Ignore
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2962,Medium
Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2963,Ignore
"Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2964,Ignore
Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2965,Ignore
Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2966,Ignore
Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs).,0,01-06-2019,1,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2967,Low
"Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and OAK): A combined analysis of two multicenter, randomized, phase II/III trials.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2968,Medium
"Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2969,High
The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a Watch and Wait strategy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2970,Ignore
Immune profiling of tumor-infiltrating T cells using mass cytometry.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2971,Ignore
"Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2972,Medium
Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2973,Low
Effect of exonic microsatellite instability of B2M on the predictability of MSI/dMMR for immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2974,Ignore
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2975,Ignore
A phase I study evaluating COM701 in patients with advanced solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2976,Ignore
"A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).",0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2977,High
"A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2978,Ignore
Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2979,Medium
"Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2980,Ignore
"A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2981,High
"A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2982,Medium
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2983,Ignore
"A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.",0,01-06-2019,0,0,0,1,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2984,High
"The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.",1,01-06-2019,0,0,1,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2985,Medium
"The INSIGHT Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2986,Medium
"An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2987,Medium
Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2988,Ignore
A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2989,Medium
"A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.",0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2990,High
"A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2991,Medium
Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2992,Medium
"An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2993,Medium
A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2994,Ignore
"Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARa) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2995,Medium
Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase immunotherapy (IO) trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2996,Ignore
"AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,1,2997,High
Measuring the long-term tail of curve survival benefits in oncology trials: A comparison of the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2998,Ignore
"Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,2999,Ignore
Community and academic partnerships: Moving a new generation of clinical trials in NCI community oncology research program (NCORP) into community oncology practices.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3000,Ignore
2D and 3D thermally bioprinted human MCF-7 breast cancer cells: A promising model for drug discovery.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3001,Ignore
Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3002,Ignore
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3003,Ignore
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3004,Ignore
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3005,Ignore
Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3006,Ignore
Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3007,Ignore
First-in-human (FIH) trial evaluating immune activation and safety of PIN- 2 administered intravenously to patients with advanced solid tumors.,0,01-06-2019,0,0,0,1,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3008,High
"Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3009,Medium
"Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3010,Ignore
Organ dysfunction (dys) and clinical outcomes in patients (pts) treated with immune checkpoint inhibitors (ICIs).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3011,Medium
Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3012,Ignore
"Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3013,Medium
Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3014,Ignore
Association of an inflammatory gene signature with CD8 expression by immunohistochemistry (IHC) in multiple tumor types.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3015,Ignore
Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3016,Ignore
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3017,Ignore
Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3018,Ignore
Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3019,Ignore
Cardiovascular complications of immune checkpoint inhibitor therapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3020,Ignore
"Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3021,Medium
Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3022,Low
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3023,Ignore
"A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3024,Medium
Patient survival with immune checkpoint inhibitors and targeted agents in phase 1 trials: A propensity score weighted analysis.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3025,Medium
Understanding contribution and independence of multiple biomarkers for predicting response to atezolizumab.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3026,Ignore
Association between past medical history (PMH) of autoimmune events and adverse events of special interest (AESI).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3027,Ignore
"Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3028,Ignore
A donor-dependent in vivo model for single agent and drug combination cytokine release syndrome safety evaluation.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3029,Medium
"A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3030,Medium
A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3031,Medium
Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3032,Ignore
Survival by stage and tumor measurability in metastatic melanoma patients treated with autologous dendritic cell tumor cell vaccines.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3033,Ignore
Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3034,Medium
"Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3035,High
Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3036,Ignore
Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3037,Ignore
THOR-707: Using synthetic biology to reprogram the therapeutic activity of interleukin-2 (IL-2).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3038,Ignore
TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3039,Ignore
"A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3040,Medium
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3041,Medium
"Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3042,Ignore
"Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3043,Medium
"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3044,Medium
High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3045,Low
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3046,Medium
Can serum IL-6 levels predict sarcopenia and poor outcome in relapsed/refractory gynecologic cancer patients?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3047,Ignore
"First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3048,High
Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3049,Ignore
JAVELIN BRCA/ATM: A phase 2 trial of avelumab (antiPD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3050,Medium
Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3051,Medium
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3052,Medium
"A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.",0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3053,High
"A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3054,Medium
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3055,Medium
SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3056,Medium
Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3057,Ignore
A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3058,Ignore
SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3059,Medium
Prospective observational study for treatment resistance-related gene screening using plasma circulating tumor DNA in the third generation EGFR TKI osimertinib therapy elucidator.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3060,Low
A phase I study of [<sup>225</sup>Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3061,Medium
Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3062,Low
Machine learning algorithm analysis using a commercial 592-gene NGS panel to accurately predict tumor lineage for carcinoma of unknown primary (CUP).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3063,Ignore
Development and clinical validation of Lantern Pharmas AI engine: Response algorithm for drug positioning and rescue (RADR).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3064,Ignore
"First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.",0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3065,High
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3066,Medium
FGFR2: A pan-genomic target.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3067,Ignore
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.,1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3068,High
"The landscape of <em>RET</em> alterations from 56,970 adult patients with cancer: Clinical implications.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3069,Ignore
"A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3070,Medium
Long-term follow-up of pharmacokinetics (PK) and immunogenicity of the antiPD-1 antibodies nivolumab (Nivo) and pembrolizumab (Pembro) in real-world practice.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3071,Ignore
"Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3072,Medium
A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3073,Ignore
Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3074,Medium
Analytical validation of a tumor-agnostic integrated multianalyte circulating tumor DNA (ctDNA) assay in early-stage cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3075,Ignore
c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3076,Ignore
"Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3077,Medium
"Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3078,Medium
"A phase I multiple-dose escalation study to assess the safety, tolerability, and pharmacokinetics of VEGF-receptor inhibitor telatinib (EOC315) in Chinese patients with advanced solid tumors.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3079,Medium
A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3080,Medium
No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3081,Medium
Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3082,Ignore
Genomic somatic alterations of human epidermal growth factor-2 (HER2) gene: A pan-cancer analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3083,Ignore
"Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3084,Medium
A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3085,Ignore
Radiomics features to identify distinct subtypes of triple-negative breast cancers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3086,Ignore
MET exon 14 skipping analogs: Rare but potentially clinically actionable.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3087,Ignore
Identification and validation of a serum microRNA panel for detection of early-stage breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3088,Ignore
A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3089,Medium
Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3090,Ignore
NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3091,Ignore
"PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancersSafety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3092,Medium
Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3093,Ignore
CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3094,Ignore
Concomitant intake of abiraterone and food to increase pharmacokinetic exposure: Real-life data from a therapeutic drug monitoring program.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3095,Ignore
The dynamic detection of drug area under curve (AUC) guides clinical usage of docetaxel in solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3096,Ignore
Whole transcriptome sequencing in metastatic cancer: A review of expression outliers in 113 metastatic breast cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3097,Ignore
"Prediction of biomarker status, diagnosis and outcome from histology slides using deep learning-based hypothesis free feature extraction.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3098,Ignore
MET<em> </em>kinase domain rearrangements across 10 cancer types.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3099,Ignore
Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3100,Ignore
Utility of somatic mutation panel testing in patients with advanced cancer receiving treatment in an Irish teaching hospital.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3101,Ignore
An artificial intelligence approach to variant calling of ALK resistance mutations.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3102,Ignore
A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3103,Ignore
Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK<em> </em>resistance mutations on amplicon-based liquid biopsy in ALK<em> </em>positive non-small cell lung cancer (NSCLC) patients (pts).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3104,Medium
"Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in <em>EGFR</em>-mutated lung adenocarcinoma (LUAD).",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3105,Ignore
Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3106,Medium
First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using <sup>89</sup>Zr-Df-CPC634 PET/CT.,0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3107,High
The Cancer Molecular Screening and Therapeutics Program (MoST): Actionable mutation frequencies in a population with rare and less common cancers.,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3108,Low
Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3109,Ignore
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3110,Medium
Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (<em>DPYD)</em> genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3111,Ignore
"A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3112,Medium
"First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3113,Ignore
"A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3114,Medium
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3115,Ignore
"A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701).",0,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3116,High
Leeomic: A comprehensive proteomic analysis towards discovery of predictive patterns of protein expression to ribociclib sensitivity and resistanceA compLEEment-1 Canadian correlative sub-study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3117,Ignore
Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3118,Low
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3119,Medium
Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3120,Ignore
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3121,Medium
Determining clinical relevance of genomic heterogeneity in an ethnically diverse cohort of newly diagnosed patients with breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3122,Ignore
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3123,Ignore
Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3124,Ignore
First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.,1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,1,3125,High
Larotrectinib efficacy and safety in adult TRK fusion cancer patients.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3126,Medium
Transcriptome-based cancer type prediction for tumors of unknown origin.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3127,Ignore
"Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3128,Ignore
HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3129,Ignore
A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3130,Ignore
Correlation between <em>NDRG1 </em>gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment).,0,01-06-2019,1,0,0,0,0,0,0,0,0,1,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3131,Low
Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3132,Ignore
Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3133,Ignore
"A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH)<sup> </sup>compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3134,Medium
The whole genome landscape of adult metastatic sarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3135,Ignore
Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3136,Ignore
Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3137,Ignore
Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3138,Ignore
Machine learning methods with salivary metabolomics for breast cancer detection.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3139,Ignore
Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3140,Ignore
A modeling and simulation study of less frequent dosing of nivolumab 480 mg.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3141,Ignore
Development and analytical validation of a 523-gene clinical assay for cell-free DNA.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3142,Ignore
A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3143,Ignore
Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3144,Ignore
"Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3145,Medium
Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3146,Ignore
Mastocheck: Notable plasma protein biomarker for diagnosis of breast cancer in the real clinical practice by using multiple reaction monitoring-based mass spectrometry.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3147,Ignore
[<sup>18</sup>F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3148,Medium
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.,1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3149,High
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3150,Medium
Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3151,Ignore
The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3152,Ignore
Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in patients with solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3153,Ignore
Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3154,Ignore
Rethinking about the dose limiting toxicities (DLTs): They can be equivocal!,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3155,Ignore
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3156,Medium
"Progastrin, a novel ubiquitous cancer blood biomarker for early detection and monitoring.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3157,Ignore
Proteomic profile of high-risk luminal A early breast cancers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3158,Ignore
Clinicopathologic characteristics of <i>NRG1 </i>fusion-positive cancers: A single-institution study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3159,Ignore
Circulating bacterial DNA as a tool towards noninvasive biomarkers for colorectal adenocarcinoma and adenoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3160,Ignore
"Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anticancer treatment.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3161,Ignore
Effectiveness of ASCOs adverse event reporting decision aid: Results from an interventional study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3162,Ignore
A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3163,Ignore
A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3164,Medium
Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3165,Medium
"Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3166,Medium
"Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3167,High
Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3168,Ignore
Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3169,Ignore
"First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3170,High
Cell-specific upregulation of lung cancer signature genes in the small airway epithelium of asymptomatic smokers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3171,Ignore
"Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3172,Ignore
Boosting pazopanib exposure by splitting intake moments: A prospective pharmacokinetic study in cancer patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3173,Ignore
Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3174,Ignore
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3175,Ignore
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,1,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3176,Ignore
"Observational, multicenter, prospective study to assess the impact on patients' outcome of a systematic screening of oncogenic drivers in advanced cancer: The GETHI XX-16 study.",0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3177,Low
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3178,Medium
Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among <em>MET</em> amps in diverse advanced cancer types.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3179,Ignore
Tumor specific DNA in bronchial lavage as a new diagnostic tool in lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3180,Ignore
Integrative analyses of signaling and DNA damage repair pathways in patient-derived xenograft (PDX) models from NCIs patient-derived models repository (PDMR).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3181,Ignore
Preclinical testing of ultra-rapid FLASH total abdominal irradiation demonstrates survival benefit and decreased gastrointestinal toxicity compared to conventional external beam radiation.,0,01-06-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3182,Medium
"Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3183,Medium
The i3+3 design for phase I clinical trials.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3184,Medium
Image-guided surgery for tumor agnostic detection of solid tumors using the pH-activated micellar imaging agent ONM-100.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3185,Ignore
Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3186,Medium
A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3187,Ignore
Host transcriptomic signatures associated with dysbiosis in a preclinical model of lung cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3188,Medium
Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3189,Ignore
A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3190,Ignore
Trial in progress abstract phase I trial of 5-aza-4-thio-2-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3191,Medium
Prediction of olaparib sensitivity for variants of unknown significance in homologous repair genes.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3192,Ignore
"A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3193,High
"A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3194,High
"Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3195,Medium
A phase I open label study evaluating VT1021 in patients with advanced solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3196,Ignore
"A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3197,Medium
A phase II study for prostate cancer monitoring using <sup>18</sup>F-DCFPyL and blood-based biomarkers.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3198,Medium
"A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3199,Ignore
A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3200,Ignore
TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with <em>FGFR</em> alterations identified by circulating tumor DNA.,1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3201,Medium
FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3202,Ignore
TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3203,Medium
Clinical Trial in Progress: The FLEX Big Data Platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3204,Ignore
A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with<em> KRAS</em> G12C mutation.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3205,Medium
Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3206,Ignore
AcSé-ESMART: European Proof of Concept Therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory Tumors in children and adolescents ARM D: Olaparib and Irinotecan.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3207,Ignore
Educational attainment in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3208,Low
Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3209,Ignore
Morbidity and mortality in a national cohort of pediatric patients with hemophagocytic lymphohistiocytosis.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3210,Low
Patient-reported outcomes (PROs) in adult survivors of childhood hematopoietic cell transplant (HCT): A report from the St. Jude lifetime cohort study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3211,Ignore
Long-term health status of high-risk neuroblastoma survivors treated with high-dose chemotherapy and hematopoietic stem cell transplantation.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3212,Ignore
Poverty and survival in targeted immunotherapy clinical trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3213,Ignore
Long term morbidity and mortality among survivors of infant neuroblastoma: A report from the Childhood Cancer Survivor Study (CCSS).,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3214,Low
A novel association between <em>GSTM1</em> null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3215,Ignore
Renal function after treatment for childhood cancer: A report from the St. Jude Lifetime Cohort Study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3216,Ignore
ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3217,Ignore
"Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3218,Ignore
Polygenic risk of subsequent thyroid cancer after childhood cancer: A report from St. Jude lifetime cohort (SJLIFE) and childhood cancer survivor study (CCSS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3219,Ignore
Progression of frailty in young adult survivors of childhood cancer: St. Jude Lifetime Cohort.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3220,Ignore
What is the best therapy for grossly resected synovial sarcoma? Experience of the CWS Study Group.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3221,Ignore
A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3222,Ignore
"Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma in vivo models.",0,01-06-2019,0,0,0,0,0,0,0,0,1,0,0,Pediatric Oncology,0,0,3223,Medium
Cardiac events in survivors of childhood cancer treated in more recent eras: A report from the Childhood Cancer Survivor Study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3224,Ignore
"A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <em>RET</em>-altered cancers.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3225,Ignore
First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3226,Ignore
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3227,Medium
Sponsorship of pediatric oncology interventional trials.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3228,Ignore
Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the childhood cancer survivor study (CCSS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3229,Ignore
Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3230,Ignore
Male fertility preservation (FP) at pediatric cancer centers: A report from the Childrens Oncology Group (COG).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3231,Ignore
A phase II trial testing interventions to shorten time to diagnosis and reduce abandonment of treatment of children with Burkitt lymphoma in Kenya.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3232,Ignore
INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3233,Medium
Incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: A population-based study.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3234,Low
Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).,0,01-06-2019,0,0,1,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3235,Low
"Late toxicities, especially second malignancies, with GWAS analysis in hepatoblastoma cases treated in the Japanese study group for pediatric liver tumor protocol-2.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3236,Ignore
New insights in cisplatin and radiation-induced ototoxicity: A French Childhood Cancer Survivors Study (FCCSS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3237,Ignore
Performance of FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric hodgkin lymphoma (HL) patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3238,Ignore
Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3239,Ignore
"Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3240,Medium
Retroperitoneal soft tissue sarcoma (RPS): Recent outcome improvement and refinement of treatment strategies at a single institution.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3241,Ignore
"A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3242,Medium
MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3243,Medium
"CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3244,Ignore
A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3245,Medium
Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3246,Medium
ARST1321: Pazopanib neoadjuvant trial in non-rhabdomysarcoma soft tissue sarcomas: A report of major wound complications.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3247,Ignore
Multidisciplinary treatment of 99 adult osteosarcoma (OST) patients (pts) with synchronous and metachronous metastases (mets): A retrospective series of the French Sarcoma Group (FSG).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3248,Ignore
Neurofibromatosis 1 (NF1) and gastrointestinal stromal tumors (GISTs): Five-year experience from a regional center in United Kingdom.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3249,Ignore
Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3250,Ignore
Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3251,Ignore
Outcomes of extra-skeletal versus skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3252,Ignore
Immune signature and molecular profiling of radiation-induced sarcoma (RIS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3253,Ignore
Secondary genomic alterations in Ewing sarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3254,Ignore
"Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3255,Medium
Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3256,Ignore
"Interval-compressed vincristine, doxorubicin, cyclophosphamide (VAC), alternating with ifosfamide and etoposide (IE) for adults with Ewing or Ewing-like sarcoma.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3257,Ignore
Clinical characterization of patients with SDHC epimutation in gastrointestinal stromal tumors.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3258,Ignore
Metagenomic discovery of a distinct inflammatory subtype of human angiosarcoma associated with human herpesvirus 7.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3259,Ignore
Identification of genomic alterations by circulating tumor DNA in leiomyosarcoma: A molecular analysis of 73 patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3260,Ignore
A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3261,Medium
Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3262,Ignore
Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3263,Ignore
Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3264,Medium
A single-center retrospective study of patients treated with trabectedin (TRB) with long-term follow up.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3265,Ignore
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3266,Ignore
Determinants of secondary alterations in <em>WWTR1-CAMTA1</em> fusion epithelioid hemangioendothelioma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3267,Ignore
Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3268,Ignore
"Angiosarcoma of bone: A European Muscoloskeletal Oncology Society (EMSOS) multicenter, retrospective study.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3269,Ignore
"Clinical characteristics of nonosteogenic, non-Ewings sarcoma of the bone: Experience at the Toronto Sarcoma Program.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3270,Ignore
Correlation of imatinib plasma trough concentrations with adverse reaction in Chinese gastrointestinal stromal tumors patients.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3271,Ignore
"A phase I/II investigation of nivolumab and ABI-009 (<em>nab</em>-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: Preliminary efficacy and safety results.",1,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,3272,Medium
Frequent mutations of genes predisposing to Rho GTPase signal activation and autophagy inhibition in metastatic soft tissue sarcoma unveiled by paired somatic and germline genomic analyses.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3273,Ignore
Solitary fibrous tumor: A Brazilian cohort analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3274,Ignore
"Improved local relapse-free and overall survival with secondary surgery after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10,931 patients (pts) in NETSARC.",0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,3275,Medium
Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3276,Ignore
Racial disparity in incidence and survival for gastrointestinal stromal tumors (GIST): An analysis of SEER database.,0,01-06-2019,1,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3277,Low
Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3278,Ignore
Pathologic response rates after neoadjuvant therapy for sarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3279,Ignore
Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,3280,Medium
Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies.,1,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Sarcoma,0,0,3281,Medium
"Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.",0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3282,Ignore
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3283,Ignore
Depletion of mutant IDH1 impairs chondrosarcoma growth by downregulating integrins.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3284,Ignore
DNA damage response pathway alterations and clinical outcome in leiomyosarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3285,Ignore
Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT).,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3286,Medium
Von Hippel Lindau: Diagnosis and Emerging Therapies,0,04-06-2019,0,0,0,0,0,0,0,1,0,0,0,From Mutations to Management: Diagnosis and Treatment of Central Nervous System Tumor Susceptibility Syndromes,0,0,3287,High
Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3288,Medium
Case 2. Disparate Molecular and Clinical Risk in Older Patient with ER-Positive and 2/5 Nodes,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Controversies in Breast Cancer Adjuvant Therapy,0,0,3289,Ignore
Workshop Faculty,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,3290,Ignore
Antiviral therapy to reduce hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,3291,Ignore
Creating an Oncology Clinical Trial Information Commons - Panel Moderator,0,01-06-2019,0,0,0,0,0,0,0,0,0,1,0,Biden Cancer Initiative Colloquium: Clinical Trial Enrollment  Breaking the 5% Barrier Once and For All,0,0,3292,Medium
Correlation of BRAF V600E mutation with cardiac involvement assessed by heart imaging in a monocentric series of 205 patients with Erdheim-Chester disease.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,3293,Ignore
Risk of cancer in first-degree relatives of childhood cancer patients: A linked longitudinal population-based registry study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,3294,Ignore
Risk of anxiety and depression in breast cancer survivors compared to women who have never had cancer: A population-based cohort study in the United Kingdom.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,3295,Ignore
A phase II study of PD-1 inhibition for the prevention of colon adenomas in patients with Lynch syndrome and a history of partial colectomy.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology",0,0,3296,Medium
Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3297,Ignore
Immunotherapy disparities in metastatic melanoma.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,3298,Ignore
Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers,0,0,3299,Ignore
Effect of race/ethnicity on long-term cytopenias and major infections in adolescent young adult breast cancer survivors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,3300,Ignore
Single-fraction stereotactic versus standard conventional multifraction radiation for predominantly non-spine bone metastases: A randomized phase II trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,3301,Medium
Does distress screening lead to mental health care in older adult surgical patients?,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,3302,Low
Fitness scale-4 item (FS4) to predict six-month postoperative mortality of cancer patients aged 75.,0,03-06-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship,0,0,3303,Low
Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3304,Ignore
Results of the PI3Kd inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3305,Ignore
Efficacy and time to next treatment following lenalidomide/rituximab (R<sup>2</sup>) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3306,Medium
MAGNIFY: Phase IIIb interim analysis of induction R<sup>2</sup> followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3307,Medium
Blood-based next-generation sequencing analysis of neuroendocrine tumors.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3308,Ignore
Clinical efficacy and toxicity data on phase I study of fosbretabulin in combination with everolimus in neuroendocrine tumors.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3309,Medium
Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3310,Ignore
Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3311,Ignore
Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3312,Ignore
Antitumor efficacy of concurrent everolimus with hepatic transarterial bland embolization (evero-embo) in patients with metastatic well differentiated neuroendocrine tumor (NET).,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3313,Medium
Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3314,Medium
Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.,0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3315,Medium
Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3316,Ignore
Variation in the surgical management of locally advanced pancreatic cancer.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3317,Ignore
Molecular characterization of the tumour microenvironment in neuroendocrine malignancy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3318,Ignore
Molecular profile of ampulla of vater carcinoma (AVC): A rare tumor type with meaningful molecular alterations.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3319,Low
Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO): Results from a phase II multicenter study.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,0,0,3320,Medium
A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaMPRODIGE 63 GERCOR D17-01 study).,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer,1,0,3321,Low
"PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal type: A prospective study.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3322,Ignore
Early imaging biomarker assessment to predict long-term responses for large B-cell lymphoma (LBCL) after CAR-T therapy.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia,0,0,3323,Ignore
Continued improvement in survival in multiple myeloma (MM) including high-risk patients.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3324,Ignore
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.,1,03-06-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3325,High
Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3326,Ignore
Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3327,Ignore
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03).,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3328,Ignore
Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients.,0,03-06-2019,0,0,1,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3329,Low
"Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.",0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3330,Ignore
Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.,1,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3331,Medium
"Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3332,Medium
Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3333,Medium
Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.,1,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3334,Medium
Effect of iFISH defined 1q21 amplification/gain in multiple myeloma patients treated on total therapy protocols.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3335,Ignore
"Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.",0,03-06-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3336,Medium
Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia,0,0,3337,Ignore
Effect of tart cherry on aromatase inhibitor-induced arthralgia (AIA) in nonmetastatic hormone-positive breast cancer patients: A randomized double-blind placebo-controlled trial.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,3338,Ignore
Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: A validation study in Chinese patients.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,3339,Ignore
Immune landscape of the tumor microenvironment to predict prognosis and DNA mutations in patients with lung adenocarcinoma.,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,0,0,3340,Ignore
"Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.",0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,3341,Ignore
Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.,1,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,3342,Medium
"Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II trial (POSTCARD - GETUG-P13).",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,3343,Medium
RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer,0,0,3344,Medium
Safety and efficacy of nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy for locally advanced cervical squamous cell cancer.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,3345,Medium
Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,3346,Ignore
Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,3347,Ignore
Lynch-like syndrome in endometrial cancer: Features of a growing population.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,3348,Ignore
Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,3349,Ignore
Personalized TPF induction chemotherapy on the basis of stathmin expression in patients with locally advanced oral squamous cell carcinoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,3350,Ignore
COX-2 expression and mesenchymal-transition status on circulating tumor cells to predict survival in patients with nasopharyngeal carcinoma: A prospective analysis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,3351,Ignore
Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,3352,Ignore
"Roman: Reduction in oral mucositis with avasopasem manganese (GC4419)Phase 3 trial in patients receiving chemoradiotherapy for locally-advanced, non-metastatic head and neck cancer.",1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer,0,0,3353,Medium
Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced colitis.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3354,Ignore
Effect of subcutaneous multi-peptide active antigen-specific immunotherapy at lymph nodes and tumor sites on clinical outcomes in progressive tumors.,1,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology,0,0,3355,Medium
PDX validation of a 3D microtumor platform.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3356,Ignore
Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3357,Ignore
Changes in DNA hydroxymethylation for the detection of multiple cancers in plasma cell-free DNA.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno),0,0,3358,Ignore
Emergency department (ED) visits and hospitalizations in survivors of childhood cancer in the Childhood Cancer Survivor Study.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology,0,0,3359,Ignore
Prognostic factors and therapeutic options for epithelioid hemangioendothelioma (EHE): A multicenter analysis of a series of fifty-seven cases.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3360,Ignore
Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC).,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3361,Ignore
Efficacy and dosimetry prognostic factors of image guided <sup>125</sup>I seed implantation for locally recurrent soft tissue sarcoma.,0,01-06-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma,0,0,3362,Medium
Complete remission of patients with heavily pretreated uterine sarcomas by weekly bevacizumab and temozolomide.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3363,Ignore
Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma.,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,3364,Ignore
Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3365,Ignore
Pathological complete response rate (pCR) in thirty-three women with triple-negative breast cancer (TNBC) treated with a neoadjuvant carboplatin-based regimen.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3366,Ignore
Pharmacokinetic (PK) characterization of irinotecan liposome injection in patients (pts) with metastatic breast cancer (mBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3367,Ignore
Chemotherapy-related outcomes in triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3368,Ignore
Modeling longer-term efficacy of neratinib in the extended adjuvant setting for early-stage breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3369,Medium
Investigating the utility of breast cancer (BC) molecular signatures and immune signature profiling (ISP) as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy + trastuzumab (NAC+T) in HER2+ BC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3370,Ignore
Quality of life after preoperative radio-/chemotherapy in locally advanced breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3371,Ignore
Validation of a panel of risk factors for predicting breast cancer reappearance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3372,Ignore
Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3373,Ignore
Impact of delaying initiation of adjuvant chemotherapy and trastuzumab in patients with early-stage HER2-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3374,Ignore
"Use of ovarian suppression with endocrine therapy among premenopausal United States women with breast cancer, 2001-2016.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3375,Ignore
The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3376,Ignore
Role of adjuvant chemotherapy in small (=5 mm) node-negative and hormone receptor-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3377,Ignore
"Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3378,Ignore
"Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3379,Ignore
FDG uptake to reflect NLR and expression levels of TILs and PD-L1 in patients with primary breast cancer: Tumor inflammation and immunity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3380,Ignore
Clinical relevance of 21-gene recurrence score with lymph node involvement in HR+HER2- early breast cancer: A tumor size-match paired cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3381,Ignore
Efficacy and safety of intensified platinum-based neoadjuvant chemotherapy in locally advanced triple-negative breast cancer: Preliminary results of non-randomized phase II study.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,1,3382,High
Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+ breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3383,Ignore
Biomarkers involved in the neoadjuvant therapy response in triple-negative and Her2+ subtypes breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3384,Ignore
Genomic profiling of residual tumor after neoadjuvant chemotherapy for breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3385,Ignore
A prognostic nomogram to predict the bene<U+FB01>t of adjuvant radiotherapy for resected in<U+FB02>ammatory breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3386,Ignore
Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3387,Ignore
Impact of surgery type on survival in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3388,Ignore
"Correlation between TopIIa and ki-67 expression in tumors of luminal, primary operable breast cancer without HER2/neu overexpression in postmenopausal women as a prognostic factor.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3389,Ignore
Serial circulating tumor DNA analysis indicating the efficacy and prognosis of neoadjuvant chemotherapy for locally advanced breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3390,Medium
Clinical practice patterns on the use of adjuvant bisphosphonate for early breast cancer: A Canadian perspective.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3391,Ignore
BRCA1 tumor expression and clinical outcome in Uruguayan breast cancer patients diagnosed before the age of 40 years.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3392,Ignore
Impact of treatment on patient-reported pain and fatigue in early breast cancer patients receiving adjuvant radiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3393,Ignore
Significance of systemic and local immune responses to the pathological therapeutic effect of neoadjuvant chemotherapy in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3394,Ignore
Short versus long duration of adjuvant trastuzumab (T) in HER2+ breast cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3395,Ignore
Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3396,Ignore
Treatment and prognosis analysis of elderly patients with nonmetastatic triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3397,Ignore
Using tumor genomic profile testing and comorbidity level to personalize chemotherapy decisions among older patients with early-stage breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3398,Ignore
Biological behavior of HER2+ breast cancer: Differences based in hormone receptor expression.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3399,Ignore
Stratification of oncotype (ODX) Recurrence Score (RS) by Breast Cancer Index (BCI) and its relation to discordance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3400,Ignore
Nomogram for predicting axillary lymph node pathological complete response in node-positive breast cancer patients after neoadjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3401,Ignore
Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene Breast Recurrence Score test.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3402,Ignore
Association of pathologic non-complete response of axillary node with outcome after neoadjuvant chemotherapy in node positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3403,Ignore
Impact of chemotherapy sequence on the efficacy of scalp cooling devices for alopecia prevention.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3404,Medium
"Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and immunosuppressive effects.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3405,Ignore
Modeling the consequences of recurrences after trastuzumab treatment of HER2+ early-stage breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3406,Ignore
A prospective study to evaluate the accuracy of axillary staging using ultrasound and USG-guided fine needle aspiration cytology in early breast cancer patients in a high-volume center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3407,Ignore
Variations in compliance with different endocrine therapies in ER-positive breast cancer in elderly females in a rural population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3408,Ignore
The effects of mindfulness meditation and progressive muscle relaxation on fatigue and quality of life in breast cancer patients receiving adjuvant paclitaxel: A three-arm randomized trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3409,Ignore
Vitamin D insufficiency and risk of paclitaxel-induced peripheral neuropathy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3410,Ignore
HIF1A genetic variability and late adverse events of radiotherapy in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3411,Ignore
Influence of radiation therapy on the outcome of T1-2N0M0 triple-negative breast cancer: A SEER population-based retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3412,Ignore
Time to surgery and overall survival after breast cancer diagnosis in a universal health system.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3413,Medium
HER2 cluster amplification as a factor of an especial sensitivity for anti-HER2 neoadjuvant therapy with biosimilar of trastuzumab in Russian women with breast cancer stage II-III.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3414,Ignore
"Circulating cell-free DNA (ctDNA) assessments before, during, and after neoadjuvant therapy (NAC) in nonmetastatic inflammatory breast cancer (IBC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3415,Ignore
Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3416,Ignore
"Performance of Oncotype Dx test in patients with T1bN0, grade 1, hormone receptor-positive, HER2-negative breast cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3417,Ignore
Comparing the American Joint Committee on Cancer (AJCC) breast cancer staging eighth versus seventh edition and breast cancer biology in large databases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3418,Ignore
Use of treatment pathways reduce cost and decrease ED utilization and unplanned hospital admissions in patients (pts) with stage II breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3419,Ignore
Good Risk: low-risk patients with ductal carcinoma in situ (DCIS) benefit from whole breast radiotherapy after breast conservation surgery (BCS)long-term follow-up.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3420,Ignore
Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: A feasibility study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3421,Ignore
HER2-positive breast cancer: Combined <sup>18</sup>F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3422,Ignore
Evaluation of immunotherapy (I-O)-associated immune cell (IC) dynamics and PD-L1 expression using multispectral immunohistochemistry (mIHC) and single-cell hierarchical regression modeling in early-stage breast cancer (ESBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3423,Ignore
Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3424,Ignore
Accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A preliminary report of 57 cases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3425,Ignore
Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3426,Ignore
Predictors of adjuvant chemotherapy for breast cancer patients with an intermediate Oncotype-DX score: A SEER-based population study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3427,Ignore
Six cycles of adjuvant anthracycline-taxane-based chemotherapy compared with eight cycles for women with breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3428,Ignore
Bisphosphonate use in geriatric breast cancer patients on aromatase inhibitors in a rural population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3429,Ignore
Preoperative conventional axillary ultrasound (AUS) and sonoelastography (SE) for predicting axillary lymph node metastasis in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3430,Ignore
tRNA-derived small RNA fragments (tRFs) as potential biomarkers for doxorubicin resistance in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3431,Ignore
Impact of serum vitamin D on the response and the prognosis in breast cancer patients treated with neoadjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3432,Ignore
Chemotherapy-associated lipid changes in breast cancer patients: A retrospective analysis from a high-volume institution in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3433,Ignore
Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3434,Ignore
The prognostic role of the androgen receptor in patients with triple-negative early breast cancers and primary surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3435,Ignore
Oncotype DX DCIS use and clinical utility: A SEER population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3436,Ignore
Evaluation of androgen receptor expression in core needle biopsies and clinico-pathological factors in primary breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3437,Ignore
The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3438,Ignore
Survival and recurrence of breast cancer patients with pathologic complete response after neoadjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3439,Ignore
"Are elderly breast cancer patients offered appropriate therapy i.e. surgery, chemotherapy, radiation, and endocrine therapy, in a rural population?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3440,Ignore
Intraoperative radiotherapy in early-stage breast cancer: Multidiciplinary management and analysis of outcome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3441,Ignore
Automated artificial intelligence quantification of fibroglandular tissue on breast MRI.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3442,Ignore
Outcomes of Hispanic/Latino women with triple-negative breast cancer who achieve a  complete pathologic response after neoadjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3443,Ignore
Is it possible to predict the prognostic values of Oncotype Dx using the results of web-based mathematical prognostic value models?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3444,Ignore
Effectiveness of scalp cooling in reducing chemotherapy-induced alopecia: A single center prospective study in Lebanon.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3445,Ignore
NOTCH3 expression in metastatic TNBC cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3446,Ignore
Circulating tumor cells in patients with locally advanced breast cancer in evaluation of antitumor treatment efficacy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3447,Medium
Phase II study of preoperative chemotherapy versus standard postoperative chemotherapy in HR-negative HER2-positive breast cancer patients.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3448,Medium
Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3449,Medium
"Weight change after (neo)adjuvant chemotherapy in a cohort of breast cancer survivors: Trends by race, hormone positivity, and chemotherapy regimen.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3450,Ignore
Sequential versus concurrent use of chemotherapy and endocrine therapy in the adjuvant treatment of ER-positive breast cancer: A systematic review and Bayesian network meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3451,Ignore
The diagnostic accuracy of 12-point core biopsy of a tumor bed compared to the study of surgically obtained breast tissue in patients with locally advanced triple-negative or HER2-positive breast cancer after neoadjuvant systemic and targeted therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3452,Ignore
Clinical value of CTC in predicting the efficacy of treatment in breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3453,Medium
"Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3454,Ignore
Doxorubicin response prediction in neoadjuvant breast cancer therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3455,Ignore
Correlation analysis of radiotherapy and prognosis of elderly patients with hormone receptor-positive breast cancer in different immunohistochemical subtyping.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3456,Ignore
Does the time to initiate adjuvant chemotherapy effect outcome in patients with breast cancer? A National Cancer Database-based retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3457,Ignore
Cardioprotection in patients with cancer undergoing chemotherapy: A network meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3458,Ignore
Clinical utility of SERUM extracelullar domain of HER2 receptor (ECD) in HER2-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3459,Ignore
"Impact of discordance in estrogen receptor, progesterone receptor, and Ki-67 after neoadjuvant chemotherapy in breast cancer on survival.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3460,Ignore
Decisions on adjuvant chemotherapy for patients with breast cancer based on clinical and evolving Oncotype DX criteria.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3461,Ignore
The CYP2C19 rs4917623 single nucleotide polymorphism to predict tamoxifen efficacy in estrogen receptor-positive breast cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3462,Medium
Four versus six cycles of docetaxel and cyclophosphamide in early breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3463,Ignore
Comparative efficacy of neoadjuvant to adjuvant chemotherapy for the treatment of early-stage HER2 negative breast cancer: A population-based analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3464,Medium
Assessing adherence to hormone therapy (HT) in breast cancer (BC) patients receiving care at BC unit in a Uruguayan university of Hospital de Clínicas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3465,Ignore
The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: A single-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Publication Only: Breast CancerLocal/Regional/Adjuvant,0,0,3466,Ignore
Real-world evidence evaluating the use of single versus combination chemotherapy in salvage therapy for metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3467,Ignore
Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3468,Medium
Asymptomatic versus symptomatic metastatic breast cancer: Potential effects on prognosis and treatment strategies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3469,Ignore
Effect of RNA-binding protein MSI2 deficiency on progression in triple-negative breast cancer via stabilizing TP53INP1.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3470,Ignore
Chronobiological features of melatonin receptors (MT1) expression in breast cancer cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3471,Ignore
Nab-pa<U+0441>litaxel (Nab-P) in patients with metastatic breast cancer (mBC) with visceral crisis (VC): Efficacy and tolerability.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3472,Medium
Real-world evidence evaluating the use of an NK-1 antiemetic in the systemic chemotherapy treatment of metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3473,Ignore
17-ß estradiol promotes autophagy and induces cellular senescence in breast cancer cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3474,Ignore
Changing trends in HER-2 neu positive breast cancers in women: A study by a medical student and his preceptor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3475,Ignore
Pathological and genetic aggressiveness of left-sided breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3476,Ignore
The relationship of lncRNA NR2F1 and breast cancer angiogenesis via IL-8/lncRNA NR2F1/miR-200s/IL-8 loop.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3477,Ignore
"Prognostic values of cell free DNA, CA 15.3, and ESR1 circulating mutations variations in hormone receptor (HR)-positive metastatic breast cancer (MBC) patients under aromatase inhibitor (AI).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3478,Ignore
Genome-wide chromosomal instability by cell-free DNA sequencing to predict patient survival in metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3479,Ignore
Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3480,Medium
Acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3481,Ignore
[18F] Fluorodeoxyglucose positron emission (FDG-PET) in breast cancer: Clinical utility in neoadjuvant and metastatic setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3482,Ignore
Searching for a link between Ki-67 values and HER2 absence in 297 patients with triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3483,Ignore
Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerMetastatic: Publication Only,0,0,3484,Ignore
Histological growth pattern as a potential prognostic factor in patients operated for breast cancer liver metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3485,Ignore
Sarcoidosis as a paraneoplastic syndrome for breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Breast CancerMetastatic: Publication Only,0,0,3486,Ignore
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: A network meta-analysis (NMA) of randomized controlled trials (RCTs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3487,Ignore
Clinical value of Ki67 in risk-stratifying HR-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3488,Ignore
Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3489,Ignore
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3490,Ignore
Prognostic value of circulating cytokines in breast cancer: A prospective study in sixty breast cancer patients in Tunisia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3491,Ignore
Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3492,Ignore
Chronobiological assessment of triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3493,Ignore
Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3494,Medium
Tumor mutational burden and spectrum in hormone receptor-positive breast cancer patients from India.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3495,Ignore
Targeting serum response factor as a novel therapeutic approach for triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3496,Ignore
Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3497,Ignore
Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3498,Ignore
MYC as a therapeutic target for the treatment of triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3499,Ignore
"Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3500,Ignore
Patterns of mutation enrichment in metastatic triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3501,Ignore
Fulvestrant versus everolimus plus exemestane for patients with metastatic breast cancer resistant to aromatase inhibitors: Clinical experience from real world.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3502,Ignore
Assessing treatment benefits with CDK4/6i+ET for hormone receptor-positive advanced breast cancer: A network meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3503,Ignore
New docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3504,Ignore
A comparison of platinum-based chemotherapy versus capecitabine-based chemotherapy in the treatment of breast cancer metastasis to the liver.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3505,Ignore
Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3506,Medium
The role of miR200c in leptin-mediated triple-negative breast cancer progression to an epithelial-to-mesenchymal transition.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3507,Ignore
Different maintenance strategies versus observation in patients with hormone receptor-positive metastatic breast cancer after first-line chemotherapy: A real-world study and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3508,Ignore
Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3509,Ignore
Prognostic significance of tartrate-resistant acid phosphatase expression in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3510,Ignore
Mixed invasive ductal-lobular carcinoma: Clinicopathological characterization and clinical outcomes.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3511,Medium
CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3512,Ignore
HER2 testing: Insights from pathologists perspective on challenging HER2 cases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3513,Ignore
"Risk stratification based on a prognostic factor index among patients with HR+, HER2- MBC.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3514,Ignore
Associations with response to poly (ADP-ribose) polymerase (PARP) inhibitors in metastatic breast cancer: Results of a meta-regression analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3515,Ignore
CDK 4/6 inhibitors (CDKi) + endocrine therapy (ET) in ER-positive metastatic breast cancer (mBC) patients according ET sensitivity: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3516,Ignore
Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3517,Ignore
"Fixed dose, dose-dense capecitabine in metastatic breast cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3518,Ignore
"The landscape of palliative systemic therapy and overall survival of 2,063 advanced breast cancer patients in the China National Cancer Center.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3519,Medium
Efficacy of platinum-based regimens as the first-line therapy in Chinese patients with advanced TNBC and deleterious BRCA1/2 mutations.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3520,Medium
"REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3521,Ignore
Satellite alpha transcript levels to predict risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer who lack <em>BRCA</em>-related clinical features.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3522,Ignore
"Drug-related pneumonitis during everolimus therapy in patients with metastatic breast cancer: Incidence, radiographic findings, and correlation with clinical outcome.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3523,Low
Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3524,Ignore
CENP-U function on TNBC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3525,Ignore
High-throughput screening (HTS) of natural products with triple-negative breast cancer (TNBC) organoids.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3526,Low
Impact of mastectomy in women with stage IV HER2+ breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3527,Ignore
Immunohistochemical evaluation of Cyclin D1 and ß-Catenin expression in subtypes of triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3528,Ignore
Low-dose metronomic chemotherapy (LDMC) as an efficient treatment option in metastatic breast cancer: Results of an exploratory case-control study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3529,Ignore
Effect of additional administration of pertuzumab for the post-treatment in patients with HER2-positive locally advanced/metastatic breast cancer who were previously treated with pertuzumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3530,Ignore
Retrospective study of neuroendocrine breast cancer cases from a single institution in Québec.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3531,Ignore
Tracking the tumor evolution of patients with recurrence of ipsilateral breast tumor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3532,Ignore
Combining denosumab (D) and trastuzumab (T) as a novel treatment strategy in HER2-positive (+) breast carcinomas (BC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3533,Ignore
Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3534,Ignore
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3535,Ignore
Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3536,Ignore
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3537,Medium
HD201: Analytical biocomparability and clinical trial progression of trastuzumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3538,Ignore
Eribulin ORA: A novel oral formulation of eribulin based on combination with the P-gp inhibitor HM30181A.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3539,Ignore
Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3540,Medium
Fulvestrant in hormone receptor-positive advanced breast cancer: A UK retrospective multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3541,Ignore
Ki-67 and Cyclin D1 in subtypes of triple-negative breast cancer with different androgen profiles.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3542,Ignore
Efficacy of abemaciclib (abema) after palbociclib (palbo) in patients (pts) with metastatic breast cancer (MBC).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3543,Medium
Somatic mutations in triple-negative breast carcinoma and high-grade serous ovarian carcinoma from young women.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3544,Ignore
Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3545,Ignore
Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3546,Medium
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor as first-line therapy in metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3547,Ignore
The results of colorectal cancer screening in the Republic of Kazakhstan during the period from 2013 to 2018.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3548,Low
Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3549,Medium
Estrogen receptor (ER) status and survival outcomes in HER2 positive (+) metastatic breast cancer (mBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerMetastatic: Publication Only,0,0,3550,Ignore
Primary prevention and smoking habit among <em>BRCA1/2</em> mutation carriers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3551,Ignore
The landscape of POLE/POLD1 mutations in Chinese solid tumor patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3552,Ignore
"Prediction of attendance to the 60 days law within the patient navigation program to breast cancer in Rio de Janeiro, Brazil.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3553,Ignore
Mutational analysis of key genes in patients from the Kazakh population with early onset of breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3554,Ignore
"Effects on histologic subgroup, race, and BMI in 2,110 breast cancer patient: Results from single institution in Georgia.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3555,Ignore
Prevalence of targetable mutations in Black patients with lung cancer: A systematic review and meta-analysis.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3556,Low
Low likelihood that potential germline findings identified during somatic tumor testing are evaluated: Room for improvement.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3557,Ignore
"A non-interventional, multicenter study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal, and fallopian tube cancer patients in India.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3558,Low
Clinical impact of comprehensive versus targeted genomic analysis for precision oncology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3559,Ignore
Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3560,Ignore
Utilizing social media for cancer prevention.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3561,Ignore
Large cell neuroendocrine carcinoma of the lung: A population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3562,Ignore
Development of a plasma cell-free DNA chromosome instabilities assay for early cancer detection and treatment response monitoring of multiple tumor types.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3563,Ignore
Global burden of HPV-related cancers in men: A systematic literature review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3564,Ignore
Time to cancer diagnosis in young women presenting to surgeons with breast-related symptoms: A population-based cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3565,Ignore
"Complex multimorbidity, perceived life expectancy, and routine cancer screening receipt: Differences between older women and men.",0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3566,Low
Community-based lung cancer screening program: A five-year comprehensive review.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3567,Low
Determination of the immunogenetic risk of developing cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3568,Ignore
Genomic profiling for unfavorable carcinoma of unknown primary patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3569,Ignore
Association of atrial fibrillation with colorectal and breast cancer: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3570,Ignore
Incidence of FGFR-TACC gene fusions in Chinese non-small cell lung cancer (NSCLC): A multicenter study.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3571,Low
A novel computational tool for copy number variation detection in targeted circulating tumor DNA.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3572,Ignore
Comparative analysis of prognostic molecular signatures in Asian and Caucasian AML populations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3573,Ignore
Burden and etiologies of 30-day readmission after bone marrow transplant: Insights from National Readmission Database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3574,Ignore
"Combinational analysis of <em>IDH1</em>/<em>IDH2 </em>mutations, 1p/19q deletions and <em>MGMT</em> promoter methylation for molecular testing of glioma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3575,Ignore
Comparative gene expression analysis in gliomas with different IDH1/2 status.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3576,Ignore
Meta-analysis utilizing public data suggests role of innate immunity in the pathogenesis of hurthle cell carcinoma (HCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3577,Ignore
Genetic testing for hereditary breast and ovarian cancer in Indian population: A single institutional study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3578,Ignore
"Performance and validation of a tumor mutation profiling, based on artificial intelligence annotation, to assist oncology decision making.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3579,Ignore
VONC: A solution for the clinical assessment of somatic genomic alterations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3580,Ignore
Discussion on several problems between tumor-associated venous thrombosis and driving genes status.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3581,Ignore
RNA sequencing analysis for profiling activation of cancer-associated molecular pathways.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3582,Ignore
Epidemiological profile of lung cancer in a Nepalese population: A single-institution review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3583,Ignore
Determination of plasma EGFR mutations from non-small cell lung cancer patients at Bach Mai Hospital.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3584,Ignore
Procancerous immune cells in primary tumor is associated with breast cancer recurrence.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3585,Ignore
Auxiliary diagnosis of pulmonary nodules using liquid biopsy and deep learning/techniques.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3586,Ignore
Analysis of mutation detection in cell-free DNA in ascites using comprehensive NGS panel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3587,Ignore
EMR documentation of genetics evaluations in patients with ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3588,Ignore
Relationship between underlying causes of HCC and its complications.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3589,Ignore
"DNA Input, sequencing depth, and maximum somatic allele frequency may affect the concordance between blood TMB and tumor TMB.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3590,Ignore
A three-year epidemiological profile of cancers managed by a Haitian cancer program from 2016 to 2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3591,Ignore
Molecular characterization of NSCLC-like and SCLC-like subsets in Chinese pulmonary large cell neuroendocrine carcinoma (LCNEC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3592,Ignore
Renal cell carcinoma epidemiology in the era of widespread imaging.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3593,Ignore
Implementation of HPV vaccination pilot project in Kazakhstan: Successes and challenges.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3594,Ignore
Disparities in HER2 testing in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3595,Ignore
Diagnosis of lung cancer by canine olfactory detection in urine and breath samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3596,Ignore
Suspected and confirmed germline variants from tumor-only somatic sequencing of 864 gastrointestinal malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3597,Ignore
Bringing patient navigation to primary health care in Rio de Janeiro: Pilot project in the Andaraí community.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3598,Ignore
Vitamin D deficiency in patients with newly diagnosed cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3599,Ignore
Optimal body mass index cutoff point for predicting survival of colorectal cancer in Asian population: A National Health Information Database Analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3600,Ignore
"<em>BRCA1/2</em> and multigene panel testing among metastatic breast, pancreas, prostate, and ovarian cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3601,Ignore
Early non-invasive detection of stage Ia lung cancer using circulating tumor DNA methylation haplotypes (ctmDNA) in plasma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3602,Ignore
Risk of colonic adenoma in patients with noncolorectal cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3603,Ignore
The effect of the Affordable Care Act on genetic testing patterns and outcomes for inheritable cancer syndromes: A single institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3604,Ignore
An analysis of the sociodemographic factors contributing to patient nonadherence to recommendations for screening mammograms.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3605,Low
Enhanced family history screening is crucial to individualized cancer surveillance.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3606,Low
Design and implementation of an Internet-based cancer risk assessment tool: Use over 10 years.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3607,Ignore
"Analysis of nationwide lung, breast, and prostate cancer incidence in relation to provider availability and training programs in oncology.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3608,Low
"Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3609,Ignore
Data from an integrated cancer prevention center screening for multiple cancer types.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3610,Low
Correlation of negative PD-L1 expression with TMB-H and MSI-H rates.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3611,Ignore
Radiomics analysis for pathological classification prediction in BI-RADS category 4 mammographic calcifications.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3612,Ignore
Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer populationBRCAm group analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3613,Ignore
Towards a screening test for cancer by circulating DNA analysis.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3614,Low
Pulmonary F-18 FDG uptake of non-tumor area in lung cancer patients to provide risk stratification in postoperative acute exacerbation of interstitial lung disease.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3615,Ignore
Co-occurring genetic alterations and primary EGFR T790M mutations detected by next-generation sequencing in pre-TKI treated patients with non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3616,Ignore
Real-world large-scale study of <em>ERBB2</em> gene fusions and its response to afatinib in Chinese non-small cell lung cancer (NSCLC): A multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3617,Ignore
"Study of the expression of programmed death ligand 1 (PD-L1) on non-small cell lung cancers (NSCLCs) at Bach Mai Hospital, Vietnam.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3618,Ignore
Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in Chinese population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3619,Ignore
Clinical significance of pathogenic variants in germline <em>BRCA</em> wild type patients at risk for hereditary breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3620,Ignore
Validation of a comprehensive cancer genomic profiling assay based on massively parallel DNA sequencing.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3621,Ignore
A pharmacogenetic analysis of peripheral sensory neuropathy related to administration of taxanes in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3622,Ignore
Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3623,Ignore
The targetable mutation landscape of Chinese patients with non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3624,Ignore
Discovering HPV16 and HPV18 infection status and cancer gene variations in cervical cancer patient specimens by using Next-generation sequencing.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3625,Ignore
Screening of differentially expressed genes of esophageal squamous cell carcinoma with cDNA microarray.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3626,Low
Diagnostic accuracy of the Videssa protein-based liquid biopsy for breast cancer in suspicious mammography.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3627,Ignore
A new method towards calculating the cancer cell fraction in cell-free DNA.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3628,Ignore
Germline mutation PTCH2 1172-1173delCT in Chinese population with early-onset breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3629,Ignore
Differences in MSI phenotype between cancer types using a new PCR-based pan-cancer biomarker panel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3630,Ignore
Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3631,Ignore
Features of adolescent and young adult cancer patients in Japan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3632,Ignore
Angiotensin converting enzyme inhibitors use and development of lung cancer: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3633,Ignore
"Thank you, next: The impact of next-generation sequencing in clinical decision making.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3634,Ignore
Colorectal cancer: Improving screening in a rural clinic.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3635,Low
"HPV test self collection versus CO-testing (2015-2018): New experience in a screening program in a northern province of Argentina, Tucumán.",0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3636,Low
MUC16 germline mutations may predispose inherited cancer family members to lung adenocarcinomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3637,Ignore
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3638,Ignore
RAS activation and CDKN2A deletion to predict prognosis in cancer of unknown primary.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3639,Ignore
Germline DNA damage repair gene alterations in Chinese prostate patients: More than HRR and MMR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3640,Ignore
"Comprehensive germline panel testing across cancer types: Diagnostic yield and clinical utility in 100,000 patient dataset.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3641,Ignore
"Metformin, aspirin and statin and risk of cancer: A population-based study in Thailand.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3642,Ignore
Use of computer algorithms in the electronic health record to identify and triage primary care patients for hereditary evaluation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3643,Ignore
Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO).,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3644,Low
Association of leisure time physical activity with breast cancer risk and breast cancer sub-types in Nigerian women.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3645,Ignore
Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3646,Ignore
"Protamine sulfate may prevent infections by pathogens that require heparan sulfate proteoglycan interactions, including high- and low-risk Human Papillomaviruses and <em>Chlamydia trachomatis.</em>.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3647,Ignore
Confirmation of germline variants identified by tumor testing: A population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3648,Ignore
Landscape of multilocus inherited neoplasia alleles syndrome in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3649,Ignore
Detect and visualize tumor microsatellite instability status from next-generation sequencing data by simulating PCR techniques.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3650,Ignore
"Characteristics, treatment patterns, and survival from three cohorts of advanced or metastatic cancer patients using healthcare claims data in the United States.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3651,Ignore
Risk factors associated with a second primary lung cancer (SPLC) in patients (pts) with a previous initial primary lung cancer (IPLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3652,Ignore
Genomic alteration features of six cancers and their correlation with clinical characters using the next generation sequencing.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3653,Ignore
Do genetic testing criteria identify individuals with Lynch syndrome prior to cancer diagnoses?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3654,Ignore
Integrated genomics-based approach to identify new therapeutic targets and cancer biomarkers for lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3655,Ignore
An optimized workflow for a fast molecular diagnosis of non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3656,Ignore
An EGFR extracellular domain mutation data in the East Asian non-small cell lung cancer populations and response to icotinib: A multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3657,Ignore
Prevalence and clinicopathological factors of the EGFR mutation status of Vietnamese non-small cell lung cancer patients.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3658,Low
A retrospective study of mortality among teenage and young adult (TYA) cancer patients in India.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3659,Low
Geographic variation in the incidence of marginal zone lymphoma (MZL) subtypes and infectious risk factors.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3660,Low
Risk of arterial thromboembolic events (ATEs) with tyrosine kinase inhibitors (TKIs) used in renal cell carcinoma: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3661,Ignore
Adverse events following the use of immune checkpoint inhibitors: An analysis of the WHO VigiAccess database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3662,Ignore
Germline <em>EGFR</em> mutation and cancer predisposition in adolescent and young adult (AYA) females with adrenocortical carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3663,Ignore
A multi-institutional investigation assessing prevalence of germline genetic alterations in Chinese patients with gastric carcinoma.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3664,Low
Racial and ethnic disparities in clinical presentation and prognosis of conjunctival cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3665,Ignore
Germline analysis of DNA-damage repair genes in men with advanced prostate cancer in comparison to women with breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3666,Ignore
Influenza and mortality for non-small cell lung cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3667,Low
The association between volumetric breast density and breast cancer subtypes among women newly diagnosed with breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3668,Ignore
Pathogenic germline mutation hotspots in east Asian cancer genomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3669,Ignore
Incidence and characteristics of cancer-associated thrombosis in a racially diverse population: A population-based study.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3670,Low
Epidemiology and survival of lung cancer in a Latin American cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3671,Ignore
"Breast Cancer Cases in a Surveillance Program: Report from the Hereditary Department at South General Hospital, Sweden.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3672,Ignore
Improving access to genetic counseling services in an adolescent and young adult (AYA) clinic.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3673,Ignore
Interim analysis of the data of non-interventional study to determine the prevalence of EGFR mutations in advanced NSCLC Russian patients (ORTUS).,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3674,Low
Germline genetic testing in ovarian cancer patients: Identifying barriers to care and opportunities for improvement.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3675,Ignore
Gender differences in relative survival among patients with primary peritoneal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3676,Ignore
"Demographic characteristics of smoldering multiple myeloma patients: A hospital-based study including 11,643 patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3677,Ignore
"Enhancing access to genetic cancer risk assessment (GCRA) in Monterrey, Mexico: The beginning of a prevention program.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3678,Ignore
BRCA1/2 germline mutations and response to PARP inhibitor treatment in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3679,Ignore
Alteration of TGF-ß signaling pathway predicts worse prognosis in pancreatic ductal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3680,Ignore
Temporal trend of microbiological profiles among patients with bloodstream infections: A comparison between cancer and noncancer patients in a nationwide database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3681,Ignore
Predictive molecular tumor response through circulating DNA (cDNA) measurements and correlation with established prognostic markers in a series of solid tumors treated with multitargeted epigenetic therapy (MTET).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3682,Ignore
Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing in families with BRCA1/2 or MMR gene mutations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3683,Ignore
Pathogenic germline mutation profile in Chinese lung cancers and related-driver mutation pattern.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3684,Ignore
Lung cancer: Improving screening in rural clinic.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3685,Low
HIV associated head and neck cancers in an inner-city minority population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3686,Ignore
"SeqPlus sequencing methodology enables robust whole-genome sequencing, true variant detection, and novel genomic insights from archival esophageal carcinoma FFPE samples.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Cancer Prevention, Hereditary Genetics, and Epidemiology: Publication Only",0,0,3687,Ignore
Spine stereotactic radiosurgery as a promising modality in patients with metastatic hepatocellular and cholangiocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3688,Ignore
Impact of next-generation sequencing (NGS) in patients with high grade glioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3689,Ignore
"Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3690,Ignore
Low platelet counts in patients with glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3691,Ignore
Efficacy of a novel potent and high water-soluble selective PARP inhibitor CVL218 in glioma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3692,Medium
DDR1 may be a good biomarker for brain tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3693,Ignore
First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3694,Ignore
"MGMT status through the ages, literally.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3695,Ignore
The use of metformin to enhance radiation effects on M1 macrophage subtype polarization in bone marrow-derived macrophage in glioblastoma tumor environment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3696,Ignore
The prognosis of diffuse midline glioma H3 K27M mutant.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3697,Ignore
De novo malignancy in recipients of solid organ transplant from donors with intracranial cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3698,Ignore
A prospective study on the circulation and central nervous system after primary central nervous system B cell lymphoma treatment with rituximab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3699,Ignore
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3700,Ignore
RNA-sequencing and bioinformatic analysis to pre-assess sensitivity to targeted therapeutics in recurrent glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3701,Ignore
Safety and pharmacokinetics of BXQ-350 in a phase 1a and 1b trial of solid tumors and high-grade glioma.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3702,Medium
Effect and utility of targeted and immune therapy as single agent treatment for brain metastases in patients with non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3703,Ignore
Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3704,Ignore
Genomic analysis of paired <em>IDHwt</em> glioblastoma (GB) to reveal recurrent alterations of <em>MPDZ</em> at relapse after radiotherapy and temozolomide (RTCT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3705,Ignore
Potential biomarkers for targeted and immunotherapy in gliomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3706,Ignore
Impact of Zika virus infection in human glioblastoma cell lines.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3707,Ignore
Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3708,Ignore
Management of brain metastases in tyrosine kinase inhibitor-treated epidermal growth factor receptor-mutant non-small-cell lung cancer from the perspective of long-term radiation brain damage: A multi-institutional retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3709,Ignore
Brain metastases as a first site of recurrence in patients on chemotherapy with controlled systemic cancers: An increasingly urgent clinical scenario.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3710,Ignore
Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3711,Ignore
Hyperprogressive disease in patients with recurrent high grade gliomas treated with immune checkpoint inhibitors or other therapies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3712,Ignore
A new option in brain-metastases: Hippocampal-sparing whole-brain radiotherapy with simultaneous integrated boost VMAT-IGRT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3713,Ignore
Assessment of neurocognitive function in illiterate patients of high-grade glioma treated with chemoradiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3714,Ignore
Real-world outcome analysis of EGFR-mutated lung adenocarcinoma with brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3715,Ignore
Risk factors for synchronous brain metastases: A National Cancer Database analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3716,Ignore
The role of postradiation temozolomide in patients with newly diagnosed MGMT methylated glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3717,Ignore
Multi-parametric MRI as supplement to mRANO criteria for response assessment to MDNA55 in adults with recurrent or progressive glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3718,Ignore
Exploiting metabolic susceptibilities in glioblastoma via glycolytic inhibition and ketogenic therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3719,Ignore
Male gender is associated with seizure risk in low-grade glioma (LGG) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3720,Ignore
Lobectomy confers a survival benefit over gross-total resection without lobectomy in cases of primary glioblastoma in non-eloquent area: A retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3721,Ignore
"Access to clinical trials, multidisciplinary environment, and health care providers by facility type and outcomes of patients with newly diagnosed glioblastoma using SEER-Medicare dataset.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3722,Ignore
Impact of EGFR amplification status in newly diagnosed glioblastoma treated with Stupp protocol.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3723,Ignore
Intracerebral immunotherapy for brain tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3724,Ignore
Comparison of two dose calculation methods of intra-arterial carboplatin in the treatment of recurrent glioblastoma multiforme.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3725,Ignore
Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3726,Ignore
Evaluation of prognostic role of inflammatory index in glioblastoma multiforme patients undergoing to concomitant radio-chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3727,Ignore
Ethics consultations in patients with neuro-oncologic diseases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3728,Ignore
Impact of PET-imaging during treatment planning on outcome in meningioma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3729,Ignore
Using PIK3CB and connexin-43 inhibition to sensitize pediatric glioblastoma cells to temozolomide.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3730,Ignore
Aberrant miRNA expression in glioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3731,Ignore
The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer: A retrospective study from one single cancer institute.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3732,Ignore
Radiomics-based identification of peritumoral infiltration in de novo glioblastoma imaging presents targets amenable for potential targeted extended resection: A neurosurgical survey.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3733,Ignore
Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3734,Medium
The utility of proton MR spectroscopy in diagnosing B cell lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3735,Ignore
Presenting symptoms and patient prognosticators in neoplastic meningitis: A single institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3736,Ignore
Integrating salvage hypofractionated radiosurgery plus low-dose adjuvant bevacizumab for locally recurrent brain metastasis with high dose irradiation previously.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3737,Ignore
The utility of surgery in butterfly glioblastoma: A case-control study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3738,Ignore
Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3739,Ignore
The effect of everolimus on CNS penetration and efficacy of dasatinib in the treatment of <em>PDGFRA</em>-driven glioma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3740,Medium
Effect of SSH1/SSH2 expression changes by shRNA in glioma cell lines on response to radiotherapy and cofilin-1 reactivation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3741,Ignore
Absolute lymphocyte count in patients with glioblastoma treated with temozolomide chemoradiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3742,Ignore
"Factors associated with delays in diagnosis of pediatric, adolescent and young adult patients with central nervous system tumors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3743,Ignore
Lethality and mitotic activity of T98G glioblastoma cells under the influence of pulsed magnetic fields and ionizing radiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3744,Ignore
Albumin levels and Prognostic Nutritional Index in glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3745,Ignore
National trends in the use of immunotherapy in the up front management of glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3746,Ignore
Molecular profiling using the 92-gene assay for tumor classification of brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3747,Ignore
BRAFv600e mutated gliomas: From biology to radiology and treatments.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3748,Ignore
Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to brain tissue using drug-embedded biodegradable nanofibers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3749,Ignore
The impact of Epstein-Barr virus status on primary CNS lymphoma survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3750,Ignore
Study of a smartphone-based symptom assessment (OurBrainBank) for subjects with glioblastomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3751,Ignore
Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3752,Ignore
The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3753,Ignore
Trametinib for aggressive gliomas in adults with neurofibromatosis type 1.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3754,Ignore
Mutations of H3.3 and H3.1 in a large cohort of glioma tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3755,Ignore
Clinical outcomes in patients with melanoma brain metastases at a tertiary cancer center.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3756,Medium
A critical appraisal of the quality of glioma imaging guidelines using the AGREE II tool: A EuroAIM initiative.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3757,Ignore
Proteogenomic characterization in glioblastoma multiforme.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3758,Ignore
Targeting of CD317 by the immunotoxin HM1.24-ETA to allow immunotherapy in glioblastoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3759,Ignore
Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3760,Ignore
Leptomeningeal spread of glioma in the molecular era.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3761,Ignore
Effect of oligometastatic disease management with stereotactic body radiation therapy on survival in patients with metastatic lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3762,Ignore
Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3763,Ignore
Bevacizumab-associated intracerebral hemorrhage in patients with CNS malignancy: A single-center retrospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3764,Ignore
Targeting the androgen receptor as a novel therapeutic strategy for high-grade gliomas by suppressing glioma cancer stem cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3765,Ignore
Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3766,Ignore
Circulating endothelial cells: Prognostic value in patients with glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3767,Ignore
Treatment of cancer-associated thrombosis after craniotomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3768,Ignore
"Single center, open and prospective evaluation of genomic sequencing on cerebro-spinal fluid, brain metastatic lesions and plasma from patients in non-small cell lung cancer with brain metastasis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Central Nervous System Tumors: Publication Only,0,0,3769,Ignore
"Correlation between peripheral CD8+PD-1+ T cells diversity, tumor mutation burden (TMB) and T cell clones with anti-PD-1 antibody treatment of lung cancer patients: TCR repertoire as a novel predictive biomarker.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3770,Ignore
"GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkins lymphoma: Preliminary result of a phase II clinical trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3771,Ignore
Impact of IDO1 expression and inhibition on the sensitivity of anti-PD-1.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3772,Ignore
Discovery of a novel Toll-like Receptor 7 agonist for systemic immunotherapy of cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3773,Ignore
Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3774,Ignore
Gene expression profiles of peripheral blood mononuclear cells from patients with advanced non-small cell lung cancer treated with anti-PD-1 monoclonal antibodies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3775,Ignore
Oncolytic and protective effect of strain no. 228 of a new rotavirus group in the Reoviridae family on <U+0412>16/F10 melanoma growth in experiment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3776,Ignore
Potential elimination of multi-drug resistant cancer cells by targeted non-engrafting intentionally mismatched activated donor lymphocytes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3777,Ignore
Prognostic value of Tfh-like cells in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3778,Ignore
Safety and tolerability of immune checkpoint therapies and related adverse effects at a tertiary care hospital in Saudi Arabia.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3779,Medium
PD-L1 expression in soft tissue sarcomas and its prognostic implication.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3780,Ignore
Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3781,Low
"The interplay of adiposity, metabolic factors, and tumor infiltrating lymphocytes in an East Asian breast cancer cohort.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3782,Ignore
The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3783,Ignore
Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3784,Medium
Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3785,Ignore
Correlation of CD28 expression on CD8+ T cells with prognosis in advanced lung adenocarcinomas and squamous cell carcinomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3786,Ignore
Burden of copy number alterations predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3787,Ignore
Immune-related adverse events for different age groups using the FDA Adverse Event Reporting System.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3788,Ignore
Real-world use and survival outcomes of immune checkpoint inhibitors in patients with non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3789,Ignore
Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3790,Ignore
Bone metastases treated with immune checkpoint inhibitors: A single center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3791,Ignore
Immune checkpoint inhibitor toxicity in the clinical practice setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3792,Ignore
Human model to predict the outcome of cancer vaccine clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3793,Ignore
Safety and efficacy of PD-1 blockade-activated multiple antigen specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: A pooled analysis of two prospective trials.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3794,Medium
NSCLC mutation frequency in the central American and Caribbean region.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3795,Ignore
Immunotherapy efficacy and safety of programmed cell death 1 (PD-1) versus programmed death ligand-1 (PD-L1) inhibitors in pan-cancer: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3796,Medium
Immunotherapy discontinuation and outcome: A multicenter real-life experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3797,Ignore
Use of PD-L1 and ICOSL to discriminate innate and adaptive dendritic cells in the head and neck cancer microenvironment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3798,Ignore
"Potent targeting of B cell lymphoma and plasma cell tumors by a tetravalent, Fc-engineered antibody directed against the glycoantigen CD75s.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3799,Ignore
Pembrolizumab versus the standard of care for cancer therapy: A meta-analysis of 12 KEYNOTE trials comparing overall survival.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,1,0,3800,Low
Correlation of HERVK with efficacy on anti-PD-1/PD-L1 therapy in a pilot metagenomics study on Chinese advanced lung cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3801,Medium
Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3802,Ignore
A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3803,Medium
Proton pump inhibitors and response to immune check-point inhibitors: Single center study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3804,Ignore
Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3805,Ignore
"Long-term survival in patients (pts) with locally advanced or disseminated malignant melanoma (MM) or renal cell carcinoma (RCC), treated with tag-7 gene-modified (GMV) tumor cells: A phase II trial.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3806,Medium
Dual blockade of PD-1 and PD-L1 is effective but causes severe pneumonitis in lung metastasis: Syngeneic mice study for validation of clinical observation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3807,Ignore
A relationship-based approach to improving the clinical trial experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3808,Ignore
Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3809,Ignore
"Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3810,Ignore
Multidisciplinary approach to immune related adverse events as a potential biomarker: Single institution experience in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3811,Ignore
Plasma biomarkers to predict pembrolizumab response in HCC patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3812,Ignore
"SLAMF8, a novel biomarker for personalized immune checkpoint blockade therapy in gastrointestinal cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3813,Ignore
Analysis of Chinese acral and mucosal melanoma patient genomic and neoantigen profiles in cancer vaccine development: A pilot study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3814,Ignore
Effect of smoking on the efficacy of immune checkpoint inhibitors in advanced cancers: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3815,Medium
Treatment outcome and safety of anti-PD-1 antibody against elderly non-small cell lung cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3816,Medium
"Review of therapeutic approaches for B-cell malignancies with immune checkpoint blockade and chimeric antigen receptor t-cell therapies: Development, benefits, and limitations.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3817,Ignore
Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with advanced solid tumors treated with PD-1 inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3818,Ignore
Prevalence of immunotherapy-related adverse events due to checkpoint inhibitors: First report in Mexico.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3819,Low
Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3820,Ignore
Immunotherapy-induced endocrinopathies: A multi-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3821,Ignore
Frequency of discordance in programmed death ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3822,Ignore
Computational design of novel tetra-specific antibody (PD-1/CD47/VEGF/TGF-ß) with IgG-like architecture against non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3823,Ignore
Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3824,Ignore
Receptor-triggered lymphocyte apoptosis PC to replace Cy/Flu PC for CART.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3825,Ignore
"Comparison of biomarkers among 34,855 GI cancer samples show heterogeneity of tumor types.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3826,Ignore
Comparison of panendoscopy directed biopsies with percutaneous and image-guided biopsies during immune checkpoint inhibitor therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3827,Ignore
The influences of preoperative metformin on immunological factors in early breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3828,Ignore
Interleukin-2 boosts local and abscopal antitumor effect of radiotherapy combined with anti-PD-1: A translational research from clinical radio-memory effect.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3829,Ignore
Rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in melanoma and lung cancer patients with autoimmune diseases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3830,Ignore
Effect of radiotherapy on the residual circulating epithelial tumor cells (CETCs) and their programmed cell death ligand 1 (PD-L1) status in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3831,Ignore
Occupational health risk of pressurized intra-peritoneal aerosol chemotherapy (PIPAC) via endoscopical microcatheter system.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3832,Ignore
Cancer-testis gene-expression features in various tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3833,Ignore
Immune checkpoint inhibitor response in tumors with LRP1B variants.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3834,Ignore
Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3835,Ignore
Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3836,Ignore
A novel noninvasive biomarker based on peripheral PD-1<sup>posi </sup>CD8 T-cell receptor repertoire correlated with clinical outcomes to immunotherapy in non-small cell lung cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3837,Medium
Reovirus strain R-92 in in vitro generation of tumor-specific T-lymphocytes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3838,Ignore
Revisiting the ethics of phase 1 oncology trials in the era of precision medicine: A systematic review.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3839,Medium
Prediction the clinical outcomes of cancer patients after peptide vaccination.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3840,Medium
"Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3841,Ignore
Utilization of novel highly multiplexed immunofluorescence microscopy technology to understand immunological tumor microenvironments in small cell lung carcinoma patients receiving combination PD-L1 and PARP inhibition therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3842,Ignore
Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3843,Ignore
"Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors.",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3844,Medium
A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3845,Medium
MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3846,Ignore
Modified ketogenic diet in solid tumors: A Veteran Affairs Pittsburgh Healthcare System case series.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3847,Ignore
Electron microscopic characteristic of local immune processes during regression of developed experimental tumors under the influence of magnetite nanoparticles.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3848,Ignore
DNA repair pathway alterations and correlation with immunotherapy response.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3849,Ignore
Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3850,Ignore
"Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.",0,31-05-2019,0,0,0,1,0,0,0,0,1,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3851,Medium
Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3852,Ignore
"Correlation of inflammation-related markers with MDSC and IL-17, and use as prognostic indicators in patients with advanced gastric and colorectal cancers.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3853,Ignore
Incidence and characteristics of emergency department presentations during immune checkpoint inhibitor therapy.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3854,Low
Precision probiotic therapy enhances immune checkpoint therapy efficacy in melanoma bearing mice.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3855,Medium
Changes in tumor mutational burden in serially biopsied non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3856,Ignore
Impact of pericardial effusion for patients receiving immune checkpoint inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3857,Ignore
IRX-2 therapy with PD-L1 blockade in immunocompetent animal model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3858,Ignore
Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3859,Ignore
A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)<sup>+</sup> myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3860,Medium
Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3861,Medium
Treatment with tumor-infiltrating lymphocytes in the changing treatment landscape of metastatic melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3862,Ignore
Analysis of the relationship between ratio N/L and survival in lung cancer patients treated with immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3863,Ignore
Effect of antibiotic exposure in patients with metastatic melanoma treated with PD-1 inhibitor or CTLA-4 inhibitor or a combination of both.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3864,Ignore
Introduction of a variable electrostatic field for targeted drug application following intraperitoneal aerosol chemotherapy (PIPAC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3865,Ignore
Collagen affinity improves efficacy and safety of antibody and cytokine cancer immunotherapy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3866,Medium
Dipeptidyl peptidase inhibitor BXCL701 synergizes with immunomodulatory agents in a preclinical model of colorectal cancer (CRC) by altering the function of various components of the immune system.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3867,Medium
Biomarkers of Chinese advanced cancer patients based on real-world data: Actionable genomic alterations and tumor mutational burden.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3868,Ignore
Immunotherapy efficacy and patients' age: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3869,Medium
Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL).,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3870,Medium
Characterizing the gut microbiome of patients with triple-negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3871,Ignore
Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3872,Medium
Efficacy and safety of PD-1 inhibitors in combination with chemotherapy versus chemotherapy as first and second line treatment in advanced gastric and gastroesophageal junction cancer: Preliminary data from a real-world setting.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3873,Medium
Combined treatment of patients with bone metastases from various cancers with nivolumab plus denosumab: A retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3874,Ignore
Development of a novel dendritic cell-based immunotherapy targeting cancer stem cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3875,Ignore
"Spatially-resolved, multiplexed quantification of protein and mRNA distribution and abundance in colorectal cancer tumor microenvironment with multiple modalities of NanoString GeoMx Digital Spatial Profiler.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3876,Ignore
Characteristics of POLE and POLD1 gene variations in Chinese cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3877,Ignore
Preliminary effects on the innate immune system with the combination of cetuximab and durvalumab in metastatic/ relapsed head and neck squamous cell carcinoma in a phase II trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3878,Medium
New generation of oncolytic herpesviruses embodying immunotherapeutic genes encoding IL-12 and anti-PD-1 antibody.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3879,Ignore
Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3880,Medium
Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3881,Ignore
Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3882,Ignore
Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3883,Ignore
Stochastic cancer-immune coevolution: Implications for cancer incidence and immunotherapeutic efficacy.,0,31-05-2019,1,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3884,Low
PD-L1 expression on circulating tumor cells and prognosis of breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3885,Ignore
Differences in prescribing and patient demographics of cki agents among United States patients < 65 and 65+ years old.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3886,Ignore
Quantification of activated and exhausted immune cell populations and simultaneous characterization of circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3887,Ignore
Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3888,Ignore
DC-HIL/Gpnmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3889,Ignore
Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3890,Ignore
Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3891,Ignore
Measuring T-cell avidity and enrichment using acoustic force-based technology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3892,Ignore
"Influence of agomelatine and trastuzumab on the HER2/neu(+), MT1 (+) and MT2 (+) chemo and immunoresistant breast cancer cells lines from the previously treated patients by targeted therapy with trastuzumab.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3893,Ignore
A RNA signature predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3894,Ignore
Active postmarketing surveillance: Results from a manufacturer's patient support program for patients under treatment with the first biosimilar trastuzumab (MYL-1401O) approved in Brazil.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3895,Ignore
Development of imjSCORE for early prediction of response to nivolumab among patients with advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3896,Ignore
"Addition of immunotherapy in adjuvant setting could be a promising avenue of colorectal cancer (CRC) treatment, especially in patients with higher levels of programmed cell death ligand-1 (PD-L1) positive circulating epithelial tumor cells (CETC) after neoadjuvant chemotherapy.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3897,Ignore
Clinical implication of monitoring PD-L1+ circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3898,Ignore
A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3899,Ignore
STING-dependent preventive effect by ablative hyperfractioned radiotherapy and delayed delivery of a CSF-1R inhibitor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3900,Ignore
An immune response-associated genomic model to predict early resistance to PD1/PD-L1 blockade among real-world TMB-high Chinese cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3901,Ignore
Toxicities of single agent and combination immune checkpoint inhibitors in patients with autoimmune diseases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3902,Ignore
Correlation of radiosensitivity of lung carcinoma to CD137L endogenous expression levels.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3903,Ignore
Phase Ia clinical trial of adoptively transferring peripheral blood-derived cytotoxic T lymphocytes targeting individual neo-antigens to treat patients with advanced solid tumor.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3904,Medium
"Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.",0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3905,Medium
Real-world Merkel cell carcinoma outcomes from a tertiary care center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3906,Ignore
Endocrinopathies associated with immune checkpoint inhibitors: Standard of care at veterans administration medical centers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,1,0,3907,Low
A retrospective review of nutritional status and immunotherapy in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3908,Ignore
An effective and accurate algorithm for measuring the tumor mutation burden of cancer patients plasma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3909,Ignore
Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3910,Ignore
Major lab abnormalities as biomarkers in patients treated with immune checkpoint inhibitors: A single institution study of 1044 patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3911,Ignore
The safety and tolerability of PD-1/PDL-1 inhibitors in hematologic malignancies: A meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3912,Medium
An umbrella for the cytokine storm: Enabling precision detection of CRS in CAR-T therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3913,Ignore
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3914,Ignore
Identification of immune microenvironment subtypes of breast cancer in TCGA set: Implications for immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3915,Ignore
Novel monoclonal antibody therapeutics for metastatic castration resistant prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3916,Ignore
Characterization of a patient-specific T-cell and tumor cell coculture model of immuno-cytotoxicity in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3917,Ignore
Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3918,Ignore
Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3919,Medium
Effect of mandatory research biopsy requirements on initiation of clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3920,Ignore
A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3921,Medium
An innovative combined immunization platform for personalized cancer immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3922,Ignore
A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3923,Ignore
Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3924,Ignore
Demographic stratification of inflammatory signature in lung cancer patients in North Carolina: A prospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3925,Ignore
Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3926,Ignore
Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3927,Ignore
"Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3928,Ignore
Immune checkpoint inhibitors (ICI): An analysis of FDAs and EMAs decision patterns and times for initial approvals and extensions of indication.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3929,Ignore
Expecting the unexpected.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3930,Ignore
BRCA 1/2 mutations in high-grade serous ovarian cancer (HGS-OC) patients of three Latin American countries: Report of 412 cases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3931,Ignore
"Safety and efficacy of repeated intra-hepatic artery and intravenous infusion of ET140202, a novel anti-AFP/MHC complex T-cell, in advanced hepatocellular carcinoma.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3932,Medium
Anti-HER2/Neu antibody therapy can reduce the immunosuppressive activity of MDSCs in breast tumor model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3933,Ignore
Recapitulation of inflammatory and immune-evasive subtypes of oral cancer cells in immunodeficient mice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3934,Ignore
"Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3935,Ignore
Immunological and clinical profiles of patients with advanced or metastatic melanoma receiving immune checkpoint inhibitors to investigate potential biomarkers for immune-related adverse events.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3936,Ignore
Expression of PD-L1 and IDO in hormone receptor negative DCIS.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3937,Ignore
Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3938,Ignore
The role of different TGFß signatures in predicting outcome in high grade serous ovarian carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3939,Ignore
Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3940,Ignore
Applying machine learning strategy for microsatellite status detection in plasma sample type.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3941,Ignore
Immunotherapy: Auto-immune toxicity as a predictive factor of response.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3942,Ignore
"Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3943,Ignore
Defining tissue requirements for a reliable detection of tumor mutational burden (TMB) in clinical FFPE samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3944,Ignore
Immunotherapy clinical trials suggest predictive immune-related biomarkers are tissue specific.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3945,Ignore
Predictive value of baseline clinicopathological factors in non-small cell lung cancer (NSCLC) patients on checkpoint inhibitors (CPI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3946,Ignore
T cell receptor ß-chain repertoire analysis to reveal potential predictive biomarker for the use of immune checkpoint blockade in patients with advanced solid tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3947,Ignore
Is inmunotherapy a safe treatment in bladder cancer? A retrospective study in daily practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3948,Ignore
Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3949,Ignore
Characteristics and treatment of rheumatologic adverse events associated with immune checkpoint inhibitors: A multicentric prospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3950,Ignore
Response rate to chemotherapy after disease progression with anti-PD-1/PD-L1 in metastatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3951,Ignore
"A novel dual inhibitor of IDO and TDO, CMG017, potently suppresses the kynurenine pathway and overcomes resistance to immune checkpoint inhibitors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3952,Ignore
Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3953,Ignore
A landscape analysis of immunotherapy-related biomarkers across solid tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3954,Ignore
Preclinical development of combination therapy targeting the dominant cytokine interleukin-1ß for renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3955,Medium
TCR repertoire analysis from peripheral blood for prognostic assessment of patients during treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3956,Ignore
"Effect on anti-tumor immunity and long-term memory CD8+ T-cell generation with a novel, allogeneic cell-based, Gp96-Ig/OX40L cancer vaccine.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3957,Ignore
"Immunotherapy with checkpoint inhibitors in mismatch repair deficient (dMMR) cancers: Looking for a needle in a haystack But, joy on finding one.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3958,Ignore
"Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3959,Ignore
Prognostic interaction of smoking history with circulating regulatory T cells in advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3960,Ignore
Induction of antigen specific CD8+ T cell infiltration by a novel neoadjuvant vaccine containing HSP70 and GPC3 peptides plus soluble LAG-3 and Poly-IC:LC: Interim results of a Phase I study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,1,3961,High
Development of a PD-L1 multiplex immunofluorescence assay with advanced visual analysis for understanding the tumor microenvironment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3962,Ignore
Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3963,Medium
A retrospective cohort study of anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3964,Ignore
A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3965,Ignore
"Comparison of in vitro antitumor activity between SB3 (trastuzumab biosimilar, Ontruzant) and Herceptin combined with an antibody for subdomain II of HER2 in HER2-positive cancer cells.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3966,Ignore
Predictors and outcomes of thyroid dysfunction with immunotherapy: A single institution observational experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3967,Ignore
"Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3968,Ignore
Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3969,Medium
Comprehensive analysis of lymphocyte loss kinetics in patients treated with focal fractionated radiation therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3970,Ignore
Impact of biopsy methodology on biomarker testing in NSCLC in EU5.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3971,Ignore
Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3972,Ignore
Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3973,Medium
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3974,Ignore
Live-attenuated LCMV-based vector for active immunotherapy of HPV16+ cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3975,Ignore
Prognostic significance of NLR kinetics in operable triple negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3976,Ignore
Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3977,Medium
"A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3978,Medium
AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3979,Ignore
Recycling of residual liquid drug formation following pressurized intra-peritoneal aerosol chemotherapy (PIPAC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3980,Ignore
"Personalized multimodality therapy with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT) in advanced refractory cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3981,Ignore
Breast MRI as a radiomic biomarker of immune enrichment in HER2+ breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3982,Ignore
Surface programmable activation receptor (SPAR) cell platform for the rapid detection of melanoma-specific biomarkers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3983,Ignore
Prospective cardiac function monitoring in immunotherapy-treated patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3984,Ignore
Outcomes and toxicities in sarcopenic patients with metastatic solid tumors treated with check point inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3985,Ignore
Microsatellite instability assessment of FFPE tumor samples through targeted next-generation sequencing.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3986,Ignore
Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3987,Ignore
Some characteristics of cancer-testis gene expression regulation in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3988,Ignore
Systematic assessment of LCMV based vaccine vectors expressing melanocyte differentiation antigens in human in vitro assays and in mouse melanoma models.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3989,Ignore
Defining real-world criteria for immune-related adverse events (irAEs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3990,Ignore
Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3991,Ignore
"Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Immunotherapy and Tumor Immunobiology: Publication Only,0,0,3992,Ignore
ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3993,Ignore
Effect on tumor growth by TGF-ß1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3994,Ignore
"A phase I study investigating the absorption, metabolism, and excretion of <sup>[14C] </sup>anlotinib in patients with advanced refractory solid tumors.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3995,Medium
Influence of deuterium-depleted water as a nutritive factor on the effectiveness of experimental chemotherapy in aging rats.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3996,Ignore
"Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3997,Ignore
"Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3998,Ignore
Effect of tivantinib on VEGF signaling pathways and apoptosis of gastric cancer cells with c-MET or VEGFA amplification.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,3999,Ignore
"Detection of low abundant mutants from circulating tumor DNA of plasma, pleural effusion, and cerebrospinal fluid of lung cancer patients using a novel mutant-capture enrichment approach.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4000,Ignore
Analytical validation of the Oncomine Pan-Cancer Cell-Free Assay in a CLIA- and CAP-regulated laboratory for detection of solid tumor-derived variants in blood plasma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4001,Ignore
Prediction of lesion shrinkage using CT imaging with radiomic and deep learning approaches.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4002,Ignore
Clinical significance of circulating tumor cells identified by cell-surface vimentin in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4003,Ignore
Tracking endocrine resistance in estrogen-receptor positive breast cancer in ctDNA.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4004,Ignore
Phenotypic and functional characteristics of patient derived murine xenograft models.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4005,Ignore
EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4006,Medium
Association of Ras-Raf-MEK-Erk/JNK pathway mutations with overall survival for lung squamous cell carcinoma patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4007,Medium
Integrin ß5 in plasma-derived exosomal protein predicting liver-specific metastasis in advanced gastric cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4008,Ignore
Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4009,Ignore
A breakthrough in treatment of cancer patients with grade 4/profound febrile neutropenia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4010,Ignore
Feasibility and clinical impact of next-generation sequencing (NGS) in patients with stage IV or recurrent malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4011,Ignore
Precise prediction of the radiation pneumonitis with RPI: An explorative preliminary mathematical model using genotype information.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4012,Ignore
Cell-free DNA in uveal melanoma: Results from the first-in-human trial of mivebresib (ABBV-075).,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4013,High
Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4014,Ignore
A general approach to optimizing tumor treating fields therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4015,Ignore
"The relationship between mesenchymal stem cells, monocyte-macrophages, endothelial progenitor cells, and prognosis of hepatocellular carcinoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4016,Ignore
"RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4017,Ignore
The prognostic role of a novel TP53 mutation classifier in resectable esophageal squamous-cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4018,Ignore
Clinical-relevant model of intraductal papillary mucinous neoplasm induced by <em>ARID1A</em> loss.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4019,Ignore
Trends in case-control allocation in phase III randomized cancer clinical trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4020,Medium
Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4021,High
Assessing the risk of chemotherapy toxicity and hospital admission due to toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4022,Ignore
#earlydetection: Leveraging social media to recruit individuals at increased-risk of pancreas cancer for an early detection study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4023,Ignore
Notch family gene mutations associate with high tumor mutational burden in diverse cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4024,Ignore
Bioinformatic inspired nanoparticles engineered for enhanced delivery to the bone.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4025,Ignore
<sup>18</sup>F-alfatide PET may predict anti-angiogenic drugs toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4026,Ignore
Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4027,Medium
A comparative analysis of RNA sequencing methods with ribosome RNA depletion for degraded and low-input total RNA from formalin-fixed and paraffin-embedded samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4028,Ignore
A novel function for cyclin D1 as a transcriptional role in oncogenesis and tumor development by ChIP-Seq and RNA-Seq.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4029,Ignore
Targeted-sequencing in rare cancers and the impact on patient treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4030,Ignore
Elevated plasma cell-free DNA copy number variations to predict survival for cancer patient with spinal metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4031,Ignore
Validation and utilization of NGS based HEMEaccuTest<sup> </sup>panel and analysis software for hematological malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4032,Ignore
Use of a clinical trials screening tool in the NCI Community Oncology Research Program (NCORP) to enhance accrual and promote disparities research.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4033,Low
"Integration of radiomic, genomic and clinical data to support decision making for lung cancer.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4034,Medium
Thyrointegrin avß3 nano targeted delivery of chemotherapy into solid tumors and its microenvironment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4035,Ignore
Circulating tumor DNA (ctDNA) mutation and epigenomic patterns in early-stage lung cancer patients and its utility in identifying patients at high risk for early recurrence.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4036,Ignore
The host response to immune checkpoint inhibitors: From mechanisms to therapeutic implications.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4037,Ignore
Anticoagulants for the treatment of venous thromboembolism in patients with cancer: An updated pairwise and network meta-analysis of randomized trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4038,Ignore
Highly sensitive detection of rare mutant alleles by combining argonaute-based enrichment and XNA-PCR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4039,Ignore
The role of anticoagulants for the primary prophylaxis of venous thromboembolism in patients with malignancy: A systematic review and meta-analysis of randomized controlled trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4040,Ignore
Effect of PGK1 on radiosensitivity through regulation of CIN and CFL1 in human glioma cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4041,Ignore
Role of radiomics to differentiate benign from malignant pheochromocytomas and paragangliomas on contrast enhanced CT scans.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4042,Ignore
AcornFusion: A novel tool to detect gene fusion events in DNA-Seq data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4043,Ignore
"The relationship between response and dose in published, contemporary phase 1 oncology trials.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4044,Medium
High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4045,Ignore
An aggressive RhoC phenotype is associated with relapse after external beam radiation therapy of a prostate cancer xenograft model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4046,Ignore
Comparison of diagnostic methodologies to detect chromosomal abnormalities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4047,Ignore
Nonclinical endpoint assessment utilizing a digital vivarium cloud platform in an ovarian cancer xenograft model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4048,Ignore
"Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4049,Medium
Prognostic significance of amplifications of stemness genes in primary luminal breast cancer depending on the response to neoadjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4050,Ignore
Antitumor immune response induced by NBTXR3 activated by radiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4051,Ignore
Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4052,Ignore
Dynamic change of PD-L1 expression on circulating tumor cells in advanced breast cancer undergoing PD-1 blockade therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4053,Ignore
Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4054,Ignore
Combination mTORC1/2 and BCL- X<sub>L</sub> inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4055,Ignore
A novel mutant-allele capture method for enrichment of low abundant cancer mutants.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4056,Ignore
Longitudinal monitoring of cell-free DNA to predict for transarterial chemo-embolization failure in hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4057,Ignore
A novel CRISPR-directed gene editing method that catalyzes precise gene segment replacement <em>in vitro</em> enabling multiplex site-directed mutagenesis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4058,Ignore
A large subtype of squamous cell carcinoma enriched for TrkB-T1 mRNA.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4059,Ignore
Utility of the Breast Cancer Index (BCI) in the clinical practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4060,Ignore
A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent (ESA) administration.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4061,Ignore
The chick embryo chorioallantoic membrane assay: <em>In ovo </em>model for personalized assessment and evaluation of the most effective therapeutic approach in cancer therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4062,Ignore
Identification of new targets and biomarkers in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4063,Ignore
Real-world application of liquid biopsy in gastrointestinal tumors: Experience from a comprehensive cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4064,Ignore
Modeling of pharmacodynamic (PD) biomarkers (BM) related to CDK4/6 inhibition and exploratory BM-response (progression free survival [PFS]) analyses in patients with advanced breast cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4065,Medium
Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4066,Ignore
Analysis of AKR1B10 levels among various groups of breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4067,Ignore
Integrating CRISPR screening with tumor genomic analyses to identify therapeutic targets in hepatocellular carcinomas (HCC) independent of P53.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4068,Low
Innovative dual system for selective eradication of cancer cells using exosomes carrying natural bacterial toxin-antitoxin (TA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4069,Ignore
"Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4070,Ignore
"Effect of ligand binding domain activating mutations of ESR1 on cellular metabolism, liver tropism, and chemotherapy resistance.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4071,Ignore
Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4072,Medium
Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4073,Ignore
Relationship of <em>MET</em> exon 14 splicing variants and <em>MET</em> exon 14 skipping expression in NSCLC FFPE samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4074,Ignore
Circulating cell-free tumor DNA chromosomal instability and circulating tumor cells as tools to predict microvascular invasion of hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4075,Ignore
"A preliminary single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors: Personal precision oncology clinic and genetic diagnostics, Brazil.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4076,Ignore
"Correlation betwen MKK4 expression (exp) and clinicopathological features, KRAS/NRAS mutation in metastatic colorectal cancer (mCRC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4077,Ignore
Business versus science: High drug prices conspire against oncological research.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4078,Ignore
Preclinical studies evaluate pivotal TNFa nanomedicine clinical trial design.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4079,Medium
Urinary excretion of components of the renin-angiotensin-aldosterone system in patients having localized renal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4080,Ignore
Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4081,Ignore
Receptor status conversion between primary and recurrent/metastatic breast cancer: A single institutional study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4082,Ignore
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,1,4083,High
p53 expression and clinical outcomes in untreated and treated breast cancer patients after long-term follow-up.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4084,Medium
"Functional cell profiling (FCP) of ~100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC subtypes within and between cancer types.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4085,Ignore
Oncology precision medicine for hepatobiliary and pancreatic cancer: An institutional review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4086,Ignore
Automated breast cancer lesion detection on breast MRI using artificial intelligence.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4087,Ignore
Bone metastasis unique plasma exosomal microRNA signature in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4088,Ignore
Biofabricated tumor microenvironments for studying colorectal cancer <em>in vitro </em>and <em>in vivo</em>.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4089,Ignore
The ACC melanoma pilot project: Real-world evaluation of an NGS platform for molecular characterization of melanoma in Italy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4090,Ignore
Systemic immune-inflammation index to predict prognosis of elderly patients with newly diagnosed solid tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4091,Ignore
Direct oral anticoagulants (DOAC) versus warfarin and enoxaparin in ovarian vein thrombosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4092,Ignore
Multiplatform molecular profiling: Observational study to determine the effect of treatment selection in advanced or refractory metastatic solid tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4093,Ignore
Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4094,Ignore
RERG involvement in the RAS pathway and ER-dependent transcription in breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4095,Ignore
Detection of circulating cancer stem cells (cCSCs) as a predictive biomarker for breast cancer relapse or metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4096,Ignore
Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4097,Ignore
"A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4098,Ignore
Measuring parameters of the cancer ecosystem for cancer ecological staging.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4099,Ignore
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4100,Medium
Therapy alteration of solid tumors based on FoundationOne comprehensive genome profiling assay.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4101,Ignore
PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4102,Ignore
Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4103,Ignore
Rationale and preclinical development of LEAF-1401 and LEAF-1701: A novel class of potent next generation antifolates.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4104,Medium
MET amplification and exon 14 skipping in treatment naïve patients in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4105,Ignore
Real-world experience in advanced NSCLC using FDA approved NGS CDx.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4106,Ignore
Low-coverage whole genome sequencing of FFPE-derived-DNA and extracellular vesicle-associated DNA in patients with metastatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4107,Ignore
Genes copy number variation in tumor cells of patients with metastatic and non-metastatic lung adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4108,Ignore
Genetic mutation analysis of plasma circulating tumor DNA by ultra-deep sequencing in breast benign lesions and cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4109,Ignore
Cell-free DNA methylation markers for noninvasive early detection of nasopharyngeal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4110,Ignore
Clinical analysis of cancer associated venous thromboembolism in hospitalized patients with malignant solid tumors in real-world practices.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4111,Ignore
Real-world application of next generation sequencing to guide therapeutic options in lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4112,Ignore
The landscape of ARID1A variants and correlation with tumor mutational burden in Chinese solid tumor patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4113,Ignore
Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4114,Medium
Tumor mutational burden reference materials for assay standardization.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4115,Ignore
Differential copy number alteration profiles among gynecological malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4116,Ignore
IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4117,Ignore
Moving away from the boilerplate: Real-world evidence for clinical trial laboratory criteria.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4118,Ignore
Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4119,Ignore
Noninvasive prediction of future macrovascular invasion occurrence in hepatocellular carcinoma based on quantitative imaging analysis: A multi-center study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4120,Ignore
Analysis of lipid metabolism genes in advanced small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4121,Ignore
The impact of androgen receptor (AR) expression on the prognosis of ductal carcinoma in situ (DCIS).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4122,Ignore
"CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4123,Ignore
Identify driver mutants in lung cancer by supernatants of pleural effusion and monitor resistance to targeted therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4124,Ignore
Role of metabolic reprogramming toward fatty acid oxidation on tumor lymph node metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4125,Ignore
Sorafenib as a postoperative adjuvant therapy in patients with hepatocellular carcinoma and microvascular invasion: A propensity score matching analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4126,Ignore
Impact on U251 glioma cell radiosensitivity and CFL1 level via inhibiting cell motility regulator ROCKII of RhoA-RockII-CFL1 pathway.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4127,Ignore
Exceptions to the rule: Novel retrospective analysis of a single-center institution of the PSMA PET/CT modality.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4128,Ignore
Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4129,Ignore
Zero delay plasma vs. Streck cfDNA tubes: Does immediately centrifuging blood at the point of draw improve cell-free DNA signal-to-noise?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4130,Ignore
TrkA neurotrophin receptor and PI3K-Akt signaling involvement in cranial irradiation-induced memory deficit.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4131,Ignore
Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4132,Ignore
"CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4133,Medium
Multiplex genomic testing (MGT): Four-year real-world experience of two community oncology practices in central rural Nebraska.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4134,Ignore
Quantitative image profiling of the tumor microenvironment on double stained immunohistochemistry images using deep learning.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4135,Ignore
Clinical assessment of tumor angiogenesis and its predictive value for chemotherapy responses of colorectal metastatic hepatic tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4136,Ignore
Efficacy and toxicity of CDK 4/6 inhibitors in breast cancer: Systematic review and meta-analysis of the phase III clinical trials.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4137,Medium
Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4138,Ignore
ALK resistance mutations (muts) developed in different ALK fusion types.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4139,Ignore
Circulating tumor DNA molecular profiling in rare cancer patients from the MASTER KEY Project.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4140,Ignore
Inflammatory biomarkers as pronostic factors of mortality in critical ILL oncology patients at ICU.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4141,Low
Concurrent targeted resequencing for translocations and mutations in tumor samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4142,Ignore
Role of ultrasound contrast agent in a tertiary cancer center: Experience in 75 patients with liver biopsy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4143,Ignore
Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4144,Medium
"Somatic mutations in non-small cell lung cancer and their correlation with overall survival, tumor mutation burden, and programmed-death cell ligand-1 (PD-L1) status.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4145,Medium
DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4146,High
Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4147,Ignore
"Muscle wasting, visceral and subcutaneous adiposity, inflammation, nutritional deficiencies, and metastatic esophageal cancer (MEC) prognosis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4148,Ignore
HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4149,Ignore
The utility of circulating tumor DNA analysis to identify BRAF mutations in malignant melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4150,Ignore
cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4151,Ignore
Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4152,Ignore
Impact of precision medicine on clinical care: A single institution retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4153,Ignore
The influence of kinesin light chain-2 on the radiosensitivity of non-small cell lung cancer cells and the underlying mechanisms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4154,Ignore
A pretreatment CT model predicts survival following chemolipiodolization in patients with hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4155,Ignore
<em>REG4</em> as a novel biomarker of lung adenocarcinoma with mutated <em>KRAS</em> and TTF-1 low expression.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4156,Ignore
Effect of GPR87 on cell proliferation via KRAS signaling pathway in p53-mutant lung cancer cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4157,Ignore
Association of forkhead box protein O1 and paired box gene 3 overexpression with prognosis in patients with cervical cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4158,Ignore
Epigenomic profiling of plasma cell-free DNA (cfDNA) to predict bladder cancer recurrence after radical cystectomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4159,Ignore
Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4160,Ignore
Non-inferiority of a new advanced dry plasma thawing system compared to leading standard method: Preservation of coagulation and anticoagulation proteins necessary for use in the clinic.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4161,Ignore
Mapping the activation landscape of the MAPK\ERK pathway for variants of unknown significance (VUS) using convolutional neural networks (CNN).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4162,Ignore
FBXO4 as a novel ubiquitin ligase that targets Cyclin D in the pathogenesis of breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4163,Ignore
Prognostic value of serum apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) ratio in hepatocellular carcinoma patients with transcatheter arterial chemoembolization treatment: propensity score-matched analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4164,Ignore
Tumor volumetric correlation with plasma cell free DNA (cfDNA) mutation detection in metastatic lung cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4165,Ignore
The association between <em>BRAF</em> mutation class and clinical features in <em>BRAF</em>-mutant Chinese non-small cell lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4166,Ignore
ALK actionable mutations (muts) within cancer types and their responses to crizotinib (CZ).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4167,Ignore
"Changes of estrogen receptor, progesterone receptor and HER2 expression in breast cancer with/without neoadjuvant chemotherapy or endocrine therapy.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4168,Ignore
Assessing the impact of clonal hematopoiesis in disease monitoring using targeted cell-free DNA (cfDNA) sequencing technology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Developmental Therapeutics and Tumor Biology (Nonimmuno): Publication Only,0,0,4169,Ignore
"Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4170,Ignore
An evaluation of RAS testing and survival among mCRC patients in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4171,Ignore
Prognostic impact of mutation profiling in Chinese patients with colorectal liver metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4172,Ignore
Prospective assessment of the risk for colorectal neoplasia in a Mexican population according to risk categories.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4173,Ignore
Colorectal cancer in young patients: An institutional experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4174,Ignore
"Efficacy of quxie capsule in metastatic colorectal cancer: Update of a double-blind, randomized, placebo controlled trial.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4175,Medium
Correlation of peripheral blood markers of DNA damage and immune response with chemoradiation response in patients with locally advanced rectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4176,Ignore
Cetuximab maintenance therapy in unresectable metastatic colorectal cancer patients with wild-type RAS and BRAF: A single-center retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,1,0,4177,Low
A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4178,Medium
Current treatment strategies and patterns of recurrence in locally advanced colon cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4179,Ignore
Regorafenib-associated adverse event management in colorectal and gastrointestinal stromal cancer patients: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4180,Ignore
Utility of effect size to define populations with durable clinical outcomes across trials of metastatic colorectal cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4181,Medium
Metastatic pattern and tumor sidedness in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4182,Ignore
"Rates of genotyping for <em>KRAS</em>, <em>NRAS</em>, <em>BRAF</em>, microsatellite instability (MSI), and mismatch repair (MMR) in metastatic colon cancer patients: Gaps and implications.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4183,Ignore
Mutation profiling of BRAF gene in Chinese patients with early or advanced colorectal cancer using comprehensive NGS panel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4184,Ignore
Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4185,Ignore
Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4186,Ignore
Defining an IBD-like subgroup in consensus molecular subgroups of colorectal cancer and transcriptomic biomarker development for at-risk patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4187,Ignore
Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4188,Ignore
Liver findings and risk of recurrence in locally-advanced rectal cancer (LARC): An Italian retrospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4189,Ignore
Machine learning for CT texture analysis in chemosensitivity of colorectal liver metastases: Initial results.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4190,Ignore
Reirradiation and/or surgery for locoregionally recurrent rectal cancer: A systemic review and meta-analyses.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4191,Ignore
Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4192,Ignore
Personalized T cell therapy for metastatic colon cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4193,Ignore
Stage of disease and initial surgical intervention in colon cancer patients: An exploratory analysis of the SEER database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4194,Ignore
A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4195,Medium
Rectal cancer and pathologic complete response after preoperative chemoradiotherapy: Romanian single-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4196,Ignore
Incidence and severity of postoperative complications following neoadjuvant therapy and full-thickness local excision for moderately advanced rectal cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4197,Low
Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4198,Ignore
DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4199,Ignore
Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4200,Ignore
Utilization of surgery and its impact on survival in elderly patients with localized colon cancer in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4201,Ignore
Effect of acid-reducing agents on the efficacy of capecitabine in metastatic gastrointestinal cancers.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4202,Medium
Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4203,Ignore
3D in vitro system for measuring treatment responses to immunotherapy in CRC patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4204,Ignore
Neoadjuvant treatment of adenocarcinoma of the rectum: Historical analysis and correlation between pathological regression rate and the outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4205,Ignore
"Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4206,Ignore
LONG TERM opioid use in RURAL NON-metastatic colon cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4207,Ignore
Exosomal markers (CD63 and CD9) expression using immunohistochemistry (IHC) in patients with right-sided and left-sided colon cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4208,Ignore
The Idylla MSI Test (CE-IVD) multi-center concordance study: Microsatellite instability detection in colorectal cancer samples.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4209,Ignore
5-year survival following radiotherapy in anal cancer audit in a single center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4210,Ignore
Rectal admission of chemotherapeutic drugs in neoadjuvant treatment schemes of locally advanced rectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4211,Ignore
"Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4212,Ignore
Distance from the anal verge as an indirect measure to predict response to anti-EGFR therapy in left side metastatic colon cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4213,Ignore
"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4214,Ignore
Clinicopathologic predictors of worse outcome in early onset colorectal cancer (EO-CRC): A single-institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4215,Ignore
Prognostic factors for severe diarrhea in patients with locally advanced rectal carcinoma treated with neoadjuvant chemoradiation with capecitabine: A single-center cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4216,Ignore
Racial disparities in clinico-pathological features and survival rates of early-onset colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4217,Ignore
RAS mutations in patients with metastatic colorectal cancer in Central America and the Caribbean.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4218,Ignore
Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4219,Ignore
Stereotactic body radiotherapy (SBRT) for colorectal liver metastasis: Clinical outcomes from the international multi-institutional RSSearch Patient Registry.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4220,Medium
Nomogram incorporated the number of adjuvant chemotherapy cycles for predicting the prognosis in stage II-III rectal cancer patients without neoadjuvant therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4221,Ignore
The metabolic clinical risk score (mCRS) as a new prognostic model for surgical decision in patients with colorectal liver metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4222,Ignore
B7-H3 expression by immunohistochemistry as a negative prognostic biomarker in colorectal carcinoma (CRC) in a racially diverse population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4223,Ignore
"Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4224,Medium
The prognostic significance of magnetic resonance imaging (MRI) following neoadjuvant concurrent chemoradiation (NCCR) in patients with locally advanced rectal adenocarcinoma (LARA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4225,Ignore
Clinical efficacy and safety evaluation of nimotuzumab combined with chemotherapy in the treatment of advanced colorectal cancer: A retrospective analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4226,Medium
Clinicopathological description of a subset of schistosoma mansoni associated colorectal cancer patients in an endemic area in Brazil.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4227,Ignore
"Human papillomavirus, radiation dose and survival of patients with anal cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4228,Ignore
Mutational signatures of early-onset colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4229,Ignore
IGF-1 and IL-6 as predictors of sarcopenia in non-metastatic colorectal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4230,Ignore
"Radiomic profiles via machine learning to predict response, overall survival, and KRAS status in metastatic colorectal tumors treated with FOLFOX/bevacizumab/hydroxychloroquine.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4231,Medium
Risk factors predicting colorectal cancer recurrence in a Latin American population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4232,Ignore
The study of the significance and prognosis of the differential expressed miRNAs and their target genes associated with biological in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4233,Ignore
Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4234,Ignore
Add-on anti-vascularendothelial growth factor agents with the second-line chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4235,Ignore
Analytical and clinical validation of a novel amplicon-based NGS assay for evaluation of circulating tumor DNA in metastatic colorectal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4236,Ignore
Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4237,Low
Chemotherapy-induced neuronal dysfunction in the absence of axon degeneration.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4238,Ignore
The mutational landscape of circulating cell-free DNA to identify neoadjuvant chemotherapy response in colorectal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4239,Ignore
Investigation of an ethnic predisposition to developing brain metastases (BM) in Asian patients with colorectal cancer (CRC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4240,Ignore
The results of 3000 Fit: A prospective study led at Saint Joseph University of Beirut.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4241,Ignore
The prognostic value of KRAS mutation in locally advanced rectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4242,Ignore
HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4243,Ignore
Exosomes derived miR-454-3P to promote the progression of colorectal cancer via MIER1-mediated Notch signaling activation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4244,Ignore
Turning on the lights in gastrointestinal oncology: How digital medicines reveal clinical insights on medication adherence and patient behaviors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4245,Ignore
A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4246,Medium
Histological growth pattern as a potential marker of oligometastatic disease in patients operated for colorectal liver metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4247,Ignore
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4248,Ignore
An improved method for detection of methylated circulating tumor DNA in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4249,Ignore
Pattern of expression of CDX2 in colorectal cancer and its role in prognosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4250,Ignore
A novel RAS internal tandem duplication involving the switch II domain disrupts GAP-binding and activates oncogenic signaling.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4251,Ignore
Single center experience: Management of metastatic appendiceal cancer with peritoneal carcinomatosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4252,Ignore
Evaluating cancer outcomes of outpatient colonoscopies in elderly patients older than 85 years of age.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4253,Ignore
Prognostic nutritional index and colorectal cancer deaths: A retrospective cohort study in Chinese patients with locally advanced colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4254,Ignore
"Incidence of venous thromboembolic disease (VTE) in a cohort of patients with colorectal cancer (CRC) according to KRAS, NRAS and BRAF status.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4255,Low
Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4256,Ignore
Risk of treatment-related death in carriers of pathogenic <em>DPYD</em> polymorphisms treated with fluoropyrimidine chemotherapy: A systematic review and patient-level analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4257,Ignore
Toxicity of chemotherapy in patients with colorectal cancer: The role of age in the Latin American setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4258,Ignore
Detection of KRAS mutations in colon adenocarcinoma by droplet digital PCR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4259,Ignore
Long non-coding RNA Linc00525 as a prognostic factor to regulate proliferation and apoptosis in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4260,Ignore
The impact of nodal metastasis on survival in stage IV colon cancer: Analysis of National Cancer Database 2004-2014.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4261,Ignore
Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4262,Ignore
RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4263,Ignore
Apatinib combined with Raltitrexed in patients with metastatic colorectal cancer after failure of standard therapy (AHEAD-311): A single-arm phrase II pilot trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4264,Ignore
Evaluation of Dworak grading system as a prognostic indicator after neoadjuvant chemoradiotherapy in rectal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4265,Ignore
Meat consumption and BRAF mutation status in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4266,Ignore
"Structured literature review (SLR) and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in gastric, colorectal, and esophageal cancers.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4267,Low
Type 2 diabetes as a potential risk marker for early onset colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4268,Ignore
A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4269,Medium
Clinical significance of ZHX2 in colitis and colorectal carcinogenesis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4270,Ignore
Microsatellite instability and mutations in BRAF and KRAS in small bowel adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4271,Ignore
Exosomal microRNA-199b-5p as a potential circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4272,Ignore
Cost-effectiveness for metastatic colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4273,Ignore
Frequency of somatic mutations in the KRAS gene in patients of the South Russia diagnosed with colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4274,Ignore
"Prevalence of DNA damage response and repair, cellular signaling, tumor suppressor, and immune checkpoint gene mutations in gastrointestinal cancers.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4275,Low
Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4276,Ignore
The mutational profile analysis of extramural vascular invasion in rectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4277,Ignore
Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4278,Medium
Tumor stroma percentage (TSP) and intrinsic subtypes in stage II/III colon cancer: NRG Oncology/NSABP C-07 trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4279,Ignore
Optimizing cut-offs for high neutrophil-to-lymphocyte ratio as poor survival prognostic factor in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4280,Ignore
Genetic characteristics of lung metastasis and liver metastasis from left-sided colorectal cancer with microsatellite stability.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4281,Ignore
Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4282,Ignore
Circulating tumor DNA-based mutational landscape of advanced colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4283,Ignore
Outcomes of metastatic colorectal cancer over fifteen years from an Indian tertiary care center: A retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4284,Ignore
Colorectal cancer molecular subtypes by immunohistochemistry in a patient cohort from Nigeria.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4285,Ignore
"Association between primary tumor site, perioperative CEA ratio, smoking status, and overall survival in patients with colorectal cancer.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4286,Medium
Factors of local immunity in patients with rectal cancer after prolonged radiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4287,Ignore
Characteristics of colorectal patients who discontinued oxaliplatin therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4288,Ignore
The mutational landscape of MSI-H and MSS colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4289,Ignore
Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4290,Medium
Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4291,Ignore
Association of co-occuring mutations in exosomal DNA and clinical outcomes of patients with metastatic colorectal cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4292,Medium
Comprehensive immune transcriptomic subtypes of colorectal cancer for development of precision immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4293,Ignore
Spatial heterogeneity of <em>KRAS </em>mutations in colorectal cancers: A population-based study in northern France.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4294,Ignore
"Molecular analysis of advanced colorectal cancer in a patient cohort of Hispanics, African Americans, and Caucasians within a diverse single institution.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4295,Ignore
Predictors of survival in chemorefractory colorectal liver metastases treated with Y90 radioembolization.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4296,Ignore
Clinical downstaging and quality of life after neoadjuvant chemotherapy in patients with locally advanced rectal cancer: Interim analysis from a phase II clinical trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4297,Medium
"Effect of JAG2 on migration and invasion in colorectal cancer cell by PRAF2, independent of epithelial-mesenchymal transition.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4298,Ignore
Role of tropomyosin 4 gene misregulation in colon epithelial cell tumorigenesis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4299,Ignore
The effect of T classification on colorectal liver metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4300,Ignore
Effect of PTPRB on metastasis of colorectal carcinoma and induction of epithelial-mesenchymal transition.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4301,Ignore
"Effects of SM08502, a novel, oral small-molecule inhibitor of Wnt pathway signaling, on gene expression and antitumor activity in colorectal cancer (CRC) models.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4302,Ignore
Efficacy of PD-1/PD-L1 inhibitor-based therapies in refractory microsatellite instability (MSI)-unselected metastatic colorectal cancer (mCRC): A network meta-analysis (NMA) of randomized controlled trials (RCTs).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4303,Medium
Investigating the effect of chemotherapy combined with ketogenic diet on stage IV colon cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4304,Ignore
Patterns of metastasis and second primary malignancies (SPM) in colorectal cancer: A perspective from Peru.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4305,Ignore
"The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: An interim analysis of a multicenter, phase II trial.",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4306,Medium
Sensitive detection of microsatellite instability in tumors and liquid biopsies using nuclease-based enrichment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4307,Ignore
"Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4308,Medium
Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4309,Ignore
Characteristics and outcomes of patients with colorectal cancer and bone metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4310,Ignore
FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4311,Ignore
<em>BRAF-V600E </em>and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4312,Ignore
Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4313,Ignore
Real-world study of cetuximab used every other week versus weekly in US patients with metastatic colorectal cancer (mCRC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4314,Ignore
The association between female hormonal supplementation and molecular types in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4315,Ignore
Completion of adjuvant chemotherapy with Cape/CAPOX in colon cancer: A retrospective database study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4316,Ignore
KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4317,Low
Prognostic impact of SOX9 in stage II colon cancer: Results from a large nationwide cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4318,Ignore
KLF4 p.A472D mutation: An acquired resistant mutation to cetuximab in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4319,Ignore
Patient reported outcome measures (PROMs) in patients (pts) with locally advanced rectal cancer (LARC) managed with a watch and wait (W&W) approach after a clinical complete response to chemoradiotherapy (CRT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4320,Ignore
Validation of neoadjuvant rectal cancer(NAR) score as a surrogate endpoint for disease free survival in Chinese FOWARC study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Colorectal) Cancer: Publication Only,0,0,4321,Ignore
Expression level of NRP1 and SMAD2 in correlation to mutational status of RAS (BRAF) in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4322,Ignore
Clinical efficacy and safety in gastric cancer patients treated with apatinib: A retrospective real-world study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4323,Medium
Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4324,Ignore
"Relationship between cholangitis, initial chemotherapy regimen, and overall survival in patients with unresectable pancreatic adenocarcinoma.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4325,Medium
Molecular mechanism of chemoresistance and restoration in human gastric cancer cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4326,Ignore
Combinational strategies of immunotherapy for hepatocellular carcinoma: One institutional experience in Taiwan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4327,Ignore
Novel genomic prognostic factors for nonsurgical esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4328,Ignore
Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4329,Medium
Decreased risk of esophageal squamous cell carcinoma among metformin users in a population-based cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4330,Ignore
Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (=3.0 cm) after initial hepatectomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4331,Ignore
Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine/cisplatin/S-1 (GCS) for patients with advanced biliary tract cancer (MITSUBA /KHBO1401-1B).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4332,Ignore
Main driver genes and BRCA mutation in Chinese patients with pancreatic adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4333,Ignore
DNA repair deficiency association with prognosis in pancreatic cancer: A single-institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4334,Ignore
The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4335,Ignore
Development of radiotherapeutic rhenium-188 liposomes in alginate microspheres (Rhe-LAMs) for treatment of liver tumors and technetium-99m liposomes in alginate microspheres (Tech-LAMs) for image-guided treatment planning.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4336,Ignore
Molecular pathway activation-based analysis for personalized prescription of tyrosine kinase inhibitors for advanced solid tumor patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4337,Ignore
"An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4338,Medium
Clinical significance of peritoneal molecular markers in patients with locally advanced gastric cancer (LAGC) without macroscopic peritoneal implants treated with perioperative chemotherapy (ChT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4339,Ignore
Epigenetic alternate promoter utilization and association with PD-L1 expression in EpsteinBarr virus positive gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4340,Ignore
Factors predicting poor survival in early gastric cancer: A SEER analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4341,Ignore
Predictors of neoadjuvant chemotherapy efficacy in localized pancreatic head cancer: A 15-year experience at a high volume pancreatic cancer center.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4342,Medium
Additional prognostic value of metabolic parameters measured by dual time point pretreatment F-18 FDG PET/CT in patients with intrahepatic cholangiocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4343,Ignore
The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4344,Ignore
Effect of cholangitis on pre-operative evaluation of regional lymphadenopathy by CT in pancreato-biliary malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4345,Ignore
Methylation and mRNA analysis of differential genes between primary tumor and liver metastasis in pancreatic neuroendocrine neoplasm.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4346,Ignore
Tissue plasminogen activator in gastrointestinal adenocarcinoma: What is its role?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4347,Ignore
RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4348,Ignore
Association of pancreatic cancer stem cells with tumor stroma type.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4349,Ignore
"Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4350,Ignore
"Apatinib affects the proliferation, migration and apoptosis of esophageal cancer cells both in vitro and in xenografts by regulating Ras/Raf/MEK/ERK and JAK2/STAT3 signaling pathways.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4351,Ignore
Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective biliary drainage : A multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4352,Ignore
Circulating tumor DNA analysis of neuroendocrine tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4353,Ignore
Postsurgical multiple-sites sampling procedure for the precise detection of microvascular invasion of hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4354,Ignore
Effect of LAT2 on glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4355,Ignore
Analysis of feasibility and survival in repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in appendiceal cancer with peritoneal dissemination.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4356,Ignore
Prognostic value and clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in resected gastric cancer: A meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4357,Ignore
Comprehensive characterization of pseudomyxoma peritonei.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4358,Ignore
Prognostic stratification of locoregional esophageal cancer (EC) patients (pts) treated with definitive chemoradiotherapy (dCRT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4359,Ignore
Prognostic value of the volume time index (VTI) ratio for patients with appendiceal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4360,Ignore
Retrospective analysis of outcomes in patients with non metastatic cholangiocarcinoma: A single network experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4361,Ignore
Alpha-1-acid glycoprotein 1 (AGP1) as a novel biomarker for pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4362,Ignore
Exploiting DNA repair alterations in metastatic pancreatic cancer (mPAC): Is MGMT methylation a new therapeutic target?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4363,Ignore
Association of CDH1 mutation with prognosis in gastric adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4364,Ignore
Monitoring of neuroendocrine tumors in elderly patients in the Brittany region.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4365,Ignore
The effect of race on adherence to NCCN Guidelines for patients with biliary tract cancers (BTC) after surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4366,Ignore
Correlation of <em>CHAF1A</em> with adjuvant chemotherapy outcome and microsatellite instability in gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4367,Ignore
Change in body composition and survival in patients with pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4368,Ignore
The heterogeneity of genomic biomarkers for immune checkpoint inhibitor in therapy-naïve primary hepatocellular carcinoma and their metachronous metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4369,Ignore
Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic ductal adenocarcinoma: A Chinese single institution.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4370,Ignore
Prognostic value of lymph node positivity and number of lymph nodes required for accurate staging of pancreatic neuroendocrine tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4371,Ignore
Safety and efficacy of neoadjuvant chemotherapy with S-1 and oxaliplatin plus apatinib for locally advanced gastric cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4372,Medium
Expression and heterodimerization of Type A and B Cholecystokinin Receptors in Gallbladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4373,Ignore
Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4374,Ignore
Proton pump inhibitor (PPI) exposure and risk of pancreatic cancer (PC): Meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4375,Ignore
Integrating endogenous peptides analysis and protease mapping for identification of potential serum biomarkers in gastric adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4376,Ignore
"Prevalence of esophageal malignant and premalignant lesions in a Michigan cohort, 2013-2017.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4377,Low
<em>KRAS</em> amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4378,Ignore
Expression of CD44 and CD133 in tumor <U+0441>ells of metastatic and non-metastatic gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4379,Ignore
Relapse-free survival (RFS) after surgical resection to predict survival after relapse (SAR) and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDA).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4380,Medium
Meta-analysis of prognostic biomarkers for pancreatic neuroendocrine tumors (PNETs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4381,Ignore
Patient and physician preferences for NIH PROMIS patient-reported outcome (PRO) domains in pancreatic ductal adenocarcinoma (PDA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4382,Ignore
Dose-survival relationship in patients with hepatocellular carcinoma undergoing stereotactic body radiation therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4383,Ignore
A retrospective analysis of clinical outcomes among patients with infiltrative hepatocellular carcinoma (iHCC): A single institution study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4384,Medium
Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4385,Ignore
Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4386,Ignore
Genome-wide copy number alteration (CNA) of circulating cell-free DNA (cfDNA) as a prognostic biomarker in esophageal squamous cell carcinoma (ESCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4387,Ignore
Relationship between PET response and pathologic response in distal esophageal/gastroesophageal junction cancers: A provincial population-based analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4388,Ignore
"Prevalence of gastric cancer and premalignant changes in a Michigan cohort, 2013-2017.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4389,Low
The combination of the NT157 and sorafenib as a new therapeutic option for hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4390,Ignore
The peritoneal fluid reflects the effect on pancreatic cancer by intraoperative radiation therapy (IORT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4391,Ignore
Imaging biomarker phenotyping system (iBiopsy) to accelerate hepatocellular carcinoma (HCC) drug development.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4392,Ignore
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4393,Ignore
"Is it possible to effectively treat second-line gastric cancer, given the prognosis factors?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4394,Ignore
Role of angiogenesis factors in formation of metastatic niches.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4395,Ignore
"Characterization of tumor mutation burden, PD-L1 and hepatitis B virus in Chinese hepatocellular carcinoma patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4396,Ignore
Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4397,Ignore
Serum microRNA signatures for the detection of pancreatobiliary cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4398,Ignore
Impact of no treatment vs other nonsurgical treatments in Pancreatic Adenocarcinoma National Cancer Database: 2004-2014.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4399,Ignore
Immune biomarker expression in the tumor microenvironment in Chinese patients with esophageal squamous cell carcinoma was explored.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4400,Ignore
Genomic landscape of HBV-related hepatocellular carcinoma in south China patients with high mutational frequency of TP53 and TERT promoter.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4401,Ignore
Molecular differences between AFP-negative and AFP-positive hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4402,Ignore
Characterizing PD-L1/PD-1 expression in hepatocellular carcinoma and implications on postresection treatment response.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4403,Ignore
Association of the ratio of CD8+ and CD163+ lymphocytes with clinical outcome in hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4404,Ignore
Distribution of urokinase-type plasminogen activator and its receptor in malignant tissues of gastric adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4405,Ignore
"Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4406,Ignore
Comparison of the mutation profile between pancreatic head/neck and body/tail cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4407,Ignore
Defining the heterogeneity landscape of pancreatic cancer copy number alterations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4408,Ignore
Remnant pancreatic volume to predict short-term and long-term outcomes in patients with resected pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4409,Ignore
Impact of pretreatment serum creatinine on outcomes in pancreatic adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4410,Ignore
Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4411,Ignore
Prognostic value of systemic immune-inflammation index in elderly patients with esophageal squamous cell cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4412,Ignore
Chronotherapeutic regimen with liposomal cisplatin for systemic treatment of primary liver cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4413,Ignore
Efficacy and tolerability of adjuvant gemcitabine and capecitabine in patients with resected pancreatic cancer in US population: A single network experience.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4414,Medium
Can artificial intelligence support the clinical decision making for Barcelona clinic liver cancer stage 0/a hepatocellular carcinoma in China?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4415,Ignore
Role of neoadjuvant therapy (NAT) in pancreatic adenocarcinoma (PAC): A single center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4416,Ignore
Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4417,Ignore
Prediction of hepatocellular carcinoma patient survival using machine learning classification rules.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4418,Ignore
Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4419,Ignore
Combining neoadjuvant chemoradiation with adjuvant chemotherapy in multimodality treatment for patients with potentially curable esophageal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4420,Ignore
The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4421,Ignore
"Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: A prospective, randomized, open label, single-center trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4422,Ignore
Hospitalization cost and length of stay in pancreatic cancer population: A national inpatient database study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4423,Ignore
Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4424,Ignore
Transcriptional characterization of microenvironment and their prediction role for the prognosis of hepatocellular carcinoma after surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4425,Ignore
Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4426,Ignore
"High spatiotemporal heterogeneity, clonal selection and neoantigen evolution in acquired sorafenib-resistant patient-derived xenograft models of hepatocellular carcinoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4427,Ignore
Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4428,Ignore
Survival analysis and clinical characteristics of forty-eight patients with alpha-fetoprotein-positive gastric cancer treated by integrated Chinese and western medicine.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4429,Ignore
The prognostic factors associated with long-term survival in the patients with synchronous oligometastatic esophageal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4430,Ignore
The ratio of negative lymph node count inside the thoracic cavity to the positive lymph count is a prognostic factor in esophageal squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4431,Ignore
Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4432,Ignore
Dynamic assessment of circulating tumor DNA in prediction of response to nab-paclitaxel-based first-line chemotherapy in metastatic pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4433,Ignore
"Association between heart dosimetric parameters, cardiac events and overall survival for patients with stage III esophageal cancer treated with definitive radiotherapy.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4434,Medium
Functional personalized oncology to determine drug sensitivity in cholangiocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4435,Ignore
A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4436,Medium
Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4437,Ignore
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4438,Ignore
Sequential assessments of <em><i>KRAS-</i></em>mutated circulating tumor DNA in longitudinal monitoring enable the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4439,Ignore
Patterns of local failure after definitive radiotherapy in patients with esophageal squamous cell carcinoma: Implications for the longitudinal clinical target volume design.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4440,Ignore
Impact of Clostridium difficile infection on gastrointestinal malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4441,Ignore
tPA and PAI-1 in malignant tissues of gastric adenocarcinoma can be tumor-associated.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4442,Ignore
Chromosome 8q24 amplification predicts prognosis for patients with advanced hepatocellular carcinoma (HCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4443,Ignore
Histology and stage at presentation among patients with rare pancreatic tumors: An exploratory analysis of the SEER database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4444,Ignore
Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4445,Ignore
Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4446,Ignore
Impact of KRAS mutations in clinical features and survival in pancreatic cancer patients: A single institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4447,Ignore
Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4448,Ignore
Association of liver-directed local therapy with overall survival in metastatic intrahepatic cholangiocarcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4449,Medium
Neoadjuvant chemoradiotherapy combined with surgery in the treatment of potentially operable thoracic squamous cell carcinoma of the esophagus(ChiCTR-OIC-17011648): A phase II single center clinical study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4450,Medium
Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4451,Ignore
"Chemotherapy (CT) or chemoradiation (CTRT) in postoperative (simple cholecystectomy) carcinoma gall bladder (GBC) with residual disease, unsuitable for revision surgery.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4452,Ignore
The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4453,Ignore
Real-world assessment of healthcare costs for patients with metastatic pancreatic cancer following first-line chemotherapy initiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4454,Ignore
"Epidemiology, prevalence and national trends of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) in hospitalized US patients between 2002-2014.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4455,Low
Integrated multi-omic analysis to reveal comprehensive tumor heterogeneity and novel immunophenotypic classification in primary liver cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4456,Ignore
Postoperative adjuvant chemotherapy for thoracic pathological T3N0M0 esophageal cancer: A propensity score-matched analysis (APEC Study 1).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4457,Ignore
Predictors of peritoneal metastasis in gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4458,Ignore
Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastroesophageal cancers (EGC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4459,Medium
Liver resection in elderly patients over the age of 70 with primary liver cancer: A retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4460,Ignore
The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4461,Ignore
Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4462,Ignore
"Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4463,Medium
A MRI-based radiomics model for preoperative prediction of five-year survival status in hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4464,Ignore
Tolerability and safety of a replication-competent adenovirus-mediated double suicide gene therapy (Ad5-yCD/mutTK(SR39)rep-ADP) with chemotherapy in locally advanced pancreatic cancer: Phase 1 trial.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4465,Medium
Final results of early non-invasive gastric cancer detection study using the serum pepsinogen test method in Croatian patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,1,4466,High
Predictors of mortality following cardiac surgery for carcinoid heart disease.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4467,Low
Density of CD8+ and CD68+ lymphocyte cell infiltration is associated with clinic outcome in hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4468,Ignore
A retrospective series of centralized reviewed GEP MANECs receiving a first-line adenocarcinoma-oriented chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4469,Ignore
Patient-reported distress and symptoms predict post-esophagectomy outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4470,Ignore
Urokinase secretion by gastrointestinal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4471,Ignore
Nemesis: Non-inferiority meta-analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma: A preliminary analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4472,Ignore
Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4473,Ignore
Health-related quality-of-life in patients with cholangiocarcinoma: Results of a systematic literature review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4474,Ignore
"Adjuvant FOLFOX + nab-paclitaxel (FOLFOX-A)for pancreatic cancer, BrUOG 278: A Brown University oncology research group phase II study.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4475,Medium
A novel EUS-guided liquid fiducial marker for image-guided radiotherapy in esophageal cancer: The safety and efficacy in vitro and vivo evaluations.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4476,Medium
Impact of adjuvant treatment according to gastric cancer molecular subtypes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4477,Ignore
Clinical predictors of radiographic progression of a hepatic lesion from Li-RADS 3 to Li-RADS 5 among a population of individuals at high risk of hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4478,Ignore
Microbiome signature of bile from pancreatic and biliary tract cancer patients: A pilot study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4479,Ignore
Neoadjuvant versus adjuvant chemoradiotherapy for stage IIIII esophageal squamous cell carcinoma: A propensity score-matched analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4480,Ignore
Outcomes of treatment of carcinoma gall bladder undergoing curative intent surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4481,Ignore
Can hormone receptors prevent metastatic spread of gastric cancer?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4482,Ignore
Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDl-1 expression in Turkish patients with gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4483,Ignore
Comparison of tumor characteristics and survival between esophageal and other gastroenteropancreatic neuroendocrine neoplasms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4484,Ignore
"The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4485,Ignore
Genomic analysis of hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) replication.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4486,Ignore
Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4487,Ignore
Microvascular invasion may guide selection of candidates for combination treatment with sorafenib and TACE for intermediate recurrent hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4488,Ignore
Immune landscape of neoadjuvant/preoperative chemoradiotherapy in pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4489,Ignore
"Epidemiology, national trends and clinical associations of pancreatic adenocarcinoma in chronic pancreatitis patients: A nationwide inpatient sample (NIS) study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4490,Ignore
Apatinib inhibits tumor progression and promotes antitumor efficacy of cytotoxic drugs in esophageal squamous cell carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4491,Medium
Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4492,Ignore
Lenvatinib for the treatment of HCC: A single institute experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4493,Ignore
Effect of tumor cell-derived debris and IgG on metastasis of pancreatic cancer and inflammation through tumor-associated macrophages.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4494,Ignore
"Pancreatic cancer survival trends overall, by stage, and histologic sub-type: An analysis of Surveillance, Epidemiology and End Results (SEER) population-based data (2000-2015).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4495,Ignore
HIV associated hepatocellular cancer (HCC) in an inner-city minority population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4496,Ignore
"ET140202 t-cells: A novel therapy targeting AFP/MHC complex, that is both safe and effective in treating metastatic hepatocellular carcinoma.",0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4497,High
Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma patients with poor performance status.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4498,Ignore
The regulation effect of EGFR signaling pathway on PD-L1 expression on esophageal squamous cell carcinoma cell lines.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4499,Ignore
Esophageal cancer: Five years of experience in an oncological reference center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4500,Ignore
Retrospective determination of the correlation between the distance of tumor manifestation to peripancreatic arteries and overall survival in primary resected pancreatic ductal adenocarcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4501,Medium
Efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4502,Medium
A novel preclinical model of cholangiocarcinoma based on human aberrant FBXW7 expression.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4503,Medium
Effect of p-PAQR3<sup>Thr32</sup> on PD-L1 expression and immune evasion in gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4504,Ignore
Targeting of survivin to overcome cisplatin resistance in esophageal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4505,Ignore
Trends in pancreatic cancer chemotherapy treatment in the United States from 2008 through 2016.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4506,Ignore
Efficacy and safety of conversion therapy using chemotherapy plus anti-angiogenic therapy in unresectable gastric cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4507,Medium
Myopenia as a significant prognostic factor in BCLC-B intermediate-stage hepatocellular carcinoma treated with sorafenib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4508,Ignore
Antitumor efficacy of M3814 as a radiation sensitizer in neuroendocrine tumor (NET) preclinical models.,0,31-05-2019,0,0,0,1,0,0,0,0,1,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4509,Medium
Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4510,Medium
Nab-paclitaxel/S-1(AS) versus nab-paclitaxel/gemcitabine(AG) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A retrospective analysis of efficacy and safety.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4511,Medium
Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4512,Ignore
"FOXO1, an AKT downstream substrate, plays a role as tumor suppressor in HCC pathogenesis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4513,Ignore
Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4514,Ignore
First-in-class hafnium oxide nanoparticles NBTXR3 in the treatment of liver cancers.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4515,High
Video-based patient education on carcinoid syndrome: Positive knowledge and behavior shift for patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4516,Ignore
Identification of clinically actionable mutations and immunotherapy biomarkers in Chinese esophageal squamous cell carcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4517,Ignore
"A multicenter, single-armed, prospective phase II study of apatinib combined with chemotherapy neoadjuvant for locally advanced gastric cancer.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4518,Medium
Disassociation of ARID1A with genomic ancestry and prognostic impact in an admixed cohort of Brazilian patients with gastric cancer (GC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4519,Ignore
Association between molecular subtype of esophageal squamous cell carcinoma and survival of patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4520,Ignore
Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4521,Ignore
The characterization of <em>ERBB</em> family mutations in Chinese biliary tract cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4522,Ignore
Not all HLA loss facilitate immune escape.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4523,Ignore
Evaluation of Ki67 and other predictors of survival in metastatic neuroendocrine tumor (NET) to the liver treated with Y90 radioembolization.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4524,Ignore
Use of DNA methylation to distinguish gallbladder carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4525,Ignore
Identifying mechanisms of macrophage-induced metastasis in pancreatic ductal adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4526,Ignore
Trends from NSQIP 2015 to 2017 in neoadjuvant therapy use before pancreatic adenocarcinoma resection.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4527,Ignore
Influence of post-resection time to chemotherapy in pancreatic adenocarcinoma on overall survival.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4528,Medium
Tumor mutation burden in biliary tract cancers with ERBB family or DNA damage repair gene mutations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4529,Ignore
First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4530,High
Predictors of post-operative mortality following pancreatectomy: A contemporary nationwide analysis.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4531,Low
Treatment modalities and oncological outcomes in a cohort of patients with advanced gastric cancer in Mexico.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4532,Ignore
Investigation of enhanced antitumor effects via co-inhibition of Wnt/ß-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4533,Ignore
Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4534,Ignore
Mutant KRAS and TP53 with high mutation allelic frequency in ctDNA as poor outcome predictors in metastatic pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4535,Ignore
Profile of somatic mutations in young adults with pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4536,Ignore
Copy number instability (CNI) combined with CA19-9 as a biomarker for postoperative prognostic prediction of pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4537,Ignore
The impact of method of recurrence detection on esophageal/gastroesophageal junction (EGJ) cancer outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4538,Ignore
"Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4539,Medium
Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4540,Ignore
Investigation to metastasis of regional lymph node station and prediction to long-term survival following esophagectomy in thoracic esophageal cancer with stage T1 to T3.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4541,Ignore
Histone deacetylase 6-EGFR axis in recurrent hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4542,Ignore
Effect of irreversible electroporation (IRE) combined with chemotherapy (C) on survival in locally advanced pancreatic cancer (LAPC) patients (pts).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4543,Ignore
A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4544,Medium
Survival of gastric cancer (GC) patients is not determined by the predominant genomic ancestry (PGA): Results from an ethnically admixed Brazilian cohort of GC patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4545,Ignore
Clinical implication of telomere length-related polymorphisms in gastric cardia adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4546,Ignore
Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: A randomized controlled study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4547,Ignore
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4548,Ignore
SM-88 therapy in high risk poor prognosis pancreatic cancer (PDAC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4549,Ignore
The prevalence of hereditary pancreatitis mutations in families with pancreatic cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4550,Low
Treatment response and survival in patients with pancreatic adenocarcinoma receiving neoadjuvant chemotherapy or chemoradiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4551,Ignore
A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4552,Ignore
Hepatocellular carcinoma with tumor thrombus in portal vein branch: Transarterial chemoembolization combined with Iodine125 brachytherapy versus transarterial chemoembolization combined with sorafenib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4553,Ignore
Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4554,Medium
"Significant neutrophil accumulation, IL-18 deposition, and active inflammasome in tumor regions of human pancreatic ductal adenocarcinoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4555,Ignore
Effect of neoantigen reactive T cells combined with chemotherapy and radiation on survival in advanced pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4556,Ignore
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4557,Ignore
The impact of geography and center volume on access to care and outcomes in advanced hepatocellular carcinoma (HCC): A retrospective population based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4558,Ignore
Evaluation of prognostic factors after esophagectomy in which preoperative chemotherapy was successful.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4559,Ignore
Retrospective analysis of outcomes with different adjuvant treatments in cholangiocarcinoma: An NCDB review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4560,Ignore
Transducer array layout optimization for the treatment of pancreatic cancer using Tumor Treating Fields (TTFields) in the phase 3 PANOVA-3 trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4561,Medium
Mutation profiles in circulating tumor DNA (ctDNA) to predict the efficacy of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4562,Medium
Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4563,Ignore
Effect of neoadjuvant chemotherapy using gemcitabine and S1 before surgery for pancreatic cancer on quality of life.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4564,Ignore
The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4565,Medium
Exposure-response (E-R) analysis of efficacy of pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel + gemcitabine (AG) in patients (Pts) with metastatic pancreatic ductal adenocarcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4566,Medium
Geographic and demographic disparities in neuroendocrine tumors (NETs): A population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gastrointestinal (Noncolorectal) Cancer: Publication Only,0,0,4567,Ignore
Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4568,Ignore
Utilization of mental health services among survivors of testicular cancer: A population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4569,Ignore
Hypoxia signaling and immune infiltration in a presurgical trial of sunitinib in patients with clear cell renal cell carcinoma (RCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4570,Ignore
Programmed death-ligand 1 (PD-L1) expression in small cell carcinoma of bladder.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4571,Ignore
"Two sequential dose-dense regimens of CGP, followed by MVAC in patients with metastatic urothelial carcinoma (mUC): A single institution, explorative trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4572,Ignore
Sarcopenia as a predictor of perioperative outcomes following radical cystectomy in a contemporary cohort of patients with bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4573,Ignore
Delivery of bleomycin among patients with testicular cancer: A population-based study of pulmonary monitoring and toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4574,Ignore
The impact of gastric acid suppressive agents on pazopanib exposure.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4575,Ignore
Cardiovascular mortality in renal cell carcinoma: A population-based study.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4576,Low
Deep learning segmentation of kidneys with renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4577,Ignore
Study of the clinical characteristics of scrotal mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4578,Ignore
Efficacy of systemic therapy for metastatic renal cell carcinoma in patients over 75 years of age.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4579,Medium
Management of stage I seminomatous germ-cell cancer (SGCC): Results from 4 different risk-adapted strategies in a single institution.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4580,Ignore
Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4581,Low
Carboplatin-based chemotherapy (C) versus immunotherapy (IO) in metastatic urothelial carcinoma (mUC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4582,Ignore
High DNA damage levels to predict hematologic toxicity in testicular germ cell tumor (TGCT) patients treated with first-line chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4583,Ignore
Population-based outcomes comparing radical cystectomy with trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4584,Ignore
"Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) expression in bladder cancer (BC): Differences in recurrent, progressive, and metastatic disease.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4585,Ignore
A systematic review of the characteristics of thyroid metastases from clear cell renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4586,Ignore
"Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4587,Ignore
Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4588,Ignore
Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4589,Ignore
"Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in forty-three countries.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4590,Ignore
Molecular profile of early-stage and advanced-stage of renal cell cancer in China.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4591,Low
Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4592,Ignore
The clinical features of extragonadal germ cell tumors: A SEER analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4593,Ignore
Mutational analysis using next-generation DNA sequencing in platinum-resistant muscle-invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4594,Ignore
Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4595,Ignore
"Long term relative survival (RS) in patients with primary metastatic kidney cancer: An analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4596,Ignore
Association of immune gene expression profiling with vinflunine clinical benefit in metastatic urothelial cancer (mUC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4597,Ignore
Pilot study of [<sup>18</sup>F] fluorodexoyglucose positron emission tomography-magnetic resonance imaging (FDG-PET-MRI) for staging of muscle-invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4598,Ignore
Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4599,Ignore
Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK/RANKL signaling: New therapeutic perspective for non-muscle invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4600,Ignore
"Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment early in responding patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4601,Ignore
Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4602,Ignore
Health related quality of life analysis among testicular germ cell tumor survivors treated in a tertiary cancer hospital in India.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4603,Ignore
Renal cell carcinoma in kidney transplant recipients at Guys and Kings College Hospital (UK) between 1987-2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4604,Ignore
Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4605,Ignore
A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4606,Ignore
Impact of rural/urban residence on relative survival (RS) in patients with kidney cancer: An analysis of 14576 patients from the Austrian National Cancer Registry (ANCR).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4607,Ignore
Adjuvant carboplatin for clinical stage I testicular seminoma in New Zealand centers: Retrospective analysis of efficacy and long-term adverse effects.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4608,Medium
Correlation between FGFR mutation and PD-L1 expression of urinary bladder cancers: A real-world based biomarker study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4609,Ignore
Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs).,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4610,Medium
Efficacy of receptor tyrosine kinase inhibitors (RTKIs) and immunotherapy (PD-1/PD-L1) for treatment of osseous vs. soft tissue metastases of renal cell carcinoma (RCC).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4611,Medium
Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4612,Ignore
Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4613,Ignore
"Nivolumab in renal cancer: French evaluation of use, current practices and medico economic approach.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4614,Ignore
Overall survival with or without brain metastases from diagnosis of metastatic renal cell carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4615,Medium
Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4616,Ignore
A single center experience of the impact of treatment-related toxicity in the clinical outcomes of elderly patients with metastatic germ cell tumors.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4617,Medium
Tumor growth rate in metastatic adrenocortical carcinoma using two-dimensional computer tomography scan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4618,Ignore
Identifying predictors of pathologic complete response to neoadjuvant chemotherapy for muscle invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4619,Ignore
Trend in the use of neo-adjuvant chemotherapy for the management of muscle invasive bladder cancer at a major tertiary care hospital in Pakistan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4620,Ignore
Express-diagnosing of acute kidney injury among patients with the localized kidney cancer after partial nephrectomy under warm ischemia: A role of biomarkers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4621,Ignore
Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4622,Ignore
Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,1,4623,High
Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4624,Ignore
Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4625,Ignore
Venous thromboembolism related hospitalizations among patients with genitourinary malignancy in the United States: A nationwide analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4626,Ignore
Genomic analysis of urothelial cancer and associations with treatment choice and outcome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4627,Ignore
Impact of facility patient volume on overall survival in patients with muscle invasive bladder cancer undergoing trimodality bladder preservation therapy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4628,Medium
Comparative analysis of profiles of second-line stage IV renal cell carcinoma patients by first-line to second-line treatment sequencing in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4629,Ignore
Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4630,Ignore
Long-term sexual impairment in relationship with metabolic health in testicular germ-cell tumor survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4631,Ignore
Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4632,Ignore
Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4633,Ignore
Lymphopenia and clinical significance associated with tyrosine kinase inhibitors in metastatic renal cell cancer in Guatemalan cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4634,Ignore
Cost-effectiveness of pazopanib as first-line treatment of metastatic renal cell carcinoma from National Health Service United Kingdom perspective.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4635,Ignore
Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4636,Ignore
Single-arm phase I/II study of the safety and efficacy of OncoTherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4637,Medium
Does neutrophil to lymphocyte ratio correlate with toxicities and outcome of patients with genitourinary cancers treated with checkpoint inhibitors?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4638,Ignore
Systematic review and network meta-analysis of first-line treatments in mRCC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4639,Ignore
First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4640,Ignore
Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4641,Medium
Efficacy and safety profile of sunitinib as a first line treatment for advanced/metastatic clear-cell renal cell carcinoma: Pooled analysis of randomized controlled trials.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4642,Medium
Validation of an artificial intelligence algorithm applied to a metabolic substrate analysis of urine for detection of urothelial cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4643,Ignore
Time to surgery (TTS) in renal cell carcinoma (RCC): Predictors and association with overall survival (OS).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4644,Medium
Improved outcomes in testicular germ cell tumor patients treated at the referral center in Slovakia in the last decade.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4645,Ignore
Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4646,Ignore
Endogenous DNA damage levels in peripheral blood mononuclear cells in patients with muscle-infiltrating urothelial bladder carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4647,Ignore
Prognostic and predictive biomarkers for clear cell renal cell carcinoma utilizing next generation sequencing.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4648,Ignore
A study of tobacco abuse as a risk factor for adrenal cortical carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4649,Ignore
Real-world outcome study among patients with renal cell carcinoma (RCC) receiving checkpoint inhibitors (CPIs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4650,Ignore
Assessment of treatment patterns of nonmuscle invasive bladder cancer patients in privately insured patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4651,Ignore
Genomic landscape of circulating tumor (ct)-DNA alterations in patients with penile cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4652,Ignore
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4653,Ignore
Stereotactic radiotherapy for stage I renal cell carcinoma: Overall survival and treatment trends compared to thermal ablation and surgical resection.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4654,Medium
The clinical outcome of renal cell carcinoma with rhabdoid and sarcomatoid differentiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4655,Ignore
"A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4656,Medium
Different expression and prognostic implications of PD-L1 in tumor cells and immune cells with the SP263 monoclonal antibody in Chinese urothelial carcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4657,Ignore
Phase II study of avelumab in multiple relapsed/refractory testicular germ cell cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4658,Medium
Risk factors for renal failure (RF) during high-dose chemotherapy (HDCT) and outcomes for patients (pts) with relapsed germ-cell tumors (rGCT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4659,Ignore
An estimate of premature deaths averted with immunotherapy in treating Brazilian patients with advanced clear cell renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4660,Ignore
Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4661,Medium
Comparison of efficacy and safety of checkpoint inhibitors in patients with genitourinary cancers aged below and above 75 years.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4662,Medium
"Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4663,Ignore
Impact of cannabis (CA) use on chemotherapy (C) treatment and tumor characteristics of patients (pts) with testicular germ cell tumor (TGCT): Experience of the Centre Léon Bérard (CLB).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4664,Ignore
Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4665,Ignore
Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4666,Low
"Site, age, and gender distribution of extra-gonadal germ cell tumors in the US from 1973 to 2015.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4667,Ignore
Outcome of patients with stage 2 or stage 3 seminoma treated with 3 cycles of cisplatin-etoposide chemotherapy (EP120): Updated data from a single center retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4668,Ignore
"Full adaptome repertoire analysis of immunotherapy to predict responsiveness and correlation with CD8-LAG3, sLAG3, and hepatocyte growth factor levels in patients with renal cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4669,Ignore
Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4670,Ignore
Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Nonprostate) Cancer: Publication Only,0,0,4671,Ignore
Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4672,Medium
Classification of prostate cancer based on clinical and omics data using neural networks techniques to improve prognostic power.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4673,Ignore
Abiraterone acetate in comparison to enzalutamide in African American patients with metastatic castrate-resistant prostate cancer: A single-center retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4674,Ignore
Automated prostate lesion detection and PI-RADS assessment with deep learning.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4675,Ignore
Association between circulating miRNA-141 and miRNA-375 and treatment outcome in metastatic castration-resistant prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4676,Ignore
"Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4677,Ignore
Family history in primary hormone therapy for prostate cancer from a community-based multi-institutional Japan-wide database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4678,Ignore
The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically treated men with clinically low and intermediate-risk prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4679,Ignore
A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4680,Medium
Impact of comorbidity and age on treatment choice among men with localized prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4681,Ignore
"Predictors and rates of adverse events (AEs) among non-metastatic prostate cancer (nmPC) patients (pts) treated with bicalutamide, abiraterone, or enzalutamide following surgical/medical castration.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4682,Ignore
Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4683,Ignore
Immune-stimulatory gene expression in stroma cells of African-American prostate cancer tissues.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4684,Ignore
"Safety and clinical outcomes of GT0918 (Proxalutamide), a potent androgen receptor (AR) blocker, in patients with mCRPC progressing on standard (SoC) and experimental therapies: Phase I/II trial.",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4685,Medium
"Adherence enhancing program for patients with metastatic, castration-resistant prostate carcinoma treated with abiraterone acetate plus prednisone: A cluster randomized trial.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4686,Ignore
Shared-decision making in prostate cancer with clinical decision-support.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4687,Ignore
Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4688,Ignore
"27-year patterns in high-risk prostate cancer treatment in a racially diverse, equal-access health care setting.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4689,Ignore
Prostate carcinoma in African-Americans has miRNA expression and biological markers for aggressive disease.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4690,Ignore
<em>PMEPA1</em> gene isoforms to indicate disease progression in solid tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4691,Ignore
Longitudinal prostate cancer outcomes in a racially diverse cohort of military heath care beneficiaries: 1990-2017.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4692,Ignore
Impact of hormone-therapy used in CRPC patients: Evaluation of abiraterone acetate/prednisone or enzalutamide on activity and cognitive functions in aged castrated mice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4693,Ignore
Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic castration-naive prostate cancer in South Asian population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4694,Ignore
Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4695,Ignore
"Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4696,Ignore
Effectiveness and tolerability of depot formulations of leuprorelin acetate in real life: Analysis of 932 patients with prostate cancer from Brazil.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4697,Medium
Early PSA progression in abiraterone/enzalutamide-treated patients with metastatic castration-resistant prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4698,Ignore
Does a food intervention makes abiraterone treatment affordable?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4699,Ignore
"MiR-1271-5p: An AR-modulatory microRNA with a distinct role in prostate cancer progression, through SND1 and MORF4L1<em> </em>interaction.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4700,Ignore
Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4701,Ignore
Outcomes of men with prostate cancer managed with active surveillance and tested with clinical cell-cycle risk score.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4702,Ignore
Oncolytic HSV and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4703,Ignore
Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4704,Ignore
Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4705,Ignore
"Ten year treatment complication outcomes of radical prostatectomy versus external beam radiation therapy versus brachytherapy for 1,503 patients with intermediate risk prostate cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4706,Ignore
Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4707,Ignore
Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4708,Medium
Deep learning hybrid 3D/2D convolutional neural network for prostate MRI recognition.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4709,Ignore
Screening of <em>BRCA2</em> mutated men for detection of prostate cancer: Preliminary results from a national high volume cancer center.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,1,4710,High
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4711,Medium
NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4712,Ignore
IMPACT of putative chemopreventative agents on prostate cancer diagnosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4713,Ignore
Race as a prognostic factor in high-risk prostate cancer: An NCDB analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4714,Ignore
Pilot study to enhance FDG-PET imaging of prostate cancers with the metabolic inhibitor ranolazine.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4715,Ignore
Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.,0,31-05-2019,0,0,0,1,0,0,0,0,1,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4716,Medium
Determination of AR-V7 in plasma in patients with metastatic prostate cancer using capillary Nano-immunoassay.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4717,Ignore
Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4718,Ignore
"Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4719,Ignore
"Prostate image-guided transperineal elastic-registration biopsy, a new diagnostic tool to refine the risk-stratification of prostate cancer and improve therapeutic decisions.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4720,Ignore
Comparison of enzalutamide versus abiraterone in castration-resistant prostate cancer before docetaxel: Results of a propensity score-matched analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4721,Ignore
Relationship between body composition and hormone sensitivity for androgen deprivation therapy in metastatic prostate cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4722,Ignore
The impact of simultaneous dose escalation VMAT to the focal lesion micro boost of localized prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4723,Ignore
Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4724,Ignore
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4725,Medium
The effect of E2F7 expression in prostate cancer on apoptosis and cell cycle of prostate cancer cells.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4726,Ignore
Physician benefit-risk preferences for non-metastatic castration-resistant prostate cancer treatment (nmCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4727,Ignore
Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4728,Ignore
Cancer driver genes in prostate cancer from young men.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4729,Ignore
Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4730,Ignore
Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in intermediate and high-risk localized prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4731,Ignore
DPP4 inhibitors as novel agents in improving survival in patients with prostate cancer: A SEER-Medicare study.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4732,High
"Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4733,Medium
Multiparametric magnetic resonance imaging (mpMRI) and PSA density for the prediction of reclassification among patients under active surveillance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4734,Ignore
"An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4735,Medium
Are there any significant impacts of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer?,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4736,Medium
Prognostic value of PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the COU-AA-302 trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4737,Ignore
Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4738,Ignore
Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4739,Ignore
Radium 223 (Ra-223) experience in twenty-four castration resistant prostate cancer (CRPC) patients treated at West Virginia University (WVU) 2014-2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4740,Ignore
30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4741,Medium
Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4742,Ignore
Real-world cardiovascular outcomes with novel anti-androgen agents in prostate cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4743,Ignore
"Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted <em>Listeria monocytogenes</em>-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC).",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4744,Medium
Computer modelling in prostate anticancer therapy (COMPACT).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4745,Ignore
Next-generation sequencing of primary prostate cancer tumors to reveal actionable opportunities for clinical management.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4746,Ignore
Association between nutritional status (NS) and health-related quality of life (HRQoL) in men with early metastatic castrate-resistant prostate cancer (mCRPC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4747,Ignore
A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men = 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4748,Medium
Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non- metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Primary outcome analysis of a prospective phase II study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4749,Medium
The predictive power of free (vs. total) testosterone in aggressive prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4750,Ignore
The internet bias toward nontraditional first line prostate cancer treatments.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4751,Ignore
The National Radium-223 Dichloride Audit group: Data from patients in UK oncology centers with metastatic castration-resistant prostate cancer treated with radium-223 dichloride.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4752,Ignore
Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted <sup>99m</sup>Tc-MIP-1404 SPECT/CT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4753,Ignore
Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4754,Ignore
Association of radiomic features from prostate bi-parametric MRI with Decipher risk categories to predict risk for biochemical recurrence post-prostatectomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4755,Ignore
A single-center retrospective analysis of the effect of Radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4756,Ignore
Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genitourinary (Prostate) Cancer: Publication Only,0,0,4757,Ignore
Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4758,Medium
Incorporation of HIPEC into a high volume ovarian cancer program: Initial results and outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4759,Ignore
Hypermetabolic activity by FDG-PET after immunogenic chemotherapy and multi-peptide immunotherapy in ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4760,Ignore
Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4761,Ignore
"Effect of postoperative adjuvant treatment in the therapeutic management of stage I, morcellated uterine leiomyosarcoma: A Korean multicenter study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4762,Ignore
Mutational landscape of endometrial cancer identified by prospective clinical sequencing in a nationwide cancer network.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4763,Ignore
Does mismatch repair (MMR) deficiency have prognostic significance in low-risk endometrioid endometrial cancers?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4764,Ignore
Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4765,Ignore
How do we bridge the gap? persistent differences in the preoperative experience for patients with gynecologic cancer treated at a public hospital.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4766,Ignore
An optimized homologous recombination deficiency (HRD) algorithm ASGAD for predicting PARP inhibitor response in ovarian cancer patient.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4767,Ignore
Prognosis of ovarian cancer in the United States during 1973 to 2015.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4768,Ignore
Real time FTIR spectroscopy of tissue smears from gynecologic cancer tissues: A preliminary study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4769,Ignore
CD49d (high) T cells in the ovarian cancer microenvironment are a potential target for the optimization of immune checkpoint therapy in ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4770,Ignore
Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4771,Ignore
Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4772,Ignore
Incidence of comorbidities on death certificate data in women with gynecological cancers.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4773,Low
"Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4774,Ignore
Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,1,0,4775,Low
Hysterectomy utilization among newly diagnosed endometrial cancer patients by body mass index category: A real-world analysis using a claims and electronic health record database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4776,Ignore
Factors associated with one-year mortality after debulking surgery in older women with ovarian cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4777,Low
Significance of degree of destructive stromal invasion in early stage endocervical adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4778,Ignore
Dynamic of molecular subtypes of high-grade serous ovarian cancer in paired primary and relapsed biopsies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4779,Ignore
Prognostic value of tumor parameters measured by MRI in cervical cancer patients receiving CCRT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4780,Ignore
Accuracy of primary laparoscopic staging in patients with early ovarian malignancies: A retrospective multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4781,Ignore
Treatment outcome for primary cervix large B-cell lymphoma: A clinical analysis of thirty-seven cases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4782,Ignore
Weighted gene co-expression network analysis combined with machine learning to identify prognostic biomarkers for cervical squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4783,Ignore
Bovine milk-derived exosomes mediated delivery of resibufogenin and its effect on platinum-resistant ovarian carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4784,Ignore
"The association of marital status, socioeconomic status, and race on the survival of ovarian cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4785,Ignore
Quality of care and survival of women with uterine cancer by Hispanic origin: An NCDB analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4786,Ignore
Impact of a structured quality management program on survival of patients with advanced (AOC) and relapsed ovarian cancer (ROC) treated in a dedicated tertiary gynecologic-oncology (GO) center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4787,Ignore
Survival of patients with cervical cancer and diabetes: An exploratory study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4788,Ignore
Patient characteristics associated with treatment of cervical cancer in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4789,Ignore
Post-treatment clinical status of patients with cervical cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4790,Ignore
Inpatient burden of cervical and uterine cancer in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4791,Ignore
Survival differences based on tumor size among stage 1B cervical cancer patients in Louisiana using revised FIGO staging system.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4792,Ignore
Clinicopathological significance and prognostic value of intratumoral and peritumoral lymphocytes in endometrial cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4793,Ignore
Multiple genetic alterations to predict the clinical outcome for bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4794,Ignore
Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4795,Medium
Differential vaginal wall dosing in high-dose rate brachytherapy for endometrial cancer: The potential for superior coverage of at-risk areas while preserving organs at riskAn analysis of simulated data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4796,Ignore
ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4797,Ignore
Association between<em>BRCA1 </em>and <em>BRCA2 </em>mutations and prognosis in women with endometrial carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4798,Ignore
The influence of obesity on tumor recurrence in vulvar cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4799,Ignore
A single-center retrospective analysis to evaluate the prognostic role of lymph node density in patients with lymph node-positive cervical cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4800,Ignore
Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4801,Ignore
The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4802,Low
Trends in opioid use in patients undergoing primary surgery for cervical cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4803,Ignore
A 3D micro-tumor model capturing tumor heterogeneity of a patient's primary tumor biopsy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4804,Ignore
Telomere length and its implication as prognostic marker in ovarian cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4805,Ignore
Predictive factors of cytoreductive surgery in epithelial ovarian cancer in a Mexican women cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4806,Ignore
Patterns of distant metastases in patients with endometrial carcinoma: A SEER population-based analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4807,Ignore
Single agent of apatinib in patients with recurrent or refractory cervical cancer: A real-world multicenter retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4808,Ignore
Is uterine cancer screening indicated or possible in high risk special populations?,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4809,Low
Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4810,Ignore
"Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4811,Ignore
Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4812,Ignore
Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4813,Ignore
Interdisciplinary surgery for advanced gynecologic malignancies: Outcome and complication rate.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4814,Ignore
Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4815,Ignore
Clinical benefit of bevacizumab in Mexican ovarian cancer patients according to the intention of treatment by the oncologist.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4816,Ignore
The developmental origins of high grade serous ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4817,Ignore
Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4818,Medium
Glucocorticoid receptor expression in Müllerian carcinosarcomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4819,Ignore
The effects of Wnt inhibition on tumor progression and the tumor microenvironment in a syngeneic mouse model of ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4820,Ignore
Prognostic value of monocyte to lymphocyte ratio (MLR) in epithelial ovarian cancer (EOC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4821,Ignore
Comparison of preoperative serum VEGF in leiomyosarcoma and uterus myomatosus patients: A proof of concept study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4822,Ignore
New biomarkers to predict platinum resistance in ovarian cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4823,Ignore
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: An institutional experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4824,Ignore
Revised FIGO staging shows dramatic survival differences in cervical cancer patients with positive lymph nodes in Louisiana.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4825,Ignore
Transcriptomic characterization of endometrial cancer in order to find new therapeutic targets.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4826,Ignore
A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4827,Low
Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4828,Medium
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4829,Ignore
Overall survival trends for cervical cancer in the modern era: A U.S.A. population based analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4830,Medium
Economic burden associated with cervical cancer: An analysis of patient-reported outcomes in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4831,Ignore
Exploring racial disparities of actionable mutations in gynecologic cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4832,Ignore
Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4833,Ignore
Mutational landscape of cervical cancer identified by prospective clinical sequencing in a nationwide cancer network.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4834,Ignore
"A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4835,Medium
Cervical cancer outcomes after chemoradiation and brachytherapy in New York City comparing public versus private hospitals.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4836,Ignore
Influence of the new FIGO classification for cervical cancer on patients survival: Retrospective analysis of 265 histologically confirmed cases with FIGO stages Ia to IIb.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4837,Ignore
Value of adjuvant chemotherapy using paclitaxel plus carboplatin after radical surgery with or without radiotherapy in stage IB-iia cervical adenocarcinoma with risk factors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4838,Ignore
Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4839,Ignore
Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4840,Ignore
Half-dose olaparib reduction: Safe and efficient dose in multi-treated Mexican ovarian cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4841,Ignore
Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4842,Medium
E-consult: To better inform patient.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4843,Ignore
Non-opioid analgesics: New opportunities in early rehabilitation of patients with gynecological cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4844,Ignore
The value of tumor paramaters and dosimetry on prognostic nomograms for cervical cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4845,Ignore
Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4846,Ignore
The role of macrophage production of transforming growth factor-ß in epithelial ovarian cancer progression.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4847,Ignore
Identification of prognostic variables in advanced ovarian cancer based on real-world patients from big data analytics.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4848,Ignore
Poly adenosine diphosphate ribose polymerase inhibitors maintenance in patients with ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4849,Ignore
GPR30 signaling to regulate epithelial-mesenchymal transition and predict survival in ovarian cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4850,Ignore
Uterine corpus invasion as a risk factor in patients with early-stage cervical carcinoma receiving radical surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4851,Ignore
Prognostic implications of lymph node metastasis in advanced ovarian cancer: Analysis of the National Cancer Database 2006 to 2014.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4852,Ignore
Sonographic and histopathologic characteristics of MMR-deficient endometrial cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4853,Ignore
"FLABRA, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population: A Latin America (LA) epidemiologic study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4854,Ignore
Impact of systemic treatment associated to radiotherapy on quality of life in locally advanced head and neck cancer patients in Brazil: Prospective real-world data study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4855,Ignore
"Delay in time to adjuvant chemotherapy and its impact on outcome in completely resected advanced ovarian malignancies treated with CRS, CRS+IP and CRS +HIPEC.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer: Publication Only,0,0,4856,Ignore
Survival estimates for young patients with tongue cancer: An analysis of the SEER database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4857,Ignore
Determining the biomarker landscape and its impact on outcomes in HPV+ head and neck cancer after primary resection.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4858,Ignore
Synchronous esophageal cancer impact on survival of head and neck squamous cell carcinoma (HNSCC) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4859,Ignore
"Triple combination treatment with anti-EGFR monoclonal antibody, low-dose chemotherapy, and anti-PD1 immune check-point inhibitors for recurrent and/or metastatic head and neck squamous cell carcinoma: A single institute experience.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4860,Ignore
Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT).,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4861,Low
Factors associated with recurrence and death in patients with aggressive hobnail morphology papillary thyroid carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4862,Ignore
Does systemic treatment add value to stereotactic body radiation therapy for locoregional control in head and neck squamous cell carcinoma patients?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4863,Ignore
Preclinical study of PD-0332991 on EBV-positive NPC cell lines and xenografts.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Head and Neck Cancer: Publication Only,0,0,4864,Medium
Factors associated with non-completion of radiation therapy (RT) or radiochemotherapy (RTCT) in head and neck squamous cell carcinoma (HNSCC): A prospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4865,Ignore
Which treatment strategies are the most promising for locally advanced resectable human papillomavirus-associated oropharyngeal cancers?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4866,Ignore
Characteristics of the course of squamous cell carcinoma of the oral cavity depending on the HPV status.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4867,Ignore
Upstaging of head and neck cancers due to extranodal extension: An Indian study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4868,Ignore
PDL-1 expression in oral squamous cell carcinoma and implications for treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4869,Ignore
"Comparison of mortality and second primary oropharyngeal malignancies by human papilloma virus (HPV) status in patients (pts) with oropharyngeal squamous cell carcinoma (OPSCC) using an updated Surveillance, Epidemiology, and End Results (SEER) database.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4870,Low
"Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4871,Ignore
Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4872,Ignore
Efficacy and prognostic factors of systemic therapies for metastatic adenoid cystic carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4873,Medium
Targeted next-generation sequencing in papillary thyroid carcinoma of Chinese Han population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4874,Ignore
Cumulative odds of increased comorbid score in head and neck cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4875,Ignore
The effect of induction chemotherapy on tumor volume changes in patients with locoregionally advanced nasopharyngeal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4876,Ignore
Long-term toxicity following radiation therapy for head and neck squamous cell carcinoma: A retrospective study analyzing the effect of concurrent chemotherapy and advanced t-stage on late treatment-induced toxicities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4877,Ignore
Does weekly versus daily low-dose of concurrent cisplatin have any effect on compliance and clinical outcomes in cases of locally advanced head and neck cancers?,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4878,Medium
Risk of second primary neoplasia in patients with oropharyngeal carcinoma: Role of HPV status in the outcome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4879,Ignore
Which role plays specialized palliative care in patients with relapsed and/or metastatic head and neck cancer? A retrospective analysis in Southern Switzerland.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,1,0,4880,Low
"Analysis of race and gender disparities in mortality trends from patients diagnosed with nasopharyngeal, oropharyngeal and hypopharyngeal cancer from 2000 to 2014.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4881,Low
Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4882,Ignore
Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer: A National Cancer Database analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4883,Ignore
A Nationwide analysis of mortality trends in geriatric and non-geriatric patients with oral cavity tumors.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4884,Low
Safety of denosumab in patients with refractory differentiated thyroid cancer and advanced medullary thyroid cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4885,Medium
Efficacy and safety of apatinib as second-line or beyond therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4886,Medium
Precision oncology for the treatment of salivary gland tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4887,Ignore
Osimertinib and dihydroartemisinin: A novel drug combination targeting head and neck squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4888,Ignore
Rising thyroid cancer incidence in Kerala: Is it real or over diagnosis?,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4889,Low
Single institution preliminary analysis of geriatric head and neck squamous carcinomas treated with modulated radiotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4890,Ignore
A novel mechanism of miRNA-mediated CBX8 associated with tumorigenesis in head and neck squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4891,Ignore
Prognostic neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in locally advanced oropharyngeal cancer: a retrospective experience of two institutions.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4892,Ignore
"Changes in the proportion of squamous cell carcinoma in head and neck cancer in the United States and Canada, 1995-2015.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4893,Ignore
Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4894,Ignore
"Chemotherapy in the management of olfactory neuroblastoma/esthesioneuroblastoma: An analysis of the surveillance, epidemiology, and end results (SEER) 1973-2015 database.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4895,Ignore
Potential role of botanical drug APG-157 as immune adjuvant in patients with oral squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4896,Ignore
"Evaluating sociodemographic, behavioral and psychologic disparities in 918 head and neck cancer survivors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4897,Ignore
Mutational profile of dysplastic lesions evolving to laryngeal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4898,Ignore
Next Generation Sequencing in Salivary Gland Carcinomas: Do Actionable Mutations Lead to a Therapeutic Advantage? A Multicenter Experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4899,Ignore
Predictive score for recurrence after complete resection in locally advanced oral cavity squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4900,Ignore
Association of low neutrophil-to-lymphocyte ratios (NLR) and high lymphocyte-to-monocyte ratios (LMR) with overall survival and response to induction chemotherapy (IC) when used to select patients (pts) with locally advanced squamous cell of the larynx (LSCC) for combined chemoradiation (CRT).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4901,Medium
Associations between pretreatment body mass index and presence of post-treatment nutrition impact symptoms in head and neck cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4902,Ignore
"Selected molecular markers as indicators of clinical profile, tumor characteristics and treatment outcome in squamous cell carcinoma of the larynx.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4903,Ignore
Biomarkers of resistance to cetuximab in head and neck squamous cell carcinoma (HNSCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4904,Ignore
QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4905,Medium
Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4906,Ignore
Analysis of trends in mortality in patients with lymphoepithelial carcinoma of the head and neck.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4907,Low
A differential response to cetuximab in patients with recurrent unresectable or metastatic head and neck cancer following immunotherapy (IO) exposure: An institutional experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4908,Ignore
Retrospective analysis of outcomes of cisplatin (CDDP) versus non cisplatin based treatment regimens for concurrent chemoradiotherapy (CCRT) in locally advanced squamous cell head and neck cancer (LA-SCCHN).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4909,Ignore
Multiplexed digital PCR for detection of HPV in tissue samples from oropharyngeal cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4910,Ignore
Anaplastic thyroid cancer: A report of six consecutive cases treated successfully with nab-paclitaxel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4911,Ignore
Comparison of mortality trends in patients with non-salivary gland and salivary gland adenoid cystic carcinoma in the United States population.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4912,Low
TCGA data reveal a transcriptomic signature of Sox2 and Nanog targets associated with survival in head and neck cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4913,Ignore
Changes in KRAS mutations in patients with oral mucosa and tongue cancer (OMTC) undergoing medical treatment with cetuximab (Cet).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4914,Ignore
TREM-1 expression in HPV-related oropharyngeal squamous cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4915,Ignore
Nationwide treatment patterns of oropharyngeal cancer in the human papillomavirus era.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4916,Ignore
Prognostic models for prediction of overall survival after first-line platinum-based chemotherapy for primary metastatic nasopharyngeal carcinoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4917,Medium
Quality of life assessment in dose escalating head and neck radiation therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4918,Ignore
"Diagnostic value of cytokeratin-1, survivin and TG expression in circulating tumor cells in the differentiation of benign and malignant thyroid nodules.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4919,Ignore
Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4920,Ignore
A phase II study of concurrent nimotuzumab and intensity-modulated radiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4921,Medium
Single institute analysis of squamous cell carcinoma of the head and neck treated with concurrent chemoradiation with either cisplatin versus cetuximab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4922,Ignore
Unhealthy alcohol use and toxicity of concurrent chemoradiation for head and neck cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4923,Ignore
Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4924,Ignore
Use of prophylactic percutaneous endoscopic gastrostomy (pPEG) tube in head and neck cancer (HNC) patients and correlation of weight loss with treatment interruptions.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4925,Ignore
Association between radiotherapy and obstructive sleep apnea in cancer patients: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4926,Ignore
Impact of reactive gastrostomy tube placement on clinical course of oropharynx cancer patients treated with chemoradiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4927,Ignore
Translating transcriptome to immunophenotype in head and neck squamous cell carcinoma (HNSCC) to identify pathways promoting T-cell infiltration.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4928,Ignore
Outcomes of post-operative treatment with concurrent systemic therapy and radiotherapy (RT) in intermediate (INT) risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4929,Ignore
Patterns of local extension and nodal involvement from 1300 nasopharyngeal carcinoma patients: An imaging-based predictor of distant metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Head and Neck Cancer: Publication Only,0,0,4930,Ignore
Participation of African Americans in clinical trials supporting FDA approval of cancer drugs.,0,31-05-2019,0,0,0,0,1,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4931,High
Bone marrow donation perceptions among healthcare workers: A follow-up study at University of Cincinnati Medical Center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4932,Ignore
Staging the development and implementation of a Coordinated Cancer Care Model using risk-based survivorship care: A deliberative discussion among multiple stakeholders.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4933,Ignore
Contributive compared with subsidized insurance in colorectal cancer in the Colombian National Administrative Cancer Registry.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4934,Ignore
Update: Implementation of a multidisciplinary quality improvement initiative to improve molecular testing rates in advanced non-squamous non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4935,Ignore
A multidisciplinary-guided digital solution to data capture in early-phase clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4936,Ignore
Patients insurance status impact on biomarker testing in the United States market.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4937,Ignore
RDI as a method for reviewer performance monitoring in BICR setup for improving data quality.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4938,Ignore
"Treatment patterns, survival rate, and Parts A and B costs by line of therapy for FDA-approved/NCCN Category 1 treatments for patients with metastatic pancreatic cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4939,Ignore
Implementation of the Quality Training Program in Spain.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4940,Ignore
Brain metastasis as exclusion criteria in extensive-stage small cell lung cancer trials: A trend over five decades.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4941,Ignore
Valuing innovations in cancer treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4942,Ignore
A physician-led team approach to improve advance directive completion rates in an inpatient oncology unit.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4943,Ignore
The impact of race and socioeconomic status on outcomes for HPV-associated squamous cell carcinoma of the head and neck.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4944,Ignore
Modeling accrual of older adults to cancer clinical trials: (Alliance A151736).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4945,Ignore
Understanding cancer care coordination: Opening the black box.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4946,Ignore
Evaluating the impact of cancer awareness months in Mexico using internet search engine analytics.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4947,Ignore
Investigating racial differences in treatment responses through analysis of real-world data (RWD).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4948,Ignore
Assessing real-world outcomes in precision oncology by linking clinical genomic testing to electronic medical records.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4949,Ignore
"A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4950,Ignore
Socioeconomic disparities among uninsured cancer patients: A free clinic study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4951,Ignore
Cost effectiveness (CE) of blinatumomab (BLIN) versus inotuzumab ozogamicin (INO) in adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) with no more than one prior salvage therapy (S0/S1) from a United Kingdom health care perspective.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4952,Ignore
Elucidation of qualitative patient-reported outcome (PRO) data using latent dirichlet allocation (LDA) in patients (pts) undergoing radical cystectomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4953,Ignore
Current treatment patterns and associated outcomes in Waldenström macroglobulinemia (WM) and related hematologic malignancies: A systematic literature review (SLR).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4954,Ignore
Lack of clinician knowledge of human papillomavirus (HPV) vaccination to prevent HPV-related cancers in men: An interview study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4955,Ignore
How will the cost of biosimilars affect patients willingness to receive them?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4956,Ignore
Visualizing real-world outcomes through the lens of a molecular tumor board: Persona-typing pancreatic cancers for clinical decision support.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4957,Ignore
Factors associated with receipt and overall survival of concurrent chemoradiotherapy versus single modality therapy in unresectable stage III NSCLC.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4958,Medium
Application of deep learning for clinical predictive modeling: An artificial intelligence recognition in spinal metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4959,Ignore
Characterization of temporal relationships of comorbidities developed following cancer diagnoses in veterans.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4960,Ignore
"Development of a digital immunohistochemistry records management system at the Moi Teaching and Referral Hospital (MTRH), Eldoret, Kenya.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4961,Ignore
Cost effectiveness of updated laboratory monitoring schedule for immunotherapy regimes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4962,Ignore
Identifying cancer patients care needs after discharge hospital using health claim data linked with Hospital-based Cancer Registry data in Japan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4963,Ignore
Disparities in the receipt of palliative care (PC) in metastatic renal cell carcinoma (mRCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",1,0,4964,Low
Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4965,Low
Should pregnancy testing during chemotherapy be standardized?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4966,Ignore
Evaluating the challenges of cancer care in Botswana: Chemotherapy utilization and stock outs.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4967,Ignore
Evaluation of cancer patients perspectives on weight management counseling at a comprehensive cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4968,Ignore
Quantifying febrile neutropenia rates using electronic medical records in a large integrated delivery network.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4969,Ignore
Risk of neutropenia-related hospitalization (NRH) related to duration of short-acting granulocyte colony stimulating factor (sG-CSF) for primary prophylaxis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4970,Ignore
Online education about lung cancer immunotherapy: Outcomes over time.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4971,Ignore
Worse outcomes associated with public insurance at sarcoma diagnosis in adolescent and young adults (AYAs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4972,Ignore
A nationwide study for patterns of immune thrombocytopenia treatment in patients with chronic lymphocytic leukemia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4973,Ignore
An analysis of growth patterns of targeted therapies (TTs) using keywords from ASCO annual meeting abstracts.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4974,Ignore
Racial and insurance disparities in multiple myeloma management in a referral center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4975,Ignore
Building a data foundation: How MD Anderson and Palantir are partnering to accelerate research and improve patient care.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4976,Ignore
Artificial intelligence-based clinical decision-support system improves cancer treatment and patient satisfaction.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4977,Ignore
Recovery of symptom burden and functioning for patients with late discharge after an open surgery for GYN tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4978,Ignore
Monthly parts a and b costs by service and line of therapy for FDA-approved/NCCN category 1 treatments for patients with metastatic pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4979,Ignore
Navigating care to reduce emergency room (ER) visits in cancer patients using opioids.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4980,Ignore
Contextualizing place and health in rural America: Cancer information seeking across four categories of an urban/rural continuum.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4981,Ignore
Effects of online education on the identification and management of immune-related adverse events over time.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4982,Ignore
Patients perspectives and outcomes on an oral chemotherapy education and electronic monitoring program.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4983,Ignore
Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Delays in diagnosis and resulting effects on treatment allocation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4984,Ignore
Which social measures relate to cancer screening & healthy behaviors?,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4985,Low
Assessment of a highly curated somatic oncology mutation database to facilitate identification of clinically important variants in NGS results.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4986,Ignore
Modeling an oncology outcomes-based contract using a blockchain database approach: Cost and technology considerations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4987,Ignore
Follow-up of cancer patients at the Colorectal Multidisciplinary Clinic: The University of the Philippines - Philippine General Hospital (UP-PGH) experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4988,Ignore
Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4989,Medium
"Real-world data (RWD) and patients reported outcomes (PRO) in breast cancer (BC): Physical, emotional side effects (S/E), financial toxicity (FT), and complementary usage (CM) relations.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4990,Ignore
Social media for oncology clinical trial recruitment: Oncologists attitudes and perceptions.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4991,Ignore
Healthcare disparities among cancer patients in the emergency department: How do race and ethnicity affect bounce-back rates?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4992,Ignore
"Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: Results from a national patient advocacy survey.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4993,Ignore
Understanding differences in total cancer care cost by service site.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4994,Ignore
"Impact of dental insurance coverage on presentation, long-term outcomes, and symptom burden in locally advanced head and neck cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4995,Ignore
Interest and use of alternative/holistic therapies amongst cancer patients at a large urban safety-net hospital.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4996,Medium
Quantifying interoperability: An analysis of oncology practice electronic health record data variability.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4997,Ignore
Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4998,Ignore
A conundrum in cancer quality measurement: Performance on long-term survival reflects performance a long time ago.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,4999,Ignore
"Knowledge, attitude and practice in cancer pain management: A survey study among attending physicians, residents and nurses.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5000,Ignore
Meta-analysis of effect of hormone therapies on lipid levels in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5001,Ignore
Impact of rates of referral and systemic therapy on 1-year outcomes in metastatic NSCLC: A real-world population based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5002,Ignore
Evaluation of racial disparities in the treatment of United States veterans with pancreatic cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5003,Ignore
Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN): An analysis of NCDB.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5004,Ignore
"Comparable survival of African-Americans and Caucasian patients with multiple myeloma: A hospital-based study including 117,926 patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5005,Ignore
Quality of life and tumor location in patients with desmoid tumors: Data from the desmoid tumor research foundation natural history study.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5006,Low
Perioperative therapy in patients with metastatic colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5007,Ignore
Acceptability of mobile health technology among cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5008,Ignore
Publication rate of registered clinical trials in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5009,Ignore
Social values and cancer funding priorities: Empirical evidence for cancer policy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5010,Ignore
Artificial Intelligence (AI) and machine learning (ML) in risk prediction of hospital acquired pressure injuries (HAPIs) among oncology inpatients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5011,Ignore
Impact of international collaboration utilizing E-consult and E-tumor board in the multidisciplinary management of cancer patients: A study from Mayo Clinic Care Network (MCCN) members.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5012,Ignore
Creating the real-world medical record: Using digital patient-generated data to create an updated picture of patients outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5013,Ignore
Emergency oncology: The situation of acute general hospital in Japan.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5014,Ignore
Frequency and causes of oncologists burnout in community practices.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5015,Ignore
Examining predictors of female cancer treatment delay in Appalachian women.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5016,Ignore
Impact of dual anti-HER2 therapy on pathologic complete response rate in breast cancer in a minority-enriched population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5017,Ignore
Giving voice to patients: Understanding treatment preferences of patients with multiple myeloma (MM).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5018,Ignore
Impact of the addition of bevacizumab (Bev) to chemotherapy on survival in metastatic colorectal cancer (MCRC): A real-world population-based analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5019,Ignore
Toward early diagnosis decision support for breast cancer: Ontology-based semantic interoperability.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5020,Ignore
A population-based study of medical cannabis utilization in patients with cancer in the pre-legalization era.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5021,Ignore
Population health impact of genome-driven oncology by race and ethnicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5022,Ignore
Trends in mortality due to hypercalcemia in breast cancer.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5023,Low
Patient-reported outcomes during hospitalization for patients with late discharge after an open surgery for GYN tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5024,Ignore
Design and implementation of outpatient-based rapid MRI protocols to rule out metastatic spinal cord compression and brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5025,Ignore
Demographic factors associated with financial toxicity: Results from the multisite cost study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5026,Ignore
Feasibility of text-based symptom monitoring of ovarian and endometrial patients during treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5027,Ignore
"Analysis of a neurosurgical directed acute spinal cord compression pathway at Michigan Medicine, a tertiary referral hospital.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5028,Ignore
"Upper extremity deep venous thrombosis in 10 common malignancies: Analysis of incidence, risk factors, and effect on mortality from the California Cancer Registry.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5029,Low
Real-world evidence in the treatment of metastatic non-small cell lung cancer in a single institution of Colombia in the period August 2015 to August 2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5030,Ignore
Pharmacy cost in cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5031,Ignore
The prognostic value of patient-reported outcomes (PROs) for survival outcomes in cancer patients: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5032,Ignore
Timeliness of treatment for patients referred urgently with a high suspicion of cancer in New Zealand.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5033,Ignore
Contemporary use of inpatient antineoplastic (IP) treatment (Rx): Who is getting care and why?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5034,Ignore
A novel approach to support community oncology practices in building a clinical research program.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5035,Ignore
Diabetes mellitus: An adverse prognosis in cancer patientsStudy of a cohort treated at Instituto Oncológico Henry Moore (IOHM).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5036,Ignore
Implementing physician education to increase lung cancer screening compliance.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5037,Low
Immune-related adverse events in melanoma: A nationwide analysis 2016.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5038,Ignore
Proper dosage of primary pegylated G-CSF prophylactic use for breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5039,Ignore
Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5040,Ignore
NCI and ASCO CancerLinQ collaboration to advance quality of cancer care and surveillance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5041,Ignore
Hypertension and use of bevacizumab among patients treated in community settings.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5042,Ignore
Diagnostic utility of tele-cystoscopy for bladder cancer surveillance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5043,Ignore
Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5044,Ignore
Initial breast cancer consult: Improving satisfaction and impact on distress.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5045,Ignore
The ability of isolated fine needle aspiration of lymph nodes to provide complete diagnostic information without necessitating additional diagnostic procedures: A retrospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5046,Ignore
Association of patient characteristics with real-world ROS1 NSCLC testing patterns among community practices in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5047,Ignore
Evaluation of inpatient cancer rehabilitation by routine electronic patient-reported outcome measures (ePROM): Improvement of quality of life (QoL) and psychological distress.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5048,Ignore
Utilization and outcomes of high-dose chemotherapy and stem-cell rescue in patient with testicular cancer from 2005 to 2014 in United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5049,Ignore
Pursuit of performance: An exploration of predictors associated with achieving performance based payments for breast cancer episodes under the Oncology Care Model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5050,Ignore
Reduced blood product utilization via implementation of an anemia clinic and consult service in a large health system hospital: Focus on cardiovascular patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5051,Ignore
Racial and socioeconomic disparities in follicular lymphoma survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5052,Ignore
A survey of cancer patients rehabilitation therapy needs in Southwest China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5053,Ignore
External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5054,Ignore
Reassessing existing expanded access programs and planning forward in the time of Right to Try.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5055,Ignore
Does the quality of patient-reported outcomes (PROs) assessment in randomized controlled trials (RCTs) differ across cancer types and over time? A pooled analysis of 610 RCTs published between 2004 and 2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5056,Ignore
Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5057,Ignore
Association between the variation in hospital beds and inpatient chemo/radiotherapy for breast cancer: A retrospective study using the Japanese Diagnosis Procedure Combination database of over 500K records.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5058,Ignore
"Survival trends in elderly patients with malignant mesothelioma: An analysis utilizing Surveillance, Epidemiology, and End Results database.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5059,Ignore
Expanded access for cancer patients: The 5-year FDA CBER experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5060,Ignore
Assessment of contraception and fertility knowledge among female oncology patients of child bearing age and their providers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5061,Ignore
An algorithmic approach to deriving line of therapy in a real-world data set for non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5062,Ignore
Assessment of end-of-life care quality indicators in veterans with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5063,Ignore
Acute kidney injury in childhood cancer: An insight from Kids' Inpatient Database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5064,Ignore
Combined oral administration of analgesia and anxiolysis for pain associated with bone marrow aspiration and biopsy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5065,Ignore
Are racial differences in obesity and insulin resistance related to aggressive breast cancer?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5066,Ignore
The impact of a digital solution on tumor board preparation time for nurse navigators.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5067,Ignore
Implementation and evaluation of video-based tumor board conferencing in Haiti.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5068,Ignore
Effect of right censoring bias on survival analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5069,Ignore
Improving quality care through it/analytics for team-based care interventions.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5070,Ignore
Inpatient outcome of solid tumor associated tumor lysis syndrome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5071,Ignore
Experience and impacts of remote telepathology consultation in improving cancer patients diagnosis and management in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5072,Ignore
Barriers and facilitators to oncology clinical trial accrual: Comparing perceptions of community and academic oncologists.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5073,Ignore
Role of advanced practice providers (APP) in meeting rising demands on oncology practices.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5074,Ignore
Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5075,Ignore
Variations in patient-reported outcome (PRO) collection and reporting in novel FDA approved anticancer therapies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5076,Ignore
"Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5077,Ignore
What do doctors value about attending multi-disciplinary cancer case discussions?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5078,Ignore
The Quality Oncology Practice Initiative Program: Experience in Spain.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5079,Ignore
Employment outcomes and quality of life in patients with early breast cancer and their support persons: A dyadic study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5080,Ignore
Answering real-world questions using real-world data: Understanding dynamic treatment decisions and outcomes in metastatic colorectal cancer (mCRC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5081,Ignore
Unveiling the real-world outcomes of breast cancer (BC) patients with taxanes-induced neuropathy using a digital patient-powered network (PPN).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5082,Ignore
Use of a theoretical framework to examine declines in clinical trial enrollment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,1,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5083,Medium
The Childrens Oncology Group (COG) Adolescent and Young Adult (AYA) Responsible Investigator (RI) Network: An initiative for advancing AYA cancer research in the National Clinical Trials Network (NCTN).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5084,Ignore
Learnings from a pragmatic study to evaluate benefit of performing reflex clinical trial matching and providing clinical decision support to physicians.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5085,Ignore
Automating incidental findings in radiology reports using natural language processing and machine learning to identify and classify pulmonary nodules.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5086,Ignore
Patterns of healthcare utilization in patients with newly diagnosed advanced lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5087,Ignore
Are two sites better than one?: Sites of care and quality of myeloma treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5088,Ignore
Real-world efficacy of bone modifying agents (BMAs) in patients with breast cancer (BC) treated in an academic health system: Use of the green button.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5089,Medium
Trends in the incidence and outcomes of C<em>lostridioides</em> <em>difficile </em>infection in hematological cancers: A nationwide analysis.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5090,Low
Strategies for reducing grade 2 and 3 adverse events due to immunotherapy in a Spanish university hospital.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5091,Ignore
Anticancer therapy within the last 30 days of life: Results of an audit and re-audit cycle from a regional cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5092,Ignore
HIV associated cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5093,Ignore
Economic burden of immunotherapy as second-line treatment of patients with advanced non-small-cell lung cancer at a Latin American oncology center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5094,Ignore
Development of a patient-oriented navigation model for lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5095,Ignore
Time matters: A retrospective study of cancer care in a Brazilian public university hospital.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5096,Ignore
Economic impact of post-progression treatment in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously treated with octreotide monotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5097,Ignore
Do the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure <em>Absolute</em> or <em>Relative</em> clinical benefit?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5098,Ignore
Developing an adolescent and young adult (AYA) cancer program in an Italian adult high-volume cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5099,Ignore
Opportunity for performance measurement: 30-day mortality following cancer surgeries across U.S. hospitals.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5100,Low
Lung cancer in African-Americans and analysis of estrogen plus progestin use.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5101,Ignore
Oncologists perceived confidence in managing pre-existing chronic comorbidities during patients active cancer treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5102,Ignore
Are the nonmedical needs of cancer patients satisfied adequately.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5103,Ignore
Non-clinical needs of cancer patients in Spain under different perspectives: A comparative study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5104,Ignore
Patients preference in receiving phone call from oncologist after cancer diagnosis and before in person consultation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5105,Ignore
Is a delay in ALK inhibitor initiation associated with poorer survival? A retrospective analysis based on real-world data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5106,Ignore
Building international partnerships to improve global oncological care: Perspective from Rutgers-CINJ Global Oncology Fellowship Program.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5107,Ignore
Real-world demographic and clinical characteristics of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in the United States (US).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5108,Ignore
"Satisfaction survey from an innovative cancer care delivery model (Pendharkar model), creating access at scale: An outcome research.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5109,Ignore
Cost and time savings of subcutaneous trastuzumab (SC-T) in a public health system in Mexico.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5110,Ignore
Utility of tumor genomic profiling in guiding targeted therapy and referral for clinical trials in the community practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5111,Ignore
Barriers to clinical trial accrual: Clinical trialists' perspectives.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5112,Ignore
Treatment delays in localized breast cancer: A NCDB analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5113,Ignore
Survey to evaluate quality of cancer patient care: A questionnaire based analysis in a tertiary hospital.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5114,Ignore
Generating real-world evidence: Using automated data extraction to replace manual chart review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5115,Ignore
Liver cancer systemic treatment patterns in the largely rural state of New Mexico.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5116,Ignore
Efficacy of a stepped collaborative care intervention for comorbid cancer and depression: Health care utilization and costs.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5117,Medium
Predictors of death for patients treated with palliative intent radiation using prospective databases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5118,Ignore
Association of state Medicaid expansion with timeliness of cancer care delivery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5119,Ignore
Racial differences in intravenous bisphosphonate utilization among older patients with multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5120,Ignore
Triple blinded prospective study assessing the impact of genomics: EndoPredict and artificial intelligence Watson for Oncology (WFO) on MDTs decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5121,Ignore
Influence of timing of goals of care discussion on hospitalization outcomes in metastatic cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5122,Ignore
ChemoPalRx: Development and implementation of a chemotherapy mobile provider order entry system in a safety net hospital.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5123,Medium
Mobile short message service (SMS) alerts for reducing the toxicity and improving protocol compliance during cancer chemotherapy: A randomized controlled trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5124,Ignore
Pneumocystis jiroveci pneumonia during first and second-line chemotherapy for solid tumours.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5125,Ignore
The impact of ACA on medical financial hardship among cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5126,Ignore
"Central venous catheter-related complications in the treatment of cancer patients: A prospective study of over 124,000 catheter days.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5127,Ignore
Potential length of stay reduction with outpatient management of low risk febrile neutropenia in a regional cancer centre.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5128,Ignore
Value appraisal of FDA approved cancer drugs over the past decade.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5129,Ignore
Projecting overall survival data for health-economic models in oncology: Do maturity levels impact uncertainty?,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5130,Medium
Patients understanding and adherence to oral anti-cancer medication (OAM): Results of an institutional pilot study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5131,Ignore
Feasibility of mobile-deployed care management based on standardized ePRO and computer-interpretable-guideline engine for lymphoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5132,Ignore
"Oncology leadership development using decentralization, task shifting, techno-mentoring and creation of alternate oncology workforce.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5133,Ignore
Population kinetics of progression free survival (PFS).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5134,Medium
Predictors of financial toxicity among head and neck cancer patients: A prospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5135,Ignore
Racial disparities in setting of care in women with breast cancer in South Carolina.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5136,Ignore
Deriving real-world oral antineoplastic treatment endpoints: A comparison of automated data extraction versus manual chart abstraction.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5137,Ignore
"Arabic and Assyrian immigrants knowledge of hepatitis and liver cancer in Sydney, Australia. Findings of a community consultation process.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5138,Ignore
"Metabolites as mediator for alleviating adverse effects in chemotherapy: A new finding from a recent study of Japanese traditional Kampo medicine, rikkunshito (RKT).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5139,Ignore
BIG DATA in geriatric oncology: How could we assess effective working time?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5140,Ignore
Community oncologists perceptions and readiness to implement Medicare Access and CHIP Reauthorization Act (MACRA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5141,Ignore
Delays in diagnosis in young patients with leukemia and lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5142,Ignore
"Body composition change, safety, and efficacy with everolimus use in ethnic minorities with breast cancer.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5143,Medium
Perspectives and practices of oncology providers in addressing financial toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5144,Ignore
Factors associated with physician attitude and management of financial toxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5145,Ignore
Economic benefits of adaptive abiraterone therapy for advanced prostate cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5146,Ignore
"Rates and patterns of uninsured cancer survivors before and after implementation of the Affordable Care Act, 2000-2017.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5147,Ignore
Lower survival outcomes in patients receiving an initial cancer diagnosis after presenting to the emergency department.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5148,Ignore
Review of the treatment milestones for stage I non-small cell lung cancer at a regional rural cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5149,Ignore
Adoption and utilization of NGS-based molecular profiling in community-based oncology practices: Insights from Sarah Cannon.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5150,Ignore
An evaluation of artificial intelligence-based clinical decision supports use in Brazil.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5151,Ignore
Evaluating use of interpreters in educating immigrants on cancer prevention and screening guidelines.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5152,Low
Factors associated with metastatic presentation in HPV-related squamous cell carcinoma of the head and neck (SCCHN): A National Cancer Database (NCDB) analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5153,Ignore
Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5154,Ignore
Crowdfunding for lung cancer costs.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5155,Ignore
Symptoms and characteristics of cancer patient visits to an emergency room.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5156,Ignore
FDA analysis: Demographic trends in bladder and renal cancer trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,1,5157,High
"Real-world treatment patterns, survival, and cost among elderly cervical cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5158,Ignore
Disparities in survival by insurance status in chronic lymphocytic leukemia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5159,Ignore
AI platform in mammography to screening breast cancer: A sole-center experience.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5160,Low
Race as an independent factor for survival in breast cancer patients according to analysis of the National Cancer Database (NCDB).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5161,Ignore
Safety profile of midline catheters in patients with active malignancy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5162,Medium
A digital oncology patient-reported outcomes platform: Building innovative electronic patient symptom assessments in epic mychart to improve the quality of life and survival of patients with advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5163,Ignore
Clinical responses and survival in Hispanic patients with non-small cell lung cancer treated with immunotherapy compared with non-Hispanic whites.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5164,Ignore
Impact of a pilot patient navigator program on pediatric cancer outcomes in a low resource setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5165,Ignore
"Patient characteristics, treatment received, and outcomes of non-metastatic breast cancer patients in Haiti: Report from retrospective cohort.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5166,Ignore
Characteristics of medical oncologists participating in the Oncology Care Model.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5167,Ignore
A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5168,Medium
Enrollment disparities in cancer clinical trials: A single institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,1,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5169,Medium
Efficacy and cost-effectiveness of HER2+ early breast cancer therapies.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5170,Medium
"Biomarker testing, treatment (Tx) and survival outcomes in Medicaid compared to commercially insured (CI) patients with advanced NSCLC (aNSCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5171,Ignore
A new model of care for patients with central nervous system cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5172,Ignore
Fear of receiving less effective care: A barrier to effective cancer care cost communication.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5173,Ignore
Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5174,Ignore
Improved hepatocellular carcinoma (HCC) outcomes in a public hospital setting with increased access to procedural-based therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5175,Ignore
Quality of end-of-life care for veterans with metastatic cancer and advanced chronic kidney disease.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5176,Ignore
Cancer patients experiencing homelessness: Whats happening to them?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5177,Ignore
Patient attendance at molecular tumor board: A new means of shared decision making?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5178,Ignore
Practical exploration and research of Watson for oncology clinical decision support system in real-world and localized practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5179,Ignore
Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5180,Ignore
Oral chemotherapy follow up on a Brazilian private health care unit.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5181,Ignore
Computer-aided classification of lung nodules on CT scans via 3D CNNs.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5182,Ignore
Implementation of ICH E6 (R2) through identification of data risks using analytics in oncology clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5183,Ignore
Swallow screen and test in cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5184,Ignore
Electronic but overly eclectic: Disciplined EHR data management is needed to automate MIPS reporting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5185,Ignore
Real-world assessment of practice efficiency with the introduction of subcutaneous rituximab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5186,Ignore
Estimation of U.S. patients with cancer who may respond to cytotoxic chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5187,Ignore
Employing an oncology decision-support system to quantify treatment variation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5188,Ignore
Using a video to introduce fertility preservation to women with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5189,Ignore
Use of a modified Delphi panel to define value of combination therapy in oncology.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5190,Ignore
Harmonization of clinical data across Gen3 data commons.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5191,Medium
Experience and challenges of setting up a new lung cancer chemotherapy clinic in resource limited setting in Nepal.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5192,Ignore
"Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5193,Ignore
Barriers to clinical trial enrollment of older adults with cancer: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,1,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5194,Medium
Molecular and clinical features of hospital admissions and immunotherapy related adverse events of immune checkpoint inhibitors in thoracic malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5195,Ignore
Searching for lymphoma: An analysis of internet and social network activity and engagement.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5196,Ignore
Adherence of oral targeted agents in patients with B­­­­­-cell malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5197,Ignore
"Mutational analysis of >14,000 solid tumor NGS tests from community oncology practices: The Sarah Cannon molecular landscape.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5198,Ignore
Inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) with elderly cancer patients: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5199,Ignore
Does adding claims to EMR data improve comorbidity burden capture? A Concerto Health AI Definitive Oncology Dataset and Symphony Linkage Study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5200,Ignore
Impact of sarcopenia for patients with localized muscle invasive bladder cancer treated by neoadjuvant cisplatin based chemotherapy and radical cystectomy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5201,Ignore
Delay in diagnosis and treatment of gastrointestinal cancer in Nepal.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5202,Ignore
Impact of timing of palliative care team consults in patients with advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",1,0,5203,Low
Flu vaccination rate of patients with severe immune-related adverse events.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5204,Ignore
The impact of a digital solution on case discussion time at tumor boards.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5205,Ignore
Outcomes of immunotherapy administration for hospitalized cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5206,Ignore
Target versus non-target lesions in determining disease progression: Analysis of 581 patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5207,Ignore
"Patient reported outcomes in cancer patients: Psychological, physical and functional importance.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5208,Ignore
Economic analysis of ceritinib used as second-line versus third-line treatment for patients with ALK-rearranged non-small-cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5209,Ignore
Muscle MASS and mortality in cancer patients.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5210,Low
Clinical and molecular characteristics of non-small cell lung cancer patients from rural Maine.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5211,Ignore
Incidence patterns of early onset colon cancer by race and stage in the US.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5212,Low
Case discussion at cancer multidisciplinary meetings: What resourcing is required?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5213,Ignore
Laboratory and clinical data integration: Toward an evidence development framework.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5214,Medium
Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5215,Ignore
Impact of solid tumor brain metastases on end-of-life healthcare utilization.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5216,Ignore
Barriers to accessing healthcare services: A multidisciplinary approach towards improving pancreatic cancer survival in a Canadian province.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5217,Ignore
Cost-effectiveness of once weekly carfilzomib 70 mg/m<sup>2</sup> plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5218,Ignore
Adherence and cumulative bisphosphonate dose in relation to risk of skeletal-related events among older patients with multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5219,Ignore
"Detection of the burnout syndrome, empathy, and psychosocial profile of the health team of the oncology service, UANL University Center Against Cancer (CUCC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5220,Ignore
Impact of the Affordable Care Act on insurance for adolescents and young adults with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5221,Ignore
Vitamin D status and survival in patients with triple negative breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5222,Ignore
Pregnancies in subjects on oncology clinical trials: Analysis from the Cancer Therapy Evaluation Program (CTEP) database.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5223,Ignore
Do oral antineoplastic treatment data differ between Concerto Health AI Definitive Oncology EMR and Symphony Claims Data?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5224,Ignore
Insurance status and racial disparities in detection of early-stage breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5225,Ignore
Evaluation of selective outcome reporting bias in efficacy endpoints in print and television advertisements for oncology drugs.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5226,Medium
The burden of hyponatremia and hypercalcemia on hospitalizations and mortality in lung cancer patients in the United States: An analysis of nationwide inpatient database.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5227,Low
Remote patient monitoring using smart phone derived patient reported outcomes and Fitbit data to enable longitudinal predictive modeling in prostate cancer: Feasibility results and lessons on platform development.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5228,Ignore
"The practical ethics of medication shortages: Understanding patient preferences for allocation, decision making, and disclosure through narrative inquiry.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5229,Ignore
Patient satisfaction with oncology clinical decision support in South Korea.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5230,Ignore
Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5231,Ignore
Patient factors that drive unplanned acute care utilization in oncology care.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5232,Ignore
Profile of cancer caregivers among adult Indian rural cancer patients: A prospective survey.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5233,Ignore
Development and feasibility of virtual molecular tumor board.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5234,Ignore
Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5235,Ignore
Prescription patterns and associated cost during periods of cancer drug stockouts in a resource-limited setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5236,Ignore
Artificial intelligence (AI) to improve patient outcomes in community oncology practices.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Health Services Research, Clinical Informatics, and Quality of Care: Publication Only",0,0,5237,Ignore
Healthcare implications of Clodtridium difficile infection after bone marrow transplant: Nationwide Readmission Database review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5238,Ignore
Effect of secure clinical messaging on chemotherapy adherence.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5239,Ignore
CML patients presenting with priapism: Is there any disparity in outcome?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5240,Ignore
Clinical validation of NGS workflow in myeloid neoplasms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5241,Ignore
"Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5242,Low
Role of IL27 and IL35 as biomarkers and potential targets in acute myeloid leukemia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5243,Ignore
The prognosis of <em>NF1</em> mutations in newly diagnosed AML: A single-center retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5244,Ignore
Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5245,Medium
Comparison of PEG-rhG-CSF and common rhG-CSF after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5246,Ignore
CMV reactivation in allogeneic hematopoietic stem cell transplant patients receiving post-transplant cyclophosphamide.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5247,Ignore
Molecular prediction of chronic myeloid leukemia risk and resistance to imatinib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5248,Ignore
"The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5249,Medium
Real-world treatment patterns in adult patients (pts) with B-cell precursor acute lymphoblastic leukemia (BCP ALL) in first hematologic complete remission (CR1) with and without minimal residual disease (MRD).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5250,Medium
Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5251,Ignore
Survival outcomes in patients with good risk acute myeloid leukemia: A single-center retrospective review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5252,Ignore
"A retrospective, real-world population-based analysis of treatment patterns and outcomes in adult patients with relapsed/refractory acute myeloid leukemia in Alberta, Canada.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5253,Ignore
Treatment with FLAG followed by second allogeneic stem cell transplant for relapsed acute myeloid leukemia and myelodysplastic syndrome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5254,Ignore
Pattern of rasburicase (RAS) use in community oncology programs and impact on tumor lysis syndrome (TLS) outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5255,Ignore
Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5256,Ignore
HCT related toxicities and mortality in frail recipients.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5257,Low
A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5258,Ignore
Intensive minimal residual disease monitoring to drive early intervention after allogeneic hematopoietic stem cell transplant for pediatric acute leukemia.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5259,Medium
Validation of the EORTC QLQ-C30 Summary Score in patients with hematological malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5260,Ignore
Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5261,Ignore
LILRB4 expression in CMML and MDS based on response to hypomethylating agents.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5262,Ignore
Outcome of CML patients with de novo bleeding complications: Do they behave differently?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5263,Ignore
Mortality of acute promyelocytic leukemia in a rural tertiary care center.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5264,Low
Admissions for neutropenic fever in myelodysplastic syndromes (MDS).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5265,Ignore
In-hospital mortality in acute promyelocytic leukemia patients: A study of national inpatient sample.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5266,Low
Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,1,5267,High
The bone marrow stroma capacity to confer resistance to leukemia cells from Ara-C treatment as a prognostic factor for overall survival in AML.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5268,Medium
A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5269,Ignore
A novel anti-CD19 chimeric T cell therapy platform ET019002 was safe and effective in inducing CR in blast crisis of CML: A case study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5270,Ignore
Characteristics and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasm in a tertiary institute in India: An ambispective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5271,Ignore
Pyridoxine impact on patients with myelodysplastic syndromes with ring sideroblasts: Single institution retrospective study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5272,Ignore
Thrombotic episodes in myeloproliferative neoplasms: A population based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5273,Ignore
Evaluation of prognostic factors after induction therapy in AML.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5274,Ignore
Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5275,Ignore
Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5276,Medium
"Bayesian network meta-analysis (NMA) of complete remission without or with incomplete hematologic recovery (CR/CRi) to CPX-351, FLAG, and standard 7+3 (7+3) chemotherapy in the treatment of newly diagnosed secondary acute myeloid leukemia (sAML).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5277,Ignore
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5278,Ignore
Timed sequential therapy with high-dose cytarabine and mitoxantrone as an induction regimen for acute myeloid leukemia: An update on adverse events.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5279,Ignore
Role of ethnicity in thrombotic and hemorrhagic complications of myeloproliferative neoplasms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5280,Ignore
Analytical validation of a 47-gene NGS panel for molecular profiling of myeloid neoplasms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5281,Ignore
"The value of low, fixed, single dose rasburicase in the prevention and treatment of tumor lysis syndrome.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5282,Ignore
Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant: Publication Only",0,0,5283,Ignore
High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,1,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5284,Medium
The influence of parvovirus B19 (B19V) on the results of chemotherapy in adult patients with lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5285,Ignore
An objective based model of published treatment options for relapsed or refractory (R/R) peripheral t-cell lymphoma (PTCL): An evidence-based decision-making approach.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5286,Ignore
The role of frailty and comorbidity in treatment (tx) of elderly patients with Hodgkin lymphoma (HL).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5287,Ignore
"Phase 1 study of CA-4948, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) in patients (pts) with r/r non-Hodgkin lymphoma.",1,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5288,High
Disease characteristics of diffuse large B-cell lymphoma predicting relapse after autologous stem cell transplantation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5289,Ignore
"Outcomes of tbo-filgrastim, filgrastim-sndz or filgrastim for mobilization in patients undergoing an autologous hematopoietic stem cell transplant: A single center experience.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5290,Ignore
Impact of absolute lymphocyte count on prognosis of aggressive non-Hodgkin lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5291,Ignore
Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5292,Medium
Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5293,Ignore
Post-transplant lymphoproliferative disorder-related admissions in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5294,Ignore
Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5295,Medium
Ability of routine blood tests (RBTs) in asymptomatic patients (pts) with indolent non-Hodgkin lymphoma (iNHL) to detect relapse or clinically significant disease progression.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5296,Ignore
Cause-specific mortality in survivors of lymphoplasmacytic lymphoma (LPL) and waldenstrom macroglobulinemia (WM).,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5297,Low
"GX-G3, a long-acting G-CSF, compared with pegfilgrastim in reducing duration of severe neutropenia after chemotherapy for non-Hodgkins lymphoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5298,Ignore
A mixed method analysis of toxicities of anti-CD19-CAR T cell therapy in hematological malignancies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5299,Ignore
Treatment outcomes of HIV patients with non-Hodgkins lymphoma treated with standard dose CHOP compared with dose-modified CHOP chemotherapy at the Uganda Cancer Institute.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5300,Ignore
Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: Results from the MAVORIC study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5301,Medium
Distribution and influencing factors of tumor mutational burden in different lymphoma subtypes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5302,Ignore
Comparison of salvage therapies for relapsed or refractory diffuse large B-cell lymphoma (DLBCL): Network meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5303,Ignore
A phase I/II study of the anti-programmed cell death-1 (PD-1) antibody AK105 in patients with relapsed or refractory classic Hodgkin lymphoma (cHL).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5304,Medium
T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5305,Ignore
The efficacy of ibrutinib-based combination therapy for mantle cell lymphoma: A systematic review.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5306,Medium
Retrospective comparison of Cheson 2007 and Lugano classification criteria in independent review assessment of FDG-avid lymphomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5307,Ignore
Chronic lymphocytic leukemia: An Indian experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5308,Ignore
Tumor-associated myeloid derived suppressor cells of granulocytic nature as a potential biomarker for prognostication of response in treatment of diffuse large cell lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5309,Ignore
Activity of thymidine kinase as a prognostic marker of malignant proliferation in adolescents with lymphadenopathy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5310,Ignore
Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: A SEER population-based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5311,Ignore
Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodgkin lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5312,Ignore
Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5313,Medium
Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5314,High
Efficacy and safety of PEG-rhG-CSF in primary and secondary prevention of chemotherapy-induced neutropenia.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5315,Medium
Retrospective analysis of elderly patients with DLBCL: Single center experience with FIL.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5316,Ignore
Survival outcomes in the elderly with limited stage diffuse large B-cell lymphoma treated with chemotherapy: SEER propensity-matched analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5317,Ignore
Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5318,Ignore
Clinical characteristics and prognosis of primary breast lymphoma: Cleveland Clinic experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5319,Ignore
TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5320,Ignore
SYK inhibition with fostamatinib in Waldenström's macroglobulinemia: In vitro cell based assays.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5321,Ignore
Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5322,Ignore
Tumor-collagen digital proximity signature to indicate prognosis in diffuse large B-cell lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5323,Ignore
Unique racial patterns in rare T-cell lymphomas: A National Cancer Registry analysis from 2001 to 2015.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5324,Ignore
Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5325,Medium
A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5326,Ignore
"Sandoz rituximab (GP2013; SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL): Interim safety results of the non-interventional, observational, multicenter, open-label REFLECT study.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5327,Medium
Real-world treatment patterns among patients (pts) diagnosed with primary mediastinal large B-cell lymphoma (PMBCL) in the United States (US).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5328,Ignore
Elevated serum lactate in lymphoma: Not always infection.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5329,Ignore
"Hodgkin lymphoma in United Arab Emirates UAE, epidemeology, histological types and treatments outcome: Case series of 47 cases from Mafraq Hospital, Abu Dhabi, UAE.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5330,Ignore
NHL and rituximab biosimilar: How have prescribing behaviours changed in EU5 in 15 months?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5331,Ignore
CAP-100: First-in-class antibody for CCR7<sup>+</sup> hematological malignancies.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5332,High
Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5333,Ignore
"Long-term time trends in incidence, survival and mortality of Hodgkin lymphoma in the United States: A surveillance, epidemiology, and end results (SEER) database study 1975-2015.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5334,Low
Expression and prognostic relevance of calcium calmodulin-dependent protein kinase kinase 2 (CaMKK2) in chronic lymphocytic leukemia (CLL).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5335,Ignore
Impact and influence of PET on imaging related endpoints in patients with Lymphoma using IWG-NHL or Lugano classification.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5336,Ignore
Conceptual model of chronic lymphocytic leukemia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5337,Ignore
Substitution of single dose intravenous methylprednisolone (MP) for oral prednisone (Pred) in RCHOP in intermediate grade non-Hodgkins lymphoma (NHL).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5338,Ignore
Single-center analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein Barr virus (EBV) assessments.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5339,Ignore
"Checkpoint inhibitor therapy, with and without radiation, in diffuse large B cell lymphoma: A single-center analysis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5340,Ignore
Are double-hit lymphoma patients being adequately evaluated for CNS disease?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia: Publication Only,0,0,5341,Ignore
Treatment patterns and outcomes among t(11;14) myeloma patients in a real-world setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5342,Ignore
The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5343,Ignore
"Incidence of serious adverse events in bortezomib, lenalidomide and bortezomib plus lenalidomide maintenance for multiple myeloma: Interim analysis of MMRF-CoMMpass study.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5344,Low
Time to first treatment is an independent prognostic factor for multiple myeloma (MM).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5345,Ignore
Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5346,Ignore
"Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5347,Medium
The frequency of chromosomal abnormalities in AL amyloidosis and their impact on treatment response.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5348,Ignore
Association between immunoglobulin isotypes and cytogenetic risk groups in multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5349,Ignore
The impact of newly approved drugs on clinical and operational strategies for multiple myeloma clinical trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5350,Ignore
Safety and efficacy of four drug regimens in newly diagnosed multiple myeloma: Systematic review.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5351,Medium
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5352,Ignore
Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5353,Ignore
Factors associated with over and underuse of response evaluation in elderly myeloma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5354,Ignore
Once-weekly (70 mg/m<sup>2</sup>) versus twice-weekly (56 mg/m<sup>2</sup>) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5355,Ignore
Role of investigational monoclonal antibodies in the treatment of multiple myeloma: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5356,Ignore
Appendicular skeleton MRI in multiple myeloma: Utility and clinical implications.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5357,Ignore
Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5358,Medium
Concordance and discordance in myeloma bone marrow studies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5359,Ignore
Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5360,Ignore
Treatment patterns in patients with multiple myeloma (MM): A retrospective study using Medicare data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5361,Ignore
3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5362,Ignore
"Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5363,Low
Role of extra corporeal methods for light chain removal on renal recovery in multiple myeloma: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5364,Ignore
Contemporary therapy efficacy for high-risk multiple myeloma: A systematic review.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5365,Medium
Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5366,Medium
Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5367,Medium
Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5368,Ignore
Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5369,Ignore
The unforeseen business and medical consequences of EHR data collection for a real-world data multiple myeloma registry.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5370,Ignore
Clinical significance of CXCR5-CXCL13 signaling in multiple myeloma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5371,Ignore
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5372,Ignore
Treatment sequencing patterns for relapsed refractory multiple myeloma (RRMM) in the era of new therapies in a single center institution.,0,31-05-2019,0,0,0,0,0,0,0,1,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5373,High
Inching towards precision medicine for multiple myeloma with causal network models.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5374,Ignore
Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Hematologic MalignanciesPlasma Cell Dyscrasia: Publication Only,0,0,5375,Medium
Preliminary study of S-1 maintenance therapy in extensive stage small-cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,1,0,5376,Low
Outcomes following lobectomy and pneumonectomy in stage IIIA non-small cell lung cancer (NSCLC) after neoadjuvant chemoradiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5377,Ignore
Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5378,Ignore
Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5379,Ignore
Single agent immunotherapy for relapsed or refractory small cell lung cancer (rrSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5380,Ignore
Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5381,Low
Preoperative lymph node assessment in surgically resected pathologic T1 lung cancer patients: Real world clinical practice in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5382,Ignore
DIPNECH: The Mayo experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5383,Ignore
Impact of decision-support system and guideline treatment concordance on response rate in advanced lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5384,Ignore
A novel mutation panel for predicting etoposide in small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5385,Ignore
Identification of MET Exon 14 skipping by targeted RNA-based next-generation sequencing in Chinese Patients with NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5386,Ignore
Mutation concordance of matched tissue sample and blood sample: A result of 456 lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5387,Ignore
When is a patient high risk for resection? A changing paradigm with minimally invasive lung surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5388,Ignore
Proteomics analysis discovers biomarkers in serum months to years before small cell lung cancer: The HUNT study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5389,Ignore
Immune gene signatures and integrative spatially-resolved digital profiling of prognostic biomarkers for mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5390,Ignore
Oral vinorelbine as a second-line chemotherapy option in advanced malignant pleural mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5391,Ignore
Association of PD-L1 protein expression and TMB in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5392,Ignore
Can steroid imbalance in intracrine synthesis of sex hormones in the lung be a pathognomonic factor of lung cancer?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5393,Ignore
Multicenter phase II trial of RRx-001 in previously treated SCLC.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5394,Medium
The impact of heart radiation dose in lung SABR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5395,Ignore
Characterizing biomarker testing over time in lung cancer patients using oncology electronic medical records (EMR).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5396,Ignore
Prognostic value of tumor infiltrating lymphocytes in epithelioid malignant pleural mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5397,Ignore
Selection of patients for stereotactic body radiation therapy (SBRT) or (bi)lobectomy (L) for the treatment of cT1-T2N0M0 NSCLC by the risk of node involvement using readily available preoperative factors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5398,Ignore
The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5399,Ignore
Radiologic imaging utilization of small cell lung cancer staging and treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5400,Ignore
LUNG cancer in Lleida: An epidemiologic study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5401,Ignore
Oncogenic activation of the HRR pathway drives RAD54L expression in early stage lung adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5402,Ignore
Association between smoking status and lymph node metastasis in Chinese patients with T1 non-small cell lung cancer: A real-world observational study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5403,Ignore
Clinical observation of low-dose apatinib in the treatment of small cell lung cancer with antidiuretic hormone secretion.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5404,Ignore
Postoperative radiotherapy for stage II or III nonsmall cell lung from 1988 to 2014.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5405,Ignore
Clinical and prognostic implications of sarcopenia in patients affected by locally advanced NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5406,Ignore
TTF1 negative in non small cell lung cancer adenocarcinoma: A prognostic factor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5407,Ignore
Mutational landscape of early-stage non-small cell lung cancer patients using a 451 gene panel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5408,Ignore
Impact of invasive regional lymph node examination (IRLNE) and time to radiation on overall survival for patients with stage I NSCLC treated with SBRT- a NCDB analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5409,Medium
Genetic profiling of synchronous multiple primary lung carcinomas presenting as ground-glass opacities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5410,Ignore
Evaluation of tumor infiltrating lymphocites (TILs) and survival in patients with resected non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5411,Ignore
Contemporary patterns of racial/ethnic disparities in surgical treatment and overall survival for localized resectable non-small cell lung cancer in the United States.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5412,Medium
KMT2C mutation associated with tumor mutational burden in small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5413,Ignore
"Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5414,Ignore
Predictors associated with development of pleural and pericardial effusions in patients with small cell lung cancer treated with third-line therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5415,Ignore
Defining the role of<em> RUNX1T1</em> in combined small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5416,Ignore
Survival meta-analysis from fifteen years of a standard systemic therapy in malignant pleural mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5417,Ignore
Impact of resectable lung adenocarcinoma pathological subtypes on patients prognosis and surgical strategies determination: A SEER population-based data analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5418,Ignore
Umbrella study of anticancer agents in Chinese patients with NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5419,Ignore
The concomitant EGFR T790M/C797S in trans and cis in three osimertinib-resistant lung adenocarcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5420,Ignore
Therapeutic targeting of polyamines in malignant pleural mesothelioma xenograft models.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5421,Ignore
Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5422,Ignore
Timing of chemotherapy in small cell lung cancer: A National Cancer Database analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5423,Ignore
Report of four cases of pulmonary malignant tumors treated with SBRT using BODYFIX plus 4D-CBCT image guidance technique.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5424,Ignore
Outcomes among patients with a history of substance abuse in non-small cell lung cancer: A county hospital experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5425,Ignore
Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FDG-PET staging.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5426,Ignore
"Correlation of tumor mutational burden, tumor microenvironment and alterations of driver genes in patients with NSCLC: A retrospective analysis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5427,Ignore
Primary tumor location as an important predictor for survival in pulmonary adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5428,Ignore
The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5429,Ignore
A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5430,Ignore
Ectopic prolactin production by lung cancer cells as an indicator of aggressive nature of tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5431,Ignore
Treatment outcomes in malignant pleural mesothelioma: A single center experience of systemic therapies and biomarkers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5432,Ignore
Blood-based TMB detection and dynamic monitor in local advanced non-small cell lung cancer (NSCLC) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5433,Ignore
Identifying small cell lung cancer resistance mechanisms to cytotoxic T cells in vitro using whole genome CRISPR screening.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5434,Low
Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer (NSCLC)?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5435,Ignore
Nationwide shift in patterns of prophylactic cranial irradiation utilization for extensive-stage small cell lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5436,Ignore
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5437,Ignore
A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5438,Medium
Use of surgery and stereotactic body radiotherapy (SBRT) in very elderly patients with early-stage non-small cell lung cancer (NSCLC): A national cancer database (NCDB) analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5439,Ignore
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5440,Ignore
Thoracic radiotherapy in a cohort study of patients with metastatic small-cell lung neoplasms.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5441,Ignore
The relative impact of patient and institutional rurality on lung cancer disparities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5442,Ignore
Value of precision medicine in advanced NSCLC: Real-world outcomes associated with the use of companion diagnostics.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5443,Ignore
The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5444,Ignore
Gene expression profiling of T-cell inflammation in small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5445,Ignore
Exploring sex differences in small cell lung cancer: Is this a hormonal issue?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5446,Ignore
Longitudinal tumor size and NLR as predictive factors of individual survival compared to their baseline values in patients with non-small cell lung cancer treated with durvalumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5447,Ignore
Survival impact of thoracic cavity reduction during neoadjuvant chemotherapy in patients undergoing surgery for malignant pleural mesothelioma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Publication Only,0,0,5448,Ignore
Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5449,Ignore
Galician lung cancer group: Afatinib´s data as first-line treatment for elderly patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5450,Ignore
The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma: Fourteen cases and literature review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5451,Ignore
Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5452,Ignore
The efficacy and safety of extended use of endostatin plus platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer: An analysis of a 10-year retrospective study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5453,Medium
Cost-effectiveness analysis of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5454,Ignore
Pooled subgroup analysis of twelve randomized controlled trials of immunotherapy in non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5455,Ignore
Diverse RB1 mutations and co-occurring molecular alterations in advanced NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5456,Ignore
Rebiopsy in patients with or without prior TKIs revealed complicated histology of lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5457,Ignore
"EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer  preliminary data on safety and tolerability.",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5458,Medium
EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5459,Ignore
The use of liquid and tissue biopsy genomic testing in lung cancer: A single-institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5460,Ignore
Afatinib in the treatment of advanced NSCLC with EGFR mutation: An observational real-world study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5461,Ignore
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5462,Ignore
Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5463,Ignore
The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5464,Ignore
Model-driven metronomic vinorelbine in heavily pre-treated metastatic NSCLC and PM patients: Results of a phase I/II study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5465,Medium
"Correlation between PD-L1 level and immunotherapy outcome in NSCLC in Lebanon, 2012-2018: A multicenter observational review.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5466,Ignore
Therapeutic efficacy comparison of six major EGFR-TKIs in non-small-cell lung cancer patients with an activating EGFR mutation: A network meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5467,Medium
Matching insurance claims data with EMR molecular status data in non-small cell lung cancer (NSCLC) patients: Understanding real-world molecular testing and prevalence rates at the site and investigator level.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5468,Low
Molecular profiling as predictor of outcomes in a Brazilian cohort of stage IV lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5469,Ignore
Landscape of lung cancer molecular biology in a NON-selected population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5470,Ignore
miR-200c in extracellular vesicles as a circulating biomarker of EGFR-TKI response and a mediator of EGFR-TKI sensitivity in heterogeneous NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5471,Ignore
Neutrophils lymphocyte ratio role in predicting response to checkpoint inhibitors in metastatic non-small lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5472,Ignore
Characteristics of T-cell receptor repertoire between lung cancer patients and healthy people.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5473,Ignore
Health care utilization associated with adverse events (AEs) among metastatic non-small cell lung cancer (mNSCLC) patients treated with immunotherapy or chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5474,Ignore
Multiple mutations in the EGFR gene in patients diagnosed with lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5475,Ignore
PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5476,Ignore
Nomogram based on multivariable regression model estimates the overall survival of patients with nivolumab who were previously treated for advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5477,Medium
Autoantibodies indicating diagnostic or prognostic value in NSCLC patients were identified by protein microarrays.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5478,Ignore
Prediction of EGFR-TKI efficacy in non-small cell lung cancer patients by metabolomics and genomics.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5479,Medium
"TP53 mutations in EGFR mt+ NSCLC IV as a predictive factor for ORR, PFS, and OS irrespective of T790M.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5480,Ignore
A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5481,Ignore
"Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5482,Medium
Treatment and outcomes for patients (pts) with selected advanced/metastatic cancers by place of care.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5483,Ignore
Real-world clinical burden of aggressive disease (AD) in advanced/metastatic non small cell lung cancer (aNSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5484,Ignore
<em>RET</em> fusion in first/third-generation EGFR-TKIs resistance in advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5485,Ignore
Improvement of lung cancer risk prediction adding SNPs to the HUNT Lung Cancer Model: A HUNT Study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5486,Ignore
Predictors of benefits to chemoimmunotherapy (CIT) in stage IV non-small-cell lung cancer (NSCLC): A meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5487,Ignore
Comparative genomic profiling of paired tissue and blood samples from advanced non-small cell lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5488,Ignore
Survival analysis of anticoagulant treatment of non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5489,Ignore
Immunohistochemical expression of GRP78 in relation to angiogenesis markers VEGF-a and CD31 and other histopathological parameters in NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5490,Ignore
Platinum based chemotherapy in elderly patients with non-small cell lung carcinoma (NSCLC): Experience from an Indian tertiary cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5491,Ignore
Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5492,Ignore
Apparent diffusion coefficient and genetic mutations as effective indexes for radiotherapy time of brain metastases from lung cancer retrospective analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5493,Ignore
EGFR extracellular domain mutation in patients with lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5494,Ignore
A 18F-FDG PET/CT-based radiomics model predicts prognosis of synchronous oligometastatic non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5495,Ignore
Transcriptional characterization of immune microenvironment and their prediction role for the prognosis of local advanced lung adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5496,Ignore
Phase II study of apatinib combined with vinorelbine in second-line treatment failure non-driver gene mutation advanced non-small cell lung cancer (NCT03652857).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5497,Medium
Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5498,Ignore
"MET second-site mutations in EGFR-mutant, MET-amplified non-small cell lung cancer after resistance to combinatorial targeted therapy.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5499,Ignore
Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5500,Medium
The efficacy of ado-trastuzumab emtansine in patients with HER-2-aberrant non-small cell lung cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5501,Medium
Immune related adverse events in NSCLC patients treated with immune checkpoint therapy who received the influenza vaccination versus no vaccination.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5502,Ignore
Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5503,Ignore
Initiation of targeted therapy based on ctDNA only in metastatic NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5504,Ignore
Treatment delay and outcomes in stage IV lung cancer: The reality of a public hospital in a developing country.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5505,Ignore
Clinical importance of long noncoding RNA LINC00460 expression in plasma cell-free tumor RNA in<em> EGFR</em>-mutant adenocarcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5506,Ignore
Sex is a strong prognostic factor for overall survival in advanced non small cell lung cancer patients and should be considered for survival rates estimations.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5507,Medium
Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5508,Medium
ALK resistance mutations and co-occurring genetic alterations to the ALK tyrosine kinase inhibitors in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5509,Ignore
Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5510,Ignore
"Potential interaction of radiation therapy, antibiotic, and steroid use in non-small cell lung cancer patients treated with checkpoint inhibitors: A retrospective analysis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5511,Ignore
Real-world immuno-oncology treatment patterns and outcomes in US patients with metastatic non-small-cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5512,Ignore
Clinical implications of monitoring circulating tumor DNA in early- and late-stage non-small cell lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5513,Ignore
Homeless outcomes in non-small cell lung cancer: A county hospital experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5514,Ignore
Concurrent <em>TP53</em> mutation adversely impact the efficacy of crizotinib in <em>ROS1-</em>rearranged lung cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5515,Medium
A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5516,Ignore
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5517,Ignore
Immunotherapy plus chemotherapy versus chemotherapy alone in metastatic nonsmall-cell lung cancer: A systematic review with meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5518,Ignore
The depth of response was associated with the progression-free survival in advanced non-small cell lung cancer patients treated with EGFR-TKI.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5519,Ignore
Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5520,Ignore
Upfront EGFR TKI with or without brain radiotherapy (RT) in EGFR-driven non-small cell lung cancer (NSCLC) with brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5521,Ignore
Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5522,Ignore
Analysis of a profile of lipid metabolism genes in advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5523,Ignore
Incidence and patterns of immune related adverse events (irAEs) during chemoimmunotherapy (ChemoIO) in patients with advanced nonsquamous NSCLC.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5524,Low
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5525,Medium
Clinical implication of inflammation-based serologic biomarkers and tissue biomarkers on hyperprogression in NSCLC patients receiving immune checkpoint blockers in real world.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5526,Ignore
Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5527,Ignore
A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5528,Ignore
Impact of antibiotics (ABX) on overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (aNSCLC) and melanoma (aMel) treated with first-line immune checkpoint inhibition (ICI).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5529,Medium
Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5530,Ignore
"The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5531,Ignore
Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5532,Ignore
Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,1,0,5533,Low
"A novel biophysical based marker with multilevel, multiparameter expression for early stage cancer detection.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5534,Ignore
Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5535,Medium
Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5536,Ignore
Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5537,Ignore
Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5538,Medium
Real-world economic burden of rapid disease progression (RDP) in patients (pts) with advanced/metastatic non-small cell lung cancer (aNSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5539,Ignore
"Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV non-squamous non-small cell lung cancer (STELLA): Design of a confirmatory, double-blind, randomized, controlled study.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5540,Ignore
"Clinical haematological biomarkers: Derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non small cell lung cancer (NSCLC) treated with immunotherapy: A multicenter review.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5541,Ignore
"Clinical, pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer in a multicenter experience in Madrid: Final results.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,1,5542,High
Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (R+D) post frontline (1L) platinum based chemotherapy plus immune checkpoint inhibitors (Pt + ICI).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5543,Medium
Peripheral neuropathy among patients with NSCLC undergoing chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5544,Ignore
Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5545,Medium
Erlotinib monotherapy in the treatment of advanced non-small cell lung carcinoma: A single center experience with 187 patients from 2005-2018.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5546,Ignore
The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5547,Medium
Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5548,Medium
The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5549,Medium
"Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5550,Ignore
"Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5551,Medium
The mutation profile of EGFR in resectable Chinese lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5552,Ignore
Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5553,Medium
Third and successivelines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5554,Ignore
Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5555,Ignore
Clinical significance of Ki-67 index expression in advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5556,Ignore
"Cross-sectional imaging utilization for EGFR, EML/ALK, and KRAS mutant non-small cell lung cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5557,Ignore
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5558,Ignore
Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5559,Ignore
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5560,Ignore
"Real-world treatment patterns, survival, and cost among elderly patients with small-cell lung cancer (SCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5561,Ignore
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5562,Ignore
The clinical prognostic factors in advanced lung adenocarcinoma patients with different EGFR mutation subtype.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5563,Ignore
Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (aNSCLC) patients (pts).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5564,Ignore
Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5565,Ignore
"Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5566,Ignore
A retrospective study evaluating clinical predictors of duration of response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5567,Ignore
Immunotherapeutic efficacy in NSCLC and patients smoking status: A meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5568,Medium
The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5569,Ignore
"Costs and hazard ratios of commonly used drugs in advanced/metastatic lung cancer at Cancer Free Foundation, Dana Point, California.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5570,Ignore
The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in <em>EGFR</em>-mutant lung adenocarcinoma treated with osimertinib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5571,Ignore
Development and validation of a deep learning model to assess tumor progression to immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5572,Ignore
Effect of a multi-disciplinary approach and incorporation of reflex testing on genomic profiling of non-squamous lung cancer in a community oncology practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5573,Ignore
Effect of concurrent TP53 mutation in EGFR/ALK/ROS1 positive non-small cell lung cancer treated with first-line TKI therapy: A Single Institution Retrospective Study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5574,Ignore
Trends in immunotherapy use and survival impact in stage IV non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5575,Ignore
Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5576,Ignore
Overcoming acquired osimertinib-resistance in EGFR<i>-</i>mutant advanced non-small lung cancer mediated by activating BRAF<i> </i>V600E mutation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5577,Ignore
Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5578,Medium
"Activity of osimetrinib/AZD9291 in pretreated patients (pts) with epidermal growth factor receptor mutant (EGFRmt) non-small cell lung cancer (NSCLC), according to EGFR mutations detected in circulating plasma DNA (ctDNA).",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5579,Ignore
Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5580,Ignore
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for responsePreliminary results from the NSCLC cohort.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,1,5581,High
Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5582,Medium
"Interim report on CIV recombinant human endostatin in combination with docetaxel/cisplatin (DP)) in comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5583,Medium
"Adoption of immuno-oncology in NSCLC, a real-world study in EU5.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5584,Ignore
Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5585,Ignore
PD-1/PD-L1 immunotherapy for advanced lung cancer: An electronic medical database based real world study in China.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5586,Ignore
Chemoimmunotherapy combination: Potential option for metastatic NSCLC patients with EGFR mutation resistant to osimertinib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5587,Ignore
Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5588,Medium
Using single cell genomics to change the treatment of lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5589,Ignore
Association of allele frequency of <em>EGFR</em> mutation with efficacy of <em> EGFR</em> TKIs in advanced non-small cell lung cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5590,Medium
Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5591,Ignore
Understanding biological driver mutations and mechanism of resistance to EGFR-tyrosine kinase inhibitors in lung cancer patients using a novel translational platform.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5592,Ignore
Effect of body mass index and age on survival in patients with advanced lung cancer treated with anti-PD-1 immune checkpoint inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5593,Ignore
Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in NSCLC.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5594,Ignore
Overall survival in PEMVITASTART randomized trial comparing immediate vs. conventional strategies of vitamin supplementation in NSCLC patients on 1<sup>st</sup> line pemetrexed-platinum chemotherapy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5595,Medium
Using a multiplexed immunofluorescence approach to compare immune cell populations in subtypes of non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5596,Ignore
Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5597,Ignore
A joint model of tumor size dynamics and survival with new lesions in EGFR mutation-positive non-small cell lung cancer patients with treatment of gefitinib or carboplatin and paclitaxel.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5598,Ignore
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel with or without bevacizumab as second-line therapy or beyond for patients with metastatic non-small-cell lung cancer.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5599,Medium
Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5600,Medium
Precision medicine and actionable alterations in lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5601,Ignore
Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5602,Ignore
NTRK1 fusion identified by capture-based next-generation sequencing in non-small-cell lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5603,Ignore
"The role of low dose aspirin, vitamin D, or metformin in EGFR, ALK, and ROS positive non-small cell lung cancer: A single institution retrospective analysis.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5604,Ignore
Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5605,Ignore
Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5606,Ignore
Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5607,Medium
Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5608,Ignore
Clinical outcomes of various resistance mechanisms of osimertinib in Chinese advanced non-small cell lung cancer patients.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5609,Medium
Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2<sup>nd</sup> line osimertinib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5610,Ignore
Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5611,Ignore
Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancer.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5612,Medium
FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,1,5613,High
PD-1 versus PD-L1 inhibitors for previously treated advanced non-small cell lung cancer (NSCLC): Bayesian network meta-analysis (NMA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5614,Ignore
The HGF-MET signaling pathway is enriched in LUAC brain metastases.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5615,Ignore
Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5616,Ignore
Clinical outcomes of NSCLC patients with acquired <em>RET </em>rearrangement after resistance to osimertinib.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic: Publication Only,0,0,5617,Medium
"Nivolumab and Pembrolizumab in advanced cutaneous melanoma : Results from real-life data in patients from France Evaluation of use, current practices and medico economic approach.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5618,Ignore
Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5619,Ignore
Specificity of markers CD44 and S100 for skin melanoma and nevi tissues.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5620,Ignore
"Expression of tryptophan metabolizing enzymes (TMEs) and its transporter, LAT1, in metastatic melanoma (MM): Prognostic and therapeutic implications.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5621,Ignore
Utility of concurrent immunoradiation for locally advanced and/or medically inoperable melanoma and Merkel cell carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5622,Ignore
"Adrenal metastases in malignant melanoma, is it a privileged site?",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5623,Ignore
Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5624,Medium
Mucosal melanoma staging and classification: Firstly established.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5625,Ignore
Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with vemurafenib.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5626,Ignore
Prognostic differences and the effect of radiotherapy on survival in Merkel cell carcinoma: A retrospective analysis of a Swedish cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5627,Ignore
"Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).",1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,1,5628,High
Continuous intravenous infusion Rh-endostatin in combination with dacarbazine and cisplatin as the first-line therapy for metastatic melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5629,Ignore
Characterization of mechano-microenvironment of acral melanoma and its potential impact on tumor cell invasion.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5630,Ignore
Cyclooxygenase inhibitor use during checkpoint blockade immunotherapy and effect on time to progression for metastatic melanoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5631,Ignore
Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5632,Ignore
Does the initial biopsy type affect clinically important outcomes in malignant melanoma? A meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5633,Ignore
Patterns of major surgeries among patients diagnosed with cutaneous squamous cell carcinoma (CSCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5634,Ignore
Combined BRAF and MEK Inhibition in Patients with unresectable or metastatic cutaneous melanoma: A meta-analysis of randomized controlled trials.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5635,Ignore
Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5636,Ignore
Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5637,Ignore
Outcomes in MAGE+ cutaneous squamous cell carcinoma with perineural invasion treated with surgery followed by postoperative radiation therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5638,Ignore
Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5639,Ignore
Melanoma nodal management in Ontario following ASCO/SSO guidelines.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5640,Ignore
What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma?,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5641,Medium
Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5642,Ignore
Staccato pulse interleukin-2 (IL-2) in metastatic melanoma (MM) previously treated with checkpoint inhibitors (CPI).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5643,Ignore
Real-world clinical and economic outcomes among newly-diagnosed merkel cell carcinoma (MCC) patients initiating first-line (1L) checkpoint inhibitors (CPIs) or chemotherapy (CT) in the veterans health administration (VHA).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5644,Ignore
Clinical characteristics and treatments outcomes of patients with metastatic uveal melanoma (UM) in a Brazilian population: A retrospective unicentric study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5645,Ignore
Somatic mutational profile of Merkel cell carcinoma treated with immune checkpoint blockade: Preliminary results from a planned multiplatform analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,1,5646,High
A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5647,Ignore
Cancer Immune Control Dynamics (CICD): A clinical data driven model of systemic immunity.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5648,Medium
A real-world study of recombinant human endostatin continuous intravenous infusion combined with chemotherapy in the treatment of advanced mucosal melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5649,Ignore
Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5650,Ignore
Local experience with ipilimumab and nivolumab in treatment of metastatic melanoma: From world standards to individualized approaches in real clinical practice.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5651,Ignore
Mucosal melanoma of the female genital tract: Operation modalities.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5652,Ignore
Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5653,Medium
Outcomes of melanoma patients with brain metastases receiving immune checkpoint inhibitor (ICI) therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5654,Ignore
"Genetic relationship between pilar cysts, pilar tumors and pilar carcinomas.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5655,Ignore
A novel drug to treat advanced melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5656,Ignore
Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5657,Ignore
Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective and multicenter single-arm phase 2 trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5658,Medium
Preliminary safety results of a phase II study investigating pembrolizumab in combination with postoperative intensity modulated radiotherapy (IMRT) in resected high risk cutaneous squamous cell cancer of the head and neck.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5659,Medium
Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5660,Ignore
Clinical heterogeneity of elderly melanoma patients in the real-world setting: Potential implications for treatment outcomes following immune based therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5661,Ignore
Outcomes of melanoma soft parts/clear cell sarcoma (MSP/CCS) patients (pts) with immune and targeted therapies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5662,Ignore
Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5663,Ignore
Postoperative radiotherapy in resected sinonasal mucosal melanoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5664,Ignore
<em><U+200B></em>obesity and metastatic melanoma: A national perspective from the pre-immune checkpoint inhibitor era.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5665,Ignore
Markers of melanoma progression in the blood serum structure.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5666,Ignore
Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,1,5667,High
Nation-wide trends in mortality of patients with ocular and orbit melanoma: 2000 to 2014.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5668,Low
"Assessment of knowledge, attitude and practice and associated factors towards palliative care among health care providers to the pediatric oncology patients in southern Philippines.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,1,0,5669,Low
"Immune related adverse events (irAE) of mono-, combination, and sequential therapy regimens of ipilimumab (IPI), nivolumab (NIV), and pembrolizumab (PEM) for advanced melanoma.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Melanoma/Skin Cancers: Publication Only,0,0,5670,Ignore
A pilot study of sleep-related breathing disorders and hypersomnia in adult survivors of childhood Hodgkin lymphoma treated with thoracic radiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5671,Ignore
Tumor molecular profiling in advanced pediatric brain tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5672,Ignore
The evaluation of long term follow-up (LTFU) of children with osteosarcoma: The first report from a center in a developing country.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5673,Ignore
Peripheral-blood stem cell transplantation in pediatric recipients in Peru: Experience of a reference center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5674,Ignore
Effects of COJEC induction on neuroblastoma patient-derived xenografts (PDX).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5675,Ignore
Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5676,Medium
Developmental differences in health-related quality of life (HRQL) in adolescent and young adult (AYA) survivors of childhood cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5677,Ignore
Off label targeted therapy use in adolescents and young adults with sarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5678,Ignore
Serum biomarkers for detection of cardiomyopathy in survivors of childhood cancer: A report from the St. Jude Lifetime Cohort.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5679,Ignore
Carcinomas in the children and young adults: A report form Childrens Oncology Group APEC14B1 study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5680,Ignore
Perceptions on good death among parents of pediatric patients with hematology-oncology disease in advance.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5681,Ignore
Modeling and identifying therapeutic targets in Hepatoblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5682,Ignore
MRI based radiomic signature to predict treatment response to intraventricular natural killer (NK) cell infusion therapy for recurrent/refractory pediatric brain tumors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5683,Ignore
Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study.,0,31-05-2019,1,0,0,0,0,0,0,0,0,1,0,Pediatric Oncology: Publication Only,0,0,5684,Low
Ultrasound versus physical exam to screen for secondary thyroid cancer among high-risk childhood cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5685,Ignore
Current practices and attitudes in menstrual management in adolescents with cancer: A national survey of pediatric oncology providers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5686,Ignore
"Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation and tumor xenograft studies.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5687,Ignore
High concentration of plasma cell free DNA alerted progressive and recurrent disease in children with high risk neuroblastoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5688,Ignore
"A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5689,Medium
Late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5690,Ignore
Pediatric Cancer Registry in Turkey 2009-2018 (TPOG & TPHD).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5691,Ignore
Shared dysregulation of long non-coding RNA and developmental gene networks in histone H3 K27M gliomas and PF-A ependymomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5692,Ignore
Sedation practices in pediatric ALL patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5693,Ignore
Parental insights into phase I pediatric oncology clinical trials: Findings from a phenomenological study.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5694,Medium
Evaluation of outcome and prognostic factors in paediatric extraskeletal ewings sarcoma: A single institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5695,Ignore
"Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5696,Ignore
"Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea: A nationwide population-based, longitudinal study.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Pediatric Oncology: Publication Only,0,0,5697,Low
Personalizing cancer treatment using gene activity scores with the NIH Medical Genetics Summaries.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Professional Development: Publication Only,0,0,5698,Ignore
Toxicity and efficacy of busulfan-melphalan (BuMel) compared to treosulfan-melphalan (TreoMel) high dose chemotherapy (HDCT) consolidation in high-risk Ewing sarcoma (ES): A 12-year monoinstitutional experience.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5699,Medium
Effect of miR-506 on pirarubicin sensitivity and on mesenchymal to epithelial transition and DNA damage homologous recombination repair process in leiomyosarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5700,Ignore
Prognostic implications of tumor associated macrophages (TAMs) in soft tissue sarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5701,Ignore
Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5702,Ignore
Desmoid tumor (DT) management in dedicated sarcoma medical oncology clinic in a developing country: Lessons learnt.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5703,Ignore
A novel approach to neoadjuvant chemoradiation for soft tissue sarcoma using cisplatin and adriamycin.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5704,Ignore
Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203).,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5705,Medium
Outcome of patients with refractory malignant peripheral nerve sheath tumors (MPNST) enrolled on phase 2 trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,1,0,Sarcoma: Publication Only,0,0,5706,Medium
Prevalence of symptom clusters among sarcoma patients in active treatment.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5707,Low
A novel <em>HMGA2-YAP1 </em>fusion gene in a patient with aggressive angiomyxoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5708,Ignore
Incidence and prevalence of synovial sarcoma in the US: An analysis using SEER*Stat.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5709,Low
Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5710,Ignore
Work productivity loss in patients with tenosynovial giant cell tumors in the United States.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5711,Ignore
Renal Ewing's sarcoma: A single institute experience of seven patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5712,Ignore
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5713,Ignore
Outcomes of advanced angiosarcoma and hemangioendothelioma on propranolol based regimens from sarcoma medical oncology clinic in North India.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5714,Ignore
Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University Medical Centers experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5715,Ignore
Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Sarcoma: Publication Only,0,0,5716,Medium
Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5717,Ignore
Chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients: Efficacy data from the largest cohort study from China.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5718,Medium
Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5719,Medium
The phase Ib result of the safety and efficacy of lenvatinib (lenv) plus eribulin (eri) in advanced adipocytic sarcoma (LPS) and leiomyosarcoma (LMS): LEADER study (NCT03526679).,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5720,Medium
Copy number variations of apoptosis-regulating genes and MKI67 gene in primary and recurrent soft tissues sarcomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5721,Ignore
"Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: A retrospective analysis.",0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5722,Low
Treatment of soft tissue sarcoma with a novel cold plasma jet.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5723,Ignore
Angiosarcoma treated with checkpoint inhibitors: A single-institution experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5724,Ignore
Survival outcomes following cytoreductive nephrectomy (CN) in patients with metastatic renal cell sarcomas (MRCS).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5725,Ignore
Apatinib for epithelioid sarcoma: analysis on eight advanced stage cases in a single institute.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5726,Ignore
The long term surgical outcome of spinal giant cell tumor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5727,Ignore
Salvage chemotherapy using irinotecan and temozolamide in pediatric and adult populations with relapsed Ewing sarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5728,Ignore
The effect of gastrectomy in regorafenib treated GIST patients on outcome and drug exposure.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5729,Ignore
Systemic therapy in advanced dermatofibrosarcoma protuberans: Imatinib and beyond.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5730,Ignore
"Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5731,Ignore
Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5732,Medium
Comparative DNA cytometry of primary and recurrent soft tissue sarcomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5733,Ignore
Cardio-toxicity among patients with sarcoma: A Cardio-Oncology Registry.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5734,Ignore
Chinese largest cohort data from NCT03120846: Efficacy and safety of VEGFR2 inhibitor apatinib for metastatic soft tissue sarcomas.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5735,Medium
Efficacy of low dose pazopanib in advanced soft tissue sarcoma (STS): Experience from a dedicated sarcoma medical oncology clinic in India.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5736,Medium
Profiling of targetable aberrations in advanced sarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5737,Ignore
Molecular characterization and management of secondary resistance to serial TRK inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5738,Ignore
Combination treatment for giant cell tumors of the bone.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5739,Ignore
Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5740,Ignore
"Relationship among ETV1 genetic polymorphisms, PFS, and microRNA in gastrointestinal stromal tumors.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5741,Ignore
Alveolar soft PART sarcomas (ASPS): A tertiary care center experience from India.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5742,Ignore
Immunological and mutational characterization of non-uterine leiomyosarcoma: A pilot study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5743,Ignore
Comprehensive genomic profiling of patients with favorable prognosis in osteosarcoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5744,Ignore
Clinical features and prognosis of patients with liposarcoma: Single-center experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5745,Ignore
10-year follow-up results of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG0304.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5746,Ignore
Creation and characterization of a novel human PDGFRA D842V-mutant GIST cell line.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5747,Ignore
No relevant activity of olaratumab in patient-derived soft tissue sarcoma xenografts selected for expression of platelet-derived growth factor receptor a.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5748,Ignore
Tumor control with palliative external beam radiation therapy (EBRT) in advanced and unresectable osteosarcoma (OS) progressing after standard treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5749,Ignore
The importance of surgical margins in dedifferentiated liposarcoma survival.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma: Publication Only,0,0,5750,Ignore
Evaluation of the TPO-receptor agonist Eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Sarcoma: Publication Only,0,0,5751,Medium
Successful generation of patient-derived xenografts and cell lines as preclinical models for sarcomas.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Sarcoma: Publication Only,0,0,5752,Medium
Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5753,Ignore
Analysis of proportion of geriatric patients in phase III cancer clinical trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5754,Medium
Physical methods of rehabilitation (PMR) in patients with lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5755,Ignore
Cachexia in head and neck squamous cell carcinoma (HNSCC) patients (pts) after cisplatin-based chemoradiation (CRT): A cross-sectional study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5756,Ignore
HOME palliative care-Nepal: A cell-phone/website it system.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,1,0,5757,Low
Effect of temozolomide on neurogenesis and anxiety in the adult mouse brain.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5758,Ignore
Oncology provider perceptions of shared-decision making.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5759,Ignore
A survey of healthcare professionals and oncology patients at the McGill University Health Centre reveals enthusiasm towards establishing a post-mortem rapid tissue donation program.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5760,Ignore
Complementary medicine and cancer: A French multicenter survey.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5761,Ignore
Chronic adverse effects after axillary lymphadenectomy in breast cancer patients after weaker and stronger postoperative analgesia: Results of a prospective double-blind randomized study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5762,Ignore
Empaglifozin has cardioprotective and anti-inflammatory effects during doxorubicin treatment: A preclinical study.,0,31-05-2019,0,0,0,0,0,0,0,0,1,0,0,Symptoms and Survivorship: Publication Only,0,0,5763,Medium
"Delay in time from diagnosis to treatment in metastatic melanoma, lung, and colon cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5764,Ignore
Factors affecting sleep quality and its association to quality of life in adult Filipinos with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5765,Ignore
Profiling cancer-related distress and problems: A latent class analysis approach.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5766,Ignore
Lactate response during acute exercise in cancer survivors undergoing exercise rehabilitation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5767,Ignore
"Knowledge, attitude and practices regarding use of medical cannabis: A national survey among israeli oncologists.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5768,Ignore
Metastatic presentations of previously treated early stage breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5769,Ignore
Are patients with advanced colon cancer availing of palliative care services?: Findings from a high-volume urban center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,1,0,5770,Low
A prospective study of anti-mullerian hormone (AMH) as a predictor of chemotherapy-induced menopause.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5771,Ignore
Cognitive impairment and treatment effects among gastrointenstinal stromal tumor survivors: Results of a large online survey.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5772,Ignore
Effects of a personal trainer led exercise intervention on physical activity and physical function of breast cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5773,Ignore
Oncology Associated Symptoms and Individualized strategies ( OASIS): Precision symptoms management for rural patients with advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5774,Ignore
Communication challenges among medical oncologists in Mexico.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5775,Ignore
"The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5776,Ignore
Baseline laboratory tests as predictors of early death risk in 746 elderly oncologic patients: A prospective cohort study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5777,Ignore
"Delirium incidence, risk factors, and treatment in older adults receiving chemotherapy: A scoping review.",0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5778,Low
"The impact of chemotherapy on sleep quality in women undergoing cytotoxic treatment for breast, ovarian, and endometrial cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5779,Ignore
Cancer survivors challenges with ostomy appliances and self-management.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5780,Ignore
End-of-life care and prognosis of elderly patients with advanced cancer in palliative care unit.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,1,0,5781,Low
Comparison of mortality trends in geriatric and nongeriatric patients with salivary gland tumors.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5782,Low
"Mutational status and thromboembolic risk in lung, gastrointestinal and breast cancer patients.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5783,Ignore
Advance care planning and terminal intensive care unit admissions for cancer patients: We can do better.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5784,Ignore
An observational study to evaluate the potential of Onlife to improve chemotherapy-induced peripheral neuropathy: Final results of the STEFANO trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,1,5785,High
Defining cardiotoxicity of doxorubicin and trastuzumab.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5786,Ignore
Persistent radiation-induced alopecia in patients with central nervous system tumors and head and neck sarcomas.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5787,Ignore
A retrospective analysis of elderly population with metastatic colorectal cancer treated with raltitrexed in the target therapy era.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5788,Ignore
Empowering lung cancer survivors and family members to breathe easier: Adaptation and evaluation of a m-health intervention.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5789,Ignore
Systematic review and meta-analysis of definitions and reported incidences of anthracycline cardiotoxicity.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5790,Ignore
"Patient-reported outcomes for dental health, shoulder-neck dysfunction, and overall quality of life after treatment with radiation for head and neck cancer.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5791,Ignore
Detection of bone metastases through diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) compared with PET/CT <sup>18</sup>F-NaF.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5792,Ignore
"Implementing a web-based patient reported outcomes (PRO) assessment: Uptake, usability, and lessons learned.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5793,Ignore
The impact of blinding on patient-reported outcomes (PROs) in randomized controlled trials of immune checkpoint inhibitors versus traditional chemotherapies.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5794,Ignore
Risk of secondary hematologic malignancies and tolerability in patients with ovarian cancer treated with PARP inhibitors: A systematic review and meta-analysis of four phase III randomized controlled trials.,1,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5795,Medium
Implementation of a brief screening tool to identify needs of cancer survivors.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5796,Low
iMETX (Individualized Metabolic RX): An environmental intervention to increase energy expenditure in breast cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5797,Ignore
Investigation of the efficacy of imidazolyl ethanamide pentandioic acid (IEPA) to reduce chemotherapy-induced myelosuppression (CIM) in breast cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5798,Medium
Patient experience of an intervention combining nurse navigators and e-Health technologies for use of oral anticancer agents.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5799,Ignore
Risk factors of psychological distress and quality of life in lung cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5800,Ignore
The effects of wheatgrass juice administration in colon cancer patients during adjuvant chemotherapy and the treatment reflection on the extracellular vesicles.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5801,Ignore
Ondansetron versus palonosetron as a marker of non-adherence to antiemetic prophylaxis guidelines in highly emetogenic chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5802,Ignore
Non-invasive assessment of chemotherapy-induced peripheral neuropathy using neuromuscular ultrasound in breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5803,Ignore
Comprehensive geriatric assessment prior to autologous stem cell transplant as a predictor of patient outcomes: A retrospective review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5804,Ignore
"Psycho-Oncology: Cancer patients with past suicide attempts, or a family history of suicide.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5805,Ignore
"Medical cannabis in cancer patients: Prevalence, efficacy, and safety.",0,31-05-2019,1,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5806,Low
"Severity, implications, and understanding of cancer related fatigue in cancer survivors of South Asian ethnicity.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5807,Ignore
Perceptions of medical status and treatment goal in older adults with advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5808,Ignore
Effect of pre-treatment anxiety and depression on long term survival of prostate cancer patients treated radically with radiation and hormone therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5809,Ignore
Depression and health care utilization and costs in patients diagnosed with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5810,Ignore
Patient perceptions of treatment benefit in advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5811,Ignore
Efficacy of different TCM treatment techniques combined with standardized step therapy for cancer pain: A network.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5812,Medium
Incidence of Infection-related mortality in cancer patients: Trend and survival analysis.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5813,Low
Novel smartphone app for daily symptom reporting for active chemotherapy patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5814,Ignore
Use of remote symptom monitoring with breast cancer survivors using patient-reported outcome (PRO) measures in MyChart.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5815,Ignore
Tumor mutation burden and depression in lung cancer: Association with inflammation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5816,Ignore
Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5817,Ignore
The efficacy and safety of exercise in metastatic solid cancer: A meta-analysis of randomized control trials.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5818,Medium
Effect of free amino acids mix with medium triglycerides and Withania somnifera on cancer cachexia.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5819,Ignore
Impact of high-dose vitamin d supplementation on short physical performance battery and bioelectrical impedance analysis in older patients with prostate cancer on ADT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5820,Ignore
Real-time detection of patient-reported outcomes (PRO) through an app: A Brazilian experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5821,Ignore
Evaluation of mental and social adaptation of patients with breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5822,Ignore
Percutaneous pericardiocentesis versus pericardial window: A retrospective subset analysis in a cancer population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5823,Ignore
A prospective study of the impact of chemotherapy-related toxicities on the quality of life in elderly patients with cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5824,Ignore
The development of an instrument to identify cancer caregivers at risk for metabolic syndrome.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5825,Ignore
Modeling causal associations between frailty components and mortality in older patients with cancer: A structural equation approach.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5826,Low
Coping with end-of-life stress (EOLS): Poetry as a therapeutic communication intervention.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5827,Ignore
Mindfulness and concerns about adjuvant endocrine therapy (AET).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5828,Ignore
Unscheduled hospitalization in advanced cancer patients: Time to rethink about the illness.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5829,Ignore
Predictors of anxiety and depression risk among individuals with lung cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5830,Ignore
Experiences of general practitioners and medical specialists with incurable cancer patients with a protracted disease trajectory: A focus group study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5831,Ignore
Effect of fractures on overall survival in cancer patients: The NHANES database.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5832,Medium
Evaluation of the diagnostic and prognostic performance of the modified G8 screening instrument in oncological patients with age of 60 YEARS or age: Prospective cohort of 889 Brazilian elderly cancer patients.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5833,Low
Mobile text messaging to improve adjuvant hormone therapy and side effect management among breast cancer patients: A pilot RCT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5834,Ignore
Genetic variability of tramadol pharmacokinetic genes and pain treatment outcome after breast cancer surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5835,Ignore
Demoralization and associated features in an Italian sample of end-of-life cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5836,Ignore
Treatment and outcome of elderly patients with PCNSL: A Beaumont experience.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5837,Ignore
Contraception and fertility counseling in patients receiving chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5838,Ignore
Defining undertreatment and overtreatment in older patients with cancer: A scoping review of the literature.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5839,Ignore
Cutaneous eruption as a prognosis indicator for cancer patients treated with EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5840,Ignore
Is in vivo reflectance confocal microscopy a useful assessment tool in chemotherapy-induced peripheral neuropathy (CIPN)?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5841,Ignore
Teleoncology: Prospects and challenges for cost effective cancer care.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5842,Ignore
Association of the quality of psychosocial support and quality of life in patients with chronic oncological pain.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5843,Ignore
Bridging the information gap: A scoping review of radiation oncology patient education scholarship.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5844,Ignore
The comprehensive geriatric assessment in malignancies and prognostic factors: Description of a prospective cohort of 889 Brazilian elderly cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5845,Ignore
Exercise trends among previously non-exercising breast cancer survivors: Analysis of an ethnically diverse sample.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5846,Ignore
Impact of cisplatin-related hearing loss (HL) and tinnitus on patient functioning.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5847,Ignore
Tobacco cessation practices among primary care physicians in northern Illinois.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5848,Ignore
A community oncology end-of-life care program: Results for hospice length of stay analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5849,Ignore
Evaluation of readmission rates for gastrointestinal bleeds in high risk oncologic patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5850,Ignore
"A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5851,Ignore
Neighborhood effects and obesity in adult survivors of pediatric cancer: A report from the St. Jude Lifetime Cohort Study.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5852,Ignore
National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5853,Low
Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5854,Ignore
Recommendations from clinical practice guidelines on discussion of costs of care in adult patients with advanced cancer: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5855,Ignore
Development of the patient-reported outcomes (PRO) based survival prediction model for survivors who underwent lung cancer surgery.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5856,Ignore
Preliminary result of phase II study of megestrol combined with 5-hydroxytryptamine 3 inhibitor and dexamethasone for the prevention of nausea and vomiting induced by high emetogenic chemotherapy.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5857,Medium
Competing causes of death in patients with neuroendocrine tumor.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5858,Ignore
Development of a comprehensive prognostic model of lymphedema risk for breast cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5859,Ignore
The effect of a structured weekly patient meeting on patient reported outcomes (PRO) and resource utilization for patients with metastatic breast cancer (MBC).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5860,Ignore
How often do metastatic brain disease patients prescribed ten fractions of whole brain radiation therapy die without completing treatment?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5861,Ignore
Annual lung cancer screening by chest x-ray results in higher profits for the exclusion of lung cancer.,0,31-05-2019,0,0,1,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5862,Low
Spiritual and psychological distress in older and the oldest-old living with advanced cancer patients (O-OOAdCa) in a comprehensive cancer center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5863,Ignore
Fast time estimation to predict levels of anxiety in cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5864,Ignore
Mortality results from an oral oncolytic symptom management trial.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5865,Low
The efficacy of placebo for the treatment of cancer-related fatigue: A systematic review and meta-analysis.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5866,Medium
Neutrophil to lymphocyte ratio =4 correlates with 6-month postoperative mortality in cancer patients age >75.,0,31-05-2019,1,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5867,Low
Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: A systematic review and network meta-analysis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5868,Ignore
Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5869,Medium
Dealing with emotional states during cancer diagnosis and treatment by using cognitive strategies in oncology patients: Comparison to noncancer population.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5870,Ignore
Unpacking clinical trial offers: A qualitative analysis of interactions with physicians and patients potentially eligible for a prostate cancer trial.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5871,Ignore
Identifying psychosocial distress in cancer patients in a community center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5872,Ignore
Endocrine therapy discontinuation rates in older women with early stage breast cancer who are candidates for omission of radiation.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5873,Ignore
"Cancer patients: Assessing awareness, attitudes and claimed behavior around key decision points upon being diagnosed.",0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5874,Ignore
"A double-blind, placebo-controlled randomized phase II study: Evaluating the effect of curcumin for treatment of cancer anorexia-cachexia syndrome in solid cancer patients.",1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5875,Medium
The ideal amount of physical activity to improve quality of life and symptoms in lung cancer patients: A systematic review.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5876,Ignore
Utilizing the patient-reported outcomes measurement information system (PROMIS) to assess quality of life among breast cancer patients at an academic center.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5877,Ignore
Needs assessment for sexual health support following cancer diagnosis.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5878,Ignore
Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.,0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5879,Medium
Treatment approaches and survival outcomes of older patients with locally advanced esophageal cancer (LAEC) in Ireland.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5880,Ignore
Study on influencing factors and survival analysis of patients with malignant tumors treated by music therapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5881,Ignore
Delphi consensus on the follow-up of cancer patients with breakthrough pain under opioid treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5882,Ignore
Propensity score matching analysis of the survival outcome and toxicity of different treatment modalities for the elderly nasopharyngeal carcinoma patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5883,Ignore
Long-term symptom burden and quality of life in metastatic melanoma patients treated with checkpoint inhibitors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5884,Ignore
A pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (CIPN).,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5885,Ignore
Place of death and chemotherapy use at the end of life in colorectal cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5886,Ignore
Clinical course of patients with cisplatin (CDDP)-associated neuropathy compared to other neurotoxic chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5887,Ignore
Clinical outcomes of manual aspiration thrombectomy for Ilio-femoral venous thrombosis in cancer patients.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5888,Medium
The effect of <em>sukshma vyayama</em> joint loosening yoga on aromatase inhibitor-induced arthralgia (AI) in breast cancer patients: A feasibility study conducted on Facebook.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5889,Ignore
Acupuncture: Real-world patient-reported outcomes of treatment-related symptoms in breast cancer survivors.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5890,Ignore
What type of information is needed by AYA cancer survivors in Japan?,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5891,Ignore
Assessing quality of life (QoL) of patients and their caregivers on phase I clinical trials.,1,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5892,Medium
Long-term neurotoxicity in women with breast cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5893,Ignore
Comparative analysis of molecular aberration in different genders for identification of key pathways in hepatocellular carcinoma.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5894,Ignore
Is cancer associated thrombosis (CAT) an underestimated issue in oncology clinical practice? Real-world data regarding long term management of CAT.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5895,Ignore
Understanding patient advance directives status in a community oncology practice using an electronic patient-reported outcomes (ePRO) system.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5896,Ignore
Risk factors in pregnant women with an oncological diagnosis and their impact in the post-partum period.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5897,Ignore
Estimating survival time in older adults receiving chemotherapy for advanced cancer.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5898,Ignore
Chemotherapy and trastuzumab-induced cardiotoxicity in geriatric breast cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5899,Ignore
Breast cancer patients quality of life: Real-world data.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,1,Symptoms and Survivorship: Publication Only,0,0,5900,Ignore
One-minute time interval estimation as a novel potent indicator of need for help in cancer patients prior to starting chemotherapy.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5901,Ignore
"Elderly patients have limited access to systemic therapy for metastatic renal cell carcinoma (mRCC) and shorter overall survival in Russia, Belarus and Kazakhstan.",0,31-05-2019,0,0,0,1,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5902,Medium
Therapy preference scale: A novel questionnaire to understand patients preferences of cancer treatment.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5903,Ignore
Implementing strain imaging to identify early childhood cancer survivors at risk for cardiovascular disease.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5904,Ignore
Differences in quality of life and emotional health by diagnosis among women with early-stage gynecological cancers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5905,Ignore
Validation of G8 and its acuracy as a predictor of object in oncological patients with age of = 60 YEARS. prospective cohort of 889 brazilian elderly cancer patients.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5906,Ignore
Knowledge and attitudes of permanent chemotherapy-induced alopecia among health care providers.,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Symptoms and Survivorship: Publication Only,0,0,5907,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Post-Plenary Clinical Application and Discussion: Pancreatic Cancer (LBA4),0,0,5908,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Post-Plenary Clinical Application and Discussion: Sarcoma (LBA3),0,0,5909,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Post-Plenary Clinical Application and Discussion: Prostate Cancer (LBA2),0,0,5910,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Post-Plenary Discussion: Health Services Research and Health Policy (LBA1),0,0,5911,Ignore
Chair,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,"ASCO Book Club: <em>Cancerland: A Medical Memoir</em> by David Scadden, MD",0,0,5912,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genomics for Oncologists 101,0,0,5913,Ignore
Workshop Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Enhancing Cultural Literacy in Oncology: Strategies for Delivery of High-Quality Cancer Care,0,0,5914,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Hyper-Progression: Myth or Reality?,0,0,5915,Ignore
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,"Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant",0,0,5916,Ignore
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,5917,Ignore
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Gynecologic Cancer,0,0,5918,Ignore
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,5919,Ignore
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Lung CancerNon-Small Cell Metastatic,0,0,5920,Ignore
Chair,0,01-06-2019,0,0,0,0,0,0,0,0,0,0,0,Fine-Tuning Checkpoint Inhibition: Biomarkers of Response and Resistance,0,0,5921,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,A Conversation on Innovation and Incentives,0,0,5922,Ignore
Chair,1,30-05-2019,0,0,0,0,0,0,0,0,0,0,0,Clinical Updates in Genetics,0,0,5923,Medium
Chair,0,03-06-2019,0,0,0,0,0,0,0,0,0,0,0,Sarcoma,0,0,5924,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,1,Breast CancerLocal/Regional/Adjuvant,0,0,5925,Ignore
Chair,0,02-06-2019,0,0,0,0,0,0,0,0,0,0,0,Are We Hitting the Bull's-eye With Targeted Therapy?,0,0,5926,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Genomics for Oncologists 101,0,0,5927,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,How to Initiate and Integrate Clinical Trials Into Your Practice,0,0,5928,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Immune Toxicities: A Case-Based Discussion with Experts,0,0,5929,Ignore
Chair,0,31-05-2019,0,0,0,0,0,0,0,0,0,0,0,Managing Immune Toxicities: A Case-Based Discussion with Experts,0,0,5930,Ignore
